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SUMMARY	
All	 currently	 known	high	 to	 intermediate	 risk	 “breast	 cancer	genes”,	 including	BRCA1	 and	
BRCA2,	are	involved	in	the	DNA	damage	response	pathway.	Heterozygous	germline	mutations	
in	these	genes	predispose	to	breast	and	ovarian	cancer.	In	addition,	such	mutations	may	also	
result	 in	enhanced	 radiosensitivity	mediated	by	chromosomal	 instability	after	exposure	 to	
ionizing	 radiation,	 leading	 to	 a	 higher	 risk	 to	 develop	 radiation-induced	 breast	 cancer.	
However,	results	of	currently	available	clinical	studies	evaluating	carcinogenesis	and	in	vitro	
studies	 comparing	 chromosomal	 radiosensitivity	 in	mutation	 carriers	 and	non-carriers	 are	
inconclusive.	Nevertheless,	 insights	 into	the	radiosensitive	phenotype	of	healthy	tissues	of	
mutation	 carriers	 is	 of	 the	 utmost	 importance	 for	 the	 safe	 use	 of	 ionizing	 radiation	 for	
diagnostic	 purposes	 or	 radiotherapy	 treatment.	 In	 this	 thesis,	 we	 evaluated	 in	 vitro	
radiosensitivity	 in	carriers	of	a	mutation	 in	DNA	damage	response	genes	by	means	of	 two	
different	assays.		
	
The	first	assay,	the	G2	micronucleus	assay,	is	a	cytogenetic	assay	in	which	MN	are	analyzed	in	
cells	 irradiated	 in	 the	 G2	 phase	 of	 the	 cell	 cycle.	 This	 assay	 was	 developed	 to	 evaluate	
radiosensitivity	 in	cells	with	a	heterozygous	BRCA1	or	BRCA2	mutation.	BRCA1	and	BRCA2	
have	a	function	in	homologous	recombination	(HR),	the	main	DNA	double	strand	break	repair	
pathway	activated	in	late	S	and	G2	phase	of	the	cell	cycle.	Furthermore,	BRCA1	is	also	involved	
in	 the	 G2/M	 cell	 cycle	 checkpoint.	 The	 G2	micronucleus	 assay	 allows	 evaluation	 of	 both	
functions	by	means	of	two	distinct	endpoints:	(1)	the	radiation-induced	micronucleus	yield,	
which	 reflects	 DNA	 double	 strand	 break	 repair	 capacity	 and	 (2)	 the	 G2/M	 checkpoint	
efficiency	ratio,	which	allows	evaluation	of	the	G2	arrest	capacity.		
	
Before	 applying	 the	 G2	 micronucleus	 assay	 on	 BRCA	 mutation	 carriers,	 the	 assay	 was	
validated	 in	 a	 patient	 with	 Ataxia	 Telangiectasia	 (AT).	 AT	 patients	 are	 characterized	 by	 a	
manifest	increased	radiosensitivity.	AT	patients	show	biallelic	inactivation	of	ATM,	involved	
in	both	DNA	double	strand	break	repair	by	means	of	HR	and	G2/M	checkpoint	activation.	We	
demonstrated	a	severely	increased	radiosensitivity	with	both	endpoints	when	applying	the	
G2	micronucleus	assay	in	lymphocytes	of	this	AT	patient.	In	lymphocytes	of	healthy	relatives	
with	 a	 heterozygous	 ATM	 mutation	 the	 radiosensitivity	 observed	 with	 this	 assay	 was	
intermediate	between	the	AT	patient	and	the	control	cohort.	
	
When	 applying	 the	 G2	micronucleus	 assay	 on	 lymphocytes	 of	 healthy	BRCA1/2	mutation	
carriers,	we	demonstrated	significantly	enhanced	radiation-induced	MN	yields	in	both	BRCA1	
and	BRCA2	 germline	mutation	 carriers,	 pointing	 to	 an	 impaired	DNA	double	 strand	break	
repair	capacity	in	both	groups.	Furthermore,	an	impaired	G2	arrest	capacity	was	observed	in	
BRCA1	mutation	carriers.	 In	healthy	relatives	who	did	not	 inherit	the	familial	mutation,	no	
enhanced	radiosensitivity	was	observed.	Although	a	significantly	enhanced	radiosensitivity	
was	demonstrated	for	the	cohort	of	BRCA1	and	BRCA2	mutation	carriers	compared	to	the	
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control	cohort,	individual	radiosensitivity	evaluation	was	less	straightforward	due	to	overlap	
in	 micronucleus	 yields	 between	 both	 cohorts.	 Therefore,	 a	 scoring	 system	 to	 evaluate	
individual	radiosensitivity	was	implemented.		
	
As	both	BRCA1	and	BRCA2	are	involved	in	HR,	we	evaluated	if	the	accumulation	of	RAD51,	a	
key	protein	involved	in	this	pathway,	at	the	double	strand	break	site	can	be	used	to	assess	HR	
functionality	 and	 radiosensitivity.	 To	 this	 end,	 a	 radiation-induced	 RAD51	 foci	 assay	 was	
optimized	 in	 a	 breast	 epithelial	 cell	 line	 (MCF10A)	 expressing	 ±50%	 reduced	 BRCA1	 and	
BRCA2	 protein	 levels,	 obtained	 by	 RNA	 interference.	 RAD51	 foci	 were	 analyzed	 in	 cells	
synchronized	in	S	phase	by	aphidicolin	as	HR	is	upregulated	during	this	phase	of	the	cell	cycle.	
We	demonstrated	significantly	reduced	RAD51	foci	formation,	and	thus	impaired	HR	capacity,	
in	 response	 to	 the	 induction	 of	 radiation-induced	 double	 strand	 breaks	 in	 the	 BRCA	
knockdown	 cells	 compared	 to	 control	 cells.	 As	 no	 overlap	 in	 RAD51	 foci	 distribution	 is	
observed	 between	 knockdown	 and	 control	 cells,	 we	 think	 that	 this	 assay	 could	 better	
differentiate	between	normal	cells	and	cells	with	a	heterozygous	BRCA1	or	BRCA2	mutation	
than	the	G2	micronucleus	assay.	This	will	be	further	explored	in	synchronized	lymphocytes	of	
heterozygous	germline	mutation	carriers.	
	
In	 addition	 to	 the	detection	of	 unequivocal	 deleterious	mutations	 in	BRCA1	 and	BRCA2,	 ,	
variants	of	unknown	clinical	significance	(VUS)	are	detected	during	diagnostic	screening.	The	
associated	breast	cancer	risk	is	unknown,	which	creates	a	challenge	for	genetic	counselling.	
mRNA	analysis	to	assess	variants	that	might	impair	proper	RNA	splicing,	a	highly	regulated	
process,	are	widely	used.	We	evaluated	the	outcome	at	cDNA	level	of	21	putative	splicing	
variants	in	BRCA1	and	BRCA2	and	demonstrated	aberrant	splicing	for	12	variants,	suggesting	
that	these	are	likely	pathogenic.	Furthermore,	we	demonstrated	that	in	silico	prediction	tools	
might	 assist	 in	 the	 evaluation	 of	 these	 putative	 splicing	 variants.	 However,	 further	
optimization	 is	 warranted	 to	 allow	 reliable	 application	 outside	 the	 highly	 conserved	
consensus	splice	sites.	
	
The	 results	 obtained	 in	 this	 thesis	may	 indicate	 that	 care	 should	be	 taken	when	 applying	
ionizing	 radiation	 for	 diagnostic	 or	 therapeutic	 purposes	 in	 individuals	 with	 a	 germline	
mutation	in	BRCA1	or	BRCA2	as	they	may	be	at	higher	risk	of	developing	radiation-induced	
breast	cancer.			
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SAMENVATTING	
Alle	tot	op	heden	gekende	borstkanker	predispositie	genen,	inclusief	BRCA1	en	BRCA2,	zijn	
betrokken	bij	 het	herstel	 van	DNA	 schade.	 Individuen	met	een	 kiembaan	mutatie	 in	deze	
genen	hebben	dus	niet	alleen	een	hoger	risico	op	het	ontwikkelen	van	borstkanker,	ze	worden	
mogelijks	 ook	 gekenmerkt	 door	 een	 verhoogde	 stralingsgevoeligheid	 gelinkt	 aan	
chromosomale	 instabiliteit;	 daardoor	 is	 de	 kans	 op	 het	 ontwikkelen	 van	 een	
stralingsgeïnduceerde	tumor	voor	deze	individuen	eventueel	groter.	Echter,	klinische	studies	
die	 carcinogenese	 evalueren	 in	 mutatie	 dragers	 of	 in	 vitro	 studies	 die	 de	 chromosomale	
stralingsgevoeligheid	 in	 de	 aanwezigheid	 van	 een	 mutatie	 nagaan	 na	 blootstelling	 aan	
ioniserende	 straling	 kunnen	 dit	 niet	 éénduidig	 bevestigen	 of	 weerleggen.	 Het	 is	 evenwel	
cruciaal	om	de	stralingsgevoeligheid	van	gezonde	weefsels	 in	mutatiedragers	te	evalueren	
voor	het	veilig	gebruik	van	ioniserende	straling	in	diagnostische	of	therapeutische	setting.	In	
deze	thesis	wordt	de	in	vitro	stralingsgevoeligheid	van	mutatiedragers	in	kaart	gebracht	aan	
de	hand	van	twee	verschillende	testen.		
	
De	 eerste	 test,	 de	G2	micronucleus	 assay,	 is	 een	 cytogenetische	 test	waarbij	micronuclei	
worden	 geanalyseerd	 in	 cellen	 bestraald	 in	 de	 G2	 fase	 van	 de	 celcyclus.	 Deze	 test	 werd	
ontwikkeld	 voor	 de	 evaluatie	 van	 de	 stralingsgevoeligheid	 in	 lymfocyten	 met	 een	
heterozygote,	inactiverende	mutatie	in	BRCA1	of	BRCA2.	BRCA1	en	BRCA2	zijn	immers	beiden	
betrokken	in	homologe	recombinatie	(HR),	een	belangrijke	pathway	voor	het	herstellen	van	
DNA	 dubbelstrengbreuken.	 Deze	 pathway	 is	 vooral	 actief	 in	 de	 late	 S	 en	 G2	 fase	 van	 de	
celcyclus.	 Daarenboven	 is	 BRCA1	 ook	 betrokken	 in	 de	 activatie	 van	 de	 G2/M	 celcyclus	
checkpoint.	De	G2	micronucleus	assay	maakt	het	mogelijk	om	beide	 functies	 te	evalueren	
door	middel	van	2	unieke	eindpunten:	(1)	de	stralingsgeïnduceerde	micronucleus	opbrengst,	
dewelke	 de	 DNA	 dubbelstrengbreuk	 herstelcapaciteit	 in	 kaart	 brengt	 en	 (2)	 de	 G2/M	
checkpoint	efficiëntie	ratio,	een	ratio	die	de	G2	arrest	capaciteit	reflecteert.		
	
Alvorens	deze	assay	werd	toegepast	op	lymfocyten	van	BRCA	mutatiedragers,	werd	de	assay	
gevalideerd	 in	 een	 patiënt	 met	 Ataxia	 Telangiectasia	 (AT).	 AT	 patiënten	 worden	 immers	
gekenmerkt	worden	door	een	uitgesproken	verhoogde	stralingsgevoeligheid.	Daarenboven	is	
ATM,	 het	 gen	 gemuteerd	 in	 deze	 patiënten,	 net	 als	BRCA1	 en	BRCA2,	 betrokken	 in	 DNA	
dubbelstrengbreuk	herstel	en	G2/M	checkpoint	activatie.	Bij	de	AT	patiënt	werd	een	sterk	
verhoogde	 stralingsgevoeligheid	 waargenomen	 met	 beide	 eindpunten	 van	 de	 G2	
micronucleus	assay.	Verder	werd	ook	vastgesteld	met	deze	 test	dat	 familieleden	met	een	
heterozygote	ATM	mutatie	 een	 verhoogde	 stralingsgevoeligheid	 vertoonden,	 intermediair	
tussen	de	AT	patiënt	en	de	controle	groep.		
	
Wanneer	 de	 G2	 micronucleus	 assay	 werd	 toegepast	 op	 lymfocyten	 van	 gezonde	 BRCA	
mutatiedragers,	 werd	 een	 significant	 verhoogde	 micronucleus	 waarde	 gedetecteerd,	 wat	
wijst	op	een	verminderde	DNA	dubbelstrengbreuk	herstel	capaciteit	voor	zowel	BRCA1	als	
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BRCA2	 mutatiedragers.	 Daarnaast,	 werd	 ook	 aangetoond	 dat	 lymfocyten	 van	 BRCA1	
mutatiedragers	een	verminderde	G2	arrest	capaciteit	bezitten.	Familieleden	die	de	familiale	
mutatie	 niet	 dragen,	 vertoonden	 geen	 verhoogde	 stralingsgevoeligheid.,	 Hoewel	 een	
significante	 verhoogde	 stralingsgevoeligheid	 voor	 mutatiedragers	 ten	 opzichte	 van	 een	
controlegroep	 werd	 bevestigd,	 bleek	 het	 niet	 mogelijk	 om	 op	 individueel	 niveau	
stralingsgevoeligheid	 bij	 BRCA1	 als	 BRCA2	 mutatiedragers	 eenduidig	 te	 evalueren	 door	
overlap	in	micronucleus	waarden	tussen	beide	groepen.	Daarom	werd	een	scoring	systeem	
ontwikkeld	voor	de	bepaling	van	de	individuele	stralingsgevoeligheid.		
	
Aangezien	zowel	BRCA1	en	BRCA2	betrokken	zijn	in	HR,	werd	nagegaan	of	de	accumulatie	van	
RAD51,	een	belangrijk	eiwit	voor	deze	pathway,	ter	hoogte	van	de	DNA	dubbelstrengbreuken	
gebruikt	kan	worden	om	HR	activatie	en	stralingsgevoeligheid	te	evalueren.	Hiervoor	werd	
een	 stralingsgeïnduceerde	 RAD51	 foci	 assay	 geoptimaliseerd	 in	 een	 borstepitheel	 cellijn	
(MCF10A)	 met	 ±50%	 gereduceerde	 BRCA1	 en	 BRCA2	 eiwit	 niveaus.	 RAD51	 foci	 werden	
geanalyseerd	 in	 cellen	 gesynchroniseerd	 in	 S	 fase.	 We	 demonstreerden	 dat	
gesynchroniseerde	MCF10A	cellen	met	een	gereduceerd	BRCA1	of	BRCA2	eiwit	niveau	een	
significant	lager	aantal	stralingsgeïnduceerde	RAD51	foci	vertoonden	in	vergelijking	met	de	
controle	cellijn,	wat	wijst	op	een	gedaalde	HR	functionaliteit.	Daarenboven	werd	geen	overlap	
geobserveerd	 tussen	 de	 distributies	 van	 RAD51	 foci	 in	 controle	 cellen	 en	 cellen	met	 een	
reductie	in	BRCA1	of	BRCA2	eiwit.	Dit	laat	vermoeden	dat	deze	assay	een	betere	discriminatie	
tussen	normale	cellen	en	cellen	met	een	heterozygote	BRCA1/2	mutatie	zou	kunnen	toelaten	
in	 vergelijking	 met	 de	 G2	 micronucleustest.	 Dit	 zal	 verder	 onderzocht	 worden	 in	
gesynchroniseerde	lymfocyten	van	heterozygote	kiembaan	mutatie	dragers.	
	
Naast	de	identificatie	van	pathogene	mutaties	in	BRCA1	en	BRCA2,	die	aanleiding	geven	tot	
een	verhoogd	risico	op	borstkanker,	worden	er	tijdens	mutatie	screening	ook	varianten	van	
ongekende	 significantie	 gedetecteerd.	 Aangezien	 het	 onduidelijk	 is	 of	 deze	 varianten	
geassocieerd	zijn	met	een	verhoogd	borstkanker	risico	wordt	adequate	genetische	counseling	
in	 personen	 met	 zo’n	 variant	 sterk	 bemoeilijkt.	 mRNA	 analyse	 om	 de	 impact	 van	 deze	
varianten	 op	 correcte	mRNA	 splicing,	 een	 sterk	 geconserveerd	 proces,	 na	 te	 gaan,	 is	 een	
strategie	 om	de	pathogeniciteit	 van	deze	 varianten	 te	 evalueren.	 In	 deze	 thesis	werd	het	
effect	op	cDNA	niveau	van	21	potentiële	splice	site	varianten	in	BRCA1	en	BRCA2	nagegaan.	
Voor	 12	 varianten	 werd	 aberrante	 splicing	 –	 en	 dus	 een	 potentieel	 pathogeen	 effect	 –	
bewezen.	Verder	toonden	we	aan	dat	in	silico	predictie	tools,	verdere	optimalisatie	vergen	
om	deze	adequaat	te	kunnen	aanwenden	om	het	effect	op	splicing	van	varianten	gelegen	
buiten	de	sterk	geconserveerde	splice	sites	adequaat	te	kunnen	voorspellen.		
	
De	 resultaten	 voorgesteld	 in	 deze	 thesis	 tonen	 aan	 dat	 er	 best	 omzichtig	 wordt	
omgesprongen	met	de	blootstelling	van	BRCA1	en	BRCA2	mutatiedragers	aan	 ioniserende	
straling	voor	diagnostische	en	therapeutische	doeleinden.	
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ACRONYMS	
53BP1	 	 tumor	suppressor	p53-binding	protein	1	
	
AA	 	 amino	acid	
alt-EJ	 	 alternative	end	joining	
AT	 	 ataxia	telangiectasia	
ATM	 	 ataxia	telangiectasia	mutated	
ATR	 	 ataxia	telangiectasia	related	
	
b-NHEJ	 	 backup	non-homologous	end	joining	
BARD1	 	 BRCA1	associated	RING	domain	1	
BER	 	 base	excision	repair	
BIR	 	 break-induced	replication	
BLM	 	 bloom	syndrome	protein	
BN	 	 binucleated	
BRCA1	 	 breast	cancer	early	onset	1	
BRCA2	 	 breast	cancer	early	onset	2	
	
c-NHEJ	 	 classical	non-homologous	end	joining	
CDC	 	 cell-division	cycle	protein	
CDK	 	 cyclin	dependent	kinase	
cDNA	 	 complementary	DNA	
CI	 	 confidence	interval	
CHEK2	 	 checkpoint	kinase	2	(gene)	
CHK2	 	 checkpoint	kinase	2	(protein)	
CtIP	 	 ctPB-interacting	protein	
Cyto	B	 	 cytochalasin	B	
	
DDR	 	 DNA	damage	response	
DNA	 	 deocyribonucleic	acid	
DNA-PKcs	 DNA-dependent	protein	kinase,	catalytic	subunit	
DSB	 	 double	strand	break	
DSBR	 	 double	strand	break	repair	
DSE	 	 single-ended	DSB	
	
EMA	 	 European	Medicines	Agency	
ER	 	 estrogen	receptor	
ERR	 	 excess	relative	risk	
ESE	 	 exonic	splicing	enhancer	 	
ESS	 	 exonic	splicing	silencer	
Exo	 	 exonuclease	
	
FA	 	 fanconi	anemia	
FANC	 	 fanconi	anemia	complementary	group	
FDA	 	 American	food	and	drugs	administration	
FISH	 	 fluorescent	in	situ	hybridization		
	
Gy	 	 gray	
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H2AX	 	 H2A	histone	family	member	X	
HER2	 	 human	epidermal	growth	factor	receptor	type	2	
HR	 	 homologous	recombination	
	
IARC	 	 International	Agency	for	Research	on	Cancer	
IR	 	 Ionizing	Radiation	
	
KAP	 	 KRAB-associated	protein	1	
KCE	 	 Federaal	Kenniscentrum	voor	de	Gezondheid	 	
kDa	 	 kilo	dalton	
kV	 	 kilo	volt	
	
LC	 	 lethal	concentration	
LCL	 	 lymphoblastoid	cell	line	
LET	 	 linear	energy	transfer	
LNT	 	 linear	no	treshold	
LSS	 	 life	span	study	
	
M/I	 	 mortality	to	incidence	ratio	
MDC1	 	 mediater	of	DNA	damage	checkpoint	protein	1	
MMEJ	 	 micro-homology	end	joining	
MN	 	 micronucleus	
MOMP	 	 mitochondrial	outer	membrane	
MRI	 	 magnetic	resonance	imaging	
MRN	 	 Mre11-RAD50-NBS1	complex	
mRNA	 	 messenger	RNA	
	
NAD	 	 nicotinamide	adenine	dinucleotide	
NBS	 	 nibrin	
NER	 	 nucleotide	excision	repair	
NMD	 	 nonsense-mediated	decay	
Nt	 	 nucleotide	
	
P16	 	 tumor	protein	16	
P21	 	 tumor	protein	21	
P53	 	 tumor	protein	53	
PALB2	 	 partner	and	localizer	of	BRCA2	
PARP	 	 poly	ADP	ribose	polymerase		
PARPi	 	 PARP	inhibition	
PARylation	 poly	ADP	ribosylation	
PAXX	 	 paralog	of	XRCC4	and	XLF	
PHA	 	 phytohaemaglutinin	 	
(DNA-)	POL…	 (DNA)	polymerase	…	
PR	 	 progesterone	receptor	
Pre-mRNA	 primary	mRNA	
PTM	 	 posttranslational	modification	
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RB	 	 retinoblastoma	protein	
RBE	 	 relative	biological	effectiveness	
RC	 	 replication	complex	
RIP	 	 receptor	interacting	protein	
RIND	 	 radiosensitivity	indicator	
RNA	 	 ribonucleic	acid	
RPA	 	 replication	protein	A	
RR	 	 relative	risk	
RS	 	 radiosensitivity	
	
snRNP	 	 small	nuclear	ribonucleoproteins	
SDSA	 	 synthesis-dependent	strand	annealing	
SSA	 	 single	strand	annealing	
SSB	 	 single	strand	break	
ssDNa	 	 single	stranded	DNA	
Sv	 	 sievert	
	
Tdt		 	 terminal	deoxynucleotidyl	transferase	
TMEJ	 	 theta-mediated	end	joining	
TNBC	 	 triple	negative	breast	cancer	
TNM	 	 tumor	node	metastasis	grading	system	
TS	 	 template	switching	
	
UZ	Gent	 Universitair	Ziekenhuis	Gent	(University	Hospital	Ghent)	
	
VUS	 	 variants	of	unknown	clinical	significance	
	
WHO	 	 World	Health	Organisation	
WSR	 	 world	standard	population;	age-standardized	rate	
	
XLF	 	 XRCC4-like	factor	
XRCC	 	 X-ray	repair	cross-complementing	protei
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1 BREAST	CANCER	
1.1 Breast	tissue	and	breast	cancer	
The	breast	consists	predominantly	of	adipose	tissue,	connective	tissue	and	mammary	glands.	
However,	 composition	 evolves	 pending	 on	 age	 and	 hormones.	 The	mammary	 glands	 are	
modified	sweat	glands	present	 in	both	sexes	but	only	functional	 in	 lactating	females.	Each	
gland	 consists	 of	 15	 to	 25	 lobes	 and	 each	 lobe	 consists	 of	 smaller	 units,	 called	 lobules	
containing	 alveoli	 (see	 Figure	 1.1).	 These	 alveoli	 are	 lined	with	 cuboidal	 epithelium	 cells,	
capable	of	producing	milk.	Furthermore,	the	breast	tissue	holds	a	system	of	 lymph	vessels	
which	drain	into	the	axillary	lymph	nodes	in	the	armpit	(see	Figure	1.1)	(Marieb	et	al.	2008).		
	
	
Figure	1.1:	Breast	anatomy	©Mayo	foundation	
	
Breast	 cancer	 is	 usually	 derived	 from	 the	 epithelial	 cells	 lining	 the	 ducts	 and	 lobules.	
Approximately	85%	of	all	 carcinoma	arise	 in	 the	ducts,	 referred	 to	as	ductal	 carcinoma.	A	
minority	is	formed	in	the	lobule	itself	(lobular	carcinoma).	Furthermore,	the	carcinoma	can	
remain	in	situ,	meaning	that	it	remains	restricted	to	the	particular	tissue	compartment.	The	
tumor	can	also	penetrate	the	surrounding	tissue	(invasive	carcinoma),	which	can	eventually	
lead	 to	 invasion	of	 the	 lymph	nodes	and	metastasis	 (Marieb	et	al.	2008).	Breast	 cancer	 is	
divided	in	five	stages,	using	the	Tumor	Node	Metastasis	(TNM)	system.	This	staging	is	based	
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on	 three	 characteristics:	 the	 tumor	 size	 (T),	 the	 invasion	 of	 the	 lymph	nodes	 (N)	 and	 the	
presence	of	metastases	 (M)	 (Gannon	et	al.	 2013;	 Senkus	et	 al.	 2015).	Additionally,	breast	
tumors	can	be	divided	in	five	categories,	depending	on	their	receptor	status	(Gannon	et	al.	
2013).	Assessment	of	estrogen	receptor	(ER),	progesterone	receptor	(PR)	and	HER2	provides	
prognostic	data	and	guides	treatment	selection	(see	chapter	1.6:	Breast	cancer	treatment).	If	
the	tumor	cells	do	not	express	any	of	these	three	receptors,	they	are	referred	to	as	being	
triple-negative	(Gannon	et	al.	2013).	Triple	negative	breast	cancer	(TNBC)	accounts	for	20%	
of	all	breast	cancers	worldwide	(Mirzania	2016).	
	
1.2 Incidence	and	mortality	–	Alarming	figures		
Breast	cancer	is	worldwide	the	most	common	cancer	and	in	the	Western	world,	one	in	eight	
females	will	develop	breast	cancer	in	their	lifetime	(WHO).	In	Belgium,	breast	cancer	is	the	
most	frequent	tumor	in	females	with	35%	of	all	female	malignancies	developing	in	the	breast.	
In	2013,	10.695	females	were	diagnosed	with	breast	cancer	(see	Figure	1.2).		
	
	
Figure	 1.2:	 Incidence	 (2013)	 and	 mortality	 (2012)	 for	 the	 15	 most	 frequently	 diagnosed	
malignancies	(excluding	non-melanoma	skin	cancer)	in	males	and	females	in	Belgium	(Belgian	
Cancer	Registry	2015).		
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Belgium	has	the	highest	incidence	of	female	breast	cancer	of	all	European	countries,	with	an	
age	 standardized	 rate	 of	 109,8	 per	 100	 000	 (see	 Figure	 1.3).	Moreover,	 Belgium	 has	 the	
highest	rate	of	breast	cancer	worldwide	(WCRF	2012).		
	
	
Figure	 1.3:	 Comparison	 of	 age-standardized	 breast	 cancer	 incidence	 rates	 using	 the	World	
Standard	Population	(WSR)	(per	100	000)	in	Belgium	and	a	selection	of	European	registry	data	
(Belgian	Cancer	Registry	2015).	
	
The	risk	pattern	for	breast	cancer	is	age	related,	with	the	highest	incidence	observed	in	the	
age	group	50-69	years	(see	Figure	1.4).		
	
	
Figure	1.4:	Age-specific	incidence	breast	cancer	rates	(per	100	000)	in	females	in	Belgium	2009-
2013	(Belgian	Cancer	Registry	2015).	
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Breast	cancer	is	responsible	for	20%	of	cancer	deaths	in	females.	In	2012,	2.312	women	died	
as	a	consequence	of	breast	cancer	in	Belgium	(see	Figure	1.2).	Mortality	to	incidence	(M/I)	
ratio	is	21%.	This	is	relatively	low	which	may	be	due	to	intensified	screening	programs	(see	
chapter	 1.5:	Breast	 cancer	 screening),	 as	 reflected	 in	 the	 fact	 that	 the	majority	of	 female	
breast	cancer	(up	to	80%)	is	diagnosed	in	the	prognostic	more	favorable	stages	I	and	II.	 In	
addition,	extensive	treatment	options	result	in	a	high	5-year	relative	survival	rate	of	89,6%.	
For	comparison,	the	M/I	ratio	for	the	third	most	common	cancer	in	females,	lung	cancer,	is	
77%	and	the	5-year	relative	survival	rate	is	merely	20%	(Belgian	Cancer	Registry	2015).		
	
Breast	cancer	in	males	is	very	rare	with	only	83	new	diagnoses	in	2013	and	22	deaths	in	2012	
in	 Belgium.	 Prognosis	 is	 more	 or	 less	 comparable	 to	 female	 breast	 cancer	 with	 a	 5-year	
relative	survival	of	83.1%	(Belgian	Cancer	Registry	2015).		
	
1.3 Risk	factors	
Different	factors	are	known	to	increase	the	risk	of	breast	cancer.	The	best	known	risk	factor,	
besides	gender,	is	having	a	familial	history	of	breast	cancer.	Breast	cancer	risk	increases	with	
the	number	of	affected	relatives	and	decreases	with	increasing	age	of	diagnosis.	Twin	studies	
estimate	the	effect	of	hereditary	 factors	 to	be	around	31%	for	breast	cancer	 (Mucci	et	al.	
2016).	However,	a	mere	5	to	10	%	of	all	breast	cancers	have	a	strong	inherited	background	
and	only	a	fraction	of	all	breast	cancers	(5	%)	are	due	to	high	penetrance	genes,	referred	to	
as	“breast	cancer	genes”,	discussed	in	the	next	chapter	1.4:	Hereditary	breast	cancer	(Lalloo	
&	Evans	2012).	
	
Another	risk	factor	is	breast	density.	Breast	density	is	evaluated	by	means	of	mammography	
imaging	and	scored	according	to	different	systems	(e.g.	Wolfe	grade	and	BIRADS).	Basically,	
dense	 breasts	 contain	 a	 high	 percentage	 of	 glandular	 and	 connective	 tissue	whereas	 less	
dense	breast	contain	a	higher	portion	of	fat.	The	meta-analysis	by	Mccormack	demonstrated	
that	increasing	breast	density	is	associated	with	an	increased	breast	cancer	risk,	which	is	as	
high	 as	 4.64-fold	 (95%	 confidence	 interval	 (CI):	 3.64	 –	 5.91)	 for	 the	 most	 dense	 (>75%	
glandular	and	connective	tissue)	compared	to	the	least	dense	category	(<5%	glandular	and	
connective	tissue)	(Mccormack	et	al.	2006).			
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A	couple	of	life	style	related	risk	factors	have	also	been	identified.	One	of	those	factors	is	the	
use	of	alcohol.	The	International	Agency	for	Research	on	Cancer	(IARC)	classifies	alcohol	as	a	
group	1	 carcinogen	 for	 breast	 and	other	 types	of	 cancer,	meaning	 that	 there	 is	 sufficient	
evidence	 that	 the	 compound	 is	 carcinogenic	 to	humans	 (IARC	2016).	Repetitive	moderate	
(approx.	one	drink/day)	or	high	(>	one	drink/day)	alcohol	intake	confers	in	an	elevated	risk	of	
breast	 cancer	 (Relative	 risk	 (RR)	 =	 1.3	 (95%	CI:	 1.1	 –	 1.7)	 and	 RR	 =	 1.6	 (95%CI:	 1.3	 –	 2.0	
respectively))	(Rice	et	al.	2016).	Another	life	style	factor	influencing	breast	cancer	risk	is	body	
weight.	Interestingly,	childhood	and	adolescent	obesity	is	associated	with	a	lower	pre-	and	
postmenopausal	 breast	 cancer	 risk	 (WCRF/AICR	 2007;	 Rice	 et	 al.	 2016).	 On	 the	 contrary,	
postmenopausal	weight	gain	is	associated	with	an	increased	breast	cancer	risk	at	a	ratio	of	
8%	increase	per	5	kg/m2	weight	gain	(WCRF/AICR	2007).		
	
Another	well	documented	risk	factor	is	the	lifetime	exposure	to	estrogen.	An	early	menarche,	
late	natural	menopause,	late	first	pregnancy	(after	the	age	of	30)	or	no	child	bearing	result	in	
an	 increased	 breast	 cancer	 risk	 (WCRF/AICR	 2007).	 Furthermore	 exposure	 to	 exogenous	
hormones,	by	means	of	oral	contraceptives	and	post-menopausal	hormonal	therapy	(both	
estrogen	and/or	progestin),	is	also	associated	with	an	increased	risk	of	breast	cancer	(e.g.	RR	
for	oral	contraceptives	=	1.33	(95%CI=	1.03-1.73))	(Rice	et	al.	2016).		
	
A	 last	well	documented	risk	 factor	–	also	classified	as	group	1	carcinogen	–	 is	exposure	to	
ionizing	radiation	(IARC	2016).	A	valuable	cohort	to	evaluate	the	effect	of	exposure	to	ionizing	
radiation	are	the	atomic	bomb	survivors.	The	Hiroshima	and	Nagasaki	survivors	and	a	fixed	
group	of	non-exposed	Japanese	controls	are	combined	in	the	Life	Span	Study	(LSS)	to	evaluate	
late	 health	 effects	 of	 ionizing	 radiation.	 The	 cohort	 follow-up	 between	 1950	 to	 2003,	
demonstrated	a	significant	increase	in	mortality	in	both	females	and	males	as	a	consequence	
of	breast	cancer	with	an	excess	relative	risk	(ERR)	of	1.5	(95%	CI	=	0.91	–	2.3)	and	9.1	(95%Ci	
=	0.51	-128)	per	gray	(Gy)	respectively	(Ozasa	et	al.	2012).	In	addition	to	the	Atomic	bomb	
survivors,	a	lot	can	be	learned	from	follow-up	of	individuals	exposed	to	ionizing	radiation	in	a	
medical	 setting.	 After	 all,	 these	 studies	 provide	 data	 in	 a	 non-Japanese	 cohort	 and	
demonstrate	the	effect	of	various	organs	receiving	various	doses.	Furthermore,	organ	specific	
doses	 can	 be	 as	 high	 as	 50Gy	 or	 more.	 Exposure	 to	 ionizing	 radiation	 from	 medical	
applications,	e.g.	X-ray	based	chest	fluoroscopies,	also	result	 in	an	increased	breast	cancer	
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incidence	as	reviewed	by	Gilbert	(2009).	However,	a	clear	influence	of	age	at	exposure	could	
be	 distinguished.	 Exposure	 to	 ionizing	 radiation	 at	 a	 younger	 age	 implies	 a	 higher	 risk	 of	
radiation-induced	breast	cancer	compared	to	exposures	later	in	life	(e.g.	after	the	age	of	50)	
(Gilbert	2009).		
	
1.4 	Hereditary	breast	cancer	due	to	germline	mutation	in	“breast	cancer	genes”	
By	far	the	strongest	risk	factor	is	the	genetic	predisposition.	To	date,	several	genes	have	been	
identified	as	“genes	associated	with	an	increased	risk	for	breast	cancer”.	Germline	mutations	
in	these	genes	result	in	a	raised	breast	cancer	risk	compared	to	the	population	risk,	which	is	
approximately	13%	(World	Health	Organization).	The	level	of	this	increase	is	inherent	to	the	
gene	in	which	the	germline	mutation	occurred	and,	in	some	particular	cases,	the	mutation	
itself.	The	best	known	highly	penetrant	breast	cancer	genes	are	BRCA1	and	BRCA2	(breast	
cancer	 susceptibility	 gene	 1	 and	 2).	 Mutations	 in	 these	 genes	 are	 rare,	 but	 are	 highly	
penetrant	(see	Figure	1.5)	(Foulkes	&	Shuen	2013).	More	recently,	PALB2	was	identified	as	a	
hereditary	breast	cancer	gene	(Antoniou	et	al.	2014).	 
Germline	mutations	in	other	genes	were	shown	to	be	associated	with	a	moderate	increase	of	
breast	cancer	risk	such	as	Ataxia	Telangiectasia	mutated	(ATM)	and	CHEK2	(see	Figure	1.5)	
(Lalloo	&	Evans	2012).	Finally,	a	high	number	of	low-risk	common	alleles	have	been	identified	
through	genome	wide	association	studies	(see	Figure	1.5)	(Figueroa	et	al.	2011;	Darabi	et	al.	
2016;	Michailidou	et	al.	2014).	
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Figure	1.5:		Genetic	architecture	of	cancer	risk:	relative	risk	(x-axis)	compared	to	minor	allele	
frequency	(y-axis)	for	breast	cancer.	Three	distinct	groups	can	be	observed,	see	text	for	further	
details	(www.cancer.gov/	2016).		
	
1.4.1 High	risk	breast	cancer	genes	
1.4.1.1 BRCA1	
BReast	CAncer	1	(BRCA1)	was	the	first	gene	in	which	DNA	alterations	were	associated	with	an	
increased	risk	of	breast	cancer.	It	was	discovered	in	1990,	when	Hall	et	al.	linked	the	gene	on	
chromosome	17q21	with	inherited	breast	cancer	in	families	with	early-onset	disease	(Hall	et	
al.	1990).	In	1994,	the	gene	was	cloned	for	the	first	time	(Miki	et	al.	1994).		
	
BRCA1	 is	a	large	gene	containing	24	exons.	It	codes	for	a	2843	amino	acid	(AA)	or	220	kDa	
protein.	It	 is	a	pleiotropic	DNA	damage	response	protein	important	for	DNA	double	strand	
break	(DSB)	repair	and	cell	cycle	checkpoint	activation.	It	has	several	functional	domains	and	
numerous	binding	partners	to	fulfill	its	many	functions	as	a	care	taker	gene	(Foulkes	&	Shuen	
2013;	Roy	et	al.	2012).	An	overview	of	the	functional	domains,	binding	partners	and	functions	
is	provided	in	Figure	1.6	and	Table	I.	The	role	of	BRCA1	in	the	cell	cycle	checkpoints	and	DSB	
repair	will	be	discussed	in	detail	in	chapter	3:	DNA	damage	response.		
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Figure	 1.6:	 Overview	 of	 the	 functional	 domains	 of	 BRCA1	 (a)	 and	 BRCA2	 (b)	 and	 their	
interaction	partners	(Roy	et	al.	2012).	
	
Table	I:	Overview	of	the	functions,	functional	domains	and	interaction	partners	of	BRCA1	and	
BRCA2	(Roy	et	al.	2012).	
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1.4.1.2 BRCA2	
BReast	CAncer	2	(BRCA2)	was	discovered	in	1994	by	Wooster	et	al.	and	cloned	by	the	same	
research	group	a	year	later	(Wooster	et	al.	1994;	Wooster	et	al.	1995).	Mutations	in	BRCA2	
account	for	approximately	10%	of	all	familial	breast	cancers	(Lalloo	&	Evans	2012).		
	
BRCA2	is	a	very	large	protein	containing	3416	AA	(390kDa)	for	which	the	gene	is	located	on	
chromosome	 13q13	 (Strachan	 &	 Read	 2011).	 Compared	 to	 BRCA1,	 BRCA2	 holds	 less	
preserved	domains,	despite	being	a	larger	protein.	In	addition,	BRCA2	has	fewer	interaction	
partners	and	 is	predominantly	 involved	 in	homologous	 recombination	 (HR),	a	specific	DSB	
repair	pathway	(Roy	et	al.	2012;	Narod	&	Foulkes	2004).	An	overview	of	functional	domains	
and	 interaction	partners	 is	 provided	 in	 Figure	1.6	 and	Table	 I.	 The	 role	of	BRCA2	 in	HR	 is	
discussed	in	chapter	3:	DNA	damage	response.		
	
1.4.1.3 PALB2	
A	more	recently	discovered	‘breast	cancer	gene’	 is	PALB2	(partner	and	localizer	of	BRCA2)	
(Antoniou	et	al.	2014).	PALB2	is	located	on	chromosome	16	and	encodes	a	131kDa	(1186	AA)	
protein	 containing	 two	 distinct	 functional	 domains	 being	 an	 amino-terminal	 coiled-coil	
structure	 and	 a	 carboxy-terminal	 WD40-repeat	 domain.	 The	 former	 domain	 enables	
interaction	with	BRCA1	while	the	latter	is	necessary	for	BRCA2	binding.	Via	these	interactions,	
PALB2	mediates	HR-specific	DSB	repair	(see	chapter	3:	DNA	damage	response)	(Zhang	et	al.	
2009;	Park	et	al.	2014).		
	
1.4.1.4 Associated	risks		
Mutations	 in	BRCA1	account	 for	7	 to	10%	of	 familial	breast	cancer	 (Lalloo	&	Evans	2012).	
Heterozygous	pathogenic	mutations	in	BRCA1	result	in	a	lifetime	breast	cancer	risk	of	70	to	
80%.	Furthermore,	BRCA1	mutation	carriers	are	at	high	risk	of	ovarian	cancer	with	a	lifetime	
risk	up	to	50%	(Roy	et	al.	2012).	Individual	variations	in	breast	or	ovarian	cancer	incidence	in	
mutation	 carriers	 can	 be	 explained	 by	 differences	 in	 genotype,	 genetic	 modifiers	 and	
environmental	 factors	 (Levy-Lahad	 &	 Friedman	 2007).	 BRCA1	 mutation	 associated	 breast	
cancers	are	characterized	by	an	early	age	of	onset,	originate	predominantly	from	the	duct	
epithelial	cells	and	are	defective	for	HR.	Furthermore,	the	percentage	of	triple	negative	breast	
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cancers	is	considerably	higher	in	mutation	carriers	(71%)	than	in	the	general	population	(17%)	
(Peshkin	et	al.	2010)	and	in	approximately	10%	of		patients	with	triple	negative	breast	cancer,	
a	germline	BRCA1	was	identified	(Severson	et	al.	2015).		
	
Heterozygous	pathogenic	mutations	in	BRCA2	result	in	a	life	time	breast	cancer	risk	of	50	to	
60%.	Furthermore,	mutations	in	BRCA2	incline	a	life	time	ovarian	cancer	risk	of	up	to	30%.	
Again,	 individual	variation	 is	observed	which	can	be	explained	by	differences	 in	genotype,	
genetic	modifiers	and	environmental	background.	For	example,	mutations	in	the	central	part	
of	the	gene	(nucleotide	c.3035	–	c.6629	of	exon	11)	are	linked	with	a	high	ovarian	cancer	risk	
(RR=1.88;	95%	CI:	1.08-3.33)	(Levy-Lahad	&	Friedman	2007).	BRCA2	mutations	are	also	linked	
with	 a	higher	 than	average	male	breast	 cancer	 risk	demonstrated	by	 a	 cumulative	 risk	of	
approximately	7%	(Tai	et	al.	2007).	The	percentage	triple	negative	breast	cancers	in	BRCA2	
mutation	carriers	is	comparable	to	the	population	incidence.	Furthermore,	lobular	cancer	is	
as	frequent	as	in	sporadic	breast	cancers	(Peshkin	et	al.	2010;	Roy	et	al.	2012).			
	
Heterozygous	loss	of	function	mutations	in	PALB2	result	in	an	increased	breast	cancer	risk.	
The	cumulative	risk	of	 female	mutation	carriers	 is	 just	short	of	50%	by	the	age	of	70.	This	
increase	 is	 comparable	 to	 that	 associated	with	mutation	 in	BRCA2.	However,	mutation	 in	
PALB2	are	less	frequent	and	so	far,	no	link	with	ovarian	cancer	is	reported	(Antoniou	et	al.	
2014;	Zhang	et	al.	2009;	Kleibl	&	Kristensen	2016;	Flanagan	et	al.	2015).	
	
Individuals	harboring	a	germline	mutation	are	not	only	at	high	risk,	they	also	tend	to	develop	
breast	cancer	at	younger	age	compared	to	the	control	cohort.	Firstly	described	by	Knudson	
in	retinoblastoma,	the	formation	of	the	tumor	is	based	on	two	mutational	events.	Given	that	
the	first	event	is	already	present	in	mutation	carriers,	only	a	second	event	is	needed	to	induce	
carcinogenesis	(Knudson	1971).	Moreover,	for	these	breast	cancer	predisposing	genes,	the	
first	event	occurs	in	key	DSB	repair	genes,	known	as	tumor	suppressor	genes.	Previous	studies	
have	demonstrated	 that	 BRCA1	 and	BRCA2	haploinsufficiency	 is	 sufficient	 to	 compromise	
genome	 instability.	 This	 facilitates	 additional	 genetic	 alterations	 and	 accounts	 for	 the	
increased	risk	of	cancer	promoting	mutations	(Cousineau	&	Belmaaza	2014).	This	accelerates	
breast	carcinogenesis,	resulting	in	a	young	age	at	time	of	diagnosis	and	an	overall	high	lifetime	
cancer	 risk	 (Konishi	et	al.	2011;	Venkitaraman	2014;	Nikkilä	et	al.	2013;	Salmena	&	Narod	
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2012;	Cousineau	&	Belmaaza	2014).	The	inactivation	of	the	wild	type	allele	is	not	necessarily	
due	to	a	second	mutation	but	might	also	be	 the	result	of	alternative	mechanisms	such	as	
promotor	methylation	and	miRNA	deregulation	(Luzi	et	al.	2012;	Pronina	et	al.	2017).	
	
Biallelic	germline	mutation	in	either	three	genes	result	in	fanconi	anemia.	Fanconi	anemia	is	
an	autosomal	recessive	disorder	caused	by	mutation	in	several	genes,	called	FANC	genes,	to	
date	mutation	 in	19	different	genes	have	been	described.	The	majority	of	their	respective	
proteins	form	a	core	protein,	which	is	necessary	for	DNA	crosslink	repair.	Other	proteins,	from	
genes	such	as	FANCS	(BRCA1),	FANCD1	(BRCA2)	and	FANCN	(PALB2),	are	important	for	DNA	
double	strand	break	(DSB)	repair	through	HR.	Both	repair	pathways	interact	and	mutations	in	
these	genes	lead	to	impaired	DNA	damage	repair	and	a	diverse	phenotype,	including	short	
stature,	 developmental	 delay	 and	 cancer.	 Identification	 of	 this	 disorder	 is	 performed	 by	
mutation	 analyses	 and	 by	 detection	 of	 cross	 linking	 sensitivity	 (e.g.	 mytomycin	 C	 assay)	
(Sawyer	et	al.	2015;	Strachan	&	Read	2011;	Dong	et	al.	2015).	
	
1.4.1.5 Risk	reducing	surgeries	in	high	risk	individuals	
Woman	at	high	risk	because	of	the	presence	of	a	mutation	in	BRCA1	or	BRCA2	may	consider	
reducing	this	risk	by	prophylactic	mastectomy	and/or	salpingo-oophorectomy	(Domchek	et	
al.	2010).	Prophylactic	mastectomy	reduces	the	risk	of	breast	cancer	by	90%	or	more.	Risk	
reducing	salpingo-oophorectomy	is	usually	performed	between	the	ages	of	35	to	40	and	after	
childbearing	has	been	completed.	This	results	in	a	reduction	of	ovarian	cancer	risk	of	80%	in	
BRCA1	 and	 BRCA2	 carriers.	 Furthermore,	 the	 salpingo-oophorectomy	 might	 also	 reduce	
breast	cancer	risk	by	approximately	50%	when	performed	before	menopause	(Longo	et	al.	
2016).	
	
A	couple	of	years	ago,	actress	Angelina	Jolie	–	carrier	of	a	BRCA1	mutation	–	wrote	an	opinion	
piece	 in	 the	 New	 York	 Times	 titled	 ‘my	 medical	 choice’	 about	 her	 choice	 to	 perform	 a	
mastectomy,	thereby	creating	awareness	for	genetic	testing	and	the	surgery	(Jolie	2013).	
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1.4.2 Moderate	risk	genes	-	ATM	as	an	example		
Over	the	years,	numerous	intermediate	risk	genes	(see	Figure	1.5)	have	been	identified	
including	CHEK2	and	ATM	(Lalloo	&	Evans	2012).	Furthermore,	specific	mutation	in	high	risk	
genes	such	as	R1699Q	in	BRCA1	were	classified	as	moderate	penetrant	(Spurdle	et	al.	2012).			
	
In	 the	 frame	 of	 this	 thesis,	ATM	will	 be	 discussed	 elaborately.	ATM	 (ataxia	 telangiectasia	
mutated)	 is	 located	 on	 chromosome	 11q23	 and	 encodes	 a	 3056	 AA	 long	 (350kDa)	
serine/threonine	kinase	responsible	for	the	detection	and	signaling	of	DSB	(Taylor	et	al.	2015;	
Strachan	&	Read	2011).		
	
Heterozygous	mutations	in	ATM,	a	known	DNA	damage	response	gene,	result	in	an	increase	
in	breast	cancer	risk.	Estimated	relative	breast	cancer	risk	for	individuals	with	a	heterozygous	
ATM	mutation	vary	across	different	studies.	Van	Os	et	al.	combined	all	published	data	in	a	
recent	 review.	 The	 lifetime	 risk	 of	 developing	 breast	 cancer	 for	 female	 carriers	 is	 38%,	
compared	 to	 13%	 in	 the	 general	 population.	 Furthermore,	 for	 young	 female	 carriers,	 the	
cumulative	risk	reaches	16%	at	the	age	of	50,	compared	to	2.3%	in	an	age	matched	general	
population.		One	particular	ATM	mutation,	c.7271T>G,	results	in	an	estimated	lifetime	breast	
cancer	risk	of	up	to	69%	in	heterozygous	carriers.	This	is	comparable	to	the	risk	of	BRCA1	and	
BRCA2	mutation	carriers.	Furthermore,	ATM	carriers	are	also	at	higher	risk	for	cancers	of	the	
digestive	tract	(van	Os	et	al.	2016).		
	
Ataxia	Telangiectasia	
Biallelic	inactivation	of	this	gene	result	in	Ataxia	Telangiectasia	(AT).	AT	is	a	rare	autosomal	
recessive	 disorder.	 This	 neurodegenerative	 disease	with	 early	 onset	 is	 characterized	 by	 a	
range	of	neurological	signs	including	progressive	cerebellar	ataxia,	oculomotor	abnormalities	
and	cognitive	dysfunction.	The	syndrome	is	furthermore	associated	with	multiple	symptoms	
including	immunodeficiency,	an	extreme	radiosensitivity	due	to	DSB	repair	defects	and	cancer	
predisposition,	 predominantly	 from	 lymphoid	origin	 (Teive	 et	 al.	 2015;	 Taylor	 et	 al.	 2015;	
Kühne	et	al.	2004).	AT	is	also	linked	with	an	increased	serum	 a-fetoprotein	level,	which	is	
used	in	diagnostic	testing	(Schieving	et	al.	2014).	Incidence	is	estimated	to	be	between	one	in	
40	000	 to	one	 in	200	000	births	depending	on	 the	population	 (Shiloh	&	Lederman	2017).	
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Unfortunately,	 no	 cure	 is	 available.	 Current	 treatment	 is	 limited	 to	 a	 multidisciplinary,	
symptom-based	approach	(Lavin	et	al.	2007).	
	
AT	presents	as	a	very	heterogeneous	disease.	Usually,	it	is	diagnosed	in	its	classical,	severe	
form,	due	to	frameshift	mutations	in	ATM	and	a	complete	loss	of	ATM	protein.	This	is	linked	
with	a	younger	age	at	time	of	diagnosis	(median	age	=	5.9	years)	and	a	young	mean	survival	
age	(median	age	=	15.9	years)	However,	patients	with	at	least	one	missense	mutation	or	a	
leaky	splice	site	mutation,	resulting	in	a	residual	level	of	ATM	protein,	present	a	milder	variant	
of	the	disease.	These	patients	are	typically	a	few	years	older	at	time	of	diagnosis	(median	age	
=	8.0	years),	tend	to	live	longer	(median	age	=	20.4	years)	and	develop	tumors	at	a	later	age	
compared	to	patients	with	a	complete	absence	of	ATM.	Several	mild	founder	mutations	have	
been	reported	in	Europe	(Taylor	et	al.	2015;	Micol	et	al.	2011).		
	
1.4.3 Breast	cancer	gene	panels	
“Multiple	 sequencing	 panels,	 or	 gene	 panels,	 are	 an	 important	 tool	 to	 evaluate	 genetic	
variation	that	may	be	associated	with	an	 increased	risk	of	breast	cancer.	Given	the	recent	
efforts	 to	 improve	 its	 cost-effectiveness,	 the	 use	 has	 grown	 exponentially.	 However,	 their	
clinical	validity	–	whether	the	test	result	correctly	predicts	the	high	cancer	risk	–	and	clinical	
utility	–	whether	the	test	result	enables	better	patient	care	and	outcome	-	must	be	evaluated	
(Kurian	et	al.	2016).	To	date,	breast	cancer	risk	is	established	for	a	number	of	genes,	however,	
reliable	estimates	of	risk	are	lacking	for	the	majority	as	this	is	challenging,	especially	for	rare	
mutations.	 For	 instance,	 many	 studies	 on	 pleiotropic	 tumor	 syndromes	 (like	 Li	 Fraumeni,	
Cowden	syndrome	neurofibromatosis	type	1,	etc.)	in	which	breast	cancer	is	only	one	feature,	
are	 subject	 to	 ascertainment	 bias	 and	 may	 therefore	 overestimate	 the	 associated	 risk.	
Furthermore,	 there	 are	 problems	 of	 publication	 bias,	 in	 which	 negative	 studies	 are	 not	
published.	Many	gene-discovery	studies	oversample	for	early-onset	cases	of	disease	or	cases	
with	a	family	history.	This	leads	to	seriously	biased	risk	estimates	unless	the	ascertainment	is	
allowed	 for	 in	 the	 analysis.	Moreover,	 risk	 estimates	 based	 on	 data	 from	 highly	 selected	
families	may	not	reflect	the	true	“average”	risk	for	all	carriers	of	pathogenic	variants.	
	
In	 Belgium,	 currently	 a	 panel	 of	 five	 genes	 is	 offered	 to	 patients	 with	 a	 presumed	
predisposition	for	breast	cancer.	This	panel	includes	genes	associated	with	a	high	to	moderate	
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increased	risk	of	breast	cancer	(BRCA1,	BRCA2,	TP53,	PALB2	and	CHEK2).	But	discussions	are	
going	on	to	expand	the	panel	to	other	genes	involved	in	HR,	like	BARD1,	ATM,	etc.	Especially	
in	 patients	 with	 ovarian	 cancer	 evidence	 is	 emerging	 to	 include	 also	 genes	 like	 RAD51C,	
RAD51D	 and	 BRIP1	 (personal	 communication).	 However,	 exact	 risk	 assessments	 are	 not	
available.	Recently,	NCCN	published	recommendations	for	genetic	testing	and	counseling	for	
hereditary	 breast/ovarian	 cancer	 syndromes	 and	 risk	 management	 recommendations	 for	
patients	 who	 are	 diagnosed	 with	 a	 syndrome.	 The	 authors	 stress	 that	 insights	 are	 still	
changing	and	will	be	subject	of	regular	updates	(Daly	et	al.	2017).			
This	was	recently	illustrated	for	mutations	in	BRIP1.	Whereas	the	gene	is	incorporated	in	
numerous	commercially	available	gene	panels	for	breast	cancer	(Easton	et	al.	2015),	a	
recent	study	demonstrated	that	truncating	variants	in	BRIP1	are	not	associated	with	an	
increased	risk	of	breast	cancer	(OR=0.90,	95%CI:0.48-1.7)(Easton	et	al.	2016).		
	
Expanded	testing	will	provide	better	insight	in	the	associated	breast	and	ovarian	cancer	risk,	
but	 as	 risks	 associated	 with	 different	 mutations	 in	 these	 genes	 are	 still	 unclear,	 genetic	
counseling	is	a	challenge.	In	order	to	achieve	risk	assessments	for	these	genes	in	large	cohorts,	
multicenter	studies	have	been	started.	Results	of	those	studies	will	either	confirm	or	rule	out	
their	 use	 in	multiple	 sequencing	panels	 and	will	 aid	 patient	 counseling	 (van	Marcke	 et	 al.	
2016).	At	the	moment	family	history	remains	an	important	tool	for	genetic	counselling	and	
patient	management	(van	Marcke	et	al.	2016).		
	
In	addition	to	the	challenge	created	by	genes	included	in	gene	panels	for	which	breast	cancer	
risk	is	unclear	or	not	unequivocally	established,	variants	of	unknown	significance	(VUS)	–	
detected	at	high	rate	–	pose	another	problem	(van	Marcke	et	al.	2016).”	
	
1.4.4 Deleterious	germline	mutations	versus	Variants	of	Unknown	Clinical	Significance		
For	 all	 above	 discussed	 high	 risk	 genes,	 risk	 assessment	 is	 based	 on	 the	 presence	 of	
deleterious	mutations.	These	incline	the	loss	of	function	of	one	allele,	either	due	to	frameshift	
mutations	 or	 nonsense	 mutations,	 both	 leading	 to	 a	 premature	 termination	 codon	 and	
degradation	of	the	mRNA	due	to	nonsense-mediated	decay	(NMD).	On	the	other	hand,	the	
mutant	allele	might	still	be	present,	but	deleterious	missense	mutation	or	(small)	 in-frame	
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insertions	or	deletions	may	affect	a	functional	domain,	thereby	inhibiting	proper	functionality	
of	the	protein	(Strachan	&	Read	2011).		
	
However,	 due	 to	 an	 evolution	 in	 sequencing	 technologies,	 the	 number	 of	 individuals	
undergoing	screening	drastically	increased	and	led	to	a	significant	rise	in	the	number	of	VUS	
(Kraus	et	al.	2017).	The	detection	of	a	VUS	 is	a	challenge	 for	health	care	providers	as	 the	
impact	on	breast	or	ovarian	cancer	risk	is	unclear.	For	missense	variants,	a	large	number	of	
functional	 tests	 have	 been	 proposed	 (Millot	 et	 al.	 2012;	 Hendriks	 et	 al.	 2014) but	 the	
implementation	on	a	large	scale	in	a	clinical	diagnostic	setting	is	not	feasible.	Messenger	RNA	
(mRNA)	analyses	 to	 investigate	 intronic	and	exonic	variants	 that	might	 impair	proper	RNA	
splicing,	are	more	widely	used.	
	
During	RNA	splicing,	the	intervening	intronic	sequences	are	removed	from	the	primary	mRNA	
(pre-mRNA),	thereby	linking	the	exonic	sequences	to	generate	a	mature	mRNA.	It	is	a	highly	
regulated	 process	 orchestrated	 by	 the	 spliceosome,	 which	 is	 a	 complex	 formed	 by	 small	
nuclear	 ribonucleoproteins	 (snRNP),	 each	 composed	 of	 small	 nuclear	 RNA	 and	 associated	
proteins	(see	Figure	1.7).	Accurate	splicing	relies	on	conserved	areas	in	the	intron	and	exon.	
The	 best-defined	 regions	 necessary	 for	 accurate	 splicing	 are	 the	 highly	 conserved	
dinucleotides	at	the	splice	donor	and	acceptor	sites	situated	at	the	intron	boundaries.	Splicing	
is	 furthermore	guided	by	the	conserved	adjacent	sequences	and	the	branch	point.	Finally,	
splicing	 is	 influenced	 by	 exonic	 splicing	 regulatory	 elements,	 both	 enhancers	 (ESE)	 and	
silencers	(ESS)	(Strachan	&	Read	2010).	
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Figure	1.7:	Schematic	representation	of	pre-mRNA	splicing	(Strachan	&	Read	2010).	
	
Variants	in	these	highly	conserved	regions	may	lead	to	aberrant	splicing	and	be	pathogenic	if	
this	results	in	a	truncated	protein	or	in	complete	loss	of	one	allele	if	a	premature	termination	
codon	 leads	 to	NMD.	 Aberrant	 splicing	 of	 putative	 variants	 can	 be	 evaluated	 in	 silico,	 by	
means	 of	 numerous	 prediction	 tools.	 However,	 mRNA	 analysis,	 e.g.	 in	 in	 vitro	 cultured	
peripheral	blood	lymphocytes	of	an	individual	with	the	variant	of	interest,	is	the	designated	
approach	to	assess	the	effect	of	a	variant	on	mRNA	splicing	(Strachan	&	Read	2010;	Houdayer	
et	al.	2012;	Spurdle	et	al.	2008;	Colombo	et	al.	2013).	
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1.5 Breast	cancer	screening	
Breast	 cancer	 screening	 is	 predominantly	 performed	 by	 mammography	 screening.	
Mammography	 screening	uses	 low	energy	X-rays,	 typically	28-30kV,	 to	 image	 the	breasts.	
Usually,	two	images	are	taken	from	each	breast	resulting	in	a	mean	glandular	dose	between	
3.7	and	4.7	mGy.	Digitalization	of	mammography	screening	 tends	 to	 result	 in	 lower	doses	
(Gillet	et	al.	2011;	Hendrick	2010).	The	screening	enables	physicians	to	detect	breast	cancer	
before	clinical	symptoms	appear	(see	Figure	1.8),	thus	allowing	an	early	treatment	and	a	good	
survival	 rate.	 However,	 one	 has	 to	 take	 into	 account	 the	 disadvantages	 of	 this	 screening	
method.	Disadvantages	include,	but	are	not	limited	to,	the	false	positive	and	false	negative	
results,	 treatment	 of	 tumors	 that	 would	 not	 progress	 in	 life	 threatening	 cancer	 and	 the	
possibility	that	the	ionizing	radiation-based	screening	method	can	result	in	radiation-induced	
tumors.	 In	order	 to	 justify	 the	use	of	mammography	screening,	 the	gain	derived	 from	the	
number	of	detected	tumors	must	outweigh	the	number	of	induced	tumors	excessively	(Gillet	
et	al.	2011).		
	
	
Figure	 1.8:	Mammogram	of	 breast	with	 breast	 cancer	 (indicated	with	 arrows),	 visible	 as	 a	
white,	dense	mass.	©Bakerstmd	(Wikipedia)	
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Other	screening	methods	such	as	ultrasound	and	magnetic	resonance	imaging	(MRI)	avoid	
the	 use	 of	 ionizing	 radiation	 and	 are	 usually	 offered	 to	 women	 at	 high	 risk.	 The	 use	 of	
ultrasound	 usually	 results	 in	 high	 number	 of	 false	 positives	 and	 often	 accompany	
mammography	 screening.	 However,	 the	 application	 in	 breast	 cancer	 screening	 is	 not	
recommended	(Gillet	et	al.	2011).	MRI	has	proven	to	be	a	high	sensitivity	screening	tool	for	
women	 at	 high	 risk	 and	 is	 implemented	 in	 breast	 cancer	 screening,	 often	 in	 addition	 to	
mammography	 screening,	 in	 these	 individuals,	 despite	 being	 an	 expensive	 procedure	
(Enriquez	&	Listinsky	2009).	
	
1.5.1 Population	screening	
In	Flanders,	Belgium,	all	woman	between	the	age	of	50	and	69	years	are	offered	a	2-yearly	
mammography	screening	to	allow	detection	of	breast	cancer	in	an	early	stage.	In	2014,	47%	
of	all	eligible	woman	responded	to	this	 initiative,	another	18%	arranged	screening	on	own	
initiative	 (CvKO	 n.d.).	 Population	 screening	 is	 limited	 to	 this	 particular	 age	 group	 as	 the	
highest	breast	cancer	incidence	is	observed	between	the	ages	of	50	and	69	(see	chapter	1.2:	
Incidence	and	mortality,	Figure	1.4).	Contemplating	to	the	principal	“foremost,	do	no	harm	
(primum	non	nocere)”	and	taking	 into	account	the	 limited	beneficial	effect	on	survival,	an	
expansion	of	this	program	to	include	women	between	the	ages	of	40	to	49	(Mambourg	et	al.	
2010)	or	older	than	70	is	advised	against	(Mambourg	et	al.	2010;	Mambourg	et	al.	2012).	
	
1.5.2 Breast	cancer	screening	in	individuals	at	high	risk	
The	Belgian	Federaal	Kenniscentrum	voor	de	Gezondheid	 (KCE)	issued	guidelines	for	breast	
cancer	screening	in	individuals	at	high	risk	in	KCE	report	172A.	Proper	screening	management	
of	these	individuals	is	necessary	as	they	are	not	only	more	prone	to	breast	cancer,	but	develop	
tumors	at	a	younger	age	(Gillet	et	al.	2011).		
Individuals	 are	 divided	 in	 three	 risk	 classes	 based,	 predominantly,	 on	 familial	 anamnesis	
(Gillet	et	al.	2011):	
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Average	Risk	
- No	or	one	first-	or	second-degree	relative	with	breast	cancer	diagnosed	after	the	age	
of	40	(see	chapter	1.5.1:	Population	screening)	
Raised	Risk	(lifetime	risk	of	17-30%)	
- One	first-degree	relative	with	breast	cancer	diagnosed	before	the	age	of	40	
- Two	first-	or	second-degree	relatives	with	breast	cancer	diagnosed	before	the	age	of	
50	
- Three	first-	or	second-degree	relatives	with	breast	cancer	diagnosed	before	the	age	of	
60	
High	Risk	(lifetime	risk	of	30%	and	higher)	
- Two	first-	or	second-degree	relatives	with	breast	cancer	before	the	mean	age	of	50,	
of	which	at	least	one	first	degree	relative.		
- Three	first-	or	second-degree	relatives	with	breast	cancer	before	the	mean	age	of	60,	
of	which	at	least	one	first-degree	relative	
- Four	 relatives	 diagnosed	with	 breast	 cancer	 at	 any	 age,	 of	which	 at	 least	 on	 first-
degree	relative.		
- Jewish	decent	
- One	of	the	following	criteria	in	the	familial	anamneses	
o Bilateral	breast	cancer	
o Breast	cancer	in	men	
o Ovarian	cancer	
o Sarcoma	before	the	age	of	45	
o Glioma	or	adrenal	cortical	carcinoma	during	childhood	
o Multiple	carcinoma	at	young	age	
o Strong	indication	in	the	paternal	pedigree	
	
This	risk	assessment	does	not	directly	take	into	account	the	presence	of	a	familial	mutation.	
Individuals	of	Jewish	decent	are	classified	as	being	at	high	risk	because	of	the	presence	of	
three	 founder	 mutations	 in	 BRCA1	 and	 BRCA2	 in	 this	 population	 (McClain	 et	 al.	 2005).	
Individuals	with	a	raised	risk	are	offered	a	yearly	mammogram	between	the	ages	of	40-49	and	
a	two-yearly	mammogram	between	50	and	69	years	(see	Figure	1.9).	Individuals	at	high	risk	
are	 offered	 yearly	mammography	 screening	 and	MRI	 starting	 at	 the	 age	 of	 30	 or	 5	 years	
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before	the	age	of	diagnoses	of	the	youngest	diagnosed	family	member	(but	not	before	the	
age	of	25)	(see	Figure	1.9)	(Gillet	et	al.	2011).	In	UZ	Gent	and	several	other	Belgian	hospitals,	
the	 consensus	 is	 to	 commence	 screening	 with	 yearly	 MRI	 and	 only	 offer	 regular	
mammography	after	the	age	of	50	(personal	communication).	However,	 this	gentle	use	of	
ionizing	radiation	based	screening	is	not	applied	worldwide.	For	example,	current	guidelines	
in	the	US	involve	an	annual	MRI	(or	mammography	if	MRI	is	unavailable)	between	the	ages	of	
25	 to	 29	 and	 annual	 MRI	 and	 mammography	 screening	 between	 30	 and	 75	 years	 for	
individuals	with	a	BRCA	mutation	(NCCN	2016).	This	annual	screening	approach	starting	at	30,	
results	in	a	relatively	high	cumulative	burden	in	these	individuals,	increasing	the	chance	to	
develop	a	radiation-induced	tumor.	
	
	
Figure	1.9:	KCE	guidelines	for	breast	cancer	screening	in	all	three	risk	groups	(Gillet	et	al.	2011).	
	
1.6 Breast	cancer	treatment	
The	best	 option	 for	 breast	 cancer	 treatment	 depends	 on	 several	 factors	 including:	 breast	
cancer	type,	tumor	size,	the	possible	invasion	of	lymph	nodes,	the	presence	of	metastasis	and	
the	presence	of	hormonal	receptors	on	the	tumor	cell	surface.	Treatment	strategies	include	
systemic	 treatment	 or	 a	 more	 local	 approach.	 Local	 treatment	 options	 comprise	 surgery	
and/or	radiotherapy.	The	goal	of	radiotherapy	is	to	deliver	a	sufficiently	high	dose	of	ionizing	
radiation	at	 the	 tumor	 site	 to	eliminate	 the	 tumor	cells	whilst	preserving	 the	 surrounding	
healthy	tissue.	Unfortunately,	ionizing	radiation	will	also	interact	with	all	surrounding	healthy	
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tissues	and	organs	without	specificity	for	the	tumor	cells	resulting	in	normal	tissue	effects	as	
well	as	tumor	cell	killing.	In	order	to	achieve	maximal	tumor	response	while	protecting	normal	
tissue,	high	total	doses	(50Gy	or	more)	are	delivered	in	small	daily	fractions	of	2Gy	over	a	long	
period	of	time	(La	Torre	Travis	1989;	Löbrich	&	Jeggo	2007).	
	
Systemic	treatment	consists	of	a	general	chemotherapy	or	a	more	specific	approach,	such	as	
hormonal	therapy	in	case	of	ER	and	PR	positive	status.	Additionally,	targeted	therapies,	which	
can	be	selected	if	the	tumor	exhibits	certain	features	are	a	possibility.	One	well-known	target	
is	HER2	status.	Overexpression	of	HER2	is	correlated	with	a	more	aggressive	breast	cancer	
and	poor	outcome.	Several	compounds	specifically	targeting	HER2,	yield	good	responses	and	
improve	survival	rates	(Rutqvist	2004;	Gradishar	2012).	Another	of	these	characteristics	is	HR	
deficiency,	which	 is	 frequently	observed	 in	 tumors	of	BRCA1	and	BRCA2	mutation	carriers	
(Lord	&	Ashworth	2016).	HR	and	the	targeted	therapy	using	PARP	inhibitors,	will	be	discussed	
in	chapter	3.3.2.2	and	3.3.2.4	respectively.		
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2 IONIZING	RADIATION	
2.1 What	is	ionizing	radiation?	
Ionizing	radiation	is	radiation	that	carries	sufficient	energy	to	ionize	atoms	or	molecules	by	
ejecting	one	or	more	orbital	electrons.	 It	 is	 characterized	by	a	 localized	 release	of	a	 large	
amount	of	energy	and	the	dose	 to	biological	material	 is	defined	by	 the	amount	of	energy	
absorbed	per	unit	of	mass,	expressed	in	Gray	(Gy).	Besides	ionizations,	ionizing	energy	also	
possesses	sufficient	energy	to	excite	atoms	by	displacing	an	orbital	electron.	Two	types	of	
ionizing	radiation	are	described.		
(1) particle	 irradiation	 consists	of	 subatomic	particles,	 ions	or	 atoms	 travelling	 at	high	
speed	and	can	be	described	by	mass	and	charge.		
(2) electromagnetic	waves	are	photons	which	have	no	mass	or	charge.	X-rays	and	 g-rays	
are	the	best	known	examples	(La	Torre	Travis	1989;	Lehnert	2008).	
	
In	order	to	quantify	energy	deposits	in	the	tissue,	Linear	Energy	Transfer	(LET)	was	introduced.	
LET	 is	 the	 ratio	between	energy	deposition	and	 the	 corresponding	path	 length	 in	units	of	
keV/microM.	 It	 depends	on	 several	parameters	 including	 velocity	of	 the	particle.	 Low-LET	
radiation	 includes	 electrons	 and	 electromagnetic	 waves	 such	 as	 X-rays	 and	 g-rays	 and	
produces	a	limited	number	of	ionizations	and/or	excitations	throughout	the	cell	(See	Figure	
1.10).	 High-LET	 radiation	 includes	 a-particles	 and	 other	 large	 ion	 particles	 generated	 by	
accelerators.	High-LET	irradiation	results	in	a	dense	ionization	and	excitation	deposit	along	
the	track	of	the	particle	(see	Figure	1.10)	(Pouget	&	Mather	2001).	Because	of	differences	in	
energy	deposits	in	the	tissue,	equal	doses	of	different	LET	radiation	will	not	produce	the	same	
biological	effect.	To	evaluate	the	biological	effect	of	a	certain	type	of	ionizing	radiation	in	the	
cell,	the	relative	biological	efficiency	(RBE)	is	determined.	RBE	is	defined	as	the	ratio	of	a	dose	
of	test	radiation	to	a	dose	of	reference	radiation	(e.g.	250kV	X-rays)	that	produces	the	same	
biological	effect	(La	Torre	Travis	1989).		
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Figure	1.10:	Schematic	visualization	of	ionizations	and	excitations	by	high-LET	(a-particle)	and	
low-LET	(g-ray)	ionizing	radiation	(Pouget	&	Mather	2001).	
	
2.2 Radiation-induced	damage	
When	ionizing	radiation	interacts	with	cells,	the	nucleus	and	its	DNA	are	the	most	vulnerable	
parts	(Pouget	&	Mather	2001).	Damage	to	the	DNA	may	be	induced	directly,	in	which	case	an	
ejected	 electron	 interacts	 directly	 with	 the	 DNA	 (see	 Figure	 1.11).	 Damage	 may	 also	 be	
inflicted	 in	an	 indirect	manner.	 In	this	process,	the	ejected	electron	 interacts	with	a	water	
molecule	producing	a	free	radical	(e.g.	reactive	oxygen	species)	which	damages	the	DNA	(see	
Figure	1.11).	As	80%	of	the	cell	consists	of	water,	indirect	damage	to	the	DNA	is	much	more	
likely	 to	 occur	 than	 direct	 damage.	 Furthermore,	 the	 ratio	 direct/indirect	 damage	 also	
depends	on	the	type	of	radiation	used.	High-LET	ionizing	radiation	will	result	in	more	direct	
damage	 compared	 to	 low-LET	 radiation.	 Besides	 damage	 to	 the	 DNA	 caused	 by	 ionizing	
radiation,	the	DNA	is	continuously	exposed	to	endogenous	damaging	agents	which	are	also	
capable	of	producing	highly	reactive	radicals	(Pouget	&	Mather	2001;	Lehnert	2008;	La	Torre	
Travis	1989).	
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Figure	 1.11:	 Schematic	 visualization	 of	 direct	 and	 indirect	 induced	DNA	 lesions	 by	 ionizing	
radiation	(Pouget	&	Mather	2001).	
	
DNA	damage	occurs	 in	many	 forms	and	 includes	base	damage,	crosslinks	and	DNA	strand	
breaks	(see	Figure	1.11).	Base	damage	occurs	at	high	rate	in	the	cell	upon	exposure	to	ionizing	
radiation	and	includes	either	loss	or	modification	of	the	base.	DNA-protein	and	DNA	intra-
strand	crosslinks	are	produced	when	DNA	radicals	interact	with	DNA	or	protein	radicals.	DNA	
strand	breaks	are	the	result	of	a	breakage	in	the	sugar-phosphate	bond	of	the	DNA.	Strand	
breaks	include	both	single	and	double	strand	breaks.	Breaks	in	only	one	strand	of	the	DNA	
(single	strand	breaks)	are	relatively	easy	to	repair	with	limited	long	term	consequences	for	
the	cell	as	the	proper	DNA	sequence	remains	available	on	the	complementary	DNA	strand.	
However,	DNA	double	strands	pose	a	 larger	threat	to	the	cell.	A	DNA	double	strand	break	
comprises	 of	 two	 single	 strand	 breaks	 on	 opposite	 strands	 in	 close	 proximity	 (within	 20	
basepairs).	Repair	is	more	difficult	and	maintenance	of	the	correct	DNA	sequence	might	be	
impaired	(La	Torre	Travis	1989;	Pouget	&	Mather	2001).	DSB	and	the	repair	mechanisms	are	
discussed	in	chapter	3:	DNA	damage	response.	
Furthermore,	 ionizing	radiation	also	causes	damage	to	other	parts	of	 the	cell	and	 impairs,	
amongst	others,	the	integrity	of	the	cell	membrane	(reviewed	by	(Corre	et	al.	2010)).		
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2.3 Health	effects	of	exposure	to	ionizing	radiation	
2.3.1 Exposure	to	ionizing	radiation		
Exposure	to	ionizing	radiation	predominantly	occurs	from	background	radiation	or	via	ionizing	
radiation-based	medical	applications.	Daily	background	levels	are	limited	to	approximately	5	
µSv.	Doses	of	exposure	to	X-rays	from	diagnostic	tools,	such	as,	mammography	screening,	
thorax	X-rays	and	CT	scans	vary	between	1	and	30	mSv	(see	Figure	1.12)	(Brenner	et	al.	2003;	
Löbrich	&	Jeggo	2007).	Another	medical	application	of	ionizing	radiation	is	radiotherapy	(see	
chapter	1.6:	Breast	cancer	treatment).	Radiotherapy	delivers	high	doses	of	ionizing	radiation	
in	a	fractionated	pattern.	Cumulative	doses	of	radiotherapy	can	be	as	high	as	50	Sv	(see	Figure	
1.12)	(La	Torre	Travis	1989;	Löbrich	&	Jeggo	2007).		
	
Figure	 1.12:	 Exposure	 to	 ionizing	 radiation	 and	 cancer	 risk	 estimation.	 For	 reference,	 a	
transatlantic	flight,	moon	walk	and	Mars	travel	are	indicated.	Whole	body	exposure	of	5Sv	is	
lethal	(Löbrich	&	Jeggo	2007).	(Note:	Sievert	represents	the	equivalent	biological	effect	of	the	
deposit	of	a	joule	of	radiation	energy	in	a	kilogram	of	human	tissue	and	is	used	to	express	the	
health	effect	of	ionizing	radiation	in	the	human	body.	For	whole	body	exposures	with	X-rays,	
1Sv	equal	to	1Gy	(Löbrich	&	Jeggo	2007)).		
	
2.3.2 Health	effects	of	ionizing	radiation	
Health	consequences	of	exposure	to	ionizing	radiation	due	to	cellular	damage	can	be	divided	
in	two	main	categories.	The	first	category	is	the	deterministic	effect.	Deterministic	effects	are	
adverse	effects	observed	after	exposure	to	higher	doses	(usually	acute	doses	in	excess	of	500	
mGy)	and	severity	 is	directly	 linked	to	 the	dose.	These	effects	and	the	dose	threshold	are	
related	 to	 the	 irradiated	 tissue.	Deterministic	effects	are	due	 to	cell	death	 in	 the	exposed	
tissues	and	tend	to	appear	shortly	after	irradiation,	however,	some	deterministic	effects	may	
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take	several	months	to	develop.	Examples	 include	 infertility,	skin	damage	and	cataract	(La	
Torre	Travis	1989;	HPA	2013).		
	
The	second	category	 is	 the	stochastic	effect.	The	best	known	and	most	 studied	stochastic	
effect	is	cancer.	There	is	no	dose	limit	for	this	effect	and	it	only	appears	several	years	after	
the	original	exposure.	Furthermore,	the	risk,	but	not	the	severity,	 is	 linked	with	 increasing	
doses.	Cancer	risk	is	well	documented	for	doses	above	100	mGy	(see	Figure	1.12)	and	follows	
a	 linear	 regression	 (Averbeck	2009;	 La	Torre	Travis	1989;	 Löbrich	&	 Jeggo	2007).	Data	 for	
these	higher	dose	ranges	are	predominantly	obtained	from	the	LSS	cohort	of	Atomic	bomb	
survivors	and	patients	exposed	to	ionizing	radiation	for	medical	purposes	(e.g.	radiotherapy	
or	multiple	X-ray	examinations)	(Mattsson	&	Nilsson	2015).	In	the	higher	dose	range,	a	total	
body	dose	of	2-3	Sv	(or	2-3	Gy	in	case	of	exposure	to	X-rays)	results	in	a	doubling	of	cancer	
risk	(Löbrich	&	Jeggo	2007).		The	risk	of	breast	cancer	upon	exposure	to	ionizing	radiation	was	
previously	discussed	in	chapter	1.3:	Risk	factors.	
	
Evaluation	of	the	stochastic	risk	after	exposure	to	low	doses	(below	100	mGy)	and	very	low	
doses	 (below	10	mGy)	of	 ionizing	 radiation	 remains	difficult.	However,	understanding	 the	
impact	of	(very)	low	doses	of	ionizing	radiation	is	important	as	exposure	to	ionizing	radiation	
for	 diagnostic	 purposes	 is	 situated	mainly	 in	 this	 (very)	 low	dose	 range	 (see	 Figure	 1.12).	
Although	the	effect	of	low	dose	exposure	as	used	in	diagnostic	X-rays	might	be	small,	it	could	
still	result	 in	a	large	impact	when	applied	to	a	large	cohort	(e.g.	population	screening	with	
mammography)	 (Brenner	 et	 al.	 2003).	Unfortunately,	 epidemiological	 data	 are	 not	 strong	
enough	to	identify	a	small	increase	in	risk	as	an	extremely	high	number	of	exposed	individuals	
would	be	necessary	to	achieve	sufficient	power	(Brenner	et	al.	2003).		
	
To	estimate	the	risk	effect	of	low	doses	of	ionizing	radiation,	data	of	high	doses	of	ionizing	
radiation	are	extrapolated	to	the	low	dose	ranges.	The	standard	for	extrapolation	is	the	linear	
no	threshold	model	(see	Figure	1.13).	This	model	is	based	on	a	linear	increase	of	cancer	risk	
with	increasing	doses	of	ionizing	radiation.	However,	whereas	the	linear	no	threshold	model	
has	proven	its	application	for	doses	above	100	mSv,	its	usage	for	dose	<	100	mSv	is	challenged	
by	recent	developments	and	new	insights	(Averbeck	2009).		
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Figure	1.13:	Schematic	representation	of	possible	extrapolations	of	high-dose	data	to	low	and	
very	low	doses	(Robertson	et	al.	2013).		
	
Nowadays,	it	is	known	that	cells	and	tissues	act	differently	in	response	to	low	doses	of	ionizing	
radiation	compared	to	high	doses.	These	effects	might	either	be	beneficial	or	detrimental	for	
cells	 or	 tissue.	One	 effect	 to	 take	 into	 account	when	 investigating	 the	 effect	 of	 low	dose	
radiation	exposure	is	low	dose	hypersensitivity	(see	Figure	1.13).	This	phenomenon	might	be	
caused	by	the	bystander	effect,	which	is	based	on	the	induction	of	ionizing	radiation-linked	
effects	 in	non-targeted	cells	and	 involves	 intercellular	communication	via	 intercellular	gap	
junctions	or	release	of	cellular	mediators	in	the	medium.	It	is	only	relevant	at	lower	doses,	as	
not	 all	 cells	 will	 be	 hit	 by	 the	 ionizing	 radiation	 directly.	 On	 the	 other	 hand,	 low	 dose	
hypersensitivity	might	 also	be	 the	 result	 of	 increased	 cell	 lethality	 at	 very	 low	doses	 as	 a	
threshold	 of	 induced	 damage	 is	 needed	 to	 activate	 DNA	 damage	 response	 and	 repair.	 A	
reduced	DNA	damage	repair	after	low	dose	exposure	could	subsequently	result	in	a	higher	
than	expected	cell	lethality.	Low	dose	hypersensitivity	would	imply	an	underestimation	of	the	
risks	after	exposure	to	low	doses	of	ionizing	radiation	by	the	linear	no	threshold	model.	Its	
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counterparts,	 namely	 radioadaptation,	 threshold	 hypothesis	 and	 beneficial	 low-level	
radiation	 effects	 (hormesis),	 imply	 an	 overestimation	 by	 the	 linear	 no	 threshold	 risk	
extrapolation	model.	Radioadaptation	suggests	that	small	doses	of	ionizing	radiation	(below	
20	mGy)	prepare	 the	cells	 for	higher	doses.	Hormesis	 (see	Figure	1.13)	proposes	 that	 low	
doses	of	ionizing	radiation	may	have	beneficial	effects	for	cells	or	tissue.	Finally,	the	threshold	
hypothesis	(see	Figure	1.13)	implies	that	below	a	certain	dose,	no	risk	exists	for	a	particular	
endpoint	(Brenner	et	al.	2003;	Averbeck	2009).		
	
2.3.3 Radiosensitivity	
Consequences	of	exposure	to	ionizing	radiation	depend	on	the	radiation	dose	but	will	also	
depend	on	the	sensitivity	to	ionizing	radiation	which	is	important	for	proper	risk	assessment.	
Radiosensitivity	–	sensitivity	to	ionizing	radiation	–	can	be	evaluated	at	several	levels	using	
different	endpoints.	 It	 is	therefore	essential	that,	whenever	discussing	radiosensitivity,	the	
precise	parameters	are	defined.	Radiosensitivity	can	be	defined	on	a	cellular	level,	in	regard	
to	specific	tissues	or	for	a	complete	organism.	End	points	include	cancer	formation,	cell	death	
and	chromosomal	damage	(see	Table	II)	(HPA	2013).		
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Table	II:	Summary	of	frequently	applied	radiosensitivity	forms	and	assays	(HPA	2013).	
Whole	 tissue	
radiosensitivity	
Measured	by	assays	such	as	LC50/30,	which	refers	to	the	radiation	dose	
required	to	kill	50%	of	a	given	population	within	30	days	of	exposure.	
Normal	 tissue	
radiosensitivity	
Generally	 used	 in	 the	 context	 of	 the	 reaction/damage	 to	 non-target	
tissues	 as	 a	 consequence	 of	 radiotherapy	 for	 cancer	 and	 other	
conditions.	 They	 are	 assessed	by	 clinical	 evaluation	of	 tissue	damage	
using	a	variety	of	scoring	schemes.	The	main	tissues	of	concern	include	
skin	(burning),	lung	and	connective	tissue	(fibrosis).	
Susceptibility	to	
radiation	
carcinogenesis	
Refers	to	differences	in	susceptibility	amongst	individuals	to	radiation-
induced	 cancer	 in	 specific	 tissues.	 It	 is	 measured	 in	 epidemiological	
(human)	 studies	 or	 experimental	 animal	 carcinogenesis	 studies.	
Generally,	 this	 is	 considered	 in	 terms	of	yield	of	 tumors	 (in	a	 specific	
tissue)	per	unit	of	absorbed	dose.	
Tissue	
radiosensitivity	
(for	cancer)	
Refers	to	the	difference	in	sensitivity	of	individual	tissues	in	organisms	
to	radiation-associated	carcinogenesis.	Most	information	for	this	comes	
from	 epidemiological	 studies	 and	 is	 generally	 considered	 in	 terms	 of	
yield	 of	 tumors	 (in	 a	 specific	 tissue)	 per	 unit	 absorbed	 dose.	 Tissue	
radiosensitivity	can	also	refer	to	differences	in	response	to	radiotherapy	
of	tissues	in	terms	of	their	function	or	structure.	
Cellular	
radiosensitivity	
Refers	 to	 a	wide	 range	of	 phenomena	measured	 at	 the	 cellular	 level	
where	response	to	radiation	can	vary	between	individuals	or	cell	types.	
Endpoints	can	be	cell	killing,	chromosomal	damage,	damage/repair	to	
DNA,	cell	cycle	endpoints,	apoptosis	and	others.	It	is	measured	in	yield	
of	 the	 endpoint	 per	 unit	 absorbed	 dose	 or	 parameters	 derived	 from	
dose-response	relationships.	
	
	
Part	I:	Introduction	–	DNA	damage	response	
	 41	
3 DNA	DAMAGE	RESPONSE	
3.1 DNA	damage	response	
As	the	cell,	and	especially	the	DNA,	are	vulnerable	to	damage	caused	by	both	endogenous	
and	exogenous	agents,	proper	DNA	damage	response	is	crucial.	Despite	differences	pending	
on	the	 type	of	DNA	damage,	a	general	pattern	can	be	 identified.	This	pattern	 inclines	 the	
detection	 and	 signaling	 of	 the	 damage,	 followed	 by	 a	 cellular	 response	 (see	 Figure	 1.14)	
(Pouget	&	Mather	2001;	Jackson	&	Bartek	2010;	Matt	&	Hofmann	2016).		
	
	
Figure	1.14:	The	DNA	damage	response.	DNA	damage	caused	by	endogenous	or	exogenous	
sources	is	recognized	by	sensor	proteins	(detectors)	which	activate	a	signaling	cascade.	The	
signal	is	amplified	by	mediators/transducers	and	finally	reaches	the	effector	proteins,	which	
are	involved	in	triggering	the	cellular	responses	to	DNA	damage	(Rupnik	et	al.	2010).	
	
The	DNA	damage	response	will	be	discussed	in	regard	to	radiation-induced	DSB	as	this	type	
of	DNA	damage	is	the	main	focus	of	this	research.	The	DNA	double	strand	break	is	the	most	
toxic	 type	of	DNA	damage	 induced	by	 ionizing	 radiation.	 The	 formation	of	 local	 clustered	
lesions	due	to	radiation-induced	double	strand	breaks	combined	with	single	strand	breaks	
and	base	damage	within	a	small	region	of	ten	to	20	bp	further	complicates	the	repair.	This	
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type	of	lesions	is	more	common	after	exposure	to	more	densely	ionizing	forms	of	radiation	
(Rothkamm	&	Lobrich	2002;	Borgmann	et	al.	2016;	Mladenov	et	al.	2016).		
	
Detection	of	the	DSB	involves	the	activation	of	MRN	complex,	ATM	and/or	ATR	(See	chapter	
3.3.1)	 (Matt	 &	 Hofmann	 2016;	 Awasthi	 et	 al.	 2015;	 Rupnik	 et	 al.	 2010).	 The	 subsequent	
signaling	 cascade	 will	 determine	 the	 ultimate	 cellular	 response.	 The	 cellular	 response	
includes,	 but	 is	 not	 limited	 to,	 repair	 of	 the	 induced	 DNA	 damage	 via	 appropriate	 repair	
mechanisms	 (discussed	 in	 chapter	 3.3.2),	 activation	 of	 checkpoints	 to	 delay	 cell	 cycle	
progression	 to	 allow	 repair	 (discussed	 in	 chapter	 3.2.2)	 and	 controlled	 cell	 death	 or	
proliferation	arrest	if	the	damage	is	to	extensive	for	repair	(discussed	in	chapter	3.5)	(Jackson	
&	Bartek	2010;	Matt	&	Hofmann	2016).		
	
3.2 Cell	cycle	&	cell	cycle	checkpoints	
3.2.1 The	cell	cycle	
In	order	to	discuss	cell	cycle	checkpoint	arrest	and	DNA	damage	repair,	insight	in	the	cell	cycle	
is	necessary.	During	cell	proliferation	the	cell	passes	four	phases:	G1	phase,	S	phase,	G2	phase	
and	mitosis	(or	M	phase)	(see	Figure	1.15).	Besides	engaging	in	cell	proliferation,	the	cell	may	
enter	a	quiescent	and	often	reversible	G0	phase	instead	(Weinberg	2007).	The	first	phase	of	
the	 cell	 cycle	 is	 the	G1	 phase.	 During	G1	 phase,	 growth-regulating	 factors	 present	 in	 the	
extracellular	environment	might	influence	the	decision-making	process.	At	this	point,	the	cell	
decides	whether	conditions	are	favorable	to	continue	cell	division	or	whether	an	arrest	in	G1	
phase	or	progress	in	G0	phase	is	necessary.	Once	committed	to	cell	division	-	 indicated	by	
passing	the	R-point	of	G1	phase	-,	the	cell	prepares	itself	to	complete	the	cell	cycle	consisting	
of	the	S	phase,	followed	by	the	G2	phase	and	mitosis.	Progression	through	these	phases	of	
the	cell	 cycle	 is	highly	 regulated	by	cyclins	and	cyclin	dependent	kinases	 (see	Figure	1.15)	
(Weinberg	2007;	Strachan	&	Read	2011).	
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Figure	 1.15:	 Scheduled	 rise,	 decline	 and	 (de)phosphorylation	 of	 certain	 cyclins	 and	 cyclin	
dependent	kinases	(CDK)	in	function	of	the	cell	cycle	phases	result	in	a	tight	interplay	between	
these	proteins	and	the	cell	cycle	progression.	During	G1	phase	of	the	cell	cycle,	CDK4	and	CDK6	
interact	with	D-type	cyclins.	Once	past	 the	R	point,	E-type	cyclins	will	associate	with	CDK2.	
Whilst	progressing	to	the	S-phase,	A-type	cyclins	replace	the	E-type	cyclins.	Towards	mid/end	
S-phase	and	during	G2	phase,	A-type	cyclins	interact	with	CDC2	(also	known	as	CDK1).	Finally,	
CDC2	will	interact	with	B-type	cyclins	in	preparation	of	Mitosis	(M-phase).	Immediately	after	
M	phase,	B-type	cyclin	levels	drop	due	to	protein	degradation	and	the	scheme	repeats	itself.	
The	cell	also	possesses	four	cell	cycle	checkpoints,	one	in	every	phase	of	the	cell	cycle.	The	
checkpoints	and	its	purpose	are	indicated	in	grey.	Adapted	from	(Weinberg	2007).	
	
The	main	goal	of	the	S-phase	is	a	complete	and	accurate	DNA	replication.	This	is	an	enormous	
challenge	as	the	genome	contains	an	estimated	3.2	billion	base	pairs.	In	order	to	duplicate	
the	 genome	 within	 an	 acceptable	 time	 frame,	 replication	 starts	 at	 several	 100	 to	 1000	
replication	origins.	At	each	site,	a	pre-replicative	complex	(pre-RC)	initiates	unwinding	of	the	
DNA	 double	 helix	 by	 means	 of	 helicases	 at	 the	 replication	 origin	 (see	 Figure	 1.16).	
Furthermore,	 the	pre-RC	recruits	B-family	DNA	polymerases	to	the	site.	This	 results	 in	 the	
formation	of	replication	forks	(Takeda	&	Dutta	2005;	Lodish	et	al.	2007).	The	DNA	replication	
fork	is	in	essence	the	unwound	DNA	complete	with	all	necessary	proteins	of	the	replication	
machinery	 (see	Figure	1.16).	 The	 replication	 fork	always	proceeds	 from	5’	 to	3’	 along	 the	
leading	strand	for	which	duplication	can	progress	continuously,	starting	from	one	RNA	primer,	
by	 DNA	 polymerase.	 The	 lagging	 strand	 is	 duplicated	 in	 smaller,	 discontinuous	 segments,	
called	Okazaki	fragments.	Each	fragment	is	formed	by	an	RNA	primer	(created	by	primase)	
and	 subsequent	 elongated	 by	 DNA	 polymerase.	 RNA	 primer	 fragments	 are	 subsequently	
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replaced	with	DNA	by	the	DNA	polymerase	of	the	adjacent	fragment	and	subsequent	ligation	
to	 the	 neighboring	 fragment.	 While	 duplication	 takes	 place,	 RPA	 (replication	 protein	 A)	
protects	the	single	stranded	DNA	(Lodish	et	al.	2007).		
	
	
Figure	1.16:	Overview	of	the	origin	of	replication	and	the	replication	fork	(see	text).	Adapted	
Figure.	Copyright	©	2008	Pearson	Education,	Inc.	Pearson	Benjamin	Cummings.		
	
In	order	to	avoid	extensive	induction	of	errors	during	duplication,	DNA	polymerase	 d	–	the	
dominant	replication	polymerase	in	humans	–	possesses	proofreading	capacity	and	the	ability	
to	correct	errors.	Still,	the	process	is	not	completely	error	free	and	on	average	one	mistake	
will	be	made	every	billion	nucleotides	(Lodish	et	al.	2007;	Takeda	&	Dutta	2005).		
Not	 only	 proper	 DNA	 duplication	 itself	 is	 a	 challenge	 for	 the	 replication	machinery,	 also	
unresolved	DNA	damages	form	a	challenge.	These	obstacles	lead	to	slowing	or	stalling	of	the	
replication	fork,	also	referred	to	as	replication	stress.	The	cell	has	the	possibility	to	rely	on	
other	 replication	 origins	 to	 finish	 replication	 or	 can	 activate	 replication-stress-response	
proteins	 (amongst	 which	 ATM	 and	 ATR)	 to	 maintain	 fork	 stability,	 overcome	 replication	
obstacles	and	complete	DNA	duplication	under	stress.	However,	stalled	replication	forks	can	
also	lead	to	formation	of	double	strand	breaks	upon	natural	collapse	(passive	breakage)	or	
due	to	endonuclease	activity	in	an	attempt	to	resolve	the	stalled	replication	fork	(Lim	&	Kaldis	
2013;	 Zeman	&	 Cimprich	 2014).	 Once	 a	 cell	 surpasses	 all	 challenges	 and	 completes	 DNA	
replication,	the	S	phase	is	finalized	and	the	cell	can	progression	to	G2	phase	of	the	cell	cycle	
(Takeda	&	Dutta	2005).	
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In	 the	 G2	 phase	 of	 the	 cell	 cycle	 the	 cell	 contains	 a	 double	 DNA	 content.	 This	 phase	 is	
characterized	 by	 rapid	 cell	 growth	 and	 protein	 synthesis	 in	 preparation	 of	 the	 mitosis	
(Weinberg	2007;	Strachan	&	Read	2010).			
	
During	M	phase	or	mitosis,	the	duplicated	DNA	–	in	the	form	of	chromosomes	each	consisting	
of	two	sister	chromatids	–	is	divided	amongst	the	two	daughter	cells.	The	mitosis	is	divided	in	
four	stages	(prophase,	metaphase,	anaphase	and	telophase)	and	ends	with	the	cytokinesis,	
which	is	the	division	of	the	cytoplasm	and	the	formation	of	two	new	daughter	cells	(Weinberg	
2007;	Lodish	et	al.	2007).		
	
A	 complete	 cell	 cycle	 varies	 in	 time	pending	on,	 amongst	 others,	 the	 cell	 type.	Usually,	 a	
complete	cell	division	 in	 in	vitro	circumstances	takes	20-30	hours	(Strachan	&	Read	2011).	
However,	in	highly	proliferating	cells,	the	cycle	is	shorter	and	takes	between	10	to	20	hours	
(Lodish	et	al.	2007)	and	extremely	fast	proliferating	cells	in	embryos	may	do	so	even	more	
rapidly	(Weinberg	2007).		
	
The	position	of	the	cell	in	the	cell	cycle	at	time	of	irradiation	has	an	influence	on	the	cellular	
response.	In	general,	cells	are	most	radiosensitive	in	G2	and	M	phase	of	the	cell	cycle	as	a	
double	DNA	content	is	present.	On	the	contrary,	they	are	most	radioresistant	in	S	phase,	at	
time	 of	 DNA	 duplication,	 due	 to	 activated	DNA	 repair	mechanisms	 for	 supervision	 of	 the	
replication	process	(La	Torre	Travis	1989).	
	
3.2.2 Cell	cycle	checkpoints	
In	 order	 to	 prevent	 DNA	 damage	 transmission	 to	 the	 daughter	 cells,	 a	 cell	 possesses	
monitoring	mechanisms,	called	checkpoints.	Throughout	the	cell	cycle,	four	checkpoints	aid	
in	the	maintenance	of	genomic	stability	(see	Figure	1.15).	They	act	on	cell	cycle	progression	
through	inactivation	of	several	cyclins	and	cyclin	dependent	kinases,	either	via	induction	of	
transcription	of	certain	inhibitory	proteins	or	through	posttranslational	modifications	(PTM)	
of	mediator	proteins.	Checkpoint	arrest	through	PTM	of	mediators	is	generally	considered	to	
be	a	fast	process	whereas	induction	of	arrest	by	means	of	transcription	induction	is	relatively	
slow.	 Removal	 of	 the	 PTM	 by	 specific	 enzymes	 or	 degradation	 of	 transcribed	 proteins	
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ultimately	results	 in	checkpoint	silencing	and	completion	of	the	cell	cycle	(Weinberg	2007;	
Lodish	et	al.	2007;	Shaltiel	et	al.	2015).		
	
The	 G1/S	 checkpoint	 prevents	 cells	 from	 starting	 DNA	 synthesis	 when	 DNA	 damage	 is	
detected.	 Upon	 detection	 by	 MRN	 and	 ATM	 of	 the	 DSB	 in	 the	 G1	 phase,	 a	 fast	 p53-
independent	 and	a	 slower	p53-dependent	pathway	 result	 in	 the	 inactivation	of	 the	 cyclin	
E/CDK2	complex	 in	order	 to	prevent	 transition	 to	S	phase	 (Shaltiel	et	al.	2015).	The	ATM-
dependent	G1/S	phase	checkpoint	is	highly	sensitive	and	is	activated	after	the	detection	of	a	
single	double	strand	break	(see	Figure	1.17)	(Deckbar	et	al.	2011).		
	
The	mid	 S	 phase	 checkpoint,	 prevents	 CDC2	 activation	 and	 progression	 to	 G2	 phase	 and	
mitosis	before	completion	of	DNA	duplication.	In	addition,	this	checkpoint	responds	to	double	
strand	breaks	by	the	activation	of	both	ATM	(detection	of	a	double	strand	break)	and	ATR	
(Ataxia	telangiectasia	and	Rad3	related)	(detection	of	single	strand	DNA	due	to	end	resection).	
The	p53-dependant	pathway	loses	its	importance	as	downstream	p21	is	degraded	in	S	phase.	
The	 p53	 independent	ATM	pathway	 and	 the	 activation	 of	 ATR	 ultimately	 results	 in	 cyclin	
A/CDK2	inactivation	and	arrest	in	S	phase	(see	Figure	1.17)	(Shaltiel	et	al.	2015).		
	
The	G2/M	checkpoint	prevents	cells	with	an	incomplete	or	damaged	genome	to	enter	mitosis.	
ATM	activation	upon	detection	of	a	double	strand	break	in	G2	phase	of	the	cell	cycle	leads	to	
a	similar	response	as	in	the	G1	phase.	Furthermore,	ATR	activation	due	to	DNA	end	resection	
results	in	an	additional	reinforcing	pathway.	All	activated	pathways	target	cyclin	A/CDK2	and	
cyclin	B/CDK1	(or	CDC2)	activity	to	prevent	entering	of	the	mitoses	and	provide	sufficient	time	
for	double	strand	break	repair	(Shaltiel	et	al.	2015).	The	G2/M	checkpoint	is	less	sensitive	than	
the	G1/S	checkpoint.	As	much	as	ten	to	20	double	strand	breaks	would	be	necessary	to	arrest	
(highly	damaged)	cells	 in	G2	phase	(see	Figure	1.17)	(Deckbar	et	al.	2011;	Löbrich	&	Jeggo	
2007).		
The	 M	 phase	 checkpoint	 is	 important	 for	 proper	 execution	 of	 the	 mitosis	 rather	 than	
detection	 and	 signaling	 of	 DNA	 damage.	 M	 phase	 arrest	 is	 activated	 by	 improper	
chromosome/mitotic	spindle	organization	(Weinberg	2007;	Lodish	et	al.	2007).	Detection	of	
a	double	strand	break	does	not	result	in	checkpoint	activation	as	downstream	factors	are	not	
activated	(see	Figure	1.17)	(Shaltiel	et	al.	2015).		
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Figure	1.17:	DNA	damage	signaling	after	double	strand	break	induction	
a.	 the	 presence	 of	 a	 double	 strand	 break	 in	 the	 G1	 phase	 of	 the	 cell	 cycle	 results	 in	 the	
activation	of	ATM.	ATM	subsequently	activates	Chk2	 (checkpoint	kinase	2),	a	kinase	which,	
together	with	ATM	stabilizes	p53.	P53	leads	to	transcription	of	p21	which	in	turn	inhibits	Cylcin	
E/CDK2	in	prevention	of	progression	to	S	phase.	In	addition,	Chk2	phosphorylates	Cdc25A	(cell	
division	cycle	protein),	which	leads	to	its	inactivation.	Absence	of	the	phosphatase	activity	of	
Cdc25A	keeps	the	Cylcin	E/CDK2	complex	in	its	phosphorylated	form,	unable	to	activate	cell	
cycle	progression	to	S	phase.	
b.	In	S	phase,	a	double	strand	break	undergoes	end	resection	due	to	CDK2	phosphorylation	of	
CtIP	 and	 Exo1	 leading	 to	 single	 strand	 fragments.	 The	 double	 strand	 break	 activates	 ATM,	
whereas	 the	single	 strand	DNA	results	 in	ATR	activation.	ATM	activates	chk2	and	 results	 in	
Cdc25	phosphorylation.	However,	downstream	accumulation	of	p21	via	p53	is	interrupted	by	
ubiquitin	 ligase.	 ATR	 on	 the	 other	 hand	 activates	 Chk1,	 leading	 to	 both	 Cdc25A	 inhibition	
(phosphatase)	and	Wee1	(kinase)	activation.	As	during	G1	phase,	inactive	phosphatase	cdc25A	
results	 in	 phosphorylated	 CDK2.	 In	 addition,	 activated	 Wee1	 phosphorylates	 CDK2.	 Both	
pathways	lead	to	the	inactivation	of	the	Cyclin	A/CDK2	and	S	phase	arrest.	
c.	In	G2	phase,	ATM	inhibits	cell	cycle	progression	in	a	similar	manner	as	during	G1	phase.	In	
addition,	end	resection	results	in	ATR	activation	and	the	inhibition	and	activation	of	Cdc25	and	
Wee1	respectively.	The	net	result	is	the	inactivation	of	both	Cyclin	A/CDK1	(or	Cdc2)	and	Cyclin	
B/CDK1	(Cdc2)	to	arrest	the	cell	in	G2	phase	of	the	cell	cycle.	
d.	During	mitosis,	Plk1	(Polo-like	kinase	3)	and	CDK1	(Cdc2)	inhibit	activation	of	Chk1	and	Chk2	
respectively.	 Furthermore,	 both	 proteins	 phosphorylate	 several	 DNA	 repair	 proteins.	 This	
results	in	the	inhibition	of	double	strand	break	repair	and	checkpoint	arrest.		
Adapted	(Shaltiel	et	al.	2015).	
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3.2.3 BRCA1	in	cell	cycle	checkpoint	arrest	
BRCA1	is	necessary	for	both	G1/S	and	G2/M	checkpoint	activation	through	signaling	of	DNA	
damage	(Löbrich	&	Jeggo	2007).	Its	effect	on	the	G2/M	checkpoint	could	be	dual.	Yarden	et	
al.	demonstrated	an	activation	of	Chk1	by	BRCA1,	subsequently	leading	to	Cdc25	inhibition	
and	Wee1	activation.	Another	possibility	is	direct	ubiquitination	of	Cdc25	and	Cyclin	B.	This	
would	be	achieved	by	heterodimer	formation	and	subsequent	activation	of	E3	ubiquitin	ligase	
activity	 with	 BARD1	 (BRCA1	 associated	 RING	 domain	 1)	 through	 RING	 domains	 on	 both	
proteins.	All	pathways	eventually	result	in	inactivation	of	the	Cyclin	B/Cdc2	(CDK1)	complex	
and	G2	arrest	(Yarden	et	al.	2002;	Shabbeer	et	al.	2013).	
	
3.3 Repair	of	radiation-induced	DSB	
3.3.1 Detection	and	signaling	of	a	DNA	double	strand	break	
Activation	 of	 the	 DNA	 damage	 response	 begins	 with	 the	 detection	 of	 the	 DNA	 damage.	
Pending	on	the	type	of	DNA	damage,	specific	proteins	will	detect	and	signal	its	presence	to	
activate	 a	 multitude	 of	 cellular	 responses.	 For	 DNA	 DSB	 breaks,	 two	 major	 sensors	 are	
identified.		
	
The	first	sensor	is	the	MRN	complex,	reviewed	by	Rupnik	at	al.	(Rupnik	et	al.	2010).		
The	MRN	complex	is	composed	of	RAD50,	NBS1	(Nibrin)	and	MRE11.	MRE11	nuclease	forms	
a	homodimer	and	catalyzes	the	basic	MRN	function	of	DNA	binding.	The	MRE11	homodimer	
interacts	 with	 RAD50	 and	 NBS1	 by	 means	 of	 a	 C-	 and	 N-terminal	 domain	 respectively	
(Williams	et	al.	2008).	RAD50	plays	a	role	in	DNA	binding,	the	unwinding	and/or	tethering	of	
the	DNA	break	ends	(de	Jager	et	al.	2002).	NBS1	serves	as	a	regulator	protein.	 It	does	not	
possess	any	enzymatic	activities,	but	is	essential	for	the	nuclear	localization	of	both	MRE11	
and	RAD50	(Cerosaletti	et	al.	2000).	It	also	catalyzes	the	focal	assembly	of	the	complex	(Lee	
&	Paull	2004)	and	finally,	 it	 stimulates	the	activities	of	both	MRE11	and	RAD50	(Lee	et	al.	
2003).	
	
Recruitment	of	MRN	to	the	DSB	site	results	in	activation	of	DNA	checkpoint	kinase	ATM	(see	
Figure	 1.18).	 The	 inactive	ATM	dimers	 undergo	 autophosphorylation	 at	 Ser	 residue	 1981,	
which	result	in	active	monomers.	In	order	to	achieve	ATM	activation	at	DSB	sites,	blunt	ends	
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or	 short	 overhangs	 are	 needed.	 Presence	 of	 long	 overhangs	 (25	 nucleotides	 and	 more),	
inhibits	 ATM	 activation	 and	 initiates	 ATR	 activation	 (Matt	 &	 Hofmann	 2016;	 Paull	 2015).	
Activated	ATM	subsequently	activates	an	array	of	proteins	needed	for,	amongst	others,	DNA	
repair	 and	 cell	 cycle	 arrest	 (Paull	 2015).	Upon	 its	 activation,	ATM	phosphorylates	 histone	
variant	H2AX	at	serine	residue	139,	referred	to	as	gH2AX.	Phosphorylated	H2AX	subsequently	
serves	as	a	binding	substrate	for	MDC1.	Binding	and	activation	of	MDC1	protects	gH2AX	from	
dephosphorylation	and	enhances	ATM	recruitment	and	binding	at	the	DSB	site.	This	further	
promotes	 the	 total	 gH2AX	 signal	 and	 leads	 to	 an	 amplification	 loop	 (Paull	 2015;	Matt	 &	
Hofmann	2016).	Besides	coordination	of	the	DNA	repair,	ATM	is	also	directly	involved	in	the	
initiation	of	HR	(see	chapter	3.3.2.2)	(Matt	&	Hofmann	2016).		
	
	
Figure	 1.18:	 DNA	 damage	 detection	 and	 signaling	 by	 means	 of	 MRN	 and	 ATM	 (top)	 or	
Ku70/Ku80	and	DNA-PKcs	(bottom)	(Hartlerode	et	al.	2015).	
	
Besides	activation	of	the	MRN	complex/ATM	and	subsequent	initiation	of	DNA	repair	and	cell	
cycle	arrest,	DNA	DSBs	are	also	detected	by	the	Ku70/Ku80	heterodimer	which	binds	blunt	
free	DNA	ends	(Hartlerode	et	al.	2015)	(see	Figure	1.18).	This	second	sensor	relocates	to	the	
DSB	site	independently	of	the	MRN	complex.	Ku70/Ku80	is	activated	upon	DNA	binding	and	
recruits	 DNA-PKcs	 (DNA-dependent	 protein	 kinase;	 catalytic	 subunit)	 to	 the	 damage	 site.	
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DNA-PKcs	 subsequently	 coordinates	 non-homologous	 end-joining	 (discussed	 in	 chapter	
3.3.2.1)	and	is	furthermore	also	capable	of	phosphorylating	H2AX	(Matt	&	Hofmann	2016;	
Hartlerode	et	al.	2015).	Both	the	Ku	heterodimer	and	MRN	are	recruited	within	half	a	minute	
to	the	DSB	site	(Hartlerode	et	al.	2015).	
	
3.3.2 Pathways	for	the	repair	of	radiation-induced	DSB	
3.3.2.1 Non-homologous	end-	joining	
Classical	non-homologous	end-joining	(c-NHEJ)	is	the	dominant	repair	pathway	for	radiation-
induced	DSB	(DSB)	in	mammalian	cells.	NHEJ	is	active	in	all	phases	of	the	cell	cycle	except	for	
mitosis	as	there	is	no	repair	in	this	particular	phase	(Heijink	et	al.	2013).	The	initial	steps	of	c-
NHEJ	are	 the	binding	of	 the	Ku70/Ku80	heterodimer	 to	 the	DSB	site	and	 recruitment	and	
activation	of	the	catalytic	subunit	of	DNA-dependent	protein	kinase	(DNA-PKcs)	(Walker	et	al.	
2001)	 (see	 Figure	 1.19).	 DNA-PKcs	 undergoes	 autophosphorylation	 and	 subsequently	
phosphorylates	an	array	of	DDR	proteins,	thereby	regulating	c-NHEJ	(Chan	&	Chen	2002).	It	
recruits	 and	 phosphorylates	 Artemis	 nuclease	 to	 resolve	 damaged	 DNA	 ends	 of	 complex	
breaks,	for	example	induced	by	ionizing	irradiation	(Deriano	&	Roth	2013).	Furthermore,	DNA-
PKcs	 recruits	 several	 polymerases	 (e.g.	 pol	 µ	 and	 l)	 and	 Terminal	 deoxynucleotidyl	
Transferase	(TdT).	DNA	polymerase	l	stabilizes	the	DNA	ends.	Polymerase	µ	 is	able	to	add	
nucleotides	to	a	blunt	end	and	TdT	catalyzes	the	addition	of	multiple	nucleotides	without	a	
DNA	template.	These	three	DNA	end-processing	activities	create	compatible	DNA	ends	for	
ligation.	Finally,	PAXX	(Paralog	of	XRCC4	and	XLF)	is	recruited	to	the	DSB	site	by	Ku70/Ku80	to	
complete	DNA	ligation;	assisted	by	Ligase4,	XRCC4	(X-ray	repair	cross-complementing	protein	
4)	 and	 XLF	 (XRCC4-like	 factor)	 for	 stabilization	 of	 the	 DNA	 ends	 (Borgmann	 et	 al.	 2016;	
Mladenov	et	al.	2016;	Rodgers	&	Mcvey	2016	(and	references	herein)).		
	
As	c-NHEJ	restores	DSB	without	a	template,	it	can	be	associated	with	the	induction	of	small	
DNA	 alterations	 (Rodgers	 &	 Mcvey	 2016),	 but	 can	 also	 result	 in	 larger	 chromosomal	
rearrangement,	particularly	translocations	(Mladenov	et	al.	2016).		
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Figure	1.19:	Schematic	visualization	of	c-NHEJ	(see	text)	(Mladenov	et	al.	2016).	
	
3.3.2.2 Homologous	recombination	
HR	is	a	pathway	which	relies	on	the	sister	chromatid	available	during	the	S	and	G2	phase	of	
the	cell	cycle	for	DSB	repair	and	can	therefore	only	be	activated	when	DSB	are	 induced	in	
these	particular	phases	of	the	cell	cycle.	As	it	relies	on	a	template,	repair	is	largely	error-free.	
However,	the	complex	pathway	results	in	a	relatively	slow	repair	and	can	take	up	to	7	hours	
(Mladenov	et	al.	2016;	Mao	et	al.	2008a).	Upon	detection	of	the	DSB	by	the	MRN	complex	
and	signaling	by	ATM,	HR	relies	on	the	MRN	complex	and	the	recruited	CtIP	for	the	initiation	
of	the	5’	to	3’	end	resection.	Therefore,	CtIP	redirects	the	MRN	complex	role	at	the	site	of	the	
DSB	from	DSB	sensor	to	resection	activator	(You	&	Bailis	2010;	Sartori	et	al.	2007).	In	a	second	
phase,	Exo1	(exonuclease	1)	and	Dna2/BLM	(Bloom	syndrome	protein)	are	recruited	to	the	
DSB	site	for	additional	end	resection.	Exo1	binds	the	double	stranded	DNA	with	recessed	5’	
ends	as	produced	by	CtIP	(CtBP-interacting	protein)	and	MRN	end	resection.	BLM,	associated	
in	a	complex	with	Dna2	helicase,	assists	in	the	unwinding	of	the	3’	DNA.	Dna2	on	the	other	
hand	is	necessary	for	its	endonuclease	activity	in	the	DNA	resection	(Liu	&	Huang	2016).	The	
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resection-induced	single	stranded	DNA	is	subsequently	coated	with	RPA	for	stabilization.	The	
RPA	coated	ssDNA	is	in	essence	a	substrate	for	other	repair	proteins	(Zou	et	al.	2006).	One	of	
those	 proteins	 is	 BRCA1.	 BRCA1	 subsequently	 coordinates	 recruitment	 of	 BRCA2	 and	 its	
binding	partner	PALB2	to	the	DSB	site.	BRCA2,	assisted	by	RAD52,	PALB2	and	BRCA1,	mediates	
HR	by	loading	of	RAD51	on	the	ssDNA,	thus	replacing	RPA	(Liu	et	al.	2010;	Mladenov	et	al.	
2016;	 Rodgers	 &	 Mcvey	 2016).	 RAD51	 is	 the	 key	 recombinase	 of	 HR	 and	 acts	 in	 a	
microfilament	with	its	paralogs	(see	Figure	1.20).	Accumulation	of	BRCA2,	RAD51	and	RAD51	
paralogs	at	the	DSB	initiate	the	search	for	the	homologous	sequence	and	strand	invasion	(see	
Figure	1.21)	(Mladenov	et	al.	2016;	Rodgers	&	Mcvey	2016;	McIlwraith	et	al.	2000).		
	
Figure	1.20:	Schematic	visualization	of	HR	(see	text)	(Mladenov	et	al.	2016).	
	
After	 RAD51	 filament	 formation,	 the	 search	 for	 the	 homologous	 sequence	 and	 strand	
invasion,	three	different	pathways	can	be	initiated	to	allow	DSB	repair.		
The	first	pathway,	double-strand	break	repair	(DSBR)	(see	Figure	1.21	middle	panel),	results	
in	a	displacement	loop	(D-loop)	after	strand	invasion,	in	which	the	3’	end	of	the	broken	DNA	
aligns	with	the	invaded	strand.	DNA	polymerases	subsequently	elongate	the	DNA,	thereby	
extending	the	D-loop.	The	extended	D-loop	results	in	the	alignment	of	the	displaced	strand	
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with	the	3’	single	strand	tail,	with	the	formation	of	a	double	holiday	junction.	Upon	successful	
elongation	and	ligation	of	the	DNA,	this	holiday	junction	is	resolved	by	endonucleases,	more	
specifically,	 resolvases.	 This	 results	 in	 formation	 of	 either	 crossover	 or	 non-crossover	
products.	Despite	being	perceived	as	largely	error-free	because	of	the	use	of	a	DNA	template,	
DSBR	can	induce	errors	due	to	the	use	of	an	error-prone	polymerase	(polymerase	 z)	and	the	
instability	of	large	stretches	of	ssDNA	(Mladenov	et	al.	2016;	Rodgers	&	Mcvey	2016;	Li	&	Xu	
2016).		
The	 second	 pathway,	 synthesis-dependent	 strand	 annealing	 (SDSA)	 (see	 Figure	 1.21	 left	
panel),	 initially	 follows	 the	DSBR	pathway.	However,	 the	extension	of	 the	D	 loop	 leads	 to	
unwinding	of	this	loop,	re-annealing	to	the	other	3’	end	of	the	broken	strand	and	filling	of	the	
gaps.	SDSA	never	results	in	crossover	products.	SDSA	could	be	perceived	as	more	conservative	
as	the	template	DNA	remains	intact.	However,	as	the	D-loop	unwinds,	the	newly	formed	DNA	
has	the	possibility	to	align	with	sequences	other	than	the	other	end	of	the	DSB,	which	could	
result	in	mutagenesis	(Mladenov	et	al.	2016;	Rodgers	&	Mcvey	2016).		
A	third,	alternative	option	is	break-induced	replication	(BIR)	(see	Figure	1.21	right	panel).	BIR,	
in	essence	a	specific	pathway	for	repair	of	one-ended	DSB,	relies	on	the	synthesis	of	 large	
sections	of	DNA	(as	large	as	100	kb).	However,	BIR	is	also	described	as	backup	for	SDSA	and	
DSBR.	BIR	completes	repair	by	initiation	of	a	replication	fork	and	relies	on	common	replication	
factors	and	on	a	few	specific	polymerases	(Pol32/PolD3).	DNA	repair	starts	with	invasion	of	
the	template	DNA	and	synthesis	following	the	leading	strand.	DNA	synthesis	of	the	lagging	
strand	completes	BIR.	BIR	is	also	perceived	as	being	a	more	error-prone	type	of	HR	DSB	repair	
because	of	occurrence	of	template	switching.	BIR	can	even	result	in	complex	chromosomal	
translocations	if	multiple	template	switches	occur	(Mladenov	et	al.	2016;	Rodgers	&	Mcvey	
2016).		
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Figure	1.21:	Schematic	visualization	of	the	three	different	pathways	for	repair	of	the	DSB	by	
HR	(see	text)	(Mladenov	et	al.	2016).	
	
3.3.2.3 Alternative	DSB	repair	pathways		
Besides	the	previously	discussed	c-NHEJ	and	HR,	the	cell	also	resorts	to	backup	mechanisms	
to	 repair	 radiation-induced	 DSB.	 To	 date,	 there	 are	 three	 main	 alternative	 pathways	
described:	Alternative	NHEJ	(Alt-EJ)	(also	referred	to	as	theta-mediated	end	joining	(TMEJ)	or	
backup	 NHEJ	 (B-NHEJ)),	 microhomology-mediated	 end-joining	 (MMEJ)	 and	 single	 strand	
annealing	(SSA).	All	these	backup	mechanisms	lead	to	erroneous	repair	of	the	DSB,	however,	
the	different	pathways	are	not	always	 fully	understood	 (Mladenov	et	al.	2016;	Rodgers	&	
Mcvey	2016;	Deriano	&	Roth	2013).		
	
Alternative	 end-joining	 (Alt-EJ)	 starts	 with	 the	 binding	 of	 PARP1	 (poly	 (ADP-ribose)	
polymerase	 1)	 to	 the	 DSB	 site	 where	 it	 competes	 with	 the	 Ku70/Ku80	 heterodimer.	 The	
subsequent	binding	of	CtIP	and	MRN	 results	 in	DNA	end	 resection.	Polymerase	  q	 (POLQ)	
subsequently	interacts	with	the	resected	DNA	and	initiates	elongation	of	the	DNA	ends	using	
the	opposite	ssDNA	sequence	as	template.	Finally,	ligase	1	and	3	ligate	the	DSB	ends,	either	
in	absence	or	presence	of	XRCC1	(see	Figure	1.22)	(Mladenov	et	al.	2016;	Soni	et	al.	2014).		
Repair	 by	 Alt-EJ	 is	 more	 error-prone	 than	 c-NHEJ.	 Not	 only	 are	 small	 deletions	 and/or	
insertions	of	DNA	observed	after	repair,	alt-EJ	also	results	in	a	higher	number	of	chromosomal	
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translocations.	This	increase	could	be	due	to	the	absence	of	Ku-heterodimer	binding	at	the	
DSB	 site	 in	 alt-NHEJ,	which	 stabilizes	 the	ends	of	 the	DSB,	 and	 the	 slower	 repair	 kinetics,	
allowing	 for	 exchange	 at	 sites	 with	 multiple	 DSB	 close	 to	 each	 other	 and	 resulting	 in	
chromosomal	translocations	(Deriano	&	Roth	2013;	Rodgers	&	Mcvey	2016).		
	
	
Figure	1.22:	Schematic	visualization	of	alternative	end	joining	(see	text)	(Mladenov	et	al.	2016).	
	
Alternative	end-joining	may	rely	partly	or	completely	on	microhomology.	This	is	possible	due	
to	end	resection	by	CtIP	and	MRN,	and	would	rely	on	the	use	of	a	small	number	of	nucleotides	
(usually	 2-4	 nt)	 for	 DNA	 alignment,	 possibly	 catalyzed	 by	 polymerase	  q,	 and	 subsequent	
ligation.	Microhomology-mediated	end-joining	(MMEJ)	has	also	been	described	as	a	backup	
repair	 pathway	 and	 demonstrates	 large	 resemblance	 with	 microhomology-driven	 alt-EJ.	
MMEJ	would	require	larger	homologous	fractions,	typically	six	to	20	nucleotides,	but	it	also	
relies	on	DNA	end	resection	and	proteins	such	as	PARP1,	ligase	1	and	ligase	3.	Whereas	MMEJ	
relies	 on	 end	 resection	 for	 unveiling	 of	microhomologous	 fragments,	 alt-EJ	 can	 resort	 to	
activation	of	polymerase	 q	for	(template	dependent	or	independent)	synthesis	of	new	DNA,	
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which	could	mediate	as	microhomologous	sequences.	In	this	regard,	Alt-EJ	could	be	referred	
to	as	synthesis-mediated	MMEJ	(SM-MMEJ)	(Mladenov	et	al.	2016;	Rodgers	&	Mcvey	2016;	
Yu	&	McVey	2010).	
	
Single	Strand	annealing	(SSA)	is	often	described	as	an	extreme	version	of	MMEJ	or	alt-EJ	(or	
SM-MMEJ).	However,	it	also	shows	similarities	to	HR	(Mladenov	et	al.	2016;	Rodgers	&	Mcvey	
2016).	SSA	typically	occurs	when	the	DSB	is	induced	in	genomic	loci	with	extensive	homology.	
It	relies	on	extensive	end	resection	to	reveal	complementary	DNA	ends	with	the	length	of	the	
complementary	sequences	varying	between	25	nt	and	multiple	kilobases.	SSA	relies	on	CtIP	
for	end	resection	and	RPA	for	stabilization	of	the	ssDNA.	RAD52	mediates	annealing	of	the	
homologous	DNA	and	DNA	 ligase	1	 ligates	 the	DNA	 sequences.	 ERCC1	and	XFP	nucleases	
foresee	in	trimming	of	the	created	DNA	tails.	Repair	of	DSB	via	SSA	results	in	deletion	of	DNA	
sequences	of	variable	length,	but	could,	in	specific	situations,	also	result	in	translocations	(see	
Figure	1.23)	(Mladenov	et	al.	2016;	Rodgers	&	Mcvey	2016;	Bhargava	et	al.	2016)	
	
	
Figure	1.23:	Schematic	visualization	of	single	strand	annealing	(Mladenov	et	al.	2016).	
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3.3.2.4 PARP	activity	and	inhibition	–	A	breast	cancer	targeted	therapy	
PARP	function	
PARP1	 catalyzes	 poly(ADP-ribosyl)ation	 (PARylation),	 a	 post	 translational	 modification,	 of	
several	proteins	including	DNA	damage	repair	proteins.	It	was	initially	identified	as	necessary	
for	efficient	repair	of	single	strand	breaks	by	means	of	base	excision	repair	 (BER)	but	also	
appears	to	be	involved	in	nucleotide	excision	repair	and	DSB	repair	(Khodyreva	&	Lavrik	2016).	
Both	PARP1	and	PARP2	are	necessary	for	SSB	repair	by	BER.	The	proteins	have	an	overlapping	
function,	but	differences	in	their	substrate	preferences	are	noticeable	(Langelier	et	al.	2014).	
In	short,	the	detection	of	a	SSB	and	binding	of	PARP1/2,	results	in	its	activation.	This	activation	
results	in	autoPARylation	with	NAD+	as	substrate	and	subsequent	dissociation	of	PARP	at	the	
SSB.	This	allows	access	of	other	repair	factors,	such	as	XRCC1	to	bind	and	repair	the	SSB	(see	
Figure	1.24,	left	panel	(A-D))	(Pommier	et	al.	2016).		
	
	
Figure	1.24:	DNA	repair	by	PARP1	and	the	effects	of	PARP	inhibitors	(see	text)	(Pommier	et	al.	
2016)	(adapted).	DSE	=	single-ended	DSB	
	
In	addition	to	its	role	in	SSB	repair,	PARP1	is	also	involved	in	(single-ended)	DSB	repair	(see	
Figure	 1.24	M).	 PARP1	 competes	with	 the	Ku70/80	heterodimer	 for	 binding	of	DSB	ends.	
Binding	of	the	Ku	heterodimer	results	in	NHEJ.	During	NHEJ,	PARP1	binds	to	DNA-PKcs	and	
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PARylates	its	catalytic	subunit,	thus	increasing	its	kinase	activity.	On	the	other	hand,	binding	
of	PARP1	 instead	of	Ku70/Ku80	 to	 the	DSB	promotes	alt-EJ	or	HR.	 Furthermore,	PARP1	 is	
involved	in	the	resolution	of	stalled	replication	forks	(see	Figure	1.24	I	&	J).	PARP1	binds	to	
stalled	replication	forks	where	it	aids	in	recruitment	of	the	MRN	complex	and	initiations	of	
HR	 (Khodyreva	 &	 Lavrik	 2016;	 Pommier	 et	 al.	 2016).	 Finally,	 PARP1	 also	 has	 a	 role	 in	
nucleotide	 excision	 repair	 (NER),	 a	 repair	 pathway	 for	 bulky	 adducts,	 induced	 by	 short-
wavelength	UV	light	(Khodyreva	&	Lavrik	2016).		
	
PARP	inhibition	
PARP	 inhibition	 is	 a	 targeted	 therapy	 which	 exploits	 HR	 deficiency	 in	 tumor	 cells.	 This	
characteristic	 is	 predominantly	 observed	 in	 BRCA1	 and	 BRCA2	 mutation	 carriers,	 as	 the	
second,	still	functional	allele	is	lost	in	tumor	cells	(loss	of	heterozygosity).	However,	tumors	
who	exhibit	 a	HR	deficiency	without	 the	germinal	mutation	 in	BRCA1	or	BRCA2,	 so	 called	
‘BRCAness’,	may	 also	 benefit	 from	 this	 treatment.	 Impaired	HR	 activation	may	 be	 due	 to	
inactivating	mutations	or	epigenetic	alterations	in	other	genes	involved	in	HR	(see	Table	III)	
(Lord	&	Ashworth	2016).		
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Table	III.	Overview	of	all	cancer-associated	alterations	in	BRCAness	genes	(Lord	&	Ashworth	
2016).		
	
	
In	2014,	Olaparib	(commercially	available	as	Lynparza,	AstraZeneca,	UK)	was	the	first	PARP	
inhibitor	to	be	approved	by	the	American	Food	and	Drug	administration	(FDA)	and	European	
Medicines	 Agency	 (EMA)	 for	 treatment	 of	 advanced	 ovarian	 cancer	 due	 to	 a	 germline	 or	
somatic	BRCA1	or	BRCA2	mutation	carriers	(Brown	et	al.	2016;	Kim	et	al.	2015).	However,	
several	 other	 promising	 PARP	 inhibitors	 are	 currently	 tested	 in	 different	 clinical	 trials,	
including	rucaparib,	niraparib	and	veliparib.	In	June	2016,	the	FDA	accepted	the	submission	
of	rucaparib	(Clovis	Oncology,	USA)	for	accelerated	approval	(Businesswire	2016).		
	
The	activity	of	a	PARP	inhibitor,	such	as	Olaparib,	is	dual.	On	the	one	hand,	it	inhibits	repair	
of	single	strand	breaks	by	 inhibition	of	both	PARP1	and	PARP2	(see	Figure	1.24	F).	On	the	
other	hand,	it	traps	PARP	at	the	DNA	damage	site	resulting	in	toxic	PARP-DNA	complexes	(see	
Figure	1.24	G,	K,	L	and	N).	PARP	trapping	is	only	partially	understood,	but	may	be	the	result	
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of	direct	 interactions	of	 the	 inhibitor	with	 the	PARP	NAD+	binding	 site	 (Murai	et	al.	2012;	
Pommier	et	al.	2016).		
	
The	failure	to	repair	SSB	results	 in	a	stalled	replication	fork	during	synthesis.	This	unstable	
complex	might	subsequently	collapse,	resulting	in	a	single-ended	DSB	(DSE).	In	addition,	a	DSE	
can	 also	 be	 induced	 to	 resolve	 blocked	 replication	 forks.	 The	 cell	 subsequently	 relies	 on	
factors	such	as	BRCA1	and	BRCA2	and	HR	to	resolve	these	induced	DSE	(see	Figure	1.24	F)	
(Pommier	 et	 al.	 2016;	 Zeman	 &	 Cimprich	 2014;	 Lim	 &	 Kaldis	 2013).	 PARP	 trapping	 is	
considered	more	deleterious	than	the	non-repaired	SSB.	However,	the	mechanisms	are	not	
fully	 understood.	 One	 possibility	 is	 the	 collision	 of	 the	 replication	 fork	 at	 the	 PARP-DNA	
complexes.	This	subsequently	results	in	the	collapse	of	the	replication	fork	and	the	formation	
of	a	DSE.	Again,	the	cell	must	rely	on	BRCA1/BRCA2	mediated	HR	for	repair	(Pommier	et	al.	
2016).	However,	HR	deficient	tumor	cells	struggle	to	cope	with	the	 induced	damage	while	
heterozygous	cells	 still	express	BRCA1	and	BRCA2	and	 therefore,	HR	can	be	 initiated.	This	
ultimately	leads	to	tumor-specific	cell	death	and	is	referred	to	as	synthetic	lethality	as	only	
the	 combination	 of	 BRCA1/2	 protein	 loss	 in	 the	 tumor	 cell	 and	 PARP	 inhibition	 is	 lethal	
(Pommier	et	al.	2016;	Murai	et	al.	2012;	Lord	&	Ashworth	2016).		
	
3.3.3 Pathway	choice	for	repair	of	radiation-induced	DSB	
3.3.3.1 Cell	cycle	phase	
Pathway	choice	relies	on	a	complex	interplay	of	proteins	and	is	not	completely	understood.	
The	phase	of	the	cell	cycle	determines,	to	a	great	degree,	the	choice	of	DSB	repair	pathway.	
Classically,	c-NHEJ	is	presented	as	the	pathway	of	first	choice	and	its	activity	is	predominant	
throughout	all	phases	of	the	cell	cycle,	except	for	mitosis.	During	S	and	G2	phase,	the	presence	
of	 the	homologous	sister	chromatid	allows	HR.	However,	studies	demonstrated	that	HR	 is	
predominantly	upregulated	in	S-phase,	as	it	 is	 important	in	replication-induced	DSB	repair.	
The	use	of	this	repair	pathway	declines	again	during	G2	phase	in	favor	of	NHEJ	(Mao	et	al.	
2008b;	Li	&	Xu	2016;	Mladenov	et	al.	2016).	Besides	these	two	traditional	repair	pathways,	
the	cell	also	has	a	selection	of	backup	repair	pathways	which	may	be	activated	in	different	
phases	of	the	cell	cycle	(Mladenov	et	al.	2016).		
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In	essence,	DSB	end	resection	is	the	divergent	step	in	the	DSB	repair	pathway	choice	(Li	&	Xu	
2016).	In	first	instance,	the	cell	relies	on	c-NHEJ,	however,	failure	of	the	Ku	heterodimer	to	
detect	or	bind	to	the	DSB	or	failure	of	DNA-PKcs	to	initiate	c-NHEJ	allows	for	end	resection	of	
the	DSB,	 guiding	 the	 repair	 towards	 SSA,	MMEJ,	 alt-EJ	or	HR	 (Kakarougkas	&	 Jeggo	2014;	
Mladenov	et	al.	2016).	End	resection	is	upregulated	during	S	and	G2	phase	of	the	cell	cycle,	
allowing	for	an	upregulation	of	HR	in	these	phases	of	the	cell	cycle,	in	addition	to	SSA,	MMEJ	
and	alt-EJ.	This	upregulation	is	predominantly	associated	with	CtIP	activity	in	S	and	G2	phase	
of	the	cell	cycle	due	to	CDK2	and	BRCA1	modifications	(Ceccaldi	et	al.	2016;	You	&	Bailis	2010).		
	
53BP1	(p53-binding	protein	1),	on	the	other	hand,	promotes	c-NHEJ	during	G1	phase	of	the	
cell	cycle	as	it	restricts	end	resection	(Li	&	Xu	2016;	Mladenov	et	al.	2016).	53BP1	interaction	
at	the	DSB	is	mutually	exclusive	with	BRCA1.	The	presence	of	53BP1	results	in	c-NHEJ,	while	
binding	of	BRCA1	guides	repair	towards	HR	during	S	and	G2	phase	of	the	cell	cycle	(Panier	&	
Boulton	 2014;	 Li	 &	 Xu	 2016).	 However,	 as	 discussed	 previously,	 the	 underlying	 ‘decision	
process’	 is	 not	 completely	 understood.	 Recent	 studies	 demonstrated	 that	 53BP1	 also	
promotes	MMEJ	during	G1	phase	of	the	cell	cycle.	End	resection	for	MMEJ	would	involve	the	
activation	of	the	MRN	complex	and	CtIP	appears	to	be	BRCA1	dependent	(Xiong	et	al.	2015).	
Furthermore,	 alt-EJ	 is	 also	 active	 in	 G1	 phase	 of	 the	 cell	 cycle	 as	 backup	 mechanism	
(Mladenov	 et	 al.	 2016).	 In	 addition,	 BRCA1	 might	 act	 in	 a	 cell	 cycle	 dependent	 manner	
according	to	Saha	and	Davis	(2016).	They	propose	a	key	role	for	BRCA1	in	promotion	of	precise	
DSB	 repair	 as	 it	 induces	 c-NHEJ	 in	G1	phase	 and	HR	 in	 S	 and	G2	phase	 (see	 Figure	1.25).	
Pathways	known	to	be	relatively	error-free	compared	to	their	backup	mechanisms	(Saha	&	
Davis	2016).		
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Figure	1.25:	BRCA1	interactions	during	G1	and	S/G2	phase	for	repair	of	radiation-induced	DSB	
(see	text)	(Saha	&	Davis	2016).	A-NHEJ	=	Alt-EJ	
	
During	mitosis,	DSB	are	not	actively	repaired	as	certain	parts	of	the	DDR	are	blocked	despite	
ATM	signaling.	DSB	are	rather	marked	for	repair	after	completion	of	mitosis,	during	G1	phase	
of	the	cell	cycle	(Heijink	et	al.	2013).			
	
3.3.3.2 Complexity	of	the	DSB	
Another	 factor	 influencing	 DSB	 repair	 is	 the	 complexity	 of	 the	 lesion.	 High-LET	 ionizing	
radiation	gives	rise	to	complex	DSB	lesions	containing	multiple	DSB,	SSB	and	base	damage.	
Whereas	more	simple	DSB	induced	by	low-LET	radiation	are	usually	rejoined	within	a	matter	
of	hours,	 	high-LET	DSB	 lesions	are	more	persistent,	 indicating	a	repair	 failure	(Lorat	et	al.	
2016).	Okayasu’s	mini-review	 concerning	DNA	 repair	 upon	one	 specific	 high-LET	 radiation	
quality,	heavy	ion	irradiation,	provides	insights	in	DNA	repair	pathways,	repair	kinetics	and	
misrepair.	As	these	complex	lesions	are	more	difficult	to	repair,	the	slower	repair	kinetics	may	
subsequently	cause	an	increase	in	misrepair	of	DSB	and	chromosome	breaks	in	cells	exposed	
to	heavy	 ions	 (Okayasu	2012).	 Several	 studies	 revealed	 that	 c-NHEJ	 is	not	 the	pathway	of	
choice	for	repair	of	high-LET	DSB	and	demonstrated	that	the	damaged	cell	rather	relies	on	
HR,	MMEJ	and	alt-EJ	for	repair.	All	these	pathways	demand	DSB	end	resection,	which	partially	
explains	the	slower	repair	kinetics	(Lorat	et	al.	2016;	Okayasu	2012;	Wang	et	al.	2008;	Taleei	
&	Nikjoo	2013).	
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3.3.3.3 Chromatin	structure	
DSB	repair	 is	 furthermore	complicated	by	 the	chromatin	 structure.	Variation	 in	chromatin	
structure	does	not	necessarily	influence	the	pathway	choice,	but	it	affects	the	repair	kinetics	
(Taleei	&	Nikjoo	2013).	DNA	undergoes	 several	 levels	of	 compaction	 to	 fit	 the	nucleus.	 In	
order	 to	 achieve	 this	 compaction,	DNA	 is	 complexed	with	 various	 proteins,	 histones,	 and	
subjected	to	coiling	and	supercoiling	to	form	chromatin.	Chromatin	occurs	in	two	different	
degrees	 of	 compaction.	 Euchromatin	 is	 an	 active	 and	 more	 extended	 state	 of	 DNA	
condensation	which	allows	for	transcription	of	genes.	Euchromatin	allows	for	variations	 in	
gene	expression	pending	on	cell	type	or	functional	requirements.	Heterochromatin,	on	the	
other	 hand,	 is	 highly	 condensed.	 Genes	 located	 in	 heterochromatin	 are	 typically	 not	
expressed	(Strachan	&	Read	2011).	Because	of	its	high	compaction,	DSB	in	heterochromatin	
are	 difficult	 to	 access	 for	 DDR	 proteins	 and	 require	 relaxation	mediated	 by	 KAP1	 (KRAB-
associated	protein	1),	which	results	in	a	slower	repair	kinetic.	Chromatin	remodeling	by	KAP1	
is	initiated	by	ATM	activation	after	which	the	DSB	will	be	repaired	by	c-NHEJ	in	G1	phase	and	
c-NHEJ	or	HR	in	S/G2	phase.	DNA	repair	in	function	of	chromatin	condensation	is	reviewed	by	
Goodarzi	et	al.	(Goodarzi	&	Jeggo	2012;	Matt	&	Hofmann	2016;	Hartlerode	et	al.	2015;	Taleei	
&	Nikjoo	2013).	
	
3.4 Extensive	DNA	damage	and	cell	death	
If	 the	 DNA	 damage	 is	 too	 extensive	 and/or	 damage	 is	 irreparable,	 the	 cell	 can	 trigger	
proliferation	arrest	or	cell	death	instead	of	repair.	Apoptosis	is	a	highly	regulated	form	of	cell	
death	which	results	in	the	destruction	and	removal	of	the	damaged	cell	in	order	to	protect	
the	organism.	Alterations	 in	 the	control	of	apoptosis	contributes	to	cancer	 formation.	Cell	
death	can	also	occur	in	a	mitosis-linked	form,	the	mitotic	catastrophe,	which	is	the	result	of	
premature	mitosis-entry.	Senescence	on	the	other	hand	inclines	a	permanent	arrest	of	the	
cell	cycle.	However,	this	mechanism	can	be	overrun.	Furthermore,	the	cell	remains	active	and	
is	 able	 to	 secrete	 pro-inflammatory	 cytokines.	 Whereas	 apoptosis	 and	 necrosis	 create	 a	
permanent	solution,	damaged	senescent	cells	keep	posing	a	source	of	danger	(Baumann	et	
al.	2009;	Matt	&	Hofmann	2016).	Additionally,	cells,	 such	as	hematopoietic	stem	cells	can	
resort	to	differentiation	upon	detection	of	extensive	DNA	damage	to	prevent	the	transfer	of	
damage	DNA	to	daughter	cells	(Wingert	&	Rieger	2016).		
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Apoptosis	 is	a	highly	organized	cell	death	pathway.	This	pathway	 results	 in	a	 the	efficient	
removal	of	damaged	cells	either	due	to	intrinsic	or	extrinsic	damage	(Matt	&	Hofmann	2016).	
Both	pathways	ultimately	result	in	caspase	activation	and	the	formation	of	apoptotic	bodies,	
the	 first	 step	 of	 the	 orchestrated	 cell	 degradation.	 A	 dominant	 player	 in	 these	 apoptosis	
pathways	is	p53,	which	is	activated	upon	ATM	signaling	of	the	DNA	damage	results	(Matt	&	
Hofmann	2016;	Sullivan	et	al.	2012).	P53	is	not	only	necessary	for	apoptosis,	but	its	activation	
upon	detection	of	DNA	damage	also	results	in	a	multitude	of	effects	including	cell	cycle	arrest	
(discussed	 in	 chapter:	 3.2.2	 Cell	 cycle	 checkpoints).	 The	 fine-tuning	 of	 these	 different	
outcomes	is	not	well	understood.	However,	posttranslational	modification	and	differences	in	
accessibility	and	sensitivity	of	response	elements	for	cell	cycle	arrest	and	apoptosis	might	play	
a	role.	Furthermore,	cell	type	and	stimulus	specific	factors	might	have	an	influence	(Matt	&	
Hofmann	2016;	Sullivan	et	al.	2012).	In	addition	to	the	p53-dependent	apoptosis,	the	cell	can	
also	 initiate	 a	 p53-independent	 apoptosis	 pathway.	 This	 pathway	 relies	 on	 chk1/chk2	
activation	by	ATM/ATR	and	the	increased	expression	of	pro-apoptotic	factors	(Roos	&	Kaina	
2006).		
	
While	 apoptosis	 is	 a	 highly	 regulated	 form	 of	 cell	 death,	 necrosis	 is	 a	 disorganized	 and	
unregulated	variant	of	 cell	destruction.	Necrosis	 is	 the	 result	of	profound	cellular	damage	
including	membrane	disruption,	organelle	degradation	and	cellular	swelling.	Necrosis	can	be	
induced	 following	 exposure	 to	 high	 doses	 of	 ionizing	 radiation,	 for	 example	 radiotherapy	
(Lehnert	 2008;	 Baumann	 et	 al.	 2009).	 However,	 Vandenabeele	 and	 his	 research	 group	
demonstrated	the	existence	of	a	controlled	necrosis	(Vercammen	et	al.	1998),	later	defined	
as	 necroptosis.	 Induction	 of	 necroptosis	 relies	 on	 the	 activation	 of	 RIP1	 and	 3	 (receptor	
interacting	protein	kinase	1	and	3),	mediated	by	PARP1,	and	results	in	active	disintegration	of	
mitochondrial,	lysosomal	and	plasma	membranes	(Vandenabeele	et	al.	2010).	
Recently,	Nehs	et	al.	demonstrated	a	role	for	necroptosis	in	radiation-induced	cell	death	in	
endocrine	cancers	(Nehs	et	al.	2011).	As	evasion	of	programmed	cell	death	is	a	hallmark	of	
cancer	which	results	in	treatment	resistance,	(radiation-induced)	necroptosis	might	form	an	
interesting	novel	target	for	therapeutic	intervention	(Fulda	2014).	
	
Mitotic	catastrophe	is	a	delayed	cell	death	process	in	which	cell	death	occurs	during	mitosis.	
Mitotic	catastrophe	is	the	result	of	either	premature	entry	of	this	cell	cycle	phase	due	to	a	
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failure	 of	 the	 G2/M	 cell	 cycle	 checkpoint	 or	 centrosome	 hyperamplification	 (Eriksson	 &	
Stigbrand	2010).	Radiation-induced	mitotic	catastrophe	occurs	several	days	after	exposure	to	
ionizing	radiation	and	is	usually	the	result	of	failed	G2/M	arrest	capacity.	Activation	of	the	
mitotic	 checkpoint	 stops	 cell	 progression	 and	 induces	 caspase	 activation,	 predominantly	
caspase	 2,	 and	 mitochondrial	 damage.	 This	 ultimately	 leads	 to	 “delayed”	 apoptosis	 in	
metaphase	(Castedo	et	al.	2004;	Eriksson	&	Stigbrand	2010).		
	
Senescence	 is	 a	 controlled	 form	 of	 growth	 arrest.	 The	 best-known	 type	 of	 senescence	 is	
replicative	senescence,	which	 is	 the	 result	of	 telomere	attrition	by	 repeated	cell	divisions.	
DNA	damage	 induced	 senescence	 is	 triggered	by	ATM	and	ATR	activation,	promoting	p53	
signaling.	 This	 subsequently	 leads	 to	 p21	 activation	 and	 inhibition	 of	 CDK2	 and	 CDK4	
inhibition.	Inhibition	of	these	kinases	results	in	the	dephosphorylation	of	RB	(retinoblastoma	
protein).	Furthermore,	irreparable	DNA	damage	leads	to	p16	upregulation.	The	induction	of	
RB	and	p16	result	in	G0	arrest	(Burton	&	Faragher	2015;	Baumann	et	al.	2009).		
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4 RADIOSENSITIVITY	OF	BRCA1	AND	BRCA2	MUTATION	CARRIERS	
It	 is	 known	 that	 exposure	 to	 ionizing	 radiation	 results	 in	 an	 increased	 risk	 of	 cancer	
development,	 including	breast	cancer	(see	chapter	1.3	Risk	factors).	However,	exposure	to	
ionizing	radiation	of	BRCA1	and	BRCA2	mutation	carriers	 is	counterintuitive	because	these	
individuals	might	be	characterized	by	an	elevated	radiosensitivity	compared	to	non-carriers	
as	both	BRCA1	and	BRCA2	are	care	taker	genes	involved	in	the	DNA	damage	response.	BRCA1	
has	a	more	pleiotropic	role	in	DNA	damage	repair	as	it	is	involved	in	repair	pathway	selection,	
HR	and	cell	cycle	arrest.	BRCA2	on	the	other	hand	has	a	more	limited,	though	essential,	role	
in	 the	 HR	 pathway	 (Roy	 et	 al.	 2012).	 An	 inadequate	 response	 to	 radiation-induced	 DNA	
damage	in	mutation	carriers	might	result	in	an	elevated	radiosensitivity	for	these	individuals.	
The	 possible	 enhanced	 radiosensitive	 phenotype	 of	 BRCA1	 and	 BRCA2	 mutation	 carriers	
compared	to	non-carriers	has	been	the	subject	of	extensive	research	as	it	may	have	important	
consequences	 regarding	 exposure	 to	 ionizing	 radiation	 for	 diagnostic	 (e.g.	mammography	
screening)	or	therapeutic	purposes	(e.g.	radiotherapy).		
	
4.1 Clinical	studies	
The	evaluation	of	contralateral	breast	cancer	induction	in	BRCA1	and	BRCA2	mutation	carriers	
compared	to	non-carriers	due	to	radiotherapy	for	a	primary	breast	 tumor,	can	be	used	to	
evaluate	if	there	is	a	difference	in	carcinogenic	risk	for	both	cohorts.	However,	results	of	such	
studies	are	not	univocal.	Bernstein	and	colleagues	demonstrated	that	the	increased	risk	of	
contralateral	breast	cancer	incidence	in	BRCA1	and	BRCA2	mutation	carriers	observed	after	
radiotherapy	is	merely	due	to	the	mutation	status	and	could	not	be	linked	to	the	exposure	to	
ionizing	radiation.	Indeed,	mutation	carriers	not	treated	with	radiotherapy	are	also	at	high	
risk	of	contralateral	breast	cancer	(Bernstein	et	al.	2013).	Broeks	et	al.,	on	the	other	hand,	did	
demonstrate	 a	 link	 between	 mutations	 in	 DNA	 damage	 response	 genes	 (BRCA1,	 BRCA2,	
CHEK2	 and	 ATM)	 and	 radiotherapy	 on	 the	 incidence	 of	 contralateral	 breast	 cancer.	
Unfortunately,	 they	 did	 not	 evaluate	 this	 link	 for	 BRCA1	 and	 BRCA2	 mutation	 carriers	
separately	(Broeks	et	al.	2007).		
	
A	similar	 indistinct	result	 is	observed	when	evaluating	breast	cancer	 induction	in	mutation	
carriers	versus	non-carriers	upon	exposure	to	diagnostic	ionizing	radiation.	Numerous	studies	
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were	 conducted	 to	 evaluate	 the	 effect	 of	 a	 mutation	 in	 either	 BRCA1	 or	 BRCA2	 on	
carcinogenic	risk	after	mammography	screenings	or	diagnostic	chest	X-rays.	Several	studies	
demonstrate	a	significant	increased	breast	cancer	risk	in	mutation	carriers	compared	to	non-
carriers	(Pijpe	et	al.	2012;	Lecarpentier	et	al.	2011;	Gronwald	et	al.	2008;	Andrieu	et	al.	2006).	
However,	 other	 studies	 could	 not	 detect	 a	 positive	 correlation	 between	mutation	 status,	
ionizing	radiation	and	carcinogenesis	(John	et	al.	2013;	Giannakeas	et	al.	2014;	Narod	et	al.	
2006;	Goldfrank	et	al.	2006).	
	
At	present,	an	increased	carcinogenic	risk	in	BRCA1	and	BRCA2	mutation	carriers	compared	
to	 non-carriers	 cannot	 be	 excluded	 based	 on	 the	 contradictory	 data	 obtained	 in	 clinical	
studies	evaluating	the	effect	of	diagnostic	or	therapeutic	exposure	to	ionizing	radiation.	The	
observed	variation	can	be	attributed	to	differences	in	inclusion	criteria,	differences	in	follow-
up	 and	 limited	 power	 due	 to	 small	 cohorts.	 As	 proper	 studies	 are	 difficult	 to	 set-up	 and	
unethical,	 in	 vitro	 assays	may	 aid	 to	 establish	 if	BRCA1	 and	BRCA2	 mutation	 carriers	 are	
characterized	by	an	enhanced	radiosensitive	phenotype.		
	
4.2 In	vitro	radiosensitivity	testing		
4.2.1 Chromosomal	radiosensitivity	
In	 vitro	 chromosome	 aberration	 assays	 are	 effective	 tools	 to	 investigate	 radiosensitivity.	
These	assays	are	generally	performed	on	peripheral	blood	lymphocytes	which	are	a	grateful	
source	 of	 patient-own	 material	 to	 test	 individual	 radiosensitivity.	 Chromosomal	
radiosensitivity	testing	on	lymphocytes	from	BRCA1	and	BRCA2	mutation	carriers	has	been	
performed	with	techniques	such	as	the	G0	micronucleus	assay	(see	chapter	5.1)	and	the	G2	
assay	for	chromatid	breaks	(Baeyens	et	al.	2004;	Gutiérrez-Enríquez	et	al.	2011;	Trenz	et	al.	
2002;	 Ernestos	 et	 al.	 2010;	 Becker	 et	 al.	 2012;	 Bolognesi	 et	 al.	 2014;	 Barwell	 et	 al.	 2007;	
Buchholz	et	al.	2002;	Kote-Jarai	et	al.	2006;	Frankenberg-Schwager	&	Gregus	2012).	However,	
in	several	of	these	studies,	it	was	unclear	if	the	heterozygote	mutation	carriers	were	healthy	
individuals	or	breast	cancer	patients.	Furthermore,	differences	in	experimental	set-up	make	
comparisons	between	studies	difficult	(Cardinale	et	al.	2012).	Despite	these	differences,	most	
studies	could	detect	an	elevated	chromosomal	radiosensitivity	in	breast	cancer	patients	with	
a	germline	mutation	compared	to	healthy	control	individuals	(Gutiérrez-Enríquez	et	al.	2011;	
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Ernestos	et	al.	2010;	Baeyens	et	al.	2004).	Unfortunately,	comparison	with	radiosensitivity	of	
sporadic	 breast	 cancer	 patients	 was	 not	 always	 performed.	 The	 study	 of	 Baeyens	 et	 al.	
previously	 demonstrated	 enhanced	 radiosensitivity	 in	 both	 breast	 cancer	 patients	 with	 a	
BRCA1/2	 mutation	 and	 sporadic	 breast	 cancer	 patients,	 suggesting	 that	 the	 enhanced	
radiosensitivity	might	not	be	the	result	of	the	mutation	but	might	be	inherent	to	the	cancer	
status	 (Baeyens	et	al.	2004).	Chromosomal	 radiosensitivity	 testing	with	different	assays	 in	
lymphocytes	of	healthy	BRCA1	and	BRCA2	mutation	carriers	versus	healthy	control	individuals	
without	a	germline	mutation	yielded	no	univocal	results	 (Barwell	et	al.	2007;	Becker	et	al.	
2012;	Gutiérrez-Enríquez	et	al.	2011;	Ernestos	et	al.	2010;	Baeyens	et	al.	2004).		
	
4.2.2 Homologous	recombination	testing	
Another	 –	 relatively	 new	 –	 assay	 to	 study	 in	 vitro	 radiosensitivity	 in	 BRCA1	 and	 BRCA2	
mutation	carriers	might	be	 the	RAD51	 foci	assay	 (see	chapter	5.2:	RAD51	 foci	assay).	This	
assay	has	previously	been	performed	on	fresh	biopsy	samples	of	cancer	patients,	irradiated	
ex	vivo,	to	evaluate	HR	deficiency	due	to	defects	in	proteins	involved	in	the	HR	pathway	such	
as	BRCA1	and	BRCA2	(Willers	et	al.	2009;	Naipal	et	al.	2014;	AlHilli	et	al.	2016;	Mukhopadhyay	
et	al.	2010;	Shah	et	al.	2014).		
	
A	few	studies	have	also	investigated	radiation-induced	RAD51	foci	formation	in	non-tumor	
cells	with	a	BRCA1	or	BRCA2	mutation.	Sioftanos	et	al.	detected	a	significantly	reduced	RAD51	
foci	 formation	 in	 BRCA1	 and	BRCA2	heterozygous	mice	 embryonic	 stem	 cells	 after	 doses	
varying	between	2	and	4	Gy	X-rays	(Sioftanos	et	al.	2010).	Warren	et	al.	evaluated	RAD51	foci	
formation	in	the	chicken	B	cell	line	DT40	with	a	heterozygous	BRCA2	mutation	after	exposure	
to	a	dose	of	6	Gy	X-rays.	Foci	formation	was	significantly	impaired	in	mutant	cells	compared	
to	control	cells	(Warren	et	al.	2003).	Vaclova	et	al.	could	demonstrate	a	significantly	increased	
 gH2AX	foci	intensity,	an	indication	of	more	radiation-induced	DSBs,	in	human	lymphoblastoid	
cell	lines	of	heterozygous	BRCA1	mutation	carriers	compared	to	controls	after	exposure	to	10	
Gy.	However,	 no	 similar	 induction	 of	 RAD51	 foci	 could	 be	 observed,	 pointing	 towards	 an	
impaired	RAD51	foci	formation	(Vaclová	et	al.	2015).	
Part	I:	Introduction	–	Assays	to	measure	radiation-induced	DNA	damage	
	69	
5 ASSAYS	TO	MEASURE	RADIATION-INDUCED	DNA	DAMAGE	
Radiation-induced	DNA	damage	can	be	evaluated	in	different	ways.	These	assays	allow	the	
evaluation	of	DNA	damage	induction,	repair	and	cellular	outcome.	In	this	thesis,	the	G2	MN	
assay	was	used	to	evaluate	chromosomal	rearrangements	and	the	RAD51	foci	assay,	was	
applied	to	evaluate	HR-mediated	DSB	repair	after	exposure	to	ionizing	radiation.	
	
5.1 Micronucleus	assay	
5.1.1 What	are	MN?	
Exposure	 to	 ionizing	 radiation	 may	 result	 in	 chromosome	 or	 chromatid	 rearrangements.	
These	rearrangements	are	the	result	of	mis-	or	unrepaired	DSB	which	can	either	occur	within	
the	same	chromosome	(intra-)	or	between	different	chromosomes	(interchanges)	(Pouget	&	
Mather	2001).	These	mis-	or	unrepaired	DSB	may	result	in	acentric	fragments	which	lack	a	
centromere.	 Therefore,	 they	 will	 fail	 to	 attach	 to	 the	mitotic	 spindle	 during	 division	 and	
remain	in	the	cytoplasm,	where	they	will	be	enveloped	by	a	nuclear	membrane	and	form	a	
MN	(see	Figure	1.26)	(Vral	et	al.	2016).	
	
	
Figure	 1.26:	 Relation	 between	 chromosome/chromatid	 aberrations	 and	 MN.	 Acentric	
fragment	that	result	in	MN	are	indicate	in	red	(Pouget	&	Mather	2001).	
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Whether	chromosome	or	chromatid	aberrations	are	formed	depends	on	the	cell	cycle	phase	
during	which	the	damage	was	induced.	Generally,	exposure	to	ionizing	irradiation	before	S	
phase	results	in	chromosome	aberrations	as	failure	to	repair	the	lesion	before	DNA	replication	
results	 in	 damage	 of	 both	 chromatids.	 Exposure	 to	 ionizing	 radiation	 after	 S	 phase	 yields	
chromatid	 aberrations	 and	 exposure	 during	 S	 phase	 leads	 to	 a	 mix	 of	 both	 aberrations.	
Symmetric	 aberrations	 such	 as	 an	 inversion	 or	 translocation	 are	more	 stable	 and	 can	 be	
passed	on	to	the	daughter	nuclei	during	mitosis.	However,	 these	aberrations	can	result	 in	
overexpression	of	oncogenes	or	loss	of	tumor	suppressor	gene	activity	and	genome	instability	
can	eventually	lead	to	tumorigenesis.	Asymmetric	aberrations	are	predominantly	the	result	
of	misrepair	rather	than	terminal	deletions	and	will	result	in	a	MN	after	cell	division.	The	loss	
of	genetic	information	will	eventually	lead	to	mitotic	cell	death	(Pouget	&	Mather	2001).		
	
5.1.2 The	cytokinesis	block	micronucleus	assay	and	its	applications	
For	evaluation	of	the	MN	in	the	first	interphase	after	cell	division,	the	cytokinesis	block	MN	
(CBMN)	assay,	developed	by	Fenech,	 is	used	 (Fenech	2007).	 In	 this	assay,	 cytochalasine	B	
(cyto	B)	is	added	to	the	cell	cultures	to	block	cytokinesis.	This	results	in	binucleated	(BN)	cells	
in	which	MN	are	evaluated.	The	CBMN	assay	can	be	performed	in	every	cell	type	which	can	
be	stimulated	to	divide.	However,	as	lymphocytes	are	easy	to	obtain	by	means	of	a	simple	
blood	withdrawal,	they	are	the	preferred	cell	type	to	analyze.	
	
MN	can	be	the	result	of	exposure	to	various	clastogenic	agents,	including	ionizing	radiation	
and	can	therefore	be	used	as	a	biomarker	for	the	analysis	of	radiation-induced	DNA	damage.	
With	regard	to	ionizing	radiation,	the	CBMN	assay	can	be	used	for	biological	dosimetry,	during	
which	occupational,	medical	or	accidental	(and	thus	in	vivo)	exposure	to	ionizing	radiation	of	
individuals	 is	 evaluated	 in	 blood	 samples.	 On	 the	 other	 hand,	 the	 assay	 can	 be	 used	 to	
evaluate	 individual	 radiosensitivity	and	cancer	 susceptibility,	by	 in	vitro	exposure	of	blood	
samples	of	a	test	cohort	to	ionizing	radiation	(El-Zein	et	al.	2011).	The	use	of	a	CBMN	assay	
offers	several	advantages	compared	to	other	cytogenetic	assays.	These	advantages	include	
the	speed	and	ease	of	analysis	and	the	reliable	identification	of	cells	that	have	completed	one	
nuclear	division	(El-Zein	et	al.	2011).	
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Radiation-induced	 MN	 contain	 mainly	 acentric	 fragments	 that	 are	 the	 result	 of	 mis-	 or	
unrepaired	DNA	DSB	(see	Figure	1.26	and	1.27).	Besides	acentric	 fragments,	MN	may	also	
contain	whole	chromosomes	which	also	failed	to	bind	to	the	mitotic	spindle.	These	MN	are	
referred	to	as	a	spontaneous	MN	(see	Figure	1.27).	MN	containing	whole	chromosomes	can	
also	be	the	result	of	exposure	to	aneugenic	agents	(Melo	et	al.	2014).		One	drawback	of	the	
CBMN	assay	is	the	relatively	high	and	inter-individual	variable	frequency	of	spontaneous	MN	
(ranging	from	2	to	36	per	1000	BN	cells).	The	variation	in	spontaneous	MN	can	be	attributed	
to	diet,	exposure	to	environmental	mutagens,	age	and	gender	(Vral	et	al.	2011).	Due	to	this	
variable	 background,	 the	 detection	 limit	 is	 about	 0.2	 Gy	 X	 or	 g-rays.	 One	 can	 distinguish	
between	 spontaneous	 and	 radiation-induced	 MN	 by	 means	 of	 a	 fluorescent	 in	 situ	
hybridization	 (FISH)	 using	 pan-centromeric	 probes.	 MN-centromere	 analysis	 is	 especially	
useful	in	the	low	dose	area,	where	it	results	in	a	lowering	of	the	dose	detection	limit	to	0.05-
0.1	Gy	with	the	MN-centromere	assay	(Baeyens	et	al.	2011).	
	
	
Figure	 1.27:	 Schematic	 visualization	 of	 MN	 formation	 in	 cells	 during	 nuclear	 division.	 The	
binucleated	 cell	 shown	 on	 this	 figure,	 obtained	 by	 blocking	 cytokinesis	 trough	 addition	 of	
cytochalasin	B,	holds	both	a	spontaneous	MN	(left)	and	a	radiation-induced	MN	which	is	the	
result	 of	 a	mis-	 or	 unrepaired	 DSB,	 leading	 to	 an	 acentric	 fragment	 (right),	 adapted	 from	
(Fenech	2007).	
	
5.1.2.1 The	G0	CBMN	assay	for	lymphocytes	
In	the	classical	micronucleus	assay,	the	G0	micronucleus	assay,	peripheral	blood	lymphocytes	
are	exposed	 to	 ionizing	 radiation	 in	G0	phase	of	 the	 cell	 cycle.	 Samples	 are	 subsequently	
stimulated	to	divide	by	the	addition	of	phytohemagglutinin	(PHA).	After	an	initial	incubation	
period	 of	 23	 h,	 cyto	 B	 is	 added	 to	 inhibit	 cytokinesis.	 The	 lymphocytes	 are	 subsequently	
allowed	 an	 additional	 incubation	 period	 to	 become	 binucleated.	 After	 a	 total	 incubation	
period	of	70	h,	the	cells	are	harvested,	fixed,	transferred	to	slides	and	analyzed	(Baeyens	et	
al.	2002).	
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MN	 slides	 can	 be	 stained	 with	 giemsa	 for	 light	 microscopy	 or	 DAPI	 (4',6-diamidino-2-
fenylindool)	 staining	 for	 fluorescence	microscopy	 analysis.	MN	 scoring	 can	 be	 performed	
manually	 or	 by	 automated	 software	 (eg.	MSearch	 software,	Metasystems,	Germany)	 (see	
Figure	1.28).	In	general,	MN	are	scored	per	1000	BN	cells.	MN	induced	by	low-LET	radiation	
typically	follow	a	linear-quadratic	dose	response.	An	in	vitro	MN	dose	response	obtained	in	a	
reference	cohort	can	be	used	to	assess	radiosensitivity	of	an	individual	or	cohort	of	interest	
(Willems	et	al.	2010;	Rastkhah	et	al.	2016).		
	
 
Figure	1.28:	DAPI-stained	binucleated	(BN)	cells	with	one	(left)	or	two	(middle	and	right	
panel)	micronuclei	(MN)	(image	by	Metafer	4,	Metasystems).		
	
5.1.2.2 The	G2	CBMN	assay	for	lymphocytes	
The	G2	micronucleus	assay	is	a	variant	of	the	G0	micronucleus	assay	and	has	been	developed	
to	evaluate	chromosomal	radiosensitivity	of	cells	irradiated	in	S	and	G2	phase	of	the	cell	cycle	
(Claes	et	al.	2013).	The	adapted	protocol	for	lymphocytes	requires	an	initial	incubation	period	
of	3	days	in	the	presence	of	PHA	to	obtain	proliferating	lymphocytes.	As	G0	lymphocytes	start	
cycling	 at	 different	 time	 points	 after	 PHA	 stimulation,	 a	 heterogeneous	 population	 of	
lymphocytes	will	be	obtained	at	the	moment	of	irradiation.	The	proliferating	lymphocytes	are	
exposed	to	ionizing	radiation	and	cyto	B	is	added	to	the	cultures	immediately	after	exposure	
to	ionizing	radiation.	Cells	are	subsequently	allowed	a	short	post-irradiation	incubation	period	
of	 8	 h	 for	 repair	 of	 the	 radiation-induced	 DNA	 damage	 and	 BN	 formation.	 This	 short	
incubation	period	limits	the	number	of	G1	phase	cells	becoming	BN,	resulting	in	the	analysis	
of	MN	in	BN	cells	predominantly	originating	from	cells	irradiated	in	S	and	G2	of	the	cell	cycle.	
The	number	of	radiation-induced	MN	is	a	first	endpoint	of	the	G2	micronucleus	assay.	
	
In	order	 to	 test	 the	G2/M	checkpoint	 capacity	of	 the	 lymphocytes,	 caffeine	 is	 added	 to	a	
subset	of	cultures.	The	addition	of	caffeine	results	in	an	overruling	of	the	G2/M	checkpoint	
by	 ATM	 inhibition.	 Subsequently,	 the	 ratio	 of	 the	 number	 of	MN	 in	 1000	 BN	 cells	 in	 the	
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presence	 of	 caffeine	 over	 the	 number	 of	MN	 in	 1000	BN	 cells	 in	 the	 absence	 of	 caffeine	
indicates	the	checkpoint	efficiency.	This	is	the	second	endpoint	of	the	G2	micronucleus	assay.	
A	higher	 ratio,	 indicate	a	more	potent	 checkpoint	 capacity.	G2/M	checkpoint	analysis	has	
previously	 been	 evaluated	 by	 means	 of	 the	 G2	 chromatid	 break	 assay.	 If	 activation	 is	
completely	impaired,	which	is	the	case	in	AT	patients	without	functional	ATM,	a	ratio	of	one	
is	observed	(Terzoudi	2009;	Pantelias	&	Terzoudi	2011).		
	
5.2 RAD51	foci	assay	
DNA	damage	response	foci	can	be	observed	at	the	DNA	damage	site	upon	recruitment	of	DNA	
damage	proteins.	This	accumulation	of	proteins	at	the	damage	site,	for	example	at	the	site	of	
a	DSB,	can	be	visualized	by	means	of	immunostaining.	This	technique	was	first	described	for	
the	 phosphorylated	 histone	 variant	 H2AX	 (gH2AX),	 one	 of	 the	 earliest	 events	 in	 the	 DNA	
damage	response	activated	by	DSB	(see	3.3.1:	DNA	damage	detection	and	signaling).	Given	
that	the	phosphorylation	is	restricted	to	the	DSB	site	and	expands	over	several	100	to	1000	
histones,	 the	 DSB	 can	 be	 microscopically	 detected	 as	 a	 gH2AX	 focus	 after	 specific	
immunostaining.	Using	a	fluorescent	labelled	antibody,	these	foci	can	be	quantified	in	DAPI-
stained	nuclei.	This	can	be	done	in	a	manual	or	automated	modus,	for	example	by	means	of	
the	 Metafer	 4	 automated	 scanning	 platform	 and	 Metacyte	 software	 (Metasystems,	
Germany).	 The	 initial	 induction	of	gH2AX	 foci	 after	exposure	 to	 ionizing	 radiation	and	 the	
subsequent	foci	disappearance	over	time	can	be	used	to	assess	radiation-induced	DSB	and	
repair	kinetics	(Rothkamm	et	al.	2015;	Rogakou	et	al.	1999).	
	
Whereas	the	gH2AX	foci	is	a	DSB	signaling	protein,	one	can	also	evaluate	recruitment	of	DSB	
repair	proteins	to	the	DNA	damage	site.	One	of	those	proteins,	specific	for	HR,	is	RAD51	(see	
chapter	3.3.2.2:	Homologous	recombination).	In	short,	HR	relies	on	RAD51	filament	formation	
for	complementary	strand	invasion	and	repair	of	the	DSB.	RAD51	protein	recruitment	to	the	
DSB	 site	 is	 mediated	 by	 BRCA1	 and	 BRCA2	 and	 can	 be	 detected	 as	 nuclear	 foci	 upon	
immunostaining	(see	Figure	1.29)	(Mladenov	et	al.	2016;	Rothkamm	et	al.	2015).	Radiation-
induced	RAD51	foci	formation,	has	been	shown	to	be	useful	for	the	evaluation	of	HR	efficiency	
in	different	cell	types.	Also,	PARP	inhibitors,	in	combination	with	the	RAD51	foci	assay,	can	be	
used	to	analyze	HR	efficiency	(Willers	et	al.	2015).	In	contrast	to	the	gH2AX	foci,	for	which	a	
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DSB-induced	 specific	 modification	 (phosphorylation)	 is	 exploited,	 the	 RAD51	 foci	 assay	
merely	relies	on	the	accumulation	of	the	RAD51	protein	at	the	DSB	site.		
	
	
Figure	1.29:	RAD51	foci	(green)	in	DAPI-stained	nuclei	(blue)	of	MCF10A	cells	after	exposure	to	
ionizing	radiation	(5Gy	220	kV	X-rays)	(image	by	Metafer	4,	Metasystems).	
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6 AIM	OF	THIS	THESIS	
To	date,	all	known	high	to	intermediate	risk	“breast	cancer	genes”	are	involved	in	the	DNA	
damage	response	pathway.	Therefore,	heterozygous	mutation	carriers	may	show	enhanced	
radiosensitivity	 associated	 with	 an	 increased	 carcinogenic	 risk	 after	 exposure	 to	 ionizing	
radiation.	Results	obtained	 in	 clinical	 studies	evaluating	 the	effect	of	medical	exposure	 to	
ionizing	radiation	are	however	inconclusive	and	cannot	exclude	a	possible	increased	cancer-
induction	 risk	 for	 mutation	 carriers.	 Also,	 studies	 analyzing	 in	 vitro	 chromosomal	
radiosensitivity	 in	 lymphocytes	 of	 healthy	 heterozygous	 mutations	 yielded	 inconsistent	
results.	Because	of	these	indecisive	results,	more	empirical	studies	are	needed	to	determine	
the	 radiosensitivity	phenotype	of	 individuals	 carrying	germline	mutations	 in	breast	 cancer	
predisposing	genes.	Better	 insights	 into	the	radiosensitive	phenotype	of	healthy	 tissues	of	
mutation	 carriers	 is	 of	 the	 utmost	 importance	 for	 the	 safe	 use	 of	 ionizing	 radiation	 for	
diagnostic	purposes	or	radiotherapy	treatment.		
	
The	first	aim	of	this	thesis	was	to	evaluate	cellular	in	vitro	chromosomal	radiosensitivity	of	
healthy	mutation	carriers.		In	order	to	assess	chromosomal	aberrations	in	the	proper	phase	
of	the	cell	cycle,	a	G2	micronucleus	assay	has	been	developed	and	applied	on	peripheral	blood	
lymphocytes	of	mutation	carriers.	The	classical	G0	micronucleus	assay	is	not	well	designed	to	
evaluate	radiosensitivity	in	cells	with	a	BRCA1	or	BRCA2	germline	mutation	as	these	proteins	
are	mainly	involved	in	HR,	a	repair	pathway	activated	in	S/G2	phase	of	the	cell	cycle.	In	a	first	
phase	 of	 our	 study,	 the	 G2	MN	 assay	 has	 been	 optimized	 in	 an	 AT	 patient	 with	 a	 mild	
representation	 of	 the	 disease,	 who	 is	 compound	 heterozygous	 for	 two	 ATM	 germline	
mutations	(paper	I).	We	also	evaluated	the	in	vitro	chromosomal	radiosensitivity	in	several	
healthy	relatives,	who	were	heterozygous	carriers	of	an	ATM	mutation.	In	a	second	phase	of	
our	study,	the	optimized	G2	MN	assay	has	been	applied	on	a	cohort	of	healthy	BRCA1	(paper	
II)	 and	 BRCA2	 (paper	 III)	 mutation	 carriers.	 Furthermore,	 radiosensitivity	 has	 also	 been	
evaluated	in	healthy	non-carrier	relatives	(paper	III).	Also,	we	evaluated	if	there	was	a	link	
between	the	individual	radiosensitive	phenotype	of	BRCA1	mutation	carriers	and	NMD	(paper	
II).		
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The	second	aim	was	to	evaluate	the	effect	of	reduced	protein	levels	of	BRCA1	and	BRCA2	on	
radiosensitivity	and	the	functionality	of	HR	in	breast	epithelial	cells.	To	this	end,	a	radiation-
induced	RAD51	foci	assay	was	optimized	in	a	breast	epithelial	cell	line	(MCF10A)	expressing	
different	BRCA1	and	BRCA2	protein	levels,	obtained	by	RNA	interference	(paper	IV).	RAD51	
foci	were	analyzed	in	cells	synchronized	in	S	phase	by	aphidicolin,	this	to	obtain	a	maximum	
number	of	cells	in	S	phase	of	the	cell	cycle,	during	which	HR	is	active.	Also,	experiments	with	
a	PARP	inhibitor	were	set	up	to	evaluate	if	the	combined	use	of	IR	and	PARP	inhibition	result	
in	 a	 more	 distinct	 discrimination	 between	 the	 BRCA1	 and	 BRCA2	 knockdown	 cell	 lines,	
partially	deficient	in	HR,	and	the	control	cell	line.	
	
The	 third	 aim	 focusses	 on	 the	 evaluation	 of	 the	 effect	 on	 mRNA	 splicing	 of	 Variants	 of	
Unknown	clinical	Significance	(VUS).	It	is	known	that	breast	cancer	risk	increases	drastically	
in	individuals	carrying	a	deleterious	BRCA1	or	BRCA2	mutation.	However,	BRCA1	and	BRCA2	
diagnostic	screenings	also	results	in	the	identification	of	VUS	at	a	high	rate,	which	is	reflected	
in	the	large	number	of	VUS	reported	in	the	ClinVar	database	(NCBI).	Variants	that	have	not	
been	classified	are	individually	rare	and	segregation	analysis	might	be	impossible	due	to	small	
families	or	interpretation	may	be	complicated	by	the	occurrence	of	phenocopies.	VUS	are	a	
true	challenge	 for	health	care	providers	as	 the	 impact	of	 these	variants	on	breast/ovarian	
cancer	risk	is	unclear.	mRNA	analysis	to	investigate	intronic	and	exonic	variants	that	might	
impair	proper	RNA	splicing,	a	highly	regulated	process,	are	widely	used.	Here,	we	assessed	
splicing	of	BRCA1	and	BRCA2	VUS	by	means	of	both	in	silico	prediction	and	mRNA	analyses	in	
lymphocytes	of	mutation	carriers	(paper	V).		
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OUTLINE	OF	THE	RESEARCH	
Paper	I:	Variant	Ataxia	Telangiectasia:	Clinical	and	Molecular	Findings	and	Evaluation	of	
Radiosensitive	Phenotypes	in	a	Patient	and	Relatives	
Kathleen	B.M.	Claes,	Julie	Depuydt,	A.	Malcolm	R.	Taylor,	James	I.	Last,	Annelot	Baert,	Peter	
Schietecatte,	Veerle	Vandersickel,	Bruce	Poppe,	Kim	De	Leeneer,	Marc	D’Hooghe	and	Anne	
Vral	
Neuromolecular	Medicine	2013;	15	(3),	447-457	
	
The	genetic	data	of	an	AT	patient	was	analyzed	and	correlated	with	the	mild	AT	phenotype,	
data	 from	 a	 kinase	 assay,	 and	 results	 from	 two	 chromosomal	 radiosensitivity	 assays.	
Genotyping	 revealed	 compound	 heterozygosity	 for	 ATM:	 c.8122G>A	 (p.Asp2708Asn)	 and	
c.8851-1G>T,	leading	to	an	in	frame	loss	of	63	nucleotides	at	the	cDNA	level.	A	kinase	assay	
demonstrated	 remaining	 activity	 of	ATM,	which	 is	 generally	 absent	 in	 classic	AT	patients.	
Enhanced	radiosensitivity	was	demonstrated	in	lymphocytes	of	the	variant	AT	patient	with	
the	G0	micronucleus	assay,	though	less	prominent	than	observed	in	classic	AT	patients.	The	
efficiency	of	the	G2	micronucleus	assay	was	evaluated	and	demonstrated	a	more	pronounced	
increase	in	radiation-induced	MN	yield	for	the	variant	AT	patient	compared	to	the	results	of	
the	G0	micronucleus	assay.	Furthermore,	G2/M	checkpoint	activity	of	the	variant	AT	patient	
was	evaluated	by	means	of	the	G2	micronucleus	assay	and	an	impaired	arrest	capacity	was	
demonstrated	 compared	 to	 healthy	 controls.	 In	 addition,	 the	G2	micronucleus	 assay	was	
applied	 on	 lymphocytes	 of	 healthy	 relatives	 with	 a	 heterozygous	 ATM	 mutation	 and	
demonstrated	an	enhanced	radiosensitivity	for	both	radiation-induced	MN	yield	and	G2/M	
checkpoint	efficiency,	intermediate	between	the	AT	patients	and	controls.		
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Paper	 II:	 Increased	 chromosomal	 radiosensitivity	 in	 asymptomatic	 carriers	 of	 a	
heterozygous	BRCA1	mutation	
Annelot	 Baert,	 Julie	 Depuydt,	 Tom	Van	Maerken,	 Bruce	 Poppe,	 Fransiska	Malfait,	 Katrien	
Storm,	Jenneke	van	den	Ende,	Tim	Van	Damme,	Sylvia	De	Nobele,	Gianpaolo	Perletti,	Kim	De	
Leeneer,	Kathleen	B.	M.	Claes	and	Anne	Vral	
Breast	Cancer	Research	2016;	18	(1),	52-63	
	
Radiosensitivity	was	analyzed	by	means	of	the	G2	micronucleus	assay	in	a	cohort	of	18	BRCA1	
mutation	 carriers	 and	 compared	 with	 data	 from	 20	 healthy	 volunteers	 with	 no	 known	
personal	or	familial	breast	cancer	anamnesis.	A	significantly	radiation-induced	MN	yield	and	
G2/M	checkpoint	 ratio,	could	be	demonstrated	 for	 the	cohort	of	BRCA1	mutation	carriers	
compared	 to	 the	healthy	 volunteers.	 This	 points	 towards	 an	 impaired	DNA	 repair	 and	G2	
arrest	capacity	in	mutation	carriers.	In	a	second	phase	of	this	study,	a	link	between	increased	
individual	radiosensitivity	and	the	remaining	mRNA	level	of	the	mutant	allele	was	evaluated.	
Therefore,	 individual	 radiosensitivity	 of	 BRCA1	 mutation	 carriers,	 expressed	 as	 a	
Radiosensitivity	 INDicator	 (RIND)	 score,	 taking	 into	 account	 both	 MN	 yield	 and	 G2/M	
checkpoint	activity,	was	evaluated.	A	higher	RIND	score	was	observed	for	BRCA1	mutations	
leading	to	a	premature	termination	codon	in	the	central	part	of	the	gene,	prone	to	NMD	and	
thus	mRNA	degradation,	compared	to	the	control	cohort.	This	suggests	haploinsufficiency	as	
the	 mechanism	 for	 radiosensitivity.	 However,	 the	 even	 higher	 RIND	 scores	 observed	 in	
individuals	with	mutations	at	the	5’	end	of	the	gene,	which	would	escape	NMD,	suggest	a	
possible	alternative	mechanism,	such	as	a	dominant	negative	effect.		
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Paper	 III:	Analysis	of	 chromosomal	 radiosensitivity	of	healthy	BRCA2	mutation	carriers	
and	non-carriers	in	BRCA	families	with	the	G2	micronucleus	assay.	
Annelot	Baert,	 Julie	Depuydt,	Tom	Van	Maerken,	Bruce	Poppe,	Fransiska	Malfait,	Tim	Van	
Damme,	Sylvia	De	Nobele,	Gianpaolo	Perletti,	Kim	De	Leeneer,	Kathleen	B.M.	Claes	and	Anne	
Vral.	
Oncology	reports	2017;	37,	1379-1386	
	
	
In	 this	 paper,	 radiosensitivity	 of	 a	 cohort	 of	 18	 healthy	 BRCA2	 mutation	 carriers	 and	 17	
relatives	 without	 the	 familial	 BRCA	 mutation	 (non-carrier	 relatives)	 was	 compared	 with	
healthy	controls,	by	means	of	the	G2	MN	assay.	An	increased	MN	yield	in	the	cohort	of	BRCA2	
carriers	compared	to	the	healthy	volunteers	without	a	personal	or	familial	history	of	breast	
cancer	was	observed.	For	the	17	non-carrier	relatives	of	both	BRCA1	(n=9)	and	BRCA2	(n=8)	
families,	no	increased	radiosensitivity	was	observed	compared	to	the	control	cohort.		
	
Paper	IV:	The	RAD51	foci	assay	for	the	detection	of	impaired	homologous	recombination	
in	irradiated	MCF10A	cells	with	a	BRCA1	or	BRCA2	knockdown.	
Annelot	 Baert,	 Maria	 Federica	 Palermo,	 Julie	 Depuydt,	 Mattias	 Van	 Heetvelde,	 Bram	
Verstraete,	Jan	Phillippé,	Anna	Sablina,	Kathleen	Claes	and	Anne	Vral.		
Article	in	preparation	for	submission	to	Plos	One	
	
In	this	paper,	the	suitability	of	the	RAD51	foci	assay	for	the	evaluation	of	HR	activity	in	breast	
epithelial	cell	lines	(MCF10A)	with	reduced	protein	levels	of	BRCA1	and	BRCA2,	obtained	by	
RNA	interference,	was	evaluated.	MCF10A	cells	were	synchronized	in	S	phase	of	the	cell	cycle	
by	aphidicolin	for	optimal	detection	of	HR	capacity.	DSB	were	induced	by	exposing	the	cells	
to	ionizing	radiation.	Recruitment	of	RAD51,	a	key	HR	protein,	to	the	DSB	was	observed	as	
foci	formation	and	RAD51	foci	were	visualized	by	means	of	an	immunostaining.	A	significant	
decrease	 in	 RAD51	 foci	 was	 demonstrated	 in	 BRCA1	 and	 BRCA2	 knockdown	 cell	 lines	
compared	to	the	control	cell	line.	
	
	 	
Part	II:	Original	Research	–	Outline	
	 91	
Paper	 V:	 Thorough	 in	 silico	 and	 in	 vitro	 cDNA	 analysis	 of	 21	 putative	BRCA1/2	 splice	
variants	and	identification	of	activated	cryptic	splice	donor	sites	in	exon	11	of	BRCA2	
Annelot	 Baert,	 Eva	Machackova,	 Ilse	 Coene,	 Carol	 Cremin,	 Kristin	 Turner,	 Cheryl	 Portigal-
Todd,	Marie	Jill	Asrat,	Jennifer	Nuk,	Allison	Mindlin,	Young	Sean,	Andree	MacMillan,	Tom	Van	
Maerken,	Martin	 Trbusek,	Wendy	 C	McKinnon,	Marie	 E	Wood,	William	D	 Foulkes,	Marta	
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In	silico	predictions	and	mRNA	analysis	in	short-term	cultured	lymphocytes	were	performed	
for	19	putative	BRCA1	and	BRCA2	splice	site	variants.	Aberrant	splicing	was	demonstrated	
for	nine	variants	suggesting	that	these	variants	are	likely	pathogenic.	Furthermore,	the	
effect	at	the	cDNA	level	of	a	novel	tandem	duplication	with	a	5’	breakpoint	in	intron	4	and	a	
3’	breakpoint	in	exon	11	of	the	BRCA2	gene	was	studied.	This	allowed	the	identification	of	
an	actively	used	cryptic	donor	site	within	the	large	exon	11.	
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Abstract		
Research	objectives:	Variant	ataxia	telangiectasia	(A-T)	may	be	an	underdiagnosed	entity.	
We	correlate	data	from	radiosensitivity	and	kinase	assays	with	clinical	and	molecular	data	
from	a	patient	with	variant	A-T	and	relatives.	
Methods:	The	coding	region	of	ATM	was	sequenced.	To	evaluate	the	functional	effect	of	the	
mutations	we	performed	kinase	assays	and	developed	a	novel	S-G2	micronucleus	test.	
Results:	Our	patient	presented	with	mild	dystonia,	moderately	dysarthric	speech,	increased	
serum	 α-fetoprotein	 but	 no	 ataxia	 nor	 telangiectasias,	 no	 nystagmus	 or	 oculomotor	
dyspraxia.	 She	has	 a	 severe	 IgA	deficiency,	 but	does	not	have	 recurrent	 infections.	 She	 is	
compound	heterozygote	for	ATM	c.8122G>A	(p.Asp2708Asn)	and	c.8851-1G>T,	leading	to	in	
frame	loss	of	63	nucleotides	at	the	cDNA	level.	A	trace	amount	of	ATM	protein	is	translated	
from	both	alleles.	Residual	kinase	activity	is	derived	only	from	the	p.Asp2708Asn	allele.	
The	conventional	G0	micronucleus	test,	based	on	irradiation	of	resting	lymphocytes,	revealed	
a	radiosensitive	phenotype	for	the	patient,	but	not	for	the	heterozygous	relatives.	As	ATM	is	
involved	in	HR	and	G2/M	cell	cycle	checkpoint,	we	optimised	an	S/G2	micronucleus	assay,	
allowing	to	evaluate	micronuclei	in	lymphocytes	irradiated	in	the	S	and	G2	phases.	This	test	
showed	increased	radiosensitivity	for	both	the	patient	and	heterozygous	carriers.	Intriguingly,	
heterozygous	carriers	of	c.8851-1G>T	(mutation	associated	with	absence	of	kinase	activity)	
showed	a	 stronger	 radiosensitive	phenotype	with	 this	assay	 than	heterozygous	carriers	of	
p.Asp2708Asn	(mutation	associated	with	residual	kinase	activity).		
Significance:	 The	 modified	 S-G2	 micronucleus	 assay	 provided	 phenotypic	 insight	 to	
complement	the	diagnosis	of	this	atypical	A-T	patient.	
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Introduction	
Ataxia	telangiectasia	(A-T)	(MIM#208900)	is	a	rare	autosomal	recessive	disorder,	caused	by	
germline	mutations	in	the	ATM	gene	(MIM#607585).	A-T	features	include	cerebellar	ataxia,	
oculomotor	apraxia,	oculocutaneous	telangiectasia,	 immune	deficiency,	elevated	serum	α-
fetoprotein	 levels	 and	 acquired	 7-	 and	 14-chromosome	 translocations	 in	 the	 lymphocyte	
karyotype.	In	addition,	A-T	is	characterized	by	clinical	and	cellular	hypersensitivity	to	ionizing	
radiation	(IR),	and	by	an	increased	risk	of	cancer	(Chen	et	al.	1978;	Lavin	2008).		
In	 recent	 years,	 it	 has	 become	 increasingly	 evident	 that	 the	 clinical	 phenotype	 of	 ataxia	
telangiectasia	 varies	 from	 a	 severe,	 early-onset	 classic	 phenotype	 to	 a	 variant	 form	with	
milder	neurological	impairment	and	fewer	systemic	symptoms	(Hiel	et	al.	2006;	Saviozzi	et	al.	
2002;	 Silvestri	 et	 al.	 2010;	 Simonin	 et	 al.	 2008;	 Stankovic	 et	 al.	 1998;	 Sutton	 et	 al.	 2004;	
Verhagen	et	al.	2009).	Especially	in	patients	with	milder	or	atypical	presentations,	the	disease	
may	be	more	difficult	to	diagnose.		
ATM	is	transcribed	in	a	broad	range	of	tissues	to	a	mRNA	of	approximately	13	kb	encoding	a	
nuclear	protein	of	3056	amino	acids,	belonging	to	the	family	of	phosphatidylinositol-3-kinase-
related	 protein	 kinases	 (Uziel	 et	 al.	 1996).	 The	 severity	 of	 the	 clinical	 phenotype	 of	 A-T	
patients	depends	on	the	presence	of	the	ATM	protein	and	of	residual	ATM	kinase	activity.	
These	features	are	determined	by	the	genotype:	severely	affected	patients	generally	have	
truncating	mutations	resulting	in	the	total	absence	of	ATM	kinase	activity,	while	patients	with	
milder	phenotypes	carry	at	least	one	missense	or	leaky	splice	site	mutation	(still	producing	
some	normal	ATM),	resulting	in	expression	of	ATM	with	residual	kinase	activity	(Verhagen	et	
al.	2012).	A	single	study	reported	that	missense	mutations	associated	with	A-T	may	lead	to	
decreased	expression	of	the	ATM	protein	due	to	abnormal	cytoplasmic	localization	of	ATM	
(Jacquemin	et	al.	2012).	
ATM	 plays	 a	 critical	 role	 in	 regulating	 cell	 cycle	 progression	 and	 checkpoint	 activation	 in	
response	to	DSB,	and	in	the	repair	of	DSB	by	HR	and	c-NHEJ	(Deckbar	et	al.	2007;	Kuhne	et	al.	
2004;	Riballo	et	al.	2004).	These	DNA	damage	response	mechanisms	are	active	in	maintaining	
genomic	stability	in	normal	cells.	When	these	mechanisms	are	defective	(as	in	A-T	patients)	
enhanced	 susceptibility	 to	 cancer	may	occur.	DNA	DSB	can	be	 induced	by	endogenous	or	
exogenous	 agents,	 like	 ionizing	 radiation.	 Since	 ATM	 activation	 plays	 a	 crucial	 role	 in	 the	
response	to	DSB,	A-T	patients	are	also	very	sensitive	to	radiation	exposure.	It	has	been	shown	
that	exposure	to	ionizing	radiation	activates	ATM	kinase.	This	activation	is	accompanied	by	
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autophosphorylation	of	S1981,	S367,	S893	in	ATM	(Bakkenist	and	Kastan	2003;	Kozlov	et	al.	
2011;	Kozlov	et	al.	2006),	an	extensive	list	of	ATM	phosphorylation	sites	can	be	found	at	the	
PhosphoSite	 database:	 http://www.phosphosite.org/proteinAction.do?id=1393&showAllSites=true	 and	
phosphorylation	of	a	large	number	of	downstream	targets.	ATM	is	the	central	component	of	
the	signal	transduction	pathway	that	leads	to	cell	cycle	checkpoint	control	and	DNA	repair	
(Kurz	 and	 Lees-Miller	 2004).	 Consequently,	 A-T	 cells	 show	 cell	 cycle	 checkpoint	 defects	
following	irradiation	resulting	in	a	failure	of	the	cells	to	arrest	in	G1-S,	S	or	G2-M	in	order	to	
allow	proper	repair	of	DSB.	Xu	et	al.	(Xu	et	al.	2002)	showed	the	existence	of	2	distinct	G2/M	
checkpoints,	 involving	 different	 molecular	 effectors:	 (i)	 the	 “early”	 G2/M	 checkpoint,	
occurring	 immediately	after	 irradiation,	 is	ATM-dependent,	dose-independent	and	reflects	
the	 failure	 of	 cells,	 irradiated	 in	 G2,	 to	 progress	 into	 mitosis,	 and	 (ii)	 a	 “later”	 control	
mechanism,	measurable	only	several	hours	after	IR,	which	causes	G2	accumulation.	This	latter	
mechanism	 is	 ATM-independent,	 dose-dependent	 and	 accumulates	 cells	 that	 had	 been	
exposed	to	radiation	in	earlier	phases	of	the	cell	cycle	(Xu,	et	al.,	2002).		
Non-repaired	or	mis-repaired	DSB	are	responsible	 for	the	chromosomal	aberrations	 in	the	
daughter	cells.	An	enhanced	level	of	spontaneous	chromosomal	translocations		and	a	marked	
increase	 of	 chromosomal	 radiosensitivity	 are	 hallmarks	 of	 the	 A-T	 cellular	 phenotype.	
Although	an	enhanced	chromosomal	or	cellular	radiosensitivity	is	not	unique	for	A-T	patients	
-	it	is	also	observed	in	patients	carrying	mutations	in	other	DNA	damage	response	genes	(e.g.	
MRE11,	 NBS1,	 Artemis,	 DNA	 Lig4,	 FANC	 genes)-	 it	 can	 represent	 a	 valuable	 adjunctive	
phenotypic	marker	for	A-T	when	complemented	with	AFP	(serum	alpha	fetoprotein)	testing	
and	with	clinical	signs	of	the	disease	(Buck	et	al.	2006;	Gennery	2006;	Girard	et	al.	2000;	Sun	
et	al.	2002).		
The	 cytogenetic	 assays	 that	 are	 mostly	 used	 to	 detect	 chromosomal	 radiosensitivity	 in	
patients	with	cancer-prone	genetic	disorders	and	in	cancer	patients	are	the	G0	micronucleus	
assay	and	the	G2	chromatid	break	assay	(reviewed	in:	(Baria	et	al.	2001;	Parshad	and	Sanford	
2001;	 Scott	 et	 al.	 1999).	 These	 cytogenetic	 assays	 have	 the	 advantage	 of	 being	 directly	
performed	on	primary	lymphocytes	cultured	from	a	blood	sample	without	establishment	of	
lymphoblastoid	or	fibroblast	cell	 lines,	 in	contrast	with	colony	survival	assays	(Fernet	et	al.	
2004;	Sun	et	al.	2002;	West	et	al.	1995;	Chen	et	al.	1978).		
Although	 the	 above	 mentioned	 assays	 can	 be	 used	 as	 valuable	 functional	 tests	 to	
phenotypically	 complement	 the	 diagnosis	 of	 A-T	 in	 “classic”	 A-T	 patients	 (Pantelias	 and	
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Terzoudi	2011;	Terzoudi	et	al.	2009;	Tchirkov	et	al.	1997;	Vral	et	al.	1996;	Scott	et	al.	1996;	
Chen	 et	 al.	 1994;	 Sanford	 et	 al.	 1990),	 only	 scant	 data	 are	 available	 on	 the	
suitability/sensitivity	 of	 radiosensitivity	 assays	 to	 confirm	 a	 diagnosis	 of	 A-T	 in	 patients	
showing	“milder	or	atypical”	forms	of	the	disease	(Jongmans	et	al.	1998;	Gilad	et	al.	1998;	
Bartsch	et	al.	2012).		
In	the	present	study	we	characterized	the	genetic	and	phenotypic	profile	of	an	atypical	case	
of	A-T.	To	optimally	evaluate	the	radiosensitive	phenotype	of	the	A-T	pedigree	we	designed	
a	modified	micronucleus	assay	focusing	on	the	S/G2	phases	of	the	cell	cycle,	and	allowing	to	
detect	defects	in	the	HR	and	G2/M	checkpoint	pathways,	both	involving	ATM.	For	molecular	
confirmation	of	the	clinical	diagnosis,	mutation	analysis	of	the	complete	coding	region	and	
splice	site	regions	of	the	ATM	gene	was	performed.		
	
Materials	and	Methods	
Blood	sampling	
For	 this	 study	 EDTA	 and	heparinized	blood	 samples	were	 collected	 from	a	 patient	with	 a	
tentative	clinical	diagnosis	of	atypical	AT	and	from	her	family	members	(see	case	description	
in	results	section).	The	EDTA	samples	were	used	for	mutation	analysis	of	the	ATM	gene	and	
for	 the	 splicing	 assays.	 This	 study,	 has	been	approved	by	 the	ethical	 committee	of	Ghent	
University	Hospital	(registration	number	B670201111641	d.d.	20/09/2011).	All	participants	
signed	an	informed	consent.		
The	heparinized	samples	were	subjected	to	radiosensitivity	analysis	with	the	conventional	G0	
micronucleus	assay,	and	with	our	novel,	optimized	S-G2	micronucleus	assay.	Blood	samples	
were	taken	on	different	occasions	to	confirm	the	obtained	results	and	to	exclude	random	
errors.	From	the	A-T	patient,	blood	samples	were	collected	on	three	different	occasions.	Both	
parents	 were	 sampled	 in	 2	 different	 occasions.	 A	 cousin	 (paternal	 niece)	 of	 the	 patient,	
diagnosed	with	an	embryonal	rhabdomyosarcoma	at	the	age	of	7,	agreed	to	donate	a	single	
blood	sample.	For	each	radiation	experiment,	a	blood	sample	from	a	healthy	volunteer	was	
collected,	this	to	be	paired	with	the	samples	from	the	patient	or	patient’s	relatives.		
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Mutation	analysis	of	the	ATM	gene	
Genomic	DNA	was	extracted	from	EDTA	blood	samples	of	the	patient	and	relatives	according	
to	manufacturer’s	protocols	(PureGene	DNA	extraction,	Qiagen).	The	complete	coding	region	
and	splice	site	regions	of	the	ATM	gene	were	analysed	by	direct	Sanger	sequencing.	Reference	
sequence	 used:	 NM_000051.3.	 Large	 genomic	 rearrangements	 at	 the	 ATM	 locus	 were	
screened	by	MLPA	analysis	(MRC	Holland,	MLPA	P041	and	MLPA	P042).	
Furthermore,	the	effect	of	the	splice	site	mutation	was	verified	by	RNA	extracted	from	short	
term	IL2/PHA	stimulated	 lymphocyte	cultures.	At	day	7,	4–6	h	before	harvesting	the	cells,	
each	culture	was	split	evenly	and	one	part	was	treated	with	200	µg/ml	of	puromycin	(Sigma).	
RT-PCR	was	performed	with	primers	spanning	the	relevant	exons.	Primer	sequences	can	be	
found	in	Table	1.	
	
Table	1:	primer	sequences	used	for	RT-PCR	
Name	 exon	 sequence	(5'-3')	
F1	 61	 CAGGGCAAAATCCTTCCTACTCC	
R1	 64	 GGGGTCTATGGCCTGCTGTATG	
F2	 55	 CCAGCAGACCAGCCAATTA	
R2	 63	 TTCAAAGGATTCATGGTCCAG	
	
Immunoblotting	for	ATM	expression	and	ATM	activity	assays	
For	ATM	protein	expression	and	activity	assays,	patient-derived	 lymphoblastoid	cells	were	
harvested.	The	assays	were	performed	as	described	before	(Reiman	et	al.	2011).	
	
Radiosensitivity	testing	/	AT	phenotyping	
For	the	G0	micronucleus	assay	blood	samples	of	the	patient,	of	the	patient’s	relatives	and	of	
healthy	volunteers	were	sham-irradiated	or	irradiated	in	vitro	with	0.5,	1	and	2	Gy	doses	of	
60Co-gamma	rays.	Blood	cultures	(0.5	ml	blood	in	4.5	ml	RPMI	medium	containing	10	%	FCS)	
of	 irradiated/sham-irradiated	 peripheral	 blood	 lymphocytes	 (PBL)	 were	 set	 up,	 and	 cell	
division	was	stimulated	by	addition	of	100	μl	phytohaemagglutinin	(PHA)	(Life	Technologies).	
24	h	after	irradiation,	cytokinesis	was	blocked	by	addition	of	6	ug/ml	cytochalasin	B	(Sigma	
Aldrich);	 48	 h	 later	 cells	 were	 fixed	 in	 methanol-acetic	 acid.	 Micronuclei	 (MN)	 -	 small	
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extranuclear	bodies	resulting	mainly	from	acentric	chromosomal	fragments	 lagging	behind	
during	anaphase	-	were	scored	in	cells	that	underwent	a	single	cell	division.	These	cells	can	
be	 identified	as	binucleated	 (BN)	 cells.	 Fixed	 cells	were	 spread	on	a	microscope	 slide	and	
stained	 with	 fluorescent	 DAPI.	 MN	 were	 subsequently	 scored	 in	 1000	 BN	 cells	 by	 an	
automated	image	analysis	system	that	allows	high	throughput	analysis	(Metafer4,	MNscore	
software	module,	Metasystems,	Germany).	Besides	scoring	MN,	the	automated	software	also	
calculated	a	binucleation	index	(BI),	to	assess	the	number	of	once-divided	cells.		
For	the	S-G2	micronucleus	assay,	blood	cultures	were	set	up	with	the	addition	of	PHA,	in	order	
to	stimulate	division	of	resting	PBL	prior	to	in	vitro	irradiation.	Immediately	after	irradiation,	
cytochalasin	B	was	added	to	the	cultures.		
Based	on	optimization	experiments,	a	dose	of	4	Gy	and	a	post-irradiation	(PI)	time	of	8h	was	
selected	for	detecting	DNA	damage	induced	in	cells	in	the	S	and	G2	phases	of	the	cell	cycle.	
Shorter	post-irradiation	times	were	not	feasible	as	they	resulted	in	very	low	yields	of	BN	cells.	
Fixation,	 staining,	MN	 and	 BI	 scoring	 procedures	 were	 performed	 as	 described	 above	 (G0	
micronucleus	assay).	To	determine	the	percentage	of	cells	that	were	in	S	or	G2	phase	of	the	
cell	cycle	at	the	moment	of	irradiation,	we	performed	cell	cycle	analysis	by	adding	0,01mM	5-
bromo-2ʹ-deoxyuridine	(BrdU)	(Sigma-Aldrich)	to	the	cell	cultures	at	the	moment	of	irradiation.	
Subsequently,	MN	slides	were	subjected	to	anti–BrdU	staining	(Dako)	to	visualize	S	phase	cells.	
About	 48	 %	 of	 the	 BN	 cells	 were	 positively	 stained	 (and	 hence	 in	 the	 S-phase)	 while	 the	
remaining	BN	cells	(≈	52	%)	were	negative	(and	hence	in	the	G2	phase,	data	not	shown).		
In	 addition,	we	 added	4mM	caffeine	 (Sigma-Aldrich)	 to	blood	 cultures	of	 the	patient,	 the	
patient’s	 relatives	 and	 the	 healthy	 volunteers	 just	 before	 irradiation.	 Caffeine	 is	 an	 agent	
known	 to	 radiosensitize	 cells	 in	S	and	G2	by	abrogating	 the	ATM	dependent	 ‘early’	G2/M	
checkpoint,	and	by	decreasing	HR	(Terzoudi	et	al.	2009;	Wang	et	al.	2004).	The	ratio	of	MN	
yields	obtained	in	S-	and	G2-irradiated	lymphocytes	of	the	same	individual,	in	the	presence	
or	 absence	 of	 caffeine	 (ratio	 MNcaf+:MNcaf-),	 shows	 the	 efficiency	 of	 both	 the	 G2/M	
checkpoint	 and	 the	 HR	 repair	 system	 of	 an	 individual.	 This	 difference	 is	 defined	 as	 an	
individual	 radiosensitivity	 parameter	 (IRP).	 The	 lower	 the	 IRP	 value	 the	 higher	 the	
radiosensitivity	of	the	individual.		
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Results		
Case	description	
The	proband,	currently	25	years	old,	was	born	after	38	weeks	of	gestation	with	a	birth	weight	
of	2100	g.	According	to	the	parents,	she	showed	normal	early	psychomotor	development,	
except	for	a	‘peculiar’	gait.	She	has	always	been	considered	clumsy.	The	girl	is	left-handed.	
From	the	age	of	2	years	on	there	was	a	suspicion	of	athetosis.	At	the	age	of	2.5	years	she	
underwent	 strabismus	 surgery.	 During	 childhood	 and	 adolescence	 she	 suffered	 from	
recurrent	sinopulmonary	infections.	A	neurological	clinical	examination	at	the	age	of	6-8	years	
showed	 choreo-athetosis	 and	 dystonia,	 dysarthria,	 slight	 drooling,	 no	 ataxia	 and	 normal	
tendon	reflexes.	EEG	and	brain	MRI	were	normal.	A	diagnosis	of	mild	dyskinetic	cerebral	palsy	
was	 made.	 She	 had	 no	 learning	 disabilities.	 At	 the	 age	 of	 10	 years	 normal	 results	 were	
obtained	 from	 routine	 and	metabolic	 investigations	 in	 blood	 and	 urine.	 Evoked	 potential	
examinations	(VER,	BAER,	SSER)	and	analysis	of	cerebrospinal	fluid,	including	5-HIAA	en	HVA,	
revealed	normal	 results.	A	 therapeutic	 trial	with	 L-dopa,	baclofen	and	 tetrazepam	had	no	
effect.	At	the	age	of	16	years	a	normal	cerebral	MRI	and	MR-spectroscopy	was	obtained.	At	
the	age	of	18	years	psychological	problems	 led	 to	a	 temporary	psychiatric	 treatment	with	
psychotherapy	and	psycho-active	drugs.	In	the	following	years	she	successfully	completed	a	
master’s	degree.	Clinical	examination	at	the	age	of	23	years	revealed	no	ocular	or	cutaneous	
telangiectasias.	 There	 was	 no	 nystagmus	 or	 oculomotor	 dyspraxia.	 Her	 speech	 remained	
moderately	dysarthric.	The	generalized	mild	dystonia	was	somewhat	more	prominent	in	the	
face	and	in	the	neck.	There	were	difficulties	with	fine	motor	skills,	such	as	using	utensils	and	
handwriting.	The	finger-nose	test	and	the	heel-knee	test	were	normal,	except	for	a	slightly	
less	well	performed	coordination	test	in	the	right	upper	limb	compared	to	the	left	upper	limb.	
Examination	of	muscle	strength,	sensation,	deep	tendon	reflexes	and	plantar	responses	was	
unremarkable.	 No	 abnormalities	 were	 observed	 during	 the	 stance	 and	 gait	 examination,	
including	the	tandem	walking	test	and	one-leg	hop	test.		
As	 a	 variant	 form	 of	 ataxia-telangiectasia	may	 present	with	 extrapyramidal	 signs	without	
telangiectasias	nor	prominent	ataxia,	diagnostic	 tests	 for	 this	disease	were	performed.	An	
increased	value	for	serum	α-fetoprotein	(77.8	U/ml;	normal	value	<	5	U/ml)	was	found.	The	
patient	 was	 referred	 for	 genetic	 testing	 of	 the	 ATM	 gene.	 Karyotyping	 did	 not	 reveal	
rearrangements	 in	 chromosomes	 7	 and/or	 14	 by	 analysis	 of	 100	 mitoses.	 Hematologic	
investigations	showed	severe	IgA	deficiency,	unusual	in	atypical	A-T	patients	(Verhagen	et	al.	
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2009;	 Verhagen	 et	 al.	 2012).	 Besides	 the	 recurrent	 sinopulmonary	 infections	 she	 did	 not	
suffer	 excessively	 from	 infectious	 diseases,	 nor	 did	 she	 developed	 other	 immune-related	
diseases.	Both	her	parents	have	normal	IgA	values,	ruling	out	a	familial	form	of	IgA	deficiency.			
A	detailed	overview	of	the	family	pedigree	is	available	in	Figure	1.		
	
Figure	1.	Pedigree	of	the	variant	AT	patient.	
Blood	samples	were	obtained	from	individuals	IV.14	(proband),	her	parents	(III.16	and	III.17)	
and	 her	 paternal	 niece	 (IV.1)	 for	 molecular	 analysis	 and	 analysis	 of	 the	 radiosensitive	
phenotype.	
BC=	 Breast	 cancer;	 CVA=cardiovascular	 accident;	 AT=	 Ataxia	 telangiectasia	 like;	 MB=	
Medulloblastoma;	RMS=	embryonal	rhabdomyosarcoma	
Both	parents	of	the	proband	are	healthy.	In	the	maternal	branch	of	the	family	a	strong	burden	
of	breast	cancer	is	evident.	In	the	paternal	branch	of	the	family	two	cousins	with	childhood	
tumors	are	reported.	A	paternal	niece	with	an	embryonal	rhabdomyosarcoma	at	the	age	of	7	
years	was	treated	with	chemotherapy	and	postoperative	radiotherapy.	A	paternal	nephew	had	
a	medulloblastoma	at	the	age	of	14	years,	which	was	surgically	resected	and	postoperatively	
treated	with	radiotherapy.	
	
Molecular	findings	
Sequencing	 of	 the	 complete	 coding	 region	 of	 the	 ATM	 gene	 revealed	 compound	
heterozygosity	for	2	pathogenic	mutations	in	the	proband:	a	missense	mutation	in	exon	55,	
c.8122G>A	 (p.Asp2708Asn),	 inherited	 from	 her	 father,	 and	 a	 splice	 site	 mutation	 in	 the	
acceptor	site	of	exon	63,	c.8851-1G>T,	inherited	from	her	mother	(Figure	2).	These	findings	
confirm	the	diagnosis	of	a	variant	form	of	ataxia-telangiectasia	in	the	proband.	In	the	paternal	
niece	with	an	embryonal	 rhabdomyosarcoma	at	 the	age	of	7	years	heterozygosity	 for	 the	
missense	mutation	ATM	c.8122G>A	(p.Asp2708Asn)	was	shown.		
At	 the	 cDNA	 level,	we	 showed	 that	ATM	 c.8851-1G>T	activates	 a	 cryptic	 acceptor	 site	 63	
nucleotides	downstream	of	the	wild	type	acceptor	(r.8851_8913del;	p.Val2951_Gln2971del)	
(Figure	2).	In	patients	with	a	variant	form	of	A-T	leaky	splice	site	mutations	may	be	the	cause	
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of	the	milder	phenotype	(Reiman	et	al.	2011).	However,	by	amplification	with	primers	located	
in	exon	55	and	63	(Figure	2	-	primers	F2	and	R2,	located	downstream	of	ATM	c.8913	to	allow	
amplification	of	only	the	full	length	allele)	we	observed	only	the	“A”	nucleotide	at	position	
c.8122	in	exon	56.	This	indicates	that	no	full	length	product	is	transcribed	from	the	mutant	
allele	c.8851-1T	(Figure	2).		
	
	
Figure	2:	summary	molecular	results	
Direct	Sanger	sequencing	of	exon	63	and	boundaries	(panel	A)	revealed	a	heterozygous	splice	
site	mutation:	ATM	c.8851-1G>T	RT-PCR	with	primers	spanning	exon	61-64	(F1-R1)(panel	B)	
revealed	that	 the	c.8851-1G>T	mutation	alters	splicing	and	activates	a	cryptic	acceptor	site	
within	exon	63,	which	was	also	predicted	by	splice	site	prediction	programs	 (panel	C).	This	
generates	an	aberrant	transcript	with	an	in	frame	deletion	of	the	first	63	nucleotides	of	exon	
63	(r.8851_8913del).	By	amplification	of	cDNA	with	primers	located	in	exon	55	and	63	(primers	
F2	and	R2)	we	observed	only	the	A	nucleotide	at	position	c.8122	in	exon	56.	This	indicates	that	
no	full	length	product	is	transcribed	from	the	mutant	allele	c.8851-1T.	
	
Protein	expression	and	kinase	assays	
A	strongly	reduced	level	of	ATM	protein	was	observed	in	the	patient’s	cells	compared	to	a	
negative	control	(Figure	3).	Overexposure	of	the	blot	showed	trace	amounts	of	2	different	
proteins:	 the	 largest	 ATM	 protein	 is	 probably	 the	 p.Asp2708Asn	 from	 the	 c.8122G>A	
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mutation	and	the	lower	band	is	derived	from	the	c.8851-1G>T	allele	resulting	in	loss	of	21	
amino	acids	from	exon	63	(p.Val2951_Gln2971del).	
In	contrast	to	the	normal	control	there	is	a	large	reduction	in	kinase	activity	of	the	patient’s	
ATM	protein.	The	only	activity	detectable	above	the	level	of	the	classical	A-T	patient	is	with	
antibodies	to	KAP-1	ser824,	Nbn1	ser343	and	CREB	ser121	(Figure	3).		
	
Figure	3:	results	immunoblots	and	kinase	assays	
Whole	cell	extracts	were	made	from	LCLs	harvested	at	30min	post	irradiation	(2Gy).	Blots	were	
probed	with	phospho	antibodies	for	ATMser1981,	Smc1ser966,	Nbn1Ser343,	Chk2Thr68	and	
p53Ser15.	Blots	were	also	probed	with	antibodies	for	ATM,	Smc1,	Nbn1	and	p53	to	indicate	
total	levels	of	these	proteins	in	the	lysate.	Two	lanes	per	lysate	are	shown,	one	unirradiated	(-
)	and	one	irradiated	(+)	(activated	ATM).		
In	 lanes	 1	&	 2	 are	 cells	 from	 a	 normal	 ATM	positive	 control	 (RB)	 (panels	 B	&	 C),	 showing	
phosphorylation	of	the	targets	SMC1	ser966	(panel	D),	KAP-1	ser	824	(panel	F),	Nbn1	ser343	
(panel	H)	and	CREB	ser121	(panel	J	&	K).	There	is	a	strong	signal	for	each	of	these	in	lane	2	
after	activation.	The	total	levels	of	SMC1,	KAP1,	Nbn1	and	CREB	are	also	shown	in	panels	E,	G,	
I	&	L	respectively.		
The	negative	control	is	cell	lysate	from	a	classical	A-T	patient	(RN)	shown	in	lanes	3	&	4.	Here	
is	no	phosphorylation	of	these	four	targets	in	this	patient’s	cells	in	lane	4	–	consistent	with	him	
having	A-T	–	he	has	no	ATM	-	(panels	B	&	C).	
The	cell	lysate	of	our	patient	with	variant	A-T	is	in	lanes	5	&	6.	Panel	B	and	particularly	panel	C	
confirms	 the	 reduced	 level	 of	 ATM	 protein	 in	 her	 cells.	With	 regard	 to	 the	 ATM	 proteins	
present,	 there	 are	 three	 bands.	 The	 lowest	 one	 is	 probably	 non	 specific	 (it	 is	 seen	 in	 the	
classical	A-T	with	no	ATM).	The	largest	ATM	protein	is	probably	the	p.Asp2708Asn	from	the	
c.8122G>A	mutation	and	the	middle	band	from	the	c.8851-1G>T	resulting	in	loss	of	21	amino	
acids	 from	exon	63.	 In	contrast	 to	 the	normal	control	 (lane	2)	 there	 is	a	 large	 reduction	 in	
activity	of	ATM	protein	(lane	6).	The	only	activity	detectable	(above	the	level	in	lane	4	of	the	
classical	A-T)	is	with	antibodies	to	KAP-1	ser824,	Nbn1	ser343	and	CREB	ser121	(overexposed)	
in	lane	6.	However,	the	activity	is	more	than	in	the	lysate	from	a	classical	A-T	patient	(lane	4).		
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Radiosensitivity	assays	
G0	micronucleus	assay	
The	data	obtained	in	this	study	with	the	G0	micronucleus	assay	for	the	patient,	the	patient’s	
relatives	 (individuals	 III.16,	 III.17,	 IV.1	 from	 Figure	 1)	 and	 the	 healthy	 volunteers	 were	
compared	 to	 our	 reference	micronucleus	 dose	 response	 calibration	 curve	 (Willems	 et	 al.	
2010)	(Figure	4).	In	the	variant	A-T	patient,	MN	values	were	only	obtained	after	irradiation	
with	doses	of	0.5	and	1	Gy.	Irradiation	with	a	2	Gy	dose	resulted	in	a	very	low	BN	index	(<	5%)	
probably	because	G0-irradiated	lymphocytes	(ATM-/-)	are	irreversibly	blocked	in	G2	(Beamish	
and	Lavin	1994;	Xu	et	al.	2002).	In	the	ATM	heterozygous	mutation	carriers	(ATM+/-)	and	in	
healthy	volunteers	higher	BN	indexes	for	the	2	Gy	dose	point	were	obtained	(12%	and	17%,	
respectively),	and	micronuclei	could	be	scored.	The	results	shown	in	Figure	4	demonstrate	
that	the	conventional	G0	micronucleus	assay	is	sensitive	enough	to	identify	the	variant	A-T	
patient	but	not	the	monoallelic	ATM	mutation	carriers.	For	the	variant	A-T	patient	significant,	
1.8-fold	increases	in	MN	yields	were	obtained	at	0.5	and	1	Gy	doses,	when	compared	to	the	
average	 MN	 values	 of	 our	 reference	 curve.	 In	 the	 relatives,	 heterozygous	 for	 an	 ATM	
mutation,	and	in	the	three	healthy	donors	(data	of	the	healthy	donors	are	not	shown	in	Figure	
4	for	clarity	reasons),	the	MN	values	were	lying	within	the	95%	confidence	limits	(UCL,	LCL,	
Figure	 4)	 of	 the	MN	 reference	 curve.	 Although	 an	 enhanced	 radiosensitive	 phenotype	 is	
observed	in	the	variant	A-T	patient,	the	observed	MN	fold-increase	of	1.8	is	lower	than	the	
sensitivity	values	observed	in	a	previous	study	from	our	group,	performed	on	“classic”	A-T	
patients	(3	to	5	fold	MN	increase	(Vral	et	al.	1996).		
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Figure	4:	results	G0	micronucleus	assay	
Mean	MN	values	(±SD)	obtained	from	the	AT	patient	(3	repeated	independent	samplings)	and	
from	 the	 heterozygous	 parents	 (2	 repeated	 independent	 samplings),	 plotted	 against	 a	
reference	mean	MN	dose-response	curve,	and	curves	for	the	95%	upper	and	lower	confidence	
limits	(UCL,	LCL)	(n=10)	(adapted	from	Willems	et	al.	2010).	
	
S-G2	micronucleus	assay	
For	the	modified	S-G2	MN	assay,	the	MN	yields	obtained	after	exposure	to	4	Gy	in	the	variant	
A-T	patient	and	her	 relatives	were	compared	with	 the	MN	yields	 from	healthy	 individuals	
recruited	for	the	present	study.	The	results	of	the	S-G2	MN	assay	are	shown	in	Figure	5.	This	
figure	shows	the	fold	MN	increase	obtained	in	repeated,	independent	samplings	in	all	tested	
subjects.	 In	 the	 variant	 A-T	 patient,	 a	 4-fold	 increase	 in	 the	 MN	 yield	 (mean	 of	 three	
experiments)	was	 observed.	 This	 increase	 in	MN	 yield	 is	more	 pronounced	 than	 the	 one	
observed	with	the	G0	micronucleus	assay	(1.8-fold).	The	mother	of	the	patient,	carrying	the	
ATM	 c.8851-1G>A	 splice	 acceptor	 site	 mutation,	 showed	 a	 2.8-fold	 increase	 in	MN	 yield	
(mean	of	2	experiments),	while	 the	 father	and	 the	paternal	niece,	both	carrying	 the	ATM	
c.8122G>A	(p.Asp2708Asn)	missense	mutation,	showed	a	similar	1.4-fold	MN	increase.		
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Figure	5:	results	S-G2	micronucleus	assay.		
MN	yields	observed	in	the	tested	subjects	are	expressed	as	fold	increase	relative	to	the	MN	
yields	observed	in	the	healthy	donors.	The	average	fold	increase	obtained	for	the	AT	patient	
(3	samplings),	the	patient’s	parents	(2	samplings)	and	paternal	niece	(one	sampling)	as	well	as	
the	fold	increase	observed	per	single	independent	sampling	are	shown	in	the	graph.	
	
S-G2	micronucleus	assay	with	caffeine	
IRP	values,	representing	the	ratio	of	MNcaf+/MNcaf-,	are	presented	in	Figure	6.	Data	obtained	
from	 the	 variant	 A-T	 patient,	 the	ATM	 heterozygous	 family	 members	 and	 seven	 healthy	
donors	are	presented.	In	healthy	donors,	a	mean	IRP	value	(μIRP)	of	3.86	±	1.00	(SD)	(range	
IRP	 values:	 2.71-5.39)	 was	 obtained.	 According	 to	 Terzoudi	 et	 al.	 (Terzoudi	 et	 al.	 2009)	
individuals	may	be	defined	“normal”	when	IRP	=	μIRP	±	1SD,	“radiosensitive”	when	μIRP	-	2SD	
≤	IRP	<	μIRP	-	1SD,	and	“highly	radiosensitive”	when	IRP	<	μIRP	-	2SD.	Applying	this	classification	
system	to	our	data,	the	variant	A-T	patient	and	mother	of	the	patient	turned	out	to	be	highly	
radiosensitive	(IRPpatient	=	1.85;	IRPmother	=	1.6),	while	the	father	and	the	paternal	niece,	
carrying	the	same	mutation,	were	found	to	be	radiosensitive	(IRPfather		=	2.01;	IRPcousin	=	
2.6).		
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Figure	6:	results	S-G2	micronucleus	assay	with	the	addition	of	caffeine	
Individual	Radiosensitivity	Parameter	(IRP)	values,	representing	the	MNcaf+/MNcaf-	ratio,	i.e.	
the	ratio	of	micronuclei	generated	in	the	presence	(MNcaf+)	or	absence	(MNcaf-)	of	caffeine.	
IRPs	 from	the	A-T	patient,	 from	the	heterozygous	 family	members	and	 from	seven	healthy	
donors	are	presented.	The	mean	IRP	reference	value	for	the	healthy	donor	group	(μIRP	±	1SD)	
is	 3.86	 ±1.	 Individuals	 are	 defined	 “normal”	 when	 their	 IRP	 is	 equal	 to	 μIRP±1SD,	
“radiosensitive”	when	their	IRP	ranges	between	μIRP-2SD	and	μIRP-1SD	(μIRP-2SD≤IRP<μIRP-
1SD),	and	“highly	radiosensitive”	when	their	IRP<μIRP-2SD.		
	
Discussion	
Classic	ataxia	telangiectasia	is	a	severe,	childhood-onset	disease	whose	characteristic	findings	
are	 early-onset	 cerebellar	 ataxia,	 oculocutaneous	 telangiectasia,	 and	 susceptibility	 to	
pulmonary	disease.	These	patients	have	an	increased	risk	of	cancer,	especially	hematologic	
malignancies.		
The	long	diagnostic	delay	in	the	current	case	exemplifies	the	difficulties	in	diagnosing	patients	
with	a	variant	form	of	A-T.	In	these	cases	the	ATM	protein	is	still	expressed	and	residual	kinase	
activity	of	ATM	is	found.	Clinically,	these	patients	have	a	milder	and	different	neurological	
phenotype.	Extrapyramidal	 signs	 (chorea-athetosis,	 resting	 tremor,	 sometimes	myoclonus-
dystonia)	are	detected.	Telangiectasias	are	often	absent.	Ataxia	is	not	an	initial	symptom,	and	
the	later	occurring	ataxia	is	of	mild-to-moderate	degree	(Verhagen	et	al.	2009).	These	patients	
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have	 an	 extended	 lifespan.	 Cancer	may	 occur	 later	 in	 life	 and	 generally	 consists	 of	 solid	
instead	of	lymphoid	malignancies.	Serum	α-fetoprotein	is	elevated	in	both	classic	and	variant	
A-T	 (Verhagen	et	 al.	 2009;	Verhagen	et	 al.	 2012),	but	not	 in	heterozygous	 carriers	 (Stray-
Pedersen	et	al.	2007).	The	patient	presented	here	was	found	to	be	immunologically	atypical,	
with	 a	 severe	 IgA	deficiency	which	was	not	 reported	 in	 any	 variant	A-T	patient	described	
before	(Verhagen	et	al.	2009;	Verhagen	et	al.	2012).		
At	the	age	of	25	years	the	patient	has	not	developed	cancer,	but	as	with	all	A-T	patients	is	at	
increased	risk.	The	relatives,	heterozygous	for	an	ATM	mutation,	have	also	an	increased	risk	
for	cancer.	In	the	maternal	branch	a	strong	predisposition	for	breast	cancer	is	evident,	while	
in	 the	paternal	branch	2	childhood	 tumors	were	 reported	 (Figure	1).	The	paternal	 cousin,	
diagnosed	with	 an	 embryonal	 rhabdomyosarcoma,	was	 found	 to	be	heterozygous	 for	 the	
ATM	missense	mutation	 p.Asp2708Asn.	 Sarcomas	 are	 an	 established	 entity	 in	 the	 cancer	
spectrum	 occuring	 in	 classical	 A-T	 patients.	 A	 further	 link	 between	 ATM	 and	
rhabdomyosarcoma	has	previously	been	established	based	on	the	frequent	observation	of	
complete	loss	of	ATM	expression	in	rhabdomyosarcoma	(Zhang	et	al.	2003).		
The	 finding	of	a	missense	and	a	 splice	 site	mutation	 is	 compatible	with	 the	phenotype	of	
variant	ataxia	telangiectasia,	depending	on	whether	one	or	both	of	these	results	in	expression	
of	ATM	protein	with	activity.	The	missense	mutation	ATM	 c.8122G>A	 (p.Asp2708Asn)	has	
previously	been	described	in	other	A-T	patients.	An	Italian	A-T	patient,	was	described	with	a	
splice	site	mutation	on	the	second	other	allele	(ATM	c.2250G>A	–	in	the	last	nucleotide	of	
exon	14,	leading	to	in	frame	skipping	of	this	exon	at	the	cDNA	level)	(Cavalieri	et	al.	2006).	
However,	 the	 phenotype	 of	 this	 patient	 was	 not	 given.	 Furthermore,	 ATM	 c.8122G>A	
(p.Asp2708Asn)	has	been	reported	as	a	somatic	mutation	in	lung	cancer	(COSMIC	database).		
A	 low	 level	of	 residual	kinase	activity	associated	with	the	ATM	 c.8122G>A	(p.Asp2708Asn)	
mutation	 has	 previously	 been	 observed	 in	 cells	 from	 another	 patient	 with	 this	 mutation	
(Reiman	 et	 al.	 2011).	 Modelling	 of	 the	 mutation	 and	 expression	 of	 the	 mutant	 ATM	
p.Asp2708Asn	 protein	 showed	 it	 to	 have	 some	 ATM	 kinase	 activity	 (Barone	 et	 al.	 2009).	
Therefore	 the	 confirmation	of	 the	 low	 level	 of	ATM	kinase	activity	 in	our	patients	 cells	 is	
consistent	with	the	presence	of	the	p.Asp2708Asn	mutant	protein	and	diagnosis	of	variant	A-
T.		
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To	our	knowledge,	the	substitution	c.8851-1G>T	in	the	acceptor	site	of	the	penultimate	exon	
of	ATM	has	not	yet	been	described	in	A-T	patients	but	it	has	previously	been	reported	that	
heterozygous	carriers	of	this		mutation	have	an	increased	risk	of	breast	cancer	(Goldgar	et	al.	
2011;	Tavtigian	et	al.	2009).	Notably,	an	increased	incidence	of	breast	cancer	is	observed	in	
the	maternal	branch	of	the	family.	Up	till	now	we	did	not	have	access	to	genetic	material	of	
any	of	the	maternal	relatives	affected	with	breast	cancer.	The	substitution	c.8851-1G>T	leads	
to	an	aberrant	transcript	with	an	in	frame	deletion	of	21	amino	acids	(p.Val2951_Gln2971del)	
from	the	PI3_PI4_kinase	domain	(PFAM	PF00454,	2711–2962).	From	the	RT-PCR	results	it	is	
clear	that	the	aberrant	transcript	is	not	subjected	to	NMD	and,	the	shorter	protein	detected	
on	the	immunoblots	suggests	trace	amounts	of	expression	of	this	protein.	However,	we	have	
no	evidence	that	p.Val2951_Gln2971del	has	any	residual	kinase	activity.	
	
The	results	obtained	with	the	G0	and	the	S-G2	micronucleus	assay,	show	that	the	latter	was	
a	more	powerful	assay	to	demonstrate	radiosensitivity	in	this	specific	case	of	variant	A-T.	The	
finding	 of	 a	 more	 pronounced	 radiosensitive	 behaviour	 of	 lymphocytes	 with	 the	 S-G2	
micronucleus	assay	compared	to	the	G0	micronucleus	assay,	may	 indicate	that	the	role	of	
ATM	in	the	DNA	damage	response	is	more	important	when	cells	are	in	the	S	or	G2	phases	at	
the	moment	of	irradiation	thus	resulting	in	increased	chromosomal	damage.	Our	findings	in	
this	variant	A-T	patient	of	an	enhanced	micronucleus	yield	in	binucleate	cells	after	irradiation	
in	G2	are	in	agreement	with	the	enhanced	number	of	chromatid	breaks	observed	in	mitotic	
cells	of	A-T	patients	after	irradiation	in	G2	(Pantelias	and	Terzoudi	2011;	Terzoudi	et	al.	2009;	
Tchirkov	 et	 al.	 1997;	 Scott	 et	 al.	 1996;	 Chen	 et	 al.	 1994;	 Sanford	 et	 al.	 1990).	 The	main	
advantages	of	the	analysis	of	G2-phase	radiation-induced	micronuclei	compared	to	chromatid	
breaks	in	PHA-stimulated	blood	lymphocytes,	as	described	in	this	study,	are	the	high	yield	of	
binucleate	cells	that	can	be	analysed,	the	easy	slide	preparation	technique	and	the	quick	and	
objective	automated	scoring	procedure	(Willems	et	al.	2010).	This	makes	the	S-G2	MN	assay	
very	useful	in	a	clinical	setting.		
	
We	evaluated	the	effect	of	the	addition	of	caffeine,	an	agent	known	to	radiosensitize	cells	in	
S	and	G2	by	abrogating	the	ATM	dependent	‘early’	G2/M	checkpoint,	for	the	assessment	of	
individual	radiosensitivity	in	all	tested	subjects.	Although	many	inhibitors	targeting	ATM	exist	
(Khalil	et	al.	2012)	our	choice	for	caffeine	was	based	on	the	studies	of	Terzoudi	et	al.	(Pantelias	
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and	Terzoudi	 2011;	 Terzoudi	 et	 al.	 2009)	where	 the	 cytogenetic	G2-assay,	 combined	with	
caffeine,	was	 applied	 on	 blood	 samples	 of	 A-T	 homozygote	 and	 heterozygote	 patients	 to	
investigate	 radiosensitivity.	Our	 results	are	 in	agreement	with	 the	evidence	shown	by	 this	
group,	who	found	IRP	values	pointing	to	a	highly	radiosensitive	phenotype	in	A-T	homozygous	
patients,	while	A-T	heterozygotes	were	found		to	be	radiosensitive.		
Our	results	show	that	with	the	S-G2	micronucleus	assay	an	enhanced	radiosensitivity	could	
also	be	demonstrated	in	the	ATM	monoallelic	mutation	carriers	(ATM+/-).	This	in	agreement	
with	other	studies	that	reported	an	intermediate	radiosensitivity	–	compared	to	“biallelic”	A-
T	 –	 with	 the	 G2	 chromatid	 break	 assay	 in	 lymphocytes	 of	 heterozygous	 carriers	 of	ATM	
mutations	(Pantelias	and	Terzoudi	2011;	Terzoudi	et	al.	2009;	Tchirkov	et	al.	1997;	Scott	et	al.	
1996;	Chen	et	al.	1994;	Sanford	et	al.	1990)..	Interestingly,	we	found	that	the	extent	of	the	
radiosensitive	behavior	depends	on	the	underlying	mutation	and	may	be	correlated	with	the	
kinase	activity.	 In	this	study,	the	splice	site	mutation	ATM	c.8851-1G>T,	segregating	 in	the	
maternal	branch	of	 the	 family,	 results	 in	a	more	radiosensitive	phenotype	and	absence	of	
kinase	activity	 compared	 to	 the	missense	mutation	ATM	p.Asp2708Asn	segregating	 in	 the	
paternal	branch	of	the	family	and	associated	with	some	residual	kinase	activity.	The	results	
were	consistent	between	different	independent	samplings	from	the	same	individual	and	for	
different	individuals	carrying	the	same	mutation.	As	these	are	preliminary	results	obtained	in	
a	single	variant	A-T	patient	and	her	relatives,	they	need	to	be	further	confirmed	in	additional	
A-T	patients	and	relatives	carrying	a	panel	of	different	ATM	mutations.		
Recently	Prodosmo	et	al.	 reported	preliminary	results	of	a	newly	developed	cost-effective	
and	 fast	 functional	 test	 to	 determine	 mutant	 ATM	 zygosity	 based	 on	 p53	 centrosomal	
localisation	visualised	by	immunofluorescence	staining	(Prodosmo	et	al.	2013).		
The	development	of	functional	assays	allowing	the	detection	of	ATM	heterozygous	carriers	
can	also	be	of	 clinical	 importance.	 Some	 reports	 suggest	 that	ATM	 heterozygotes	may	be	
over-represented	 in	the	proportion	of	breast	cancer	cases	that	show	severe	normal	tissue	
reactions	following	radiotherapy	(Angele	et	al.	2003;	Meyer	et	al.	2004).	In	addition,	women	
who	carry	rare	deleterious	ATM	missense	variants	and	who	are	treated	with	radiation	have	
an	elevated	risk	of	developing	contralateral	breast	cancer	(Bernstein	et	al.	2010).	As	the	major	
breast	 cancer	 predisposing	 genes	 BRCA1	 and	 BRCA2	 are	 also	 involved	 in	 the	 HR	 repair	
pathway	active	in	late	S	and	G2	phases	and	in	checkpoint	control,	the	S-G2	MN	assay	may	
also	represent	a	functional	assay	to	identify	BRCA1/2	heterozygous	mutation	carriers.		
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In	all	these	cases,	genetic	analysis	and	phenotypic	profiling	should	go	hand-in-hand	in	order	
to	achieve	an	optimal	characterization	of	the	specific	cases	and	to	refine	both	diagnosis	and	
therapeutic	handling	of	cancer-prone,	genomic	instability	syndromes.	
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Abstract	
Introduction:	Breast	cancer	risk	increases	drastically	in	individuals	carrying	a	germline	BRCA1	
mutation.	The	exposure	to	ionizing	radiation	for	diagnostic	or	therapeutic	purposes	of	BRCA1	
mutation	 carriers	 is	 counterintuitive	 since	 BRCA1	 is	 active	 in	 the	 DNA	 damage	 response	
pathway.	The	aim	of	this	study	was	to	investigate	whether	healthy	BRCA1	mutations	carriers	
demonstrate	an	increased	radiosensitivity	compared	to	healthy	individuals.		
Methods:	We	 defined	 a	 novel	 radiosensitivity	 indicator	 (RIND)	 based	 on	 two	 endpoints	
measured	 by	 the	 G2	 micronucleus	 assay,	 reflecting	 defects	 in	 DNA	 repair	 and	 G2	 arrest	
capacity	after	exposure	to	doses	of	2	or	4Gy.	We	investigated	if	a	correlation	between	the	
RIND	score	and	nonsense-mediated	decay	(NMD)	could	be	established.	
Results:	We	 found	 significantly	 increased	 radiosensitivity	 in	 the	 cohort	 of	 healthy	BRCA1	
mutation	carriers	compared	to	healthy	controls.	In	addition,	our	analysis	show	a	significantly	
different	distribution	over	 the	RIND	 scores	 (p=0.034,	 Fisher	 exact	 test)	 for	 healthy	BRCA1	
mutation	carriers	compared	to	non-carriers:	72%	of	mutation	carriers	show	a	radiosensitive	
phenotype	(RIND	score	1-4)	whereas	72%	of	the	healthy	volunteers	show	no	radiosensitivity	
(RIND	score	0).	Furthermore,	28%	of	BRCA1	mutation	carriers	had	a	RIND	score	of	3	or	4	(not	
observed	in	controls).	The	radiosensitive	phenotype	was	similar	for	relatives	within	several	
families	but	not	for	unrelated	individuals	carrying	the	same	mutation.	The	median	RIND	score	
was	 higher	 in	 patients	 with	 a	 mutation	 leading	 to	 a	 premature	 termination	 codon	 (PTC)	
located	in	the	central	part	of	the	gene	than	in	patients	with	a	germline	mutation	in	the	5’	end	
of	the	gene.	
Conclusion:	We	show	that	BRCA1	mutations	are	associated	with	a	radiosensitive	phenotype	
related	to	a	compromised	DNA	repair	and	G2	arrest	capacity	after	exposure	to	either	2	or	
4Gy.	Our	study	confirms	that	haploinsufficiency	is	the	mechanism	involved	in	radiosensitivity	
in	 patients	 with	 a	 PTC	 allele,	 but	 suggests	 that	 further	 research	 is	 needed	 to	 evaluate	
alternative	mechanisms	for	mutations	not	subjected	to	NMD.		
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Introduction	
Breast	 cancer	 (BC)	 is	 the	 most	 common	 malignancy	 in	 the	 Western	 world	
(http://www.who.int/cancer/detection/breastcancer/en/).	 Approximately	 15%	 of	 all	 BC	
patients	 have	 at	 least	 one	 relative	 affected	 by	 BC.	 About	 15%	 of	 all	 familial	 BCs	 can	 be	
attributed	to	a	mutation	in	the	BRCA1	or	BRCA2	genes	[1].	Since	the	discovery	of	BRCA1,	many	
different	functions	have	been	attributed	to	this	protein.	In	its	function	as	tumour	suppressor	
gene,	BRCA1	plays	a	crucial	role	in	DNA	DSB	repair	pathways	(reviewed	in:	[2,	3]).	BRCA1	is,	
for	instance,	important	in	the	homologous	recombination	(HR),	a	pathway	for	repair	of	DSB	
in	late	S	and	G2	phases	of	the	cell	cycle	[4–6].	BRCA1	also	plays	an	important	role	in	the	G2/M	
checkpoint	control,	allowing	the	cell	to	repair	DNA	damages	before	proceeding	to	the	next	
phase	of	the	cell	cycle	[7].		
	
Carriers	of	a	heterozygous	BRCA1	mutation	may	show	enhanced	radiosensitivity,	associated	
with	 an	 increased	 carcinogenic	 risk	 after	 exposure	 to	 diagnostic	 or	 therapeutic	 ionzing	
radiation	 (IR).	 Several	 studies	 have	 shown	 that	 exposure	 to	 diagnostic	 X-rays	 may	 cause	
cancer	in	healthy	BRCA1	mutation	carriers	[8–11],	whereas	other	studies	could	not	detect	a	
positive	 association	 between	 exposure	 to	 IR	 and	 breast	 cancer	 risk	 in	BRCA1/2	mutation	
carriers	[12–15].	Also,	studies	analyzing	the	impact	of	(adjuvant)	radiotherapy	on	the	breast	
cancer	risk	in	BRCA1	and	BRCA2	mutation	carriers	reported	no	univocal	conclusion	[16].	The	
contradictory	data	obtained	in	these	studies	are	mainly	due	to	the	constraints	in	the	design	
of	the	performed	studies.	
Since	 long-term	studies	 investigating	 the	effect	of	 exposure	 to	 IR	 in	mutation	 carriers	 are	
difficult	to	setup	and	are	reputed	to	be	unethical,	it	is	clear	that	more	empiric	data	are	needed	
to	determine	in	vitro	the	radiosensitivity	of	patients	carrying	a	germline	mutation.	Research	
so	far	yielded	contradictory	results	and	lack	consistency	[17–26].		
The	G0	micronucleus	assay,	performed	on	peripheral	blood	lymphocytes	exposed	to	in	vitro	
doses	of	 2	 to	 4	Gy,	 is	 frequently	 used	 to	 assess	 chromosomal	 radiosensitivity.	 This	 assay,	
however,	is	not	optimized	to	detect	defects	in	DSB	repair	activated	during	G2	phase	of	the	
cell	cycle	or	the	G2/M	checkpoint,	 two	processes	 in	which	BRCA1	plays	a	major	role	since	
irradiation	takes	place	in	G0	phase	of	the	cell	cycle.		
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We	previously	reported	a	modified	micronucleus	assay	optimized	to	detect	defects	in	S	or	G2	
phase	of	the	cell	cycle.	This	assay	efficiently	detected	increased	radiosensitivity	in	a	patient	
with	a	mild	form	of	ataxia	telangiectasia	(AT)	and	in	heterozygous	relatives	[27].		
In	 the	present	 study,	we	applied	 the	G2	micronucleus	 assay	 to	 further	 elucidate	whether	
healthy	BRCA1	mutation	carriers	are	characterized	by	an	increased	 in	vitro	radiosensitivity.	
The	endpoints	of	the	study	were:	1)	micronucleus	yields,	and	2)	G2/M	checkpoint	efficiency	
ratio.	 Both	 endpoints	 were	 assessed	 after	 irradiating	 PHA-stimulated	 peripheral	 blood	
lymphocytes	with	doses	of	2Gy	and	4Gy.	With	this	assay,	we	assessed	the	mean	differences	
in	radiosensitivity	for	heterozygous	BRCA1	mutation	carriers	compared	to	healthy	volunteers.	
We	also	scored	the	overall	radiosensitivity	in	each	mutation	carrier	using	a	‘Radiosensitivity	
Indicator’	(RIND)	scoring	system.	In	addition,	as	our	BRCA1	population	consists	of	individuals	
carrying	different	BRCA1	mutations,	we	investigated	if	there	is	a	link	between	radiosensitivity	
and	the	degree	of	nonsense-mediated	decay	(NMD)	of	the	specific	mutant	allele.	
	
Materials	and	methods	
Sample	collection	
Blood	samples	were	collected	from	individuals	consulting	the	clinic	of	the	Centre	for	Medical	
Genetics,	Ghent	University	Hospital,	Belgium	(CMGG).	Both	EDTA	and	heparin	blood	samples	
were	collected.	EDTA	samples	were	used	for	mutation	analysis	at	CMGG,	whereas	the	G2	MN	
assay	was	performed	on	heparinized	blood	samples.		
In	addition,	we	collected	heparinized	blood	samples	from	healthy	volunteers	(n=20)	without	
a	personal	or	family	history	of	BC,	to	determine	the	normal	distribution	of	micronucleus	yields	
in	controls.		
Lymphocytes	were	isolated	from	the	blood	samples	using	lymphoprep™	and	were	preserved	
in	liquid	nitrogen	for	the	analysis	of	the	NMD	of	the	mutant	allele.	
For	a	number	of	mutation	carriers	(n=4)	and	healthy	volunteers	(n=7),	a	second	blood	sample	
was	taken	to	determine	the	reproducibility	of	the	results	obtained	with	the	G2	MN	assay	at	
different	time	points.	
This	 study	 was	 approved	 by	 the	 ethical	 committee	 of	 the	 Ghent	 University	 Hospital	
(B670201111641	d.d.	20/09/2011).	All	study	participants	(n=18)	were	counseled	by	clinical	
geneticists	in	the	context	of	a	predictive	(n=16)	or	diagnostic	test	(n=2)	for	hereditary	BC	and	
signed	an	informed	consent.	Two	of	the	18	BRCA1	mutation	carriers	had	developed	BC	but	
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cancer	 treatment	 finished	 more	 than	 2	 years	 ago;	 these	 women	 are	 both	 carrier	 of	 a	
substitution	affecting	the	start	codon	(BC01	and	BC02).	The	mean	age	of	the	mutation	carriers	
and	healthy	volunteers	was	40.9	and	35.4,	respectively	(p	=	0.26,	t-test).		
	
Molecular	analysis	
All	 patients	 selected	 for	 this	 study	 had	 a	 family	 history	 of	 breast/ovarian	 cancer	 and	 a	
germline	BRCA1	mutation.	 Targeted	 analysis	 for	 the	 familial	 mutation	 was	 performed	 by	
direct	sequencing	on	2	independently	extracted	DNA	samples.	No	molecular	analyses	were	
performed	in	healthy	volunteers	because	of	the	absence	of	a	personal	or	familial	anamnesis	
for	BC.	
	
The	G2	micronucleus	assay	
For	 the	 G2	 MN	 assay,	 a	 large	 blood	 culture	 is	 set	 up	 in	 the	 presence	 of	 the	 mitogen	
phytoheamagglutinin	(PHA).	PHA	stimulates	T-lymphocyte	division,	resulting	in	a	population	
of	cycling	lymphocytes	(G1,	S1	G2	and	M	phase)	after	3	days	of	incubation	when	the	blood	
culture	is	irradiated.	On	the	contrary,	in	the	G0	MN	assay,	blood	is	first	irradiated	and	then	
cultured	in	the	presence	of	PHA,	resulting	in	the	irradiation	of	T-lymphocytes	in	G0	phase.	
The	addition	of	cytochalasin	B	 (Cyto	B),	an	agent	 that	blocks	 the	cytokinesis,	 to	 the	blood	
cultures	allows	 the	 identification	of	 first	division	 cells	 as	binucleated	 cells	 (BN).	A	non-	or	
misrepaired	 DSB	 can	 result	 in	 an	 acentric	 chromosomal	 fragment	which	 is	 detected	 as	 a	
micronucleus	(MN)	in	the	cytoplasm	of	the	BN	cell	[17,	28].	
More	precisely,	for	the	G2	MN	assay,	a	50-ml	blood	culture	was	set	up	using	5	ml	heparinized	
blood,	45	ml	cRPMI	(RPMI,	1%	L-glutamin	and	0.5%	penicillin/streptomycin)	containing	10%	
Fetal	calf	serum	(FCS)	and	1	ml	PHA	(all	Gibco®)	in	a	T75	culture	flask	[27].	This	large	culture	
was	set	up	to	avoid	inter-culture	variation	during	the	first	days	of	incubation.	After	3	days,	
the	culture	was	split	and	sham-irradiations	as	well	as	irradiations	with	2	and	4	Gy	60Co	γ	rays	
were	performed.	An	overview	is	shown	in	Figure	1a.	Immediately	after	irradiation,	cyto	B	(6	
μg/ml,	 sigma-aldrich®)	was	added.	To	half	of	 the	 irradiated	cultures,	 caffeine	 (CAF,	4	mM,	
sigma-aldrich®),	an	agent	that	abrogates	the	G2/M	checkpoint,	was	added	to	determine	the	
G2/M	checkpoint	efficiency	ratio	[29,	30].	Based	on	5-bromo-2’-deoxyuridine	(BrdU)	results	
obtained	in	our	previous	study	on	ATM	[27]	and	new	experiments	performed	for	this	study,	
a	post-irradiation	incubation	period	of	8	h	was	selected	for	detecting	DNA	damage	induced	
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in	cells	in	G2	phase	(Figure	1b).		The	cultures	were	then	treated	with	75	mM	KCl,	fixed	once	
using	a	combination	of	methanol,	acetic	acid	and	ringer	(9	g	NaCl	+	0.42	g	KCl	+	0.24	g	CaCl2	
for	1	liter	dH2O)	(4/1/5,	4°C)	and	thrice	with	methanol	and	acetic	acid	(4/1,	4°C).	Finally,	the	
cell	suspension	was	concentrated	and	spread	on	slides.	
After	4',6-diamidino-2-phenylindole	(DAPI)	staining,	the	slides	were	scanned	with	a	Metafer	
4	 (MNscore	 software	 module,	 Metasystems,	 Germany).	 This	 automated	 image	 analysis	
system	selects	BN	and	determines	the	number	of	MN	per	BN	cell	(see	Figure	1a).	For	each	
condition,	2	cultures	were	set	up	and	2	slides	per	culture	were	analysed.	A	minimum	of	600	
BN	cells	was	scored	on	each	coded	slide	for	the	presence	of	MN.	BN	and	MN	selected	in	the	
automated	 setting	 were	 manually	 checked	 for	 false	 positives	 and	 false	 negatives.	 To	
determine	the	G2/M	checkpoint	efficiency	ratio,	the	quotient	was	determined	for	the	MN	
yield	obtained	in	the	presence	versus	the	absence	of	Caffeine	(#MNCaf+/#MNCaf-).	The	lower	
this	ratio,	the	more	radiosensitive	an	individual	is.		
	
In	order	 to	assess	 the	overall	 radiosensitive	phenotype	of	each	patient,	a	RIND	score	was	
calculated.	The	mean	and	standard	deviation	(SD)	of	the	micronucleus	yield	and	the	G2/M	
checkpoint	efficiency	ratio	assessed	in	the	cohort	of	healthy	volunteers	served	to	determine	
cut-offs	 to	define	 the	 radiosensitivity	 of	 individual	BRCA1	mutation	 carriers.	An	 individual	
value	equal	or	higher	than	the	mean	MN	yields	in	controls	+	1	SD	scored	1	point	(color-code	
orange).	A	value	equal	or	higher	than	the	mean	MN	yields	of	controls	+	2SD	scored	2	points	
(color-code	red).	An	individual	value	lower	than	the	mean	of	controls	+	1SD	was	scored	as	
naught	 (color-code	white).	For	 the	G2/M	checkpoint,	a	similar	conversion	of	 the	data	was	
performed,	with	a	value	lower	than	mean	checkpoint	ratio	assessed	in	controls	-	1SD	scored	
1	point	(color-code	orange),	mean	–	2	SD	scored	2	points	(color-code	red).	An	individual	value	
higher	 than	 the	 mean	 of	 controls	 -	 1	 SD	 was	 scored	 as	 naught	 (color-code	 white).	 The	
combined	scores	from	MN	yields	(0,1	or	2	points)	and	checkpoint	ratios	(0,1	or	2	points)	were	
then	added	to	form	a	single	Radiosensitivity	Indicator	(range:	0	to	4).		
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Analysis	of	the	cell	cycle	phase	at	time	of	irradiation	
5-bromo-2’-deoxyuridine	(BrdU)	was	added	to	blood	cultures	of	three	individuals	to	analyse	
the	phase	of	the	cell	cycle	at	time	of	irradiation.	BrdU	(0.01mM,	Sigma	Aldrich®)	was	added	
to	the	cultures	immediately	after	irradiation.	Binucleated	cells	that	incorporated	BrdU	during	
synthesis	were	in	S	or	G1	phases	of	the	cell	cycle	at	the	moment	of	irradiation,	whereas	BrdU-
negative	 binucleated	 cells	were	 irradiated	 in	G2	phase.	We	 corrected	 for	 daughter	 nuclei	
incorporating	 BrdU	 after	 binucleation	 by	 adding	 BrdU	 2	 hours	 before	 fixation	 to	 another	
subset	of	cultures.	BrdU	was	visualised	by	fluorescence	immunostaining	with	a	monoclonal	
BrdU-specific	antibody	(M0744,	Dako).	
	
Analysis	of	the	stability	of	the	mutant	allele	
For	this	experiment,	2*106	frozen	lymphocytes	were	thawed	and	cultured	in	a	mix	of	1	ml	
cRPMI,	 FCS	 (10%),	 2-mercaptoethanol	 (0.1%,	 gibco®)	 and	 Sodium	 pyruvate	 (1%,	 life	
technologiesTM).	PHA	(10	μl/ml)	was	added	to	stimulate	cell	division.	At	day	7,	whole	RNA	was	
extracted	 using	 the	 QIAamp®RNeasy	 Mini	 kit	 (Qiagen)	 according	 to	 manufacturer’s	
instructions.	 Four	hours	prior	 to	extraction,	 all	 cultures	were	 split	 in	 two	and	 to	one	part	
puromycin	(200	μg/ml,	sigma	Aldrich®)	was	added.	Puromycin	was	added	to	avoid	NMD,	a	
pathway	responsible	for	the	degradation	of	aberrant	mRNA	[31].		
The	total	RNA	and	purity	was	measured	using	the	Trinean	DropSense96	(VWR).	The	RNA	was	
converted	into	cDNA	using	the	iscriptTM	cDNA	Synthesis	Kit	(Biorad).	When	RNA	was	extracted	
from	cultures	with	puromycin,	the	converted	cDNA	is	referred	to	as	cDNAp.	Prior	to	this	cDNA	
synthesis,	samples	were	treated	with	DNase	(Heat	and	run	kit,	ArcticZymes)	to	remove	any	
possible	remaining	genomic	DNA	(gDNA).		
To	determine	the	ratio	of	 the	mutant	BRCA1	allele	versus	the	wild	 type	 (WT)	allele	at	 the	
mRNA	 level,	 we	 performed	 PCR	 amplification	 and	 Sanger	 sequencing	 of	 the	 amplicon	
harbouring	 the	 germline	 mutation	 and	 a	 heterozygous	 SNP	 (c.2311T>C),	 if	 present.	 An	
overview	 of	 the	 primers	 used	 can	 be	 found	 in	 Additional	 File	 1.	 Sanger	 sequencing	 was	
performed	using	the	BigDye®	Terminator	Cycle	Sequencing	kit	(Life	TechnologiesTM).	PCR	was	
followed	by	ethanol	precipitation	and	fragments	were	dissolved	in	a	mix	of	Hi-DiTM	formamide	
(10	 μl,	 Life	 TechnologiesTM)	 and	 GeneScanTM	 500	 LIZTM	 size	 standard	 (0.5	 μl,	 applied	
biosystems®).	The	fragments	were	analysed	on	the	ABI	PRISM®	3730KL	Genetic	Analyzer	(Life	
TechnologiesTM).	Results	were	evaluated	using	GeneMapper®	software	(Applied	Biosystems®)	
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for	visual	inspection	and	determination	of	the	ratio	of	the	peak	heights	representing	the	WT	
and	mutant	allele,	respectively	(Additional	File	2	and	3).	Data	were	normalized	with	a	control	
peak	in	the	near	vicinity.	To	confirm	the	results,	the	PCR	amplicons	were	also	sequenced	with	
the	 sequencing	 by	 synthesis	 technology	 (Illumina)	 on	 a	 MiSeq	 instrument.	 The	 library	
preparation	was	performed	using	an	adapted	NexteraXT	protocol	as	described	by	De	Leeneer	
et	al.	 [32].	Reads	were	mapped	with	CLC	genomic	Workbench	 (Qiagen).	The	variant	allele	
frequency	(VAF)	(which	reflects	the	ratio	of	WT	versus	mutant	allele)	of	both	the	mutation	
and	a	SNP	(if	available),	were	determined	in	the	mutation	carriers	and	in	controls	without	a	
germline	BRCA1	mutation.	
	
Results		
Analysis	of	the	cell	cycle	phase	at	time	of	irradiation	
Based	on	literature	data,	the	cell	cycle	of	proliferating	lymphocytes	takes	between	18	and	22	
h.	The	cell	cycle	is	presented	in	Figure	1b	and	the	mean	length	for	each	phase	is	indicated	[33,	
34].	 With	 the	 BrdU	 immunostaining	 experiments,	 we	 assessed	 that	 a	 post-irradiation	
incubation	 time	of	8	h	after	2	or	4	Gy	 irradiation	 resulted	 in	blood	cultures	 in	which	80%	
(±13%)	and	87%	(±3%)	binucleated	cells,	 respectively,	were	 in	G2	phase	(negative	at	BrdU	
staining)	 at	 the	 time	 of	 irradiation.	 In	 sham-irradiated	 samples,	 the	 percentage	 of	 BrdU-
negative	 binucleated	 cells	 was	 much	 lower	 (56%±8%).	 These	 observations	 suggest	 that	
synchronisation	 of	 the	 cells	 in	 G2	 took	 place	 due	 to	 radiation-induced	 G2	 arrest.	 When	
Caffeine,	an	agent	that	abrogates	the	G2/M	checkpoint	[29],	was	added	to	the	cultures,	the	
percentage	of	cells	in	G2	decreased	(2	Gy:	73%±6%	and	4	Gy:	79%±2%).	The	high	percentage	
of	cells	irradiated	in	G2	indicates	that	the	harvest	of	BN	cells	8	h	post-irradiation	is	optimal.	
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	Figure	1.	Design	of	the	G2	MN	assay	and	overview	of	the	cell	cycle	
a.	Day	0:	set-up	of	one	50ml	large	blood	culture	for	every	patient.	Day	3:	division	of	the	cultures	
and	 subsequent	 irradiation.	 Addition	 of	 cyto	 B	 and	 caffeine	 (if	 needed)	 immediately	 after	
irradiation,	followed	by	incubation	during	8	h	before	harvesting.	Right	panel:	image	of	a	DAPI	
stained	binucleated	cell	with	micronucleus	generated	with	the	Metafer4	(Metasystems).	
b.	Overview	of	the	cell	cycle	for	proliferating	 lymphocytes	and	approximate	duration	of	the	
different	phases	with	 indication	of	the	applied	post-irradiation	 incubation	period	(black).	At	
the	start	of	the	irradiation,	all	lymphocytes	in	the	blood	culture	are	mononucleated.	After	8	h	
of	 incubation,	 the	cultures	are	 fixed	and	BN	cells	 (cells	 that	went	 through	one	mitosis)	are	
scored	for	the	presence	of	MN.		
	
Results	of	G2	MN	assay	
The	MN	yield	obtained	for	the	sham-irradiated	samples	did	not	show	a	significantly	different	
mean	result	between	mutation	carriers	and	healthy	volunteers	(Table	1	and	Figure	2).	The	
mean	values	obtained	for	the	radiosensitivity	analysis	are	shown	in	Table	1	and	Figure	2.		
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Table	1:	Mean	MN	yields	and	G2/M	checkpoint	efficiency	ratios	obtained	with	the	G2	MN	assay	
	 Micronucleus	yield:	
#MN/1000	BN	
G2/M	checkpoint	
efficiency:	
#MNCAF+/#MNCAF-	
healthy	volunteers	 0Gy	 2Gy	 4Gy	 2Gy	 4Gy	
mean	 15	 61	 91	 2	 3.1	
SD	 10	 21	 29	 0.5	 0.8	
SEM	 2	 5	 7	 0.1	 0.2	
BRCA1	mutation	carriers	 0Gy	 2Gy	 4Gy	 2Gy	 4Gy	
mean	 16	 83	 128	 1.6	 2.2	
SD	 7	 31	 45	 0.5	 0.5	
SEM	 2	 7	 10	 0.1	 0.1	
p-value	(2-sided	t-test)	 0.83	 0.019	 0.004	 0.01	 0.0002	
	
	
In	BRCA1	mutation	carriers,	a	significantly	increased	radiosensitivity	was	observed	for	both	
endpoints	at	both	radiation	doses	of	2	and	4	Gy,	compared	to	healthy	volunteers.	Our	results	
also	show	that	the	4	Gy	dose	point	is	the	most	discriminative	(highest	significance	based	on	
p-value)	for	both	endpoints.	We	thus	selected	this	dose	to	determine	the	individual	overall	
radiosensitive	phenotype.	Results	of	the	mutation	analysis	and	individual	results	obtained	for	
the	 2	 radiosensitivity	 endpoints	 upon	 4	 Gy	 irradiation	 are	 shown	 in	 Table	 2.	 Each	 value	
received	a	colour-code	corresponding	to	a	radiosensitivity	score	from	which	a	RIND	score	was	
calculated.	
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Figure	2.	Mean	MN	yields	and	G2/M	checkpoint	efficiency	ratios	obtained	with	the	G2	MN	assay	 in	
healthy	volunteers	and	BRCA1	mutation	carriers.		
Significance	was	determined	with	a	2-sided	T-test.	P-values	for	each	of	the	endpoints	and	dose	points	
are	indicated	in	the	graph.	Error	bars	represent	the	standard	error	of	the	mean	(SEM).	
	
Significantly	different	RIND	values	were	found	for	BRCA1	mutation	carriers	(median	=	2)	and	
healthy	volunteers	(median	=	0)	(p=0.0076,	Mann	Withney).	Figure	3	shows	the	distribution	
of	the	BRCA1	mutation	carriers	and	healthy	controls	over	the	five	different	RIND	scores.	The	
distribution	 amongst	 the	 RIND	 scores	 between	 the	 two	 groups	 is	 significantly	 different	
(p=0.034,	Fisher	exact	test).	The	significantly	different	median	and	the	significantly	different	
distribution	 over	 the	RIND	 scores	 obtained	 for	 both	 groups	 point	 towards	 a	 difference	 in	
response	to	radiation.	
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Figure	3.	The	distribution	(%)	of	healthy	volunteers	and	BRCA1	mutation	carriers	over	the	different	RIND	
scores	
	
Repeated	assessments	were	performed	on	blood	specimens,	taken	on	2	different	occasions,	
from	a	random	sample	of	seven	healthy	volunteers	and	four	mutation	carriers,	 in	order	to	
exclude	intra-individual	variations.	Although	minor	variations	were	observed,	no	significant	
differences	were	observed	between	repeated	measurements	(P>0.05	for	both	MN	yield	and	
G2/M	checkpoint	efficiency;	repeated	measures	ANOVA).	
	
We	also	 investigated	whether	 relatives	of	 the	 subjects	enrolled	 in	 this	 study,	 carrying	 the	
same	mutation,	have	similar	RIND	scores.	Individuals	with	the	same	family	ID	are	known	to	
be	related	(Table	2).	For	families	BR-32-0196,	BR-32-1028	and	BR-32-2256,	we	had	access	to	
data	and	samples	of	several	relatives.	Both	father	and	daughter	of	family	BR-32-1028	showed	
a	RIND	score	of	3.	The	siblings	from	family	BR-32-2256	show	a	RIND	score	of	1	and	2	and	for	
the	 third	degree	 relatives	 in	 family	BR-32-0196,	we	obtained	a	 score	of	0	and	1.	We	 thus	
conclude	 that	 there	 were	 no	major	 differences	 in	 RIND	 scores	 within	 families.	 However,	
different	RIND	scores	(ranging	from	0-4)	were	observed	between	4	individuals	carrying	the	
same	mutation	(c.2359dup),	but	unaware	of	a	close	relationship.	
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Table	2.	Results	of	mutation	screening	and	radiosensitivity	assessment	for	each	individual	
Healthy	volunteers	 mutation	 MN	yield	
G2/M	
checkpoint	
efficiency		
Radio-
sensitivity	
indicator	
(RIND)	sample	ID	 codon	 protein	 4	Gy	 4	Gy	
D01	 N/A	 N/A	 101	 3.9	 0	
D02	 N/A	 N/A	 67	 3.5	 0	
D03	 N/A	 N/A	 164	 2.9	 2	
D04	 N/A	 N/A	 92	 2.1	 0	
D05	 N/A	 N/A	 84	 4.6	 0	
D06	 N/A	 N/A	 91	 3.3	 0	
D07	 N/A	 N/A	 64	 3.1	 0	
D08	 N/A	 N/A	 84	 3.5	 0	
D09	 N/A	 N/A	 139	 1.7	 2	
D10	 N/A	 N/A	 57	 2.6	 0	
D11	 N/A	 N/A	 90	 2.7	 0	
D12	 N/A	 N/A	 87	 3.3	 0	
D13	 N/A	 N/A	 63	 1.6	 2	
D14	 N/A	 N/A	 94	 2.5	 0	
D15	 N/A	 N/A	 123	 3.2	 1	
D16	 N/A	 N/A	 74	 3.3	 0	
D17	 N/A	 N/A	 97	 2.8	 0	
D18	 N/A	 N/A	 129	 3.1	 1	
BRCA1	mutation	
carriers	 mutation	
MN	
yield	
G2/M	
checkpoint	
efficiency	
Radio-
sensitivity	
indicator	
(RIND)	sample	
ID	 Family	ID	 Mutation	c.	 Mutation	p.	 4	Gy	 4	Gy	
BC01	 BR-32-1643	 c.1A>G	 p.Met1Val	 215	 1.9	 3	
BC02	 BR-32-3040	 c.1A>C	 p.Met1Leu	 171	 2.4	 2	
BC03	 BR-32-1848	 c.212+3A>G	 N/A	 77	 1.5	 2	
BC04	 BR-32-2016	 c.1961del	 p.Lys654fs*47	 54	 2.5	 0	
BC05	 BR-32-0373	 c.2359dup	 Glu787fs*3	 174	 1.7	 3	
BC06	 BR-32-1787	 c.2359dup	 Glu787fs*3	 163	 2.9	 2	
BC07	 BR-32-1444	 c.2359dup	 Glu787fs*3	 106	 2.5	 0	
BC08	 BR-32-1967	 c.2359dup	 Glu787fs*3	 182	 1.3	 4	
BC09	 BR-32-1548	 c.3331_3334del	 p.Gln111fs*5	 104	 2	 1	
BC10	 BR-32-2256	 c.3481_3491del	 pGlu1161fs*3	 104	 1.6	 2	
BC11	 BR-32-2256	 c.3481_3491del	 pGlu1161fs*3	 85	 1.8	 1	
BC12	 BR-32-2256	 c.3481_3491del	 pGlu1161fs*3	 121	 2.2	 2	
BC13	 BR-32-0196	 c.3661G>T	 p.Glu1221*	 119	 1.7	 1	
BC14	 BR-32-0196	 c.3661G>T	 p.Glu1221*	 112	 3.5	 0	
BC15	 BR-32-0305	 c.3661G>T	 p.Glu1221*	 83	 2.7	 0	
BC16	 BR-32-1028	 c.4327C>T	 p.Arg1443*	 176	 2.1	 3	
BC17	 BR-32-1028	 c.4327C>T	 p.Arg1443*	 164	 2.1	 3	
BC18	 BR-32-2212	 c.4931_4393delinsTT	 p.Pro1464fs*2	 94	 2.7	 0	
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Analysis	of	the	stability	of	the	mutant	allele	and	correlation	with	the	RIND	score	
The	results	of	fragment	analysis	and	massive	parallel	sequencing	were	comparable	(Table	3).	
All	results	for	cDNA,	but	not	for	gDNA,	analyses	are	obtained	by	in	duplo	experiments.	The	
results	of	the	MiSeq	analysis	are	expressed	as	the	variant	allele	frequency	(VAF)	in	%;	50%	
means	equal	expression	of	both	alleles.	The	results	of	the	fragment	analysis	(fragm.	analysis)	
are	 shown	 as	 a	 ratio	 of	 peak	 heights	 mutant/WT	 allele.	 A	 value	 of	 1	 equals	 no	 loss	 of	
expression	of	the	mutant	allele.	cDNA	samples	not	treated	with	puromycin	were	scored	as	
“evidence	of	NMD”	(Table	3)	when	an	average	VAF	≤31%	or	a	ratio	of	peak	heights	<0.7	were	
obtained.	We	observe	more	variation	for	deletions/insertions	than	for	substitutions.	This	can	
be	explained	by	 the	more	 complex	mapping	of	 reads	 containing	deletions/duplications.	A	
large	deletion	and	software	struggling	to	map	correctly	to	the	reference	sequence,	explains	a	
VAF	lower	then	50%	for	gDNA	in	some	patients	(indicated	with	*,	Table	3).	Nevertheless,	a	
drop	in	VAF	for	cDNA	and	not	for	cDNA	with	puromycin	can	still	be	distinguished.	For	BC02,	
BC08	and	BC15,	no	lymphocytes	were	available	to	perform	this	assay.	However,	as	we	had	
access	to	cDNA	from	other	individuals	with	the	same	mutation	we	were	able	to	get	an	insight	
in	the	stability	of	the	mutant	mRNA	for	these	three	mutation	carriers.	For	BC16,	no	gDNA	data	
could	be	obtained;	information	with	regard	to	mutant	mRNA	stability	for	this	mutation	carrier	
was	obtained	via	cDNAp	and	BC17.	
	
PTC	alleles	in	the	central	part	of	the	gene	
For	all	truncating	mutations	studied	in	the	central	part	of	the	gene	(7	unique	mutations	in	15	
individuals),	we	found	evidence	for	NMD.	In	general,	25-30%	residual	truncated	mRNA	was	
detected	 in	carriers	of	a	PTC	mutation.	Ten	of	15	patients	with	a	 truncating	allele	 show	a	
radiosensitive	phenotype	(RIND	score	=	1-4,	median	=	1).		
	
Mutations	located	in	the	5’	part	of	the	gene	
For	mutations	in	the	5’	part	of	the	gene	(n=3)	we	have	no	evidence	for	NMD.	The	effect	at	the	
mRNA	level	for	the	c.212+3A>G	splice	site	mutation	has	previously	been	studied	by	our	group	
with	qPCR.	We	showed	that	no	full-length	transcript	is	formed,	but	it	leads	to	a	significantly	
increased	expression	of	an	alternative	transcript	(out	of	frame	skip	of	22	last	nucleotides	of	
exon	5;	r.190_212del),	which	is	not	subjected	to	NMD	[35,	36].	As	BC03	is	not	heterozygous	
for	 any	 of	 the	 tested	 common	 SNPs,	 results	 could	 not	 be	 re-analysed	with	 the	 approach	
		 130	
described	 in	 this	 paper.	 Our	 results	 for	 BC03	 showed	 a	 RIND	 score	 of	 2,	 which	 can	 be	
attributed	to	a	decreased	G2/M	checkpoint	efficiency.	For	BC01,	carriers	of	the	c.1A>G	start	
codon	mutation,	no	decline	of	the	mutant	allele	could	be	detected	when	analyzing	the	SNP	
data	(Table	3).	This	suggests	the	conservation	of	the	start	codon	or	an	alternative	one.	The	
mutation	itself	could	not	be	quantified	because	of	the	presence	of	GC	rich	areas	near	the	start	
codon.	The	introduction	of	an	alternative	start	codon,	could	give	raise	to	an	aberrant	protein	
with	 a	 dominant	 negative	 effect	 [37].	 Interestingly,	 both	 individuals	 carrying	 a	 mutation	
affecting	the	start	codon	have	respectively	a	RIND	score	of	3	and	2.	A	median	RIND	score	of	2	
is	observed	for	carriers	of	a	mutation	in	the	5’	part	of	the	gene.	
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Table	3.	Results	of	the	stability	of	the	mutant	allele	
		 Fragm.	Analysis	 MISEQ	(VAF)	 		
Donor	
RIND	
score	
ratio	peak	height	
(mutant/WT	allele)	
cDNA	 cDNAp	 gDNA	
Evidence	
for	NMD?	
BC01	c.1A>G	 3	 0.7	(0.6-0.8)	 49	(42-55)	 52	(51-52)	 49	(49-49)	 No	
BC02	c.1A>C	 2	 /	 /	 /	 /	 No	
BC03	c.212+3A>G	 2	 /	 /	 /	 /	 No	
BC04	c.1961del	 0	 0.4	(0.4-0.4)	 29	(25-33)	 47	(43-51)	 47	(47-47)	 Yes	
BC05	c.2359dup	 3	 0.6	(0.6-0.6)	 28	(25-31)	 42	(38-45)	 48	(48-48)	 Yes	
BC06	c.2359dup	 2	 0.5	(0.5-0.5)	 24	(23-25)	 44	(41-47)	 50	(50-50)	 Yes	
BC07	c.2359dup	 0	 0.4	(0.4-0.5)	 29	(27-30)	 48	(30-67)	 57	(55-59)	 Yes	
BC08	c.2359dup	 4	 /	 /	 /	 /	 Yes	
BC09	c.3331_3334del	 1	 0.4	(0.4-0.4)	 25	(18-31)	 44	(34-48)	 49	(49-49)	 Yes	
BC10	c.3481_3491del	 2	 0.4	(0.4-0.4)	 23	(16-30)	 42	(28-52)	 39	(32-46)*	 Yes	
BC11	c.3481_3491del	 1	 0.4	(0.3-0.5)	 23	(16-32)	 41	(23-54)	 39	(34-44)*	 Yes	
BC12	c.3481_3491del	 2	 0.4	(0.4-0.4)	 26	(16-34)	 39	(28-50)	 42	(35-49)*	 Yes	
BC13	c.3661G>T	 1	 0.5	(0.3-0.6)	 29	(28-30)	 50	(41-57)	 50	(46-53)	 Yes	
BC14	c.3661G>T	 0	 0.4	(0.3-0.4)	 31	(29-32)	 52	(52-52)	 50	(50-50)	 Yes	
BC15	c.3661G>T	 0	 /	 /	 /	 /	 Yes	
BC16	c.4327C>T	 3	 0.5	(0.5-0.6)	 24	(21-27)	 51	(45-56)	 /	 Yes	
BC17	c.4327C>T	 3	 0.6	(0.4-0.7)	 26	(21-30)	 48	(44-53)	 50	(50-50)	 Yes	
BC18	c.4931_4393delinsTT	 0	 0.4	(0.3-0.4)	 30	(28-31)	 37	(28-47)	 52	(52-52)	 Yes	
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Discussion	
Our	 study	 shows	 a	 significantly	 increased	 radiosensitivity	 in	 the	 group	 of	 healthy	 BRCA1	
mutation	carriers	compared	to	healthy	controls	for	the	two	endpoints	measured	by	the	G2	
MN	 assay	 for	 both	 doses	 of	 2	 and	 4	 Gy.	 Our	 results	 indicate	 that	 radiosensitivity	 in	
heterozygous	 BRCA1	mutation	 carriers	 is	 a	 complex	 phenotype	 linked	 to	 defects	 in	 DNA	
damage	repair	as	well	as	to	defective	G2	arrest	capacity.	These	results	are	in	agreement	with	
the	studies	performed	by	Pantelias	and	Terzoudi	[30].	They	applied	the	G2	chromatid	break	
assay	and	reported	that	the	G2/M	checkpoint	efficiency	ratio	is	a	good	parameter	to	predict	
intrinsic	radiosensitivity	in	AT	and	cancer	patients.	
	
In	vitro	radiosensitivity	has	previously	been	investigated	in	BC	patients	and	BRCA1	mutation	
carriers.	Cardinale	et	al.	recently	published	a	meta-analysis	combining	all	in	vitro	case-control	
studies	in	which	the	G0	MN	assay	on	peripheral	blood	lymphocytes	was	used	to	analyse	in	
vitro	radiosensitivity	in	women	with	BC	or	with	a	known	or	putative	genetic	predisposition	to	
BC	 [17].	Other	 cytogenetic	assays,	 such	as	 the	 chromosome	aberration	and	G2	chromatid	
break	 assay,	 or	 survival	 assays,	 have	 also	 been	 applied	 to	 determine	 radiosensitivity	 in	 a	
variety	of	cell	types	heterozygous	for	BRCA1	mutations	using	different	irradiation	protocols	
[18–26].	 It	 is,	 however,	 difficult	 to	 correctly	 compare	 the	 results	 of	 these	 studies,	 as	 also	
concluded	by	Cardinale	et	al.	[17],	due	to	different	experimental	setups	to	analyze	 in	vitro	
radiosensitivity.	 However,	 despite	 the	 heterogeneity	 of	 the	 studies,	 most	 of	 the	 data	
generated,	 including	ours,	are	suggestive	of	a	different	 radiosensitive	phenotype	between	
BRCA1	 heterozygous	 mutant	 cells	 and	 control	 cells.	 Recent	 studies	 investigating	 more	
specifically	the	functionality	of	the	HR	pathway	in	BRCA1	heterozygous	cells	by	means	of	γ-
H2AX	and	RAD51	foci	assays,	point	towards	a	less	efficient	DSB	repair	by	HR.	These	findings	
further	support	the	evidence	of	increased	radiosensitivity	observed	in	BRCA1	heterozygous	
cells	 when	 irradiated	 in	 S	 or	 G2	 phase	 of	 the	 cell	 cycle	 and	 are	 compatible	 with	
haploinsufficiency	as	underlying	mechanism	[24,	25,	38].	The	strength	of	our	study	 is	 that	
radiosensitivity	was	analyzed	by	means	of	two	different	endpoints	obtained	with	a	G2	specific	
MN	assay,	developed	by	our	group	[27].		
The	radiosensitivity	results	 in	this	study	were	obtained	with	doses	of	2	and	4	Gy,	which	 is	
considerably	higher	than	any	lifetime	cumulative	dose	received	by	mammography	screening.	
The	 average	 dose	 delivered	 to	 the	 breast	 glandular	 tissue	 per	 mammographic	 screening	
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session	is	approximately	4	mGy	[39].	Thus,	direct	extrapolation	of	our	radiosensitivity	results	
towards	the	risks	of	mammography	is	not	possible.	Despite	this	limitation,	our	results	may	
suggest	 caution	 in	 the	 exposure	 to	 IR	 of	 healthy	 tissues	 of	 BRCA1	 mutation	 carriers	 for	
diagnostic	purposes.	It	is	furthermore	noteworthy	that	recent	studies	have	shown	that	30	kV	
X-rays	have	a	higher	relative	biological	effect	(RBE)	and	are	thus	more	harmful	compared	to	
conventional	high	kV	X-rays	or	60Co	γ-rays,	on	which	current	risk	assessment	is	based.	This	
implies	 that	each	mammogram	may	 induce	more	DNA	damage	than	commonly	estimated	
[40,	 41].	 Several	 papers	 suggest	 that	 mammography	 screening	 might	 preferably	 be	
substituted	by	MRI	in	order	to	avoid	IR	before	the	age	of	30	[16]	or	40	[42]	in	BRCA1	mutation	
carriers.	In	addition,	and	more	appropriate	given	the	high	doses	used	in	this	assay,	our	results	
suggest	caution	in	the	use	of	adjuvant	radiotherapy	following	breast-conserving	surgery.	In	
this	respect,	there	is	a	need	for	well	designed	studies	to	assess	the	incidence	of	second	ipsi-	
or	contralateral	cancers	upon	adjuvant	radiotherapy	in	mutation	carriers	[16].	
	
Since	 it	was	our	aim	 to	develop	a	 radiosensitivity	assay	applicable	 in	a	clinical	 setting,	we	
performed	the	G2	MN	assay	on	peripheral	blood	samples,	which	can	easily	be	obtained	during	
a	genetic	consult.	Several	studies	have	demonstrated	that	radiosensitivity	of	an	individual	is	
also	detectable	in	cells	of	a	type	different	from	cells	in	which	the	tumour	develops	[18,	43,	
44].	The	scoring	system	with	RIND	scores	varying	between	0	and	4	allowed	us	to	assess	the	
overall	radiosensitivity	due	to	both	DNA	repair	and	G2	arrest	capacity	of	each	mutation	carrier	
(results	in	Table	2	and	Figure	3).	With	the	help	of	this	scoring	system,	we	assessed	that	72%	
of	our	healthy	volunteers	showed	no	radiosensitive	phenotype.	BRCA1	mutation	carriers,	on	
the	contrary,	show	a	distinct	pattern	towards	higher	radiosensitivity.	Seventy-two	percent	of	
all	mutation	carriers	were	found	to	be	radiosensitive	(RIND	score=	1-4).	Moreover,	28%	of	
BRCA1	mutation	carriers	had	RIND	scores	equal	to	3	or	4,	scores	that	were	never	observed	in	
healthy	volunteers.	This	simple	scoring	system	can	be	valuable	to	assist	physicians	 in	their	
decision-making	for	the	clinical	follow-up	and	the	refinement	of	radiotherapy	at	the	individual	
level.		
Since	our	study	 is	 limited	 in	sample	size,	a	 larger	prospective	study	with	blood	samples	of	
BRCA1	mutation	carriers	will	be	undertaken	to	confirm	and	prove	the	 importance	of	an	 in	
vitro	radiosensitivity	scoring	system	to	assist	clinical	management	of	BRCA1	mutation	carriers.		
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Haploinsufficiency	 has	 been	 suggested	 as	 the	 main	 mechanism	 for	 hereditary	 breast	
carcinogenesis	[45].	However,	as	NMD	is	not	observed	for	mutations	located	in	the	5’	and	3’	
part	of	the	gene	[46],	a	dominant	negative	effect	can	not	be	excluded	whereby	the	aberrant	
transcript	abolishes	the	functionality	of	the	WT	allele	(for	a	review:	[37,	47]).	We	wanted	to	
evaluate	if	either	or	both	mechanisms	could	influence	the	radiosensitivity	score.	Information	
on	the	stability	of	the	mutant	allele	at	mRNA	level	was	generated	by	both	a	fragment	analysis	
and	a	novel	massive	parallel	sequencing	approach.	To	our	knowledge,	this	 is	the	first	time	
that	next	generation	sequencing	is	applied	to	evaluate	the	level	of	NMD.		The	approach	we	
describe	here	 is	 straightforward	and	cost-effective	 to	study	 the	relative	expression	of	 two	
alleles	in	a	single	individual.		
The	majority	of	patients	included	in	this	study,	are	heterozygous	for	a	mutation	located	in	the	
central	part	of	the	gene	leading	to	a	premature	termination	codon	(PTC).	These	PTC	inducing	
mutations	 result	 in	 a	 truncated	 mRNA,	 which	 can	 be	 degraded	 by	 NMD.	 Generally,	 we	
observed	that	the	mutated	PTC	allele	was	expressed	at	a	ratio	of	25-30%	of	the	WT	allele	at	
the	mRNA	level.	Our	results	are	consistent	with	the	data	of	Anczuców	et	al.	and	Perrin-Vidoz	
et	al.	[46,	47].	Both	articles	describe	a	similar	reduction	of	mRNA	expression	from	PTC	alleles	
in	the	central	part	of	the	gene	and	demonstrate	the	involvement	of	NMD	in	this	decrease	of	
mutant	 mRNA.	 A	 radiosensitive	 phenotype	 in	 10/15	 mutation	 carriers	 with	 a	 PTC	 allele	
undergoing	NMD	suggests	haploinsufficiency	as	mechanism	leading	to	this	phenotype	in	the	
large	majority	of	the	individuals.	
Equal	expression	of	the	WT	and	mutant	allele	at	the	mRNA	level	was	observed	in	the	patients	
with	 the	 start	 codon	 mutation	 (BC01	 and	 BC02).	 For	 the	 patient	 with	 the	 c.212+3A>G	
mutation	(BC03)	equal	expression	of	a	full	length	transcript	and	a	transcript	lacking	the	last	
22	nucleotides	of	exon	5	was	observed	in	previous	research	by	our	group	and	confirmed	by	
others	[35,	36].	A	higher	median	RIND	score	in	the	individuals	carrying	a	mutation	in	the	5’	
part	of	the	gene,	for	which	no	NMD	could	be	detected,	compared	to	individuals	with	a	PTC	
allele	may	point	towards	another	mechanism	involved	in	the	radiosensitive	phenotype,	like	a	
dominant	negative	effect.	However,	current	knowledge	on	translation	of	mutant	alleles	not	
subjected	 to	 NMD	 into	 proteins	 is	 limited.	 Such	 detailed	 studies	 have	 not	 yet	 been	
undertaken:	 in	most	 studies	 demonstrating	 a	 role	 for	 haploinsufficiency,	BRCA1	mutation	
carriers	are	compared	as	group	to	non-carriers	(e.g.	Vaclova	et	al;	Pathania	et	al;	Sedic	et	al.	
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[25,	 38,	 48]).	 Our	 data	 suggest	 the	 need	 for	 larger	 studies	 involving	 different	 types	 of	
mutations.		
	
Unique	for	this	radiosensitivity	study	compared	to	others	is	that	we	had	access	to	material	
from	 several	 individuals	 from	 one	 family	 and	 we	 could	 also	 evaluate	 the	 radiosensitive	
phenotype	from	several	unrelated	individuals	carrying	the	same	mutation.	For	4	unrelated	
carriers	 of	 a	 Belgian	 founder	mutation	 c.2359dup	 (p.Glu787fs*3)	 a	 large	 variation	 for	 the	
radiosensitive	 phenotype	 based	 on	 the	 RIND	 score	 was	 observed	 (range:	 0-4)	 (Table	 2).	
Repeated	assessments	on	blood	specimens,	taken	on	two	different	occasions	from	several	
individuals,	rule	out	that	the	different	RIND	scores	are	due	to	experimental	variation.	Given	
the	smaller	variation	between	related	individuals	and	because	of	the	pleiotropic	effect	of	IR	
on	DNA	(for	example,	strand	breaks,	fork	stalling,	base	damage,	DNA-adducts	[49–51]),		we	
are	convinced	that	other	genetic	factors	influence	the	radiosensitivity.	Previous	research	has,	
for	example,	demonstrated	the	effect	of	SNPs	on	individual	sensitivity	to	radiation	therapy	
[52,	53].	 In	addition,	our	group	has	demonstrated	the	 influence	of	RAD51,	Ku70	and	Ku80	
SNPs	as	a	modulator	of	in	vitro	radiosensitivity	in	BRCA1	mutation	carriers	and	BC	patients	
[54,	55].	A	larger	study	and	the	inclusion	of	a	control	population	with	relatives	not	harboring	
the	familial	germline	mutation	could	generate	important	insights.	
	
Conclusion	
Our	 study,	 using	 the	 G2	 MN	 assay,	 shows	 that	 healthy	 individuals	 carrying	 a	 germline	
mutation	in	BRCA1	are	more	radiosensitive	compared	to	healthy	controls	after	exposure	to	
doses	of	2	and	4	Gy.		
Seventy-two	percent	of	the	BRCA1	mutation	carriers	showed	a	radiosensitive	phenotype	and	
28%	of	BRCA1	mutation	carriers	had	high	RIND	scores	of	3	or	4.	Analysis	of	the	mRNA	stability	
of	the	mutant	allele	could	not	demonstrate	a	clear	link	between	nonsense-mediated	decay	of	
the	 mutant	 allele	 and	 a	 radiosensitive	 phenotype.	 This,	 combined	 with	 the	 similar	
radiosensitive	phenotype	observed	for	related	individuals	but	not	for	unrelated	individuals	
carrying	the	same	mutation,	is	indicative	for	the	fact	that	additional	genetic	factors,	beside	
the	BRCA1	mutation,	may	play	a	role	 in	the	radiation	response.	Our	study	emphasizes	the	
need	for	large	prospective	studies	correlating	the	in	vitro	findings	and	exposure	to	radiation	
with	the	risk	of	developing	breast	cancer.	
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Corrigendum	
In	table	1	of	this	article,	a	mean	based	on	20	healthy	volunteers,	was	provided.		
In	 the	 update	 version	 of	 table	 1	 (see	 below),	 the	 mean,	 SD	 and	 SEM	 values,	 together	 with	 the	
appropriate	p-values,	of	the	18	healthy	volunteers	presented	in	table	2	are	provided:	
	
Table	1:	Mean	MN	yields	and	G2/M	checkpoint	efficiency	ratios	obtained	with	the	G2	MN	assay	
	 Micronucleus	yield:	
#MN/1000	BN	
G2/M	checkpoint	
efficiency:	
#MNCAF+/#MNCAF-	
healthy	volunteers	(n=18)	 0	Gy	 2	Gy	 4	Gy	 2	Gy	 4	Gy	
mean	 16	 63	 94	 2	 3.0	
SD	 11	 21	 28	 0.5	 0.7	
SEM	 3	 5	 7	 0.1	 0.2	
BRCA1	mutation	carriers	(n=18)	 0	Gy	 2	Gy	 4	Gy	 2	Gy	 4	Gy	
mean	 16	 83	 128	 1.6	 2.2	
SD	 7	 31	 45	 0.5	 0.5	
SEM	 2	 7	 10	 0.1	 0.1	
p-value	(2-sided	t-test)	 0.83	 0.023	 0.03	 0.016	 0.002	
	
A	significant	increased	radiosensitivity	remains	clear	for	the	BRCA1	mutation	carrier	cohort	compared	
to	the	control	cohort	for	both	endpoints	and	both	dose	points.	
	
On	individual	level,	the	adapted	mean	and	SD	values,	result	in	altered	RIND	scores	for	D04	and	M12,	
which	change	from	0	to	1	and	2	to	1	respectively.		
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A	 significant	 difference	 in	 RIND	 values	 between	 BRCA1	 mutation	 carriers	 and	 healthy	 volunteers	
remains,	but	with	slightly	altered	median	values	and	p-values	(median	BRCA1	mutation	carriers	=	1.5	
versus	2	and	p-value	=	0.0143	versus	0.0076,	Mann	Withney).	The	distribution	amongst	the	different	
RIND	scores	(see	new	Figure	3	below)	between	the	two	groups	is	now	borderline	significantly	different	
(p-value	=	0.069	versus	0.034,	Fisher	exact	test).	
	
	
Figure	3.	The	distribution	(%)	of	healthy	volunteers	and	BRCA1	mutation	carriers	over	the	different	RIND	
scores	
	
We	argue	that	these	changes	do	not	affect	the	general	conclusion	of	this	article.	
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Additional	File	1:	Primers	
The	primer	sequences	(both	forward	and	reverse)		
Amplicon	(exon)	 Forward	 Reverse	
c.1A>G	(E2)	 TCTGCTCTGGGTAAAGGTAGTAGA	 GAAGGCCCTTTCTTCTGGTT	
c.1961del	(E11)	 GGAAGTCTTCTACCAGGC	 TTAACTTCAGCTCTGGGAAAG	
c.2311T>C	(E11)	=	SNP	 CCTAGCCTTCCAAGAGAAG	 CCATGAATTAGTCCCTTGG	
c.2359dup	(E11)	 CCTAGCCTTCCAAGAGAAG	 CCATGAATTAGTCCCTTGG	
c.3331_3334del	(E11)	 GTAGGTTCCAGTACTAATGAAG	 CTGAAATCAGATATGGAGAGAAATC	
c.3481_3491del	(E11)	 CCATATCTGATTTCAGATAACTTA	 GATAAGTTCTCTTCTGAGGACTC	
c.3661G>T	(E11)	 GCAGGAGTCCTAGCCCTTTC	 GGTTACTGCAGTCATTTAAGCTATTC	
c.4327C>T	(E13)	 GACTGCTCAGGGCTATCCTC	 CAGACACCTCAAACTTGTCAGC	
c.4391_4393delinsTT	(E14)	 GACTCTTCTGCCCTTGAGGA	 AAGGGGATGACCTTTCCACT	
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Additional	File	2:	Results	of	the	fragment	analysis	
Illustration	of	fragment	analysis	data	of	a	SNP	without	loss	of	the	mutant	allele	
Fragment	analysis	of	c.2311T>C	in	BC01	(forward)	
Limited	loss	of	mutant	mRNA	could	be	detected	(mean	ratio	=	0.7).	This	is	in	agreement	
with	the	MiSeq	data	with	a	VAF	of	approximately	50%.		
	
a.	cDNA	
	
b.	cDNA	with	puromycin	
	
c.	genomic	DNA	
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Additional	File	3:	Results	of	the	fragment	analysis	
Illustration	of	fragment	analysis	data	of	a	SNP	with	loss	of	the	mutant	allele	
Fragment	analysis	of	c.2311T>C	in	BC17	(forward)	
A	loss	of	the	mutant	allele	could	be	detected.	In	this	patient,	the	T	(black)	represents	the	
mutant	allele.	This	loss	of	allelic	imbalance	is	in	agreement	with	the	MiSeq	data.	The	VAF	for	
cDNA	is	26%,	or	only	half	of	the	frequency	on	gDNA.	This	is	reflected	in	the	ratio	of	0.48	for	
fragm.	analysis	in	this	particularly	example.		
	
a.	cDNA	
	
b.	cDNA	with	puromycin	
	
c.	genomic	DNA	
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Abstract		
Breast	cancer	risk	increases	drastically	in	individuals	with	a	heterozygous	germline	BRCA1	or	
BRCA2	mutation,	while	it	is	estimated	to	equal	the	population	risk	for	relatives	without	the	
familial	 mutation	 (non-carriers).	 The	 aim	 of	 this	 study	 is	 to	 use	 a	 G2	 phase	 specific	
micronucleus	assay	to	investigate	whether	lymphocytes	of	healthy	BRCA2	mutation	carriers	
are	characterized	by	increased	radiosensitivity	compared	to	controls	without	a	family	history	
of	breast/ovarian	cancer	and	how	this	relates	to	healthy	non-carrier	relatives.	BRCA2	is	active	
in	HR,	a	DNA	damage	repair	pathway,	specifically	active	 in	 the	 late	S/G2	phase	of	 the	cell	
cycle.	 We	 found	 a	 significantly	 increased	 radiosensitivity	 in	 a	 cohort	 of	 healthy	 BRCA2	
mutation	 carriers	 compared	 to	 individuals	 without	 a	 familial	 history	 of	 breast	 cancer	
(p=0.046,	Mann	Whitney	test).	At	the	individual	level,	50%	of	healthy	BRCA2	mutation	carriers	
showed	a	 radiosensitive	phenotype	 (radiosensitivity	 score	of	 1	or	 2),	whereas	83%	of	 the	
controls	showed	no	radiosensitivity	(p=0.038,	one-tailed	Fisher	Exact	test).	An	odds	ratio	of	5	
(95%CI:	 1.07-23.47)	 indicates	 an	 association	 between	 the	 BRCA2	 mutation	 and	
radiosensitivity	in	healthy	mutation	carriers.	These	results	 indicate	the	need	for	the	gentle	
use	of	ionizing	radiation	for	either	diagnostic	or	therapeutic	use	in	BRCA2	mutation	carriers.	
We	detected	no	increased	radiosensitivity	in	the	non-carrier	relatives.	
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Introduction	
BRCA1	and	BRCA2	heterozygous	mutation	carriers	have	a	strongly	increased	risk	to	develop	
breast	 (BC)	 and	ovarian	 cancer	 (OC).	 The	 lifetime	 risk	 to	develop	BC	 is	 70-80%	 for	BRCA1	
mutation	 carriers	 and	 50-60%	 for	BRCA2	mutation	 carriers	 (1).	 For	 relatives	who	 did	 not	
inherit	the	germline	BRCA1/2	mutation	segregating	in	the	family	(non-carrier	relatives),	the	
risk	of	BC	occurrence	is	generally	estimated	to	be	as	low	as	the	risk	assessed	in	the	general	
population.	This	might	imply	that	intensified	BC	detection	screening,	using	-	amongst	others	
-	mammography	screening	and	MRI,	as	applied	in	 individuals	at	high	risk	 is	unnecessary	 in	
non-carriers	(2–7).	However,	one	study	reported	a	2-5	fold	increase	of	BC	occurrence	in	non-
carriers	 of	 families	with	 either	BRCA1	or	BRCA2	mutations	 (8).	 Another	 study	 reported	 a	
younger	 than	 expected	 age	 at	 diagnosis	 of	 BC	 for	 non-carriers,	 that	was	most	 evident	 in	
BRCA1	families	(9).	Moreover,	one	study	by	Evans	and	coworkers	detected	a	possible	higher	
relative	 risk	 for	BC	 in	non-carrier	 relatives	of	BRCA2	 families,	 compared	 to	non-carriers	 in	
BRCA1	 families	 (10).	 In	 summary,	 these	studies	suggest	 that	DNA	alterations	 (for	example	
SNPs)	in	other	genes	may	modify	the	relative	risk	for	the	development	of	BC	in	non-carriers,	
compared	to	the	general	population.	Moreover,	the	authors	of	these	studies	recommended	
targeted	 BC	 detection	 screening	 using	 for	 example	 mammography	 in	 non-carriers	 at	 a	
frequency	comparable	to	the	intensive	BC	screening	performed	in	individuals	at	high	risk.		
Both	BRCA1	and	BRCA2	are	caretaker	genes	playing	different	roles	in	the	repair	of	DSB	(DSB),	
induced	by	exposure	to	genotoxic	agents	like	ionizing	radiation	(IR).	While	BRCA1	has	a	more	
general	function	in	the	detection	and	signaling	of	a	DSB	and	in	the	activation	of	the	G2/M	cell	
cycle	checkpoint,	BRCA2	exerts	a	specific	function	in	the	recruitment	of	RAD51	recombinase	
to	the	DSB	site.	This	latter	event	is	essential	for	the	activation	of	the	HR	(HR)	pathway,	that	
relies	on	the	undamaged	sister	chromatid	as	template	for	resynthesis	of	the	damaged	strand.	
This	occurs	in	the	late	S	and	G2	phase	of	the	cell	cycle	and	leads	to	error-free	repair	of	DSB	
(1).		
	
Knowing	 that	 both	 BRCA1	 and	 BRCA2	 are	 important	 in	 the	 repair	 of	 DSB,	 exposure	 of	
mutation	 carriers	 to	 IR	 -	 a	 potent	 inducer	 of	 DSB	 -	 for	 either	 diagnostic	 or	 therapeutic	
purposes	appears	to	be	counterintuitive,	as	mutation	carriers	may	be	more	prone	to	develop	
radiation-induced	BC	(11).	
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Radiosensitivity	of	BRCA1	mutation	carriers	has	previously	been	reported	in	the	literature	and	
was	investigated	and	confirmed	by	our	research	group	by	means	of	the	G2	micronucleus	(MN)	
assay	 in	 combination	with	 an	 evaluation	 of	 the	 G2/M	 checkpoint	 efficiency	 in	 peripheral	
blood	lymphocytes	of	healthy	BRCA1	mutation	carriers	compared	to	healthy	volunteers	(12).	
However,	the	impact	of	IR	on	heterozygous	cells	of	healthy	BRCA2	mutation	carriers	remains	
to	be	elucidated.		
	
So	far,	several	cohort	studies	were	able	to	prove	a	positive	correlation	between	exposure	to	
diagnostic	X-rays	and	BC	risk	in	BRCA2	mutation	carriers	(11,13,14).	Others	however,	could	
not	detect	a	similar	correlation	(15–18).	Furthermore,	Bernstein	et	al.	detected	no	increased	
induction	of	contralateral	BC	upon	exposure	to	radiotherapy	in	BRCA2	mutation	carriers	(19).	
Such	 discrepancies	 are	 likely	 due	 to	 differences	 in	 inclusion	 criteria,	 data-acquisition	 and	
other	issues	of	the	studies.	It	is	however	difficult	and	unethical	to	setup	long-term	unbiased	
studies	to	evaluate	the	relationship	between	BRCA2	mutations,	the	exposure	to	diagnostic	or	
therapeutic	 radiation	 and	 BC	 risk.	 In	 vitro	 chromosomal	 assays	 are	 effective	 tools	 to	
investigate	 radiosensitivity.	 Chromosomal	 radiosensitivity	 testing	 on	 lymphocytes	 from	
BRCA2	mutation	carriers	has	been	performed	with	techniques	such	as	the	G0	micronucleus	
(MN)	 assay	 and	 the	 G2	 assay	 for	 chromatid	 breaks,	 occasionally	 enhanced	 with	 a	 whole	
chromosome	paint	FISH	(20–25).	However,	for	several	of	these	studies,	it	was	unclear	if	the	
BRCA2	heterozygotes	were	healthy	individuals	or	BC	patients,	which	was	previously	broached	
by	Baeyens	et	al.	 (20).	 Furthermore,	differences	 in	experimental	 setup	make	comparisons	
between	studies	difficult	(26).	Despite	these	differences,	all	but	one	study	were	able	to	detect	
an	 elevated	 chromosomal	 radiosensitivity	 in	 BC	 patients	with	 a	BRCA2	mutation	 (20–25).	
However,	no	comparison	was	made	with	sporadic	BC	patients.	The	study	of	Baeyens	et	al.	
previously	 demonstrated	 enhanced	 radiosensitivity	 in	 both	 BC	 patients	 with	 a	 BRCA1/2	
mutation	and	sporadic	BC	patients,	suggesting	that	the	enhanced	sensitivity	might	not	be	the	
result	of	the	mutation	(20).	No	univocal	results	were	achieved	for	healthy	BRCA2	mutation	
carriers.	Radiosensitivity	in	non-carrier	relatives	has	not	been	studied	extensively,	only	one	
study	reported	no	 increased	radiosensitivity	measured	with	the	G0	MN	and	G2	chormatid	
break	assay	in	a	small	cohort	(n=10)	of	relatives	of	both	BRCA1	and	BRCA2	families	without	
the	familial	mutation	when	compared	to	a	population	cohort	(20).	
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In	 the	present	 study	we	aimed	 to	 investigate	 the	 chromosomal	 radiosensitivity	 in	healthy	
BRCA2	mutation	carriers	by	means	of	 the	G2	micronucleus	assay.	We	previously	used	this	
assay	and	confirmed	radiosensitivity	in	healthy	BRCA1	mutation	carriers	(n=18)	compared	to	
healthy	controls	without	a	family	history	of	BC	or	OC	(n=20)	(12),	and	in	ataxia-telangiectasia	
patients	and	family	members	(27).	In	addition,	we	also	included	healthy	relatives	not	carrying	
the	 familial	 germline	BRCA1	or	BRCA2	mutation	 in	 the	present	 study.	 This	 cohort	of	non-
carriers	was	 included	 to	evaluate	 radiosensitivity	 in	 individuals	with	a	 comparable	genetic	
background,	but	without	the	familial	BRCA1	or	BRCA2	mutation.		
	
Materials	and	methods	
Sample	collection	
Blood	samples	were	collected	from	individuals	consulting	the	Centre	for	Medical	Genetics	of	
the	Ghent	University	Hospital	(Ghent,	Belgium)	(CMGG),	in	the	context	of	predictive	testing	
for	hereditary	BC.	Heparin	blood	samples	were	collected	for	the	G2	MN	assay.	In	addition,	
EDTA	 samples	were	 collected	 for	mutation	 analysis.	We	 collected	blood	 samples	 from	18	
BRCA2	mutation	carriers	and	17	subjects	from	both	BRCA1	(n=9)	and	BRCA2	families	(n=8)	
not	 showing	 the	 familial	mutation	 (non-carriers).	None	of	 the	 individuals	 selected	 for	 this	
study	had	developed	cancer	at	time	of	blood	sample	collection.	We	also	selected	18	blood	
samples	from	a	historical	cohort	of	healthy	volunteers	without	a	personal	or	familial	history	
of	 BC	 for	 optimal	 age	 and	 gender	 match,	 to	 determine	 the	 normal	 distribution	 of	
micronucleus	yields	in	unaffected	individuals	from	the	general	population	(12).		
The	 study	 was	 approved	 by	 the	 ethical	 committee	 of	 the	 Ghent	 University	 Hospital	
(B67020111641	d.d.	20/09/2011)	and	all	participants	signed	an	informed	consent.	
	
Molecular	analysis	
All	healthy	individuals	selected	for	this	study	had	a	family	history	of	BC	or	OC	and	a	mutation	
in	either	BRCA1	or	BRCA2	was	identified	in	each	proband.	All	BRCA2	mutations	carriers	are	
heterozygous	 for	 an	 unequivocal	 deleterious	 mutation.	 This	 was	 confirmed	 by	 Sanger	
sequencing	of	the	relevant	amplicon.	Sanger	sequencing	was	performed	on	the	ABI3730XL	
instrument	 using	 the	 BigDye®	 Terminator	 Cycle	 Sequencing	 Kit	 (Life	 Technologies,	 USA),	
according	 to	 manufacturer’s	 instructions;	 sequences	 were	 analyzed	 using	 the	 SeqPilot	
software	(JSI	medical	systems,	Germany).	
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Molecular	analyses	were	not	performed	in	healthy	volunteers	because	of	the	absence	of	a	
personal	or	familial	anamnesis	for	BC	or	OC.		
	
The	G2	micronucleus	assay	
The	G2	MN	assay	was	performed	as	previously	described	(12).	In	brief,	heparinized	blood	was	
cultured	 in	 the	 presence	 of	 phytohaemagglutinin	 (PHA,	 2%v/v,	 Gibco)	 to	 stimulate	 T-
lymphocyte	division.	After	3	days,	a	population	of	cycling	lymphocytes	was	obtained	and	the	
culture	was	irradiated	with	a	2	Gy	dose	of	60Co	g	rays.	We	opted	to	use	a	dose	of	2	Gy	as	this	
is	a	well-accepted	dose	for	chromosomal	radiosensitivity	testing	in	lymphocytes	(20–22,24).	
Immediately	after	irradiation,	cytochalasin	B	(cyto	B,	6	μg/ml,	Sigma	Aldrich)	was	added	to	all	
cultures,	 including	 a	 non-irradiated	 culture.	 Cyto	 B	 blocks	 the	 cytokinesis	 and	 allows	 the	
identification	of	first	division	cells	as	a	binucleated	(BN)	cell.	After	an	incubation	period	of	8	
h,	all	cultures	were	fixed	with	the	sequential	addition	of	KCl	(75	mM),	a	solution	of	methanol,	
acetic	acid	and	Ringer	(4:1:5)	and	a	combination	of	methanol	and	acetic	acid	(4:1)	to	pelleted	
cells.	Finally,	the	cell	suspension	was	concentrated	and	spread	on	slides.	Slides	were	stained	
with	4’,6-diamidino-2-phenlylindole	(DAPI)	and	scanned	with	a	Metafer	4	platform	and	MN	
search	software	(Metasystems,	Germany).	The	automated	image	analysis	system	selects	BN	
cells	and	determines	the	number	of	MN	per	BN	cell.	BN	cells	and	MN	selection	are	manually	
checked	for	false	positives	or	false	negatives.	For	each	condition,	two	cultures	were	prepared	
and	two	slides	per	culture	were	analyzed.	A	minimum	of	600	BN	cells	was	scored	per	coded	
slide.	To	assess	individual	radiosensitivity,	a	radiosensitivity	score	(RS	score)	was	determined.	
The	mean	and	SD	of	the	MN	yield	of	the	group	of	healthy	volunteers	(HV)	was	set	as	cut-off	
value	 to	determine	 the	RS	score	of	healthy	volunteers,	BRCA2	mutation	carriers	and	non-
carrier	 relatives.	A	MN	yield	higher	 than	 the	meanHV	+1SDHV	was	 scored	as	1,	 indicating	a	
milder	radiosensitive	phenotype,	whereas	a	result	higher	than	the	meanHV	+2SDHV	was	scored	
as	2,	and	indicated	a	more	severe	radiosensitive	phenotype.	If	the	individual	value	was	lower	
than	meanHV	+1SDHV,	a	score	of	0	was	attributed	to	the	tested	subject.	
	
Statistical	analysis	
Age	and	gender	differences	across	 the	 three	groups	were	 judged	by	means	of	 a	one-way	
anova	 and	 Chi	 square	 test	 respectively.	 The	 median,	 interquartile	 range,	 average	 and	
standard	deviation	of	micronuclei	yields	(number	of	MN	per	1000	BN	cells)	were	assessed	in	
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each	 group	 of	 subjects.	 Intergroup	 differences	 of	MN	 yields	 between	 healthy	 volunteers,	
BRCA2	mutation	 carriers	 and	 non-carrier	 relatives	 of	 BRCA1	 and	 BRCA2	 pedigrees	 were	
analyzed	by	the	Mann-Whitney	Wilcoxon	test.	A	one-tailed	Fisher	exact	test	was	performed	
to	 compare	 unpaired,	 independent	 proportions	 of	 patients	 showing	 a	 radiosensitive	
phenotype,	evaluated	by	RS	scoring.	For	both	assays	a	5%	alpha	error	was	set	as	the	boundary	
for	 statistical	 significance.	 The	 odds	 ratio	 (OR)	was	 calculated,	 based	 on	 the	 RS	 scores	 in	
healthy	 individuals	 and	 BRCA2	 mutation	 carriers,	 to	 assess	 the	 association	 between	 the	
presence	of	a	BRCA2	mutation	and	radiosensitivity	according	to	the	following	formula:	!" = 	#	&"'(2	*+,-,./0	1-22.324	5.,ℎ	-0	"7 > 0	:	#	ℎ3-;,ℎ<	=/;+0,3324	5.,ℎ	-0	"7 = 0#	&"'(2	*+,-,./0	1-22.324	5.,ℎ	-0	"7 = 0	:	#	ℎ3-;,ℎ<	=/;+0,3324	5.,ℎ	-0	"7 > 0 	
The	 95%	 confidence	 interval	 (CI)	 was	 used	 as	 a	 proxy	 for	 significance.	 The	 VassarStats	
platform	and	the	SPSS	software	(IBM,	version	23)	were	used	to	perform	statistical	analysis.	
	
Results	
The	mean	age	does	not	differ	significantly	for	the	healthy	volunteers	(35.3	years),	the	BRCA2	
mutation	carriers	(40.9	years)	and	the	non-carrier	relatives	(40.0	years)	(p-value=0.56,	one-
way	anova).	Also,	no	significant	difference	in	gender	distribution	was	observed	for	these	three	
groups	(68%,	61%	and	71%	of	individuals	are	female	respectively)	(p-value=0.84,	Chi	square	
test).	 The	 number	 of	 spontaneously-occurring	 micronuclei	 (MN	 yields	 in	 non-irradiated	
samples)	was	not	significantly	different	among	the	three	groups	of	enrolled	subjects	(Table	I	
and	Figure	1).	
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Table	I.	Overview	of	the	median,	interquartile	range,	mean	and	SD	of	the	micronucleus	yield	
(#MN/1000BN).		
		 		 0	Gy	 2	Gy	
Healthy	volunteers	(HV)	 median	 12	 56	
Interquartile	range	 9.75	 27.5	
mean	 14.33	 61.22	
	SD	 8.85	 21.73	
BRCA2	mutation	carriers	(MC)	 median	 14	 74	
Interquartile	range	 7.75	 54.75	
mean	 16.11	 86.11	
	SD	 6.91	 41.87	
p	value	vs.	healthy	volunteers	(Mann-Whitney)	 0.177	 0.046	
Relatives	who	did	not	inherit	the	familial	
BRCA1/2	mutation	
median	 16	 69	
Interquartile	range	 8	 26	
mean	 17.23	 68.11	
	SD	 7.74	 22.30	
p	value	vs.	healthy	volunteers	(Mann-Whitney)	 0.116	 0.400	
SD	standard	deviation,	MN	micronucleus,	BN	binucleated	cells	
		
Compared	to	healthy	volunteers	without	a	family	history	of	BC/OC,	BRCA2	mutation	carriers	
showed	a	significant	increase	in	mean	MN	yields	after	exposure	to	2	Gy	IR	(p-value=0.046,	
Mann	Whitney).	Conversely,	the	radiation-induced	MN	yields	were	similar	in	relatives	who	
did	not	inherit	the	familial	BRCA1/2	mutation	and	healthy	volunteers	without	a	family	history	
of	BC/OC.	The	mean	MN	yield	in	BRCA2	mutation	carriers	was	higher	compared	to	the	mean	
yield	 in	 non-carriers	 (86.11	 vs.	 68.11	MN/1000	BN	 cells	 respectively).	 This	 difference	was	
however	not	significant	 (p-value=0.298,	Mann	Whitney),	probably	due	to	the	small	cohort	
and	the	high	SD	(Table	I	and	Figure	1).	Furthermore,	MN	yields	did	not	differ	between	non-
carrier	relatives	from	BRCA1	or	BRCA2	pedigrees	(Table	II).		
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Figure	1	Mean	G2	micronucleus	yield		
Mean	MN	 yield	 for	 healthy	 volunteers,	 healthy	 relatives	 who	 did	 not	 inherit	 the	 familial	 BRCA1/2	
mutation	 and	 healthy	 BRCA2	 mutation	 carriers.	 *	 indicates	 a	 significant	 difference	 (p-value<0,05)	
compared	 to	 the	healthy	volunteers	determined	by	Mann	Whitney	U	 test.	Error	bars	 represent	 the	
standard	error	of	the	mean.	MN	micronucleus,	BN	binucleated,	MC	mutation	carriers	
	
Table	II.	Overview	of	median,	interquartile	range,	mean	and	SD	of	the	micronucleus	yield	(#MN/1000BN)	for	
healthy	relatives	who	did	not	inherit	the	familial	germline	BRCA1/2	mutation.		
	 	 0	Gy	 2	Gy	
Relatives	who	did	not	inherit	the	familial	
BRCA1	mutation	(n=9)	
median	 14	 66	
	 Interquartile	range	 12	 57	
mean	 16.44	 69.04	
SD	 6.88	 27.45	
Relatives	who	did	not	inherit	the	familial	
BRCA2	mutation	(n=8)	
median	 16	 70	
Interquartile	range	 12.75	 51.71	
mean	 18.11	 66.98	
SD	 9.18	 16.59	
p	value	vs.	BRCA1	non-carriers	(Mann-Whitney)		 0.7339	 0.9601	
SD	standard	deviation,	MN	micronucleus,	BN	binucleated	cells	
	
The	individual	MN	yields	after	exposure	to	2	Gy	and	the	radiosensitivity	score	(RS	score)	for	
each	BRCA2	mutation	carrier,	non-carrier	relative	and	healthy	volunteer	are	listed	in	Table	III.	
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Furthermore,	Table	 III	 shows	mutational	data	 (both	nucleotide	and	protein	nomenclature)	
and	individuals	with	the	same	family	 ID	are	related.	Figure	2	shows	the	distribution	of	the	
three	 groups	 for	 the	 different	 RS	 scores.	 A	 significant	 higher	 number	 of	BRCA2	mutation	
carriers	 (n=9/18;	 50%)	 showed	 increased	 RS	 scores	 (score	 1	 or	 2)	 compared	 to	 healthy	
volunteers	(n=3/18;	17%)	(P=0.038,	one-tailed	Fisher	exact	test).	For	the	relatives	who	did	not	
inherit	the	familial	germline	mutation	only	24%	(n=4/17)	showed	an	elevated	radiosensitivity	
at	the	individual	 level.	RS	scoring	in	related	individuals	(see	Family	ID	in	Table	III)	however	
shows	 some	variation.	An	OR	of	 5	 (95%	CI:	 1.07	–	23.46)	 for	BRCA2	mutation	 carriers	 vs.	
healthy	 volunteers,	 indicates	 a	 significant	 association	 between	 the	 presence	 of	 a	 BRCA2	
mutation	and	radiosensitivity	according	to	our	criteria.		
All	but	one	of	the	18	mutation	carriers	enrolled	in	the	present	study	are	heterozygous	for	a	
mutation	predicted	to	result	in	a	premature	termination	codon	(PTC).	The	patient	with	the	
deleterious	missense	mutation	(BRCA2	c.8167G>C;	p.(Asp2723His)	obtained	a	RS	score	of	2.	
	
	
Figure	2	Radiosensitivity	scoring	
Distribution	 (%)	 of	 healthy	 volunteers,	 healthy	 relatives	 who	 did	 not	 inherit	 the	 familial	 BRCA1/2	
mutation	and	healthy	BRCA2	mutation	carriers	over	the	different	RS	scores.	RS	score	0	correlates	to	no	
increased	radiosensitivity,	RS	score	1	indicates	a	milder	radiosensitive	phenotype	and	RS	score	2	reflects	
a	more	severe	radiosensitive	phenotype.	RS	Radiosensitivity,	MC	mutation	carriers	
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Table	III.	Germline	mutation,	Family	ID,	micronucleus	yields	(#MN/1000BN)	and	RS	score	for	BRCA2	mutation	carriers,	relatives	who	did	not	inherit	the	familial	mutation	(non-
carrier	relatives)	and	healthy	volunteers	(numbering	of	the	nucleotides	according	to	RefSeq	nr.	NM_000059.3;	A	of	ATG	start	codon	=	nucleotide	+1)	
BRCA2	mutation	carriers	 Non-carrier	relatives	 Healthy	volunteers	
ID	
Family		 Mutation:		
Mutation:	protein	 0	Gy	 2	Gy	 RS	score	 ID	
Family		 Family	
0	Gy	 2	Gy	 RS	score		 ID	 0	Gy	 2	Gy	
RS	
score	ID	 nucleotide	 ID	 gene	
M2.01	 BR-32-2170	 c.658_659delGT	 p.(Val220fs*4)	 14	 119	 2	 NM.06	 BR-32-0156	 BRCA2	 17	 51	 0	 D01	 19	 83	 1	
M2.02	 BR-32-1748	 c.1389_1390del	 p.(Val464fs*3)	 15	 91	 1	 NM.17	 BR-32-0342	 BRCA1	 8	 29	 0	 D12	 10	 52	 0	
M2.03	 BR-32-1748	 c.1389_1390del	 p.(Val464fs*3)	 19	 83	 1	 NM.01	 BR-32-0645	 BRCA1	 20	 63	 0	 D13	 7	 47	 0	
M2.04	 BR-32-1748	 c.1389_1390del	 p.(Val464fs*3)	 12	 58	 0	 NM.10	 BR-32-1134	 BRCA1	 14	 74	 0	 D15	 12	 55	 0	
M2.05	 BR-32-1748	 c.1389_1390del	 p.(Val464fs*3)	 16	 56	 0	 NM.13	 BR-32-1225	 BRCA1	 18	 43	 0	 D16	 17	 44	 0	
M2.06	 BR-32-1758	 c.1989del	 p.(Phe663fs*5)	 12	 163	 2	 NM.12	 BR-32-1225	 BRCA1	 11	 57	 0	 D17	 7	 58	 0	
M2.07	 BR-32-0884	 c.4171del	 p.(Glu1391fs*19)	 37	 65	 0	 NM.07	 BR-32-1444	 BRCA1	 12	 66	 0	 D21	 13	 48	 0	
M2.08	 BR-32-0884	 c.4171del	 p.(Glu1391fs*19)	 20	 90	 1	 NM.08	 BR-32-1444	 BRCA1	 12	 78	 0	 D04	 12	 40	 0	
M2.09	 BR-32-1759	 c.4936_4939del	 p.(Glu1646fs*23)	 20	 65	 0	 NM.02	 BR-32-1494	 BRCA1	 24	 87	 1	 D05	 6	 30	 0	
M2.10	 BR-32-1759	 c.4936_4939del	 p.(Glu1646fs*23)	 18	 53	 0	 NM.16	 BR-32-1967	 BRCA1	 29	 125	 2	 D06	 15	 74	 0	
M2.11	 BR-32-0156	 c.6275_6276del	 p.(Leu2092Profs*7)	 12	 63	 0	 NM.03	 BR-32-0884	 BRCA2	 20	 91	 1	 D29	 9	 29	 0	
M2.12	 BR-32-1565	 c.6275_6276del	 p.(Leu2092Profs*7)	 8	 44	 0	 NM.04	 BR-32-0884	 BRCA2	 16	 73	 0	 D30	 30	 109	 2	
M2.13	 BR-32-1930	 c.6275_6276del	 p.(Leu2092Profs*7)	 23	 183	 2	 NM.09	 BR-32-1748	 BRCA2	 21	 70	 0	 D32	 7	 96	 1	
M2.14	 BR-32-1930	 c.6275_6276del	 p.(Leu2092Profs*7)	 12	 86	 1	 NM.11	 BR-32-1758	 BRCA2	 8	 45	 0	 D31	 26	 73	 0	
M2.15	 BR-32-1920	 c.8167G>C	 p.(Asp2723His)	 10	 118	 2	 NM.05	 BR-32-1759	 BRCA2	 38	 85	 1	 D35	 37	 76	 0	
M2.16	 BR-32-1628	 c.8332-?_8487-?del	 p.(Ile2778Lysfs*40)	 22	 29	 0	 NM.14	 BR-32-1759	 BRCA2	 12	 69	 0	 D37	 6	 75	 0	
M2.17	 BR-32-0937	 c.8904delC	 p.(Val2969fs*7)	 10	 131	 2	 NM.15	 BR-32-2170	 BRCA2	 13	 52	 0	 D38	 17	 52	 0	
M2.18	 BR-32-0082	 c.9256+1G>C	 r.9118_9256del;	p.(Val3040Aspfs*18)	 10	 53	 0	 	 	 	 	 	 	 D39	 8	 61	 0	
Median	 14	 74	 		 16	 69	 		 12	 56	 		
Interquartile	range	 7.75	 54.75	 		 8	 26	 		 9.75	 27.5	 		
Mean	 16.11	 86.11	 		 17.23	 68.11	 		 14.33	 61.22	 		
SD	 6.91	 41.87	 		 7.74	 22.30	 		 8.85	 21.73	 		
The	splice	site	mutation	present	in	M2.18	was	previously	described	by	Claes	et	al.	(39),	where	it	was	erroneously	defined	as	IVS24G>A.	
SD	standard	deviation,	MN	micronucleus,	BN	binucleated	cells,	RS	radiosensitivity
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Discussion	
Results	 of	 the	G2	micronucleus	 assay	 performed	 after	 exposure	 to	 2	Gy	 g-rays	 showed	 a	
significantly	 increased	 radiosensitivity	 in	 healthy	 BRCA2	 mutation	 carriers	 compared	 to	
healthy	controls.	Previous	studies	with	a	large	number	of	different	techniques	were	able	to	
demonstrate	enhanced	radiosensitivity	in	BC	patients	with	a	BRCA2	mutation,	however,	no	
univocal	 results	 were	 achieved	 for	 healthy	 BRCA2	 mutation	 carriers	 (20–25).	 Non-carrier	
relatives	 of	 either	 BRCA1	 or	 BRCA2	 families	 did	 not	 show	 an	 increased	 radiosensitive	
phenotype	compared	to	 the	cohort	of	healthy	volunteers,	which	 is	 in	agreement	with	 the	
study	of	Baeyens	et	 al.	 (20).	We	previously	performed	 the	G2	MN	assay	 in	a	 group	of	18	
healthy	BRCA1	mutation	carriers,	and	found	a	significantly	increased	MN	yield	after	exposure	
to	 2	 Gy	 g-rays	 (12).	 These	 findings	 are	 analogous	 to	 the	 results	 of	 the	 present	 study,	
performed	in	healthy	carriers	of	pathogenic	BRCA2	mutations.	Figure	3	shows	the	integration	
of	the	data	from	healthy	BRCA1	mutation	carriers	in	the	present	study.	The	detection	of	an	
increased	mean	MN	 yield	 in	 both	BRCA1	 and	BRCA2	 mutation	 carriers	 after	 exposure	 to	
ionizing	radiation	can	be	explained	by	their	mutual	role	in	DNA	double	strand	break	repair	
(reviewed	by	Roy	et	al.	(1)).	
	
Figure	3	Mean	G2	micronucleus	yield		
Mean	MN	 yield	 for	 healthy	 volunteers,	 healthy	 relatives	 who	 did	 not	 inherit	 the	 familial	 BRCA1/2	
mutation,	healthy	BRCA2	and	healthy	BRCA1	mutation	carriers.	*	indicates	a	significant	difference	(p-
value<0,05)	 compared	 to	 the	 healthy	 volunteers	 determined	 by	Mann	Whitney	 U	 test.	 Error	 bars	
represent	the	standard	error	of	the	mean.	MN	micronucleus,	BN	binucleated,	MC	mutation	carriers	
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In	 our	 previous	 study	 we	 also	 analyzed	 the	 G2/M	 checkpoint	 activity	 by	 the	 addition	 of	
caffeine,	 an	 agent	 abrogating	 the	 G2/M	 checkpoint,	 to	 the	 irradiated	 cultures	 and	
demonstrated	 a	 significantly	 impaired	 checkpoint	 activation	 in	 BRCA1	mutation	 carriers	
compared	 to	 healthy	 volunteers	 (12).	 Analysis	 of	 the	 G2/M	 checkpoint	 activation	 in	 the	
current	BRCA2	cohort	did	not	reveal	a	significant	difference	(data	not	shown).	This	result	is	in	
agreement	with	the	fact	that	BRCA2	is	not	activated	in	this	particular	checkpoint	pathway	as	
reviewed	by	Roy	et	al.	 (1),	but	does	not	 support	 the	data	obtained	by	Menzel	et	al.	 (28),	
suggesting	 a	 role	 for	 BRCA2	 as	 regulator	 of	 G2	 checkpoint	 maintenance	 following	 DNA	
damage	introduced	in	a	human	osteosarcoma	cell	line	(U2OS)	expressing	dominant-negative	
p53	by	a	high	dose	of	ionizing	radiation	(6	Gy).	
The	role	of	BRCA2	in	the	HR	pathway,	a	DNA	repair	pathway	active	in	S	and	G2	phase	of	the	
cell	 cycle,	 is	 extensively	 reported	 in	 literature	 (for	 a	 review:	 (1)).	 Our	 study,	 focusing	 on	
radiosensitivity	 testing	of	 lymphocytes	 in	 these	phases	of	 the	cell	cycle,	shows	an	OR	of	5	
(95%CI:	1.07-23.47)	for	healthy	individuals	with	a	heterozygous	BRCA2	mutation	compared	
to	healthy	controls.	This	 indicates	a	positive	association	between	the	presence	of	a	BRCA2	
mutation	 and	 radiosensitivity	 that	 could	 be	 attributed	 to	 deficient	 HR	 capacity	 in	
heterozygous	cells.		
Two	independent	research	groups	have	reported	a	decreased	DSB	repair	capacity	in	BRCA2	
heterozygous	cells.	Keimling	et	al.	used	an	enhanced	green	fluorescent	protein	(EGFP)-based	
assay	 to	 report	 impaired	 HR	 capacity	 in	 lymphoblastoid	 cells	 with	 a	 BRCA2	monoallelic	
truncating	 frameshift	 mutation.	 They	 confirmed	 this	 decrease	 in	 HR	 capacity	 in	 a	 BRCA2	
knockdown	Hela	cell	line	(29).	Arnold	et	al.	demonstrated	distinct	defects	in	DNA	DSB	repair	
in	lymphoblastoid	cell	lines	(LCL)	from	heterozygous	BRCA2	mutation	carriers	through	analysis	
of	gH2AX	repair	kinetics	(30).	Although	the	latter	study	did	not	focus	on	DNA	repair	by	HR,	it	
indicates	 a	malfunction	 of	 DSB	 repair	 in	 LCL	 from	BRCA2	mutation	 carriers	 that	 could	 be	
attributed	to	diminished	HR	activity.	
Most	mutation	carriers	enrolled	in	the	present	study	(n=17/18,	94%)	had	a	mutation	
resulting	in	a	premature	termination	codon	(PTC).	The	presence	of	a	PTC	mutation	is	
expected	to	activate	NMD	of	the	gene	transcript.	Previous	research	from	various	groups	
including	ours,	demonstrated	a	reduction	of	mutant	mRNA	to	approximately	half	of	the	WT	
mRNA	levels	in	lymphocytes	of	individuals	with	a	PTC	mutation	in	BRCA1	(12,31,32).	Arnold	
et	al.	(30)	detected	a	similar	mutant	mRNA	reduction	for	BRCA2	mutations	leading	to	a	PTC.	
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Furthermore,	Arnold	et	al.	(30)	and	Keimling	et	al.	(29)	report	distinct	reduced	protein	levels	
in	lymphoblastoid	cell	lines	from	heterozygous	BRCA2	mutation	carriers,	though	
quantitative	analysis	of	this	variation	was	not	performed.	Previously,	haploinsufficiency	has	
been	suggested	as	the	mechanism	for	hereditary	BC	development	in	BRCA1	and	BRCA2	
mutation	carriers	(33).	In	the	present	study,	a	higher	than	expected	number	of	
radiosensitive	individuals	in	the	BRCA2	mutation	carriers	indicates	that	haploinsufficiency	
might	also	be	responsible	for	the	radiosensitive	phenotype	in	carriers	of	a	mutation	
generating	a	PTC.	In	this	study,	only	one	individual	with	a	deleterious	missense	mutation	
was	included.	This	substitution	results	in	an	amino	acid	change	at	position	p.2723		and	
impairs	protein	functionality	as	shown	by	a	homology-directed	DNA	break	repair	functional	
assay	(34).	For	this	individual,	we	obtained	a	high	RS	score	of	2.	Further	research	in	larger	
patient	cohorts	with	different	types	of	mutations	is	needed	to	evaluate	if	the	type	of	
mutation	influences	the	radiosensitive	phenotype	or	if	there	are	additional	parameters	
determining	this	phenotype.	
Results	of	the	G2	MN	assay	show	no	 increased	radiosensitivity	 in	the	group	of	non-carrier	
relatives	 of	 both	BRCA1	 and	BRCA2	 families	 compared	 to	 a	 group	 of	 healthy	 volunteers.	
Furthermore,	only	24%	of	non-carriers	showed	an	elevated	radiosensitivity	at	the	individual	
level	 (RS	 score	 1	 or	 2).	 This	 was	 not	 significantly	 different	 from	 the	 fraction	 of	 healthy	
volunteers	(17%)	that	was	found	to	have	an	increased	RS	score.	In	addition,	no	difference	was	
observed	 between	 non-carriers	 from	 BRCA1	 (RS	 score=0	 in	 7/9	 investigated	 relatives)	 or	
BRCA2	 families	 (RS	 score=0	 in	 6/8	 investigated	 relatives).	 However,	 we	 observed	 some	
variation	within	the	different	groups.	We	hypothesize	that	modifiers	may	play	a	role:	indeed,	
selected	SNPs	in	DNA	damage	repair	genes	and	other	common	variants	have	been	associated	
with	an	increased	radiosensitivity	(35–37)	and	increased	BC	risk	(35,38).	Much	larger	studies	
are	 needed	 to	 evaluate	 the	 subtle	 influence	 of	 possible	modifying	 factors	 on	 BC	 risk	 and	
radiosensitivity.	
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Conclusion		
The	present	study	demonstrated	higher	radiosensitivity	in	healthy	BRCA2	mutation	carriers	
compared	to	healthy	volunteers	by	means	of	the	G2	MN	assay	after	exposure	of	peripheral	
blood	lymphocytes	to	a	dose	of	2	Gy	g-rays.	No	increased	radiosensitivity	was	observed	in	
non-carrier	relatives	of	BRCA1	and	BRCA2	 families.	When	evaluating	radiosensitivity	at	the	
individual	level,	a	significantly	higher	proportion	of	BRCA2	mutation	carriers	(50%)	showed	a	
mild	or	more	severe	radiosensitivity	compared	to	healthy	volunteers	(17%)	and	non-carriers	
(24%).	Furthermore,	an	OR	of	5	indicates	a	positive	association	between	the	BRCA2	mutation	
and	an	increased	radiosensitivity	in	healthy	mutation	carriers.	These	results	indicate	that	care	
should	 be	 taken	 when	 applying	 ionizing	 radiation	 for	 either	 diagnostic	 or	 therapeutic	
purposes	 in	 BRCA2	mutation	 carriers.	 However,	 a	 study	 including	 larger	 populations	 of	
subjects	carrying	different	types	of	BRCA2	mutations	and	non-carriers,	will	be	performed	to	
further	elucidate	the	effect	of	each	single	mutation	on	the	radiosensitive	phenotype	and	the	
influence	of	possible	underlying	factors.		
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Abstract	
Breast	cancer	predisposition	genes	BRCA1	and	BRCA2	play	an	important	role	in	HR,	a	DNA	
double	strand	break	repair	pathway	active	in	S	and	G2	phase	of	the	cell	cycle,	activated	after	
exposure	 to	 ionizing	 radiation.	 Impaired	 double	 strand	 break	 repair	 might	 implicate	 an	
increased	 radiation-induced	 breast	 cancer	 risk	 for	 individuals	 with	 a	 germline	 mutation.	
Several	 clinical	 studies	 and	 in	 vitro	 cytogenetic	 studies	 could	 not	 irrefutably	 confirm	 or	
disprove	 increased	 radiosensitivity	 in	 germline	 mutation	 carriers.	 An	 assay	 specifically	
evaluating	the	effect	of	heterozygous	BRCA1	or	BRCA2	mutations	on	HR	capacity	might	be	
more	 appropriate	 to	 determine	 radiosensitivity	 of	 these	 individuals.	 In	 this	 study,	 we	
investigated	the	suitability	of	the	RAD51	foci	assay	to	evaluate	HR	capacity	in	MCF10A	cells	
with	 reduced	 protein	 levels	 of	 BRCA1	 and	 BRCA2	 obtained	 by	 RNA	 interference.	 After	
exposure	to	ionizing	radiation,	we	determined	RAD51	foci	levels,	a	hallmark	for	HR,	in	S	and	
G2	 phase	 synchronized	 cells.	We	demonstrated	 that	 in	 cells	with	 a	 knockdown	 for	 either	
BRCA1	 or	 BRCA2,	 the	 HR	 pathway	 is	 impaired,	 as	 observed	 by	 the	 absence	 of	 radiation-
induced	RAD51	foci	in	synchronized	MCF10A	cells.	We	anticipate	that	this	assay	can	also	be	
applied	on	synchronized	lymphocytes	of	heterozygous	BRCA1	and	BRCA2	mutation	carriers	
to	 assess	 radiosensitivity	 and	 HR	 capacity.	 It	 can	 also	 be	 a	 valuable	 assay	 to	 elucidate	
pathogenicity	of	variants	of	unknown	significance	in	either	gene.	After	thorough	validation	in	
a	large	cohort	of	BRCA1/2	mutation	carriers,	this	may	open	perspectives	to	a	novel	functional	
assay	which	 can	 be	 performed	 in	 frozen	 patient	material	 without	 the	 need	 of	 cloning	 to	
distinguish	deleterious	mutations	from	neutral	BRCA1/2	variants.	
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Introduction	
Breast	 cancer	 risk	 increases	 drastically	 in	 individuals	 carrying	 a	 germline	BRCA1	 or	BRCA2	
mutation.	BRCA1	and	BRCA2	are	known	as	caretaker	genes	and	are	both	active	in	the	DNA	
damage	response	pathway.	They	are	both	important	in	HR	(HR),	a	DNA	double	strand	break	
(DSB)	repair	pathway,	active	 in	S	and	G2	phase	of	 the	cell	cycle	after	exposure	to	 ionizing	
radiation	(IR)	(Roy	et	al.	2012;	Mao	et	al.	2008).		
	
Individuals	 harboring	 a	 germline	 mutation	 in	 either	 gene	 might	 show	 enhanced	
radiosensitivity	 associated	 with	 a	 higher	 carcinogenic	 risk	 after	 medical	 exposure	 to	 IR.	
However,	studies	investigating	the	impact	of	exposure	to	diagnostic	or	therapeutic	X-rays	on	
cancer	risk	in	BRCA1	and	BRCA2	mutation	carriers	did	not	yield	univocal	results	(Pijpe	et	al.	
2012;	Lecarpentier	et	al.	2011;	Andrieu	et	al.	2006;	Gronwald	et	al.	2008;	John	et	al.	2013;	
Narod	et	al.	2006;	Giannakeas	et	al.	2014;	Goldfrank	et	al.	2006;	Bernstein	et	al.	2013;	Broeks	
et	 al.	 2007).	 Currently	 used	 techniques	 to	 evaluate	 in	 vitro	 radiosensitivity	 in	BRCA1	 and	
BRCA2	mutation	carriers	usually	focus	on	chromosomal	radiosensitivity	(Baeyens	et	al.	2004;	
Gutiérrez-Enríquez	et	al.	2011;	Trenz	et	al.	2002;	Ernestos	et	al.	2010;	Becker	et	al.	2012;	
Bolognesi	et	al.	2014;	Cardinale	et	al.	2012;	Kote-Jarai	et	al.	2006;	Frankenberg-Schwager	&	
Gregus	 2012;	 Barwell	 et	 al.	 2007).	 Also	 here,	 results	 are	 contradictory,	 especially	 when	
analyzing	radiosensitivity	 in	healthy	mutation	carriers	without	breast	cancer.	 In	our	recent	
studies,	we	developed	an	S-G2-phase	specific	micronucleus	 (MN)	assay	 to	analyze	 in	vitro	
chromosomal	radiosensitivity	in	lymphocytes	of	healthy	BRCA1	and	BRCA2	mutation	carriers	
compared	 to	 healthy	 controls.	We	 could	 demonstrate	 that	 in	 general	 BRCA1	 and	 BRCA2	
mutation	carriers	are	characterized	by	a	radiosensitive	phenotype.	However,	due	to	overlap	
in	MN	yields	between	carriers	and	controls,	the	G2	micronucleus	assay,	as	all	other	cytogenic	
assays,	still	has	limitations	when	used	as	a	biomarker	of	individual	radiosensitivity	in	mutation	
carriers	(Baert	et	al.	2016;	Baert	et	al.	2017).	The	fact	that	cytogenetic	assays	in	general	are	
not	 sensitive	 enough	 to	 detect	 radiosensitivity	 in	 healthy	 heterozygous	 BRCA1/BRCA2	
mutation	carriers	might	be	due	to	the	fact	that	radiation-induced	DSB,	even	when	induced	in	
S/G2	phase	of	the	cell	cycle,	are	mainly	repaired	by	non-homologous	end-joining	(NHEJ)	and	
not	by	HR,	the	pathway	in	which	BRCA1	and	BRCA2	play	an	important	role.	HR	is	only	involved	
in	the	repair	of	a	subset	of	DSB	induced	by	IR	in	S	and	G2	phase	of	the	cell	cycle	(Mao	et	al.	
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2008;	Li	&	Xu	2016;	Mladenov	et	al.	2016;	Ceccaldi	et	al.	2016).	So,	a	better	strategy	would	
be	to	develop	an	assay	that	analyses	the	functionality	of	HR	specifically.		
	
HR	relies	on	RAD51	filament	formation	which	subsequently	induces	strand	invasion	for	the	
repair	of	the	DSB.	RAD51	protein	recruitment	to	the	DSB	site	is	mediated	by	BRCA1	and	BRCA2	
and	can	be	detected	as	nuclear	foci	upon	immunostaining	(Mladenov	et	al.	2016;	Rothkamm	
et	al.	2015).	Recently,	the	ex	vivo	RAD51	irradiation-induced	foci	(IRIF)	assay,	performed	on	
fresh	 biopsy	 samples	 of	 cancer	 patients	 has	 shown	 to	 be	 a	 suitable	 assay	 to	 detect	 HR	
deficiency	due	to	defects	in	proteins	involved	in	the	HR	pathway	such	as	BRCA1	and	BRCA2,	
a	characteristic	which	renders	tumors	sensitive	to	PARP	inhibition	treatment	(Willers	et	al.	
2009;	Naipal	et	al.	2014;	AlHilli	et	al.	2016;	Mukhopadhyay	et	al.	2010;	Shah	et	al.	2014).	PARP	
inhibition	treatment	is	based	on	the	inhibition	of	single	strand	break	(SSB)	repair,	resulting	in	
accumulation	of	SSB	which	cause	collapse	of	the	replication	forks	and	formation	of	a	DSB	if	
encountered	during	replication	in	proliferating	cells.	Repair	of	these	stalled	replication	fork-
induced	DSB	specifically	requires	HR.	As	HR	deficient	tumor	cells	cannot	repair	this	type	of	
DSB	lesion,	cell	death	will	occur	(Pommier	et	al.	2016;	Zeman	&	Cimprich	2014;	Lim	&	Kaldis	
2013).		
	
A	small	number	of	studies	also	tested	the	influence	of	 IR	on	RAD51	foci	formation	in	non-
tumor	 cells	 and	 demonstrated	 an	 impaired	 RAD51	 foci	 formation	 in	 BRCA1/BRCA2	
heterozygous	cell	lines	compared	to	a	respective	control	(Vaclová	et	al.	2015;	Warren	et	al.	
2003;	Sioftanos	et	al.	2010).		
	
The	aim	of	this	study	was	to	investigate	the	suitability	of	the	RAD51	foci	assay	to	evaluate	HR	
capacity	 in	 MCF10A	 cells	 with	 reduced	 protein	 levels	 of	 BRCA1	 and	 BRCA2,	 which	 was	
obtained	by	RNA	interference.	DSB	were	induced	by	irradiating	the	cells	with	a	dose	of	2	Gy	
220	kV	X-rays.	To	achieve	a	maximum	number	of	cells	in	S	and	G2	phase	of	the	cell	cycle,	the	
phases	 in	which	HR	 is	active,	 the	cells	were	 synchronized	by	means	of	aphidicolin,	a	DNA	
polymerase	 inhibitor.	 In	 a	 part	 of	 the	 experiments,	 we	 added	 a	 PARP	 inhibitor	 (PARPi)	
(Olaparib).	The	addition	of	a	PARPi	in	combination	with	IR	will	block	the	repair	of	radiation-
induced	single	strand	breaks.	Subsequent	replication	fork	stalling	in	S-phase	transforms	the	
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SSB	in	a	DSB	which	is	exclusively	repaired	by	HR	resulting	in	an	extensive	activation	of	this	
pathway	(Urbin	et	al.	2012).		
	
Materials	and	methods	
Cell	lines	
MCF10A	cells	were	cultured	in	monolayers	using	equal	volumes	of	DMEM-glutamax	and	F12-
glutamax	 (both	Gibco	 by	 Life	 Technologies,	USA),	 supplemented	with	 5%	 fetal	 calf	 serum	
(Invitrogen,	Belgium),	antibiotics	(50	U/ml	Penicillin	(Invitrogen)	and	50	μg/ml	streptomycin	
(Invitrogen))	and	growth	factors	(10	μg/ml	insulin	(Sigma,	Belgium),	0.5	μg/ml	hydrocortison	
(Sigma)	 and	 20	 ng/ml	 epidermal	 growth	 factor	 (Peprotech,	 UK)).	 Experiments	 were	
performed	 on	 BRCA1	 and	 BRCA2	 knockdown	 lines	 (referred	 to	 as	 BRCA1i	 and	 BRCA2i),	
together	 with	 a	 mock-transduced	 control	 cell	 line	 (here	 after	 referred	 to	 as	 control).	
Knockdown	 was	 achieved	 by	 stable	 transduction	 with	 lentiviral	 particles	 containing	 DNA	
sequences	 encoding	 short	 hairpin	 RNA	 specific	 for	 BRCA1	 or	 BRCA2	 RNA	 interference.	 In	
short,	 lentiviruses	 were	 constructed	 using	 pLKO.1-puro	 vectors.	 The	 RNA	 interference	
sequence	 for	 BRCA1	 was	 5’-	 CCCTAAGTTTCACTTCTCTAAA	 -	 3’	 and	 5’	 –
TACAATGTACACATGTAA	-	3’	for	BRCA2.		For	the	mock-transduced	cell	line,	an	empty	vector	
was	 used.	 Furthermore,	 the	 vector	 contained	 a	 resistance	 to	 puromycin.	 Transduction	 of	
MCF10A	cells	was	achieved	by	adding	1	μg/ml	DNA,	TurboFect	(1.5	μg/ml)	and	polybrene	(1	
μg/ml)	 to	 a	 30%	 confluent	 culture.	 Two	 days	 after	 transduction,	 2	 μg/ml	 puromycin	was	
added	to	the	culture	medium	and	cells	were	grown	in	puromycin	supplemented	medium	for	
another	15	days	to	obtain	stably	transduced	cell	lines.		
	
Sample	preparation	
Cells	 were	 cultured	 in	 puromycin	 (2	 μg/ml,	 Sigma)	 supplemented	 medium	 to	 select	 for	
transduced	cells.	Cells	were	switched	to	puromycin-free	culture	medium	for	each	experiment.	
Cells	were	seeded	in	a	concentration	of	200	000	cells	in	2	ml	culture	medium	in	6-well	plates.	
Approximately	24h	after	 cell	 seeding,	 cells	were	 checked	 for	 subconfluency	and	 cell	 cycle	
synchronization	was	initiated.		
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Synchronization	of	cell	cultures	
Cell	synchronization	was	achieved	by	the	addition	of	aphidicolin	(1	μg/ml	or	2.857	μM,	Sigma)	
to	 the	 culture	 medium	 during	 24h.	 Cells	 were	 subsequently	 washed	 with	 PBS	 (1.78	 g	
Na2HPO4;	0.42	g	KH2PO4	and	7.2	g	NaCl	(all	VWR,	Belgium)	in	1l	dH2O)	and	incubated	with	
fresh	culture	medium	to	restart	synthesis.		
	
Irradiation	and	PARPi	treatment.		
Three	hours	after	aphidicolin	removal,	cells	were	irradiated	with	2	Gy	220kV-13mA	X-rays,	
produced	by	the	small	animal	radiation	research	platform	(SARRP)	(Xstrahl,	UK).	Cells	were	
subsequently	 incubated	 at	 37°C	 for	 another	 5	 h	 after	 irradiation	 for	 optimal	 RAD51	 foci	
formation.	To	determine	this	optimal	time	point,	different	time	points	varying	between	2	and	
8	h	were	tested	(data	not	shown).	To	a	part	of	the	cultures,	a	PARP	inhibitor	(Olaparib)	(5	μM,	
Bio-Connect,	The	Netherlands)	was	added	2	h	after	synchronization,	hence	one	hour	before	
irradiation.	RAD51	foci	formation	was	also	evaluated	in	non-treated	cell	cultures	and	cultures	
exposed	to	PARPi	alone.	In	total,	eight	repeats	were	performed	for	every	condition	to	test	for	
statistically	significant	differences.	
Induction	of	DNA	DSB	by	IR	was	verified	by	means	of	yH2AX	staining	according	to	Depuydt	et	
al.	 (Depuydt	et	al.	2013)	 (supplementary	data	S1).	The	 inhibition	of	PARP	by	Olaparib	was	
confirmed	by	evaluation	of	pADPr	activity	after	exposure	to	H2O2	or	ionizing	radiatin	in	the	
presence	 or	 absence	 of	 Olaparib	 as	 previously	 described	 (Barazzuol	 et	 al.	 2013)	
(supplementary	data	S2).		
	
RAD51	foci	assay	
Prior	to	RAD51	foci	staining,	cells	were	harvested,	cytospinned	on	polysine	slides	(VWR)	and	
fixed	 in	 3%	 paraformaldehyde	 for	 20	min.	 Slides	 were	 washed	 twice	 in	 PBS	 and	 antigen	
retrieval	was	achieved	by	incubation	(20	min)	in	a	heated	(95°C)	citrate	buffer	(0,02%	Citric	
acid	(Merck,	Germany)	in	dH20,	pH=6).	Slides	were	subsequently	washed	and	incubated	with	
a	 blocking	 serum	 containing	 1%	BSA	 (Roche,	 Switzerland);	 5%	normal	 goat	 serum	 (DAKO,	
Denmark)	and	0,2%	Tween	20	(VWR)	in	PBS.	Slides	were	incubated	(overnight,	4°C)	with	the	
first	 antibody	 RAD51	H-92	 (1/2000)	 (sc-8349,	 Santa	 Cruz,	USA),	washed	with	 PBS	 and	 3%	
Tween	20,	and	 incubated	 (30	min,	 room	temperature)	with	 the	second	antibody	 (1/1000)	
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(ThermoScientific,	USA).	Finally,	slides	were	washed	(PBS	and	3%	Tween	20)	and	mounted	
with	200	ng/ml	DAPI	in	fluoromount	(both	Sigma).		
Slides	were	scanned	using	the	Metacyte	software	module	on	the	Metafer4	scanning	platform	
(Metasystems,	Germany)	using	a	63X	magnification.	This	software	module	enables	automatic	
cell	detection	and	foci	counting	according	to	set	parameters	resulting	 in	an	objective	data	
acquisition.	The	number	of	RAD51	foci	was	automatically	scored	in	a	minimum	of	500	cells	
for	 every	 condition	 per	 experiment	 and	 expressed	 as	 the	 number	 of	 RAD51	 foci	 per	 cell	
(RAD51	foci/cell).		
	
Cell	cycle	analysis	
MCF10A	control	cells	were	harvested	at	various	time	points	after	synchronization	to	evaluate	
the	percentage	of	cells	in	each	phase	of	the	cell	cycle.	Cell	permeabilization	was	achieved	by	
ethanol	(95%,	-20°C)	fixation	and	DNA	was	subsequently	stained	with	Propidium	Iodide	(PI)	
in	 a	 hypotonic	 staining	 buffer	 containing	 0.1%	 Sodium	 citrate	 (Merck);	 0.3%	 Triton-X	 100	
(Sigma);	0.01%	PI	 (Sigma)	and	Ribonuclease	A	 (0.002%)	 in	dH2O.	Cells	 and	PI	 content	was	
analyzed	on	a	BD	FACSCantoTM	(BD	Biosciences,	USA).	Cells	of	interest	were	selected	based	
on	forward	and	side	scatter	area	patterns.	A	non-synchronized	sample	was	used	as	control.		
	
Western	blot	analysis	
BRCA1	 and	 BRCA2	 protein	 knockdown	 was	 evaluated	 by	 western	 blot	 analysis.	 Protein	
extraction	was	performed	in	subconfluent	cultures	of	control,	BRCA1i	and	BRCA2i	cells	using	
a	 TE	 lysis	 buffer	 containing	 0.1M	 Tris,	 50mM	 EDTA,	 1%	NP-40	 and	 1%	 protease	 inhibitor	
(sigma	P8340).	Protein	concentration	was	determined	by	means	of	the	PierceTM	Coomassie	
protein	 assay	 kit	 (ThermoScientific,	 USA).	 For	 every	 sample,	 50	 μg	 of	 protein	was	 loaded	
together	with	 LDS	 sample	buffer	 (ThermoScientific	NP0008;	25%)	and	dithiothrietol	 (DDT;	
Sigma;	43816,	10%)	on	a	3-8%	Tris-Acetate	gel	 (Novac).	 The	gel	was	 run	 in	a	Tris-Acetate	
running	 buffer	 supplemented	 with	 2.5%	 antioxidant	 during	 5	 h	 at	 25mA.	 Proteins	 were	
transferred	 to	 a	methanol	pretreated	PVDF	membrane	 in	 a	 Tris	 (25mM,	 Sigma)	&	glycine	
(0.2M,	 VWR)	 dH2O	 blotting	 buffer	 enriched	 with	 10%	 methanol	 during	 16	 hour	 at	 30V.	
Subsequently,	the	membrane	was	blocked	1	hour	in	a	tris	buffered	saline	(TBS	buffer)	with	
3%	BSA;	5%	milk	powder	and	0.1%	Tween	20.	After	blocking,	the	membrane	was	incubated	
overnight	with	the	primary	antibody	(rabbit	pAb	α-BRCA1	(sc-642,	diluted	1/1000)	or	mAb	
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antibody	 α-BRCA2	 (Millipore	 OP-95,	 diluted	 1/500),	 and	mouse	mAb	 α-actinin	 (sc-17829,	
diluted	1/30	000)	as	loading	control.	This	incubation	was	followed	by	washing	and	incubation	
with	secondary	antibodies,	conjugated	with	hrp	(GAR-hrp	(Perbio	34160,	diluted	1/1000)	or	
GAM-hrp	 (ThermoScientific	 31450,	 diluted	 1/1000)).	 Visualization	 was	 achieved	 via	
chemoluminescence	 kit	 (ThermoScientific)	 and	 images	were	 obtained	 by	 the	 Chemidoc-it	
imaging	system	(UVP,	Canada)	and	Vision	Works	LS	software	(UVP).		
	
Statistical	analysis	of	the	data	
The	mean	number	of	RAD51	foci/cell,	standard	deviation	(SD)	and	standard	error	on	the	mean	
(SEM)	were	determined	for	the	four	different	conditions	(non-treated,	PARPi,	IR	and	PARPi	+	
IR)	 in	 the	 three	 cell	 lines	 (control,	 BRCA1i	 and	 BRCA2i).	 Furthermore,	 a	 fold	 change	 was	
calculated	to	quantify	the	change	of	RAD51	foci	in	comparison	to	the	control	cell	line.	A	fold	
change	<	1	indicates	a	reduction	of	RAD51	foci	induction	in	the	cell	line	for	a	certain	condition.	
To	evaluate	changes	 in	RAD51	 foci	 formation,	 statistical	analysis	was	performed	using	 the	
Mann-Whitney	 test	 for	 unpaired	 analysis	 of	 non-parametric	 data.	 A	 5%	 alpha	 error	 as	
boundary	(p-value	≤	0.05)	was	applied	and	calculations	were	performed	using	SPSS	software	
(IBM,	version	24).		
	
Results	
Western	blot	analysis	
Western	blotting	revealed	a	BRCA1	knockdown	in	BRCA1i	cells	and	a	BRCA2	knockdown	in	
BRCA2i	cells	compared	to	the	control	cell	line	(Figure	1).	Quantification	of	the	knockdown	via	
ImageJ	 revealed	an	estimated	BRCA1	protein	 reduction	of	70%	 in	 the	BRCA1i	cells	and	an	
estimated	51%	reduction	of	BRCA2	protein	in	the	BRCA2i	cells.	
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Figure	1.	Western	Blot	analysis	
Western	blot	analysis	of	BRCA1	and	BRCA2	protein	levels	in	the	control,	BRCA1i	and	BRCA2i	
cell	lines.	Actinin	was	used	as	a	protein	loading	control.	
	
	
Cell	cycle	analysis	
Figure	1a	represents	the	mean	percentage	of	cells	in	every	phase	of	the	cell	cycle	in	a	non-
synchronized	 sample	 and	 at	 various	 time	 points	 after	 aphidicolin	 removal	 based	 on	 four	
repeats.	As	an	example,	the	histogram	charts	of	every	time	point	for	one	repeat	are	shown	in	
Figure	2b-f.	Synchronization	with	aphidicolin	clearly	resulted	in	an	increased	number	of	cells	
in	S	phase	of	the	cell	cycle.	Immediately	after	aphidicolin	synchronization	(Figure	2b),	about	
70%	of	the	cells	were	at	the	beginning	of	S	phase.	Two	(Figure	2c)	and	three	h	(Figure	2d)	
after	aphidicolin	removal	the	lowest	number	of	cells	in	G1	phase	of	the	cell	cycle	was	achieved	
whilst	the	number	of	S	phase	cells	had	doubled	compared	to	non-synchronized	cultures.	Eight	
h	after	aphidicolin	synchronization,	the	cells	shift	towards	G2	and	M	phase	of	the	cell	cycle	
(Figure	2e).	As	the	number	of	cells	in	late	S	phase	is	at	its	maximum	two	and	three	h	after	
synchronization,	these	time	points	were	selected	for	addition	of	PARPi	(2h)	and	irradiation	
(3h)	to	maximize	the	effect	of	these	agents	on	RAD51	foci	formation.	
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Figure	2.	Results	of	cell	cycle	analysis	
(a)	Mean	percentage	of	cells	 in	every	phase	of	 the	cell	cycle	before	synchronization	and	at	
various	h	after	aphidicolin	removal.	Results	are	expressed	in	%	and	error	bars	are	SEM	based	
on	 four	 repeats.	 (b-f)	 Histogram	 tables	 showing	 the	 number	 of	 cells	 in	 function	 of	 the	 PI	
content,	an	indication	for	DNA	content	(created	with	FlowJoTM),	(b)	of	a	non-synchronized	cell	
culture	as	control,	(c)	immediately	(0h)	after	synchronization,	(d)	2h	after	synchronization,	(e)	
3h	after	synchronization	and	(f)	8h	after	synchronization.	PI	Propidium	Iodide	
	
RAD51	foci	formation		
Figure	3	shows	RAD51	foci	 in	the	nuclei	of	MCF10a	control	cells.	Figure	4	shows	the	mean	
number	 of	 RAD51	 foci	 in	 synchronized	 cell	 cultures	 for	 every	 cell	 line	 for	 the	 four	 tested	
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conditions.	Fold	changes	are	presented	in	Table	1.	We	observed	a	significant	lower	number	
of	RAD51	foci	in	both	BRCA1i	and	BRCA2i	cells	compared	to	the	control	cells	after	exposure	
to	both	IR	alone	and	IR	with	PARPi.	Fold	changes	vary	between	0.51	and	0.36.	Furthermore,	
no	formation	of	radiation-induced	RAD51	foci	could	be	detected	in	the	knockdown	cell	lines.	
The	differences	in	RAD51	foci	levels	observed	when	comparing	the	knockdown	and	control	
cell	 lines	 in	 non-treated	 cell	 cultures	 or	 cell	 cultures	 solely	 exposed	 to	 PARPi	 were	 not	
statistically	different	(Figure	4	and	Table	1).		
When	comparing	the	different	conditions	per	cell	 line,	only	a	significant	increase	in	RAD51	
foci	levels	was	observed	in	the	control	cell	line	after	exposure	to	IR	and	combined	exposure	
to	IR	and	PARPi	compared	to	non-treated	cells	(Figure	4).	
		
	
Figure	3.	RAD51	foci	(green)	in	control	MCF10A	DAPI-stained	nuclei	(blue)	
Left	panel:	synchronized	control	cells,	non-irradiated.	Right	panel:	synchronized	control	cells,	
irradiated	(2	Gy).	
	
	
Table	1.	Fold	changes	
	
no	IR	
no	PARPi	
no	IR	
with	PARPi	
IR	
no	PARPi	
IR	
with	PARPi	
Control	 1	 1	 1	 1	
BRCA1i	 0.91	 0.81	 0.42	(*)	 0,51	(*)	
BRCA2i	 0.71	 0.93	 0.36	(*)	 0,40	(*)	
*	 indicate	 significant	 reductions	 in	 RAD51	 foci	 levels	 compared	 to	 the	 control	 cell	 line	 (p-
values<0.05)	IR	Ionizing	radiation,	PARPi	PARP	inhibition	
	
	
20	µm	 20	µm	 
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Figure	4.	Mean	number	of	RAD51	foci	per	cell	(RAD51	foci/cell)	in	aphidicolin-synchronized	cell	
cultures	for	every	condition.		
Cells	were	either	not	treated,	exposed	to	a	PARPi,	2	Gy	IR	or	a	combination	of	both.	Error	bars	
are	SEM	based	on	eight	repeats.	*	indicates	significant	differences	(p-value<0.05)	compared	
to	the	control	cell	line	within	one	condition,	unless	indicated	otherwise.		
IR	Ionizing	radiation,	PARPi	PARP	inhibition	
	
Discussion	
The	aim	of	this	study	was	to	investigate	the	suitability	of	the	RAD51	foci	assay	to	evaluate	HR	
capacity	 in	 MCF10A	 cells	 with	 reduced	 protein	 levels	 of	 BRCA1	 and	 BRCA2,	 which	 was	
obtained	by	RNA	 interference.	 Cells	were	 synchronized	 in	 S	 and	G2	phase	 for	 an	optimal	
evaluation	of	HR	capacity.	DSB	were	induced	by	exposure	to	IR.	To	increase	the	number	of	
DSB,	we	also	used	PARPi	that	transform	radiation-induced	SSB	in	DSB	during	S	phase.		
	
We	confirmed	that	HR	is	involved	in	repair	of	radiation-induced	DSB	in	synchronized	MCF10A	
cells.	We	demonstrated	a	significant	lower	number	of	RAD51	foci	in	BRCA1i	and	BRCA2i	cell	
lines	compared	to	the	control	cell	line	after	exposure	to	IR	alone	or	a	combination	of	IR	and	
PARPi	(Figure	4).	Moreover,	for	BRCA1i	and	BRCA2i	no	formation	of	radiation-induced	RAD51	
foci	was	observed.	The	discrepancy	between	knockdown	and	control	cells	can	be	explained	
by	the	involvement	of	both	proteins	in	RAD51	microfilament	formation	and	HR	initiation	for	
repair	of	 IR-induced	DSB.	Although	direct	comparison	between	the	results	obtained	 in	the	
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BRCA1i	and	BRCA2i	cell	line	is	difficult	as	the	remaining	protein	level	for	BRCA2	is	higher	than	
for	BRCA1	(Figure	1),	we	observed	a	lower	RAD51	foci	yield	for	BRCA2i	cells	in	three	of	the	
four	tested	conditions	compared	to	BRCA1i	cells.	This	lower	RAD51	foci	yield	despite	higher	
protein	 levels	 could	 be	 attributed	 to	 the	 more	 specific	 role	 that	 BRCA2	 has	 in	 RAD51	
recruitment	 and	 HR,	 whereas	 BRCA1	 exerts	 a	 more	 pleiotropic	 role	 in	 the	 DNA	 damage	
response	(for	a	review:	(Roy	et	al.	2012)).	Further	research	to	evaluate	this	trend	would	be	
necessary.		
	
A	number	of	studies,	investigating	the	influence	of	BRCA2	on	RAD51	foci	formation	and	HR	
functionality,	have	been	performed	using	human	cell	 lines,	CHO	cells,	DT40	cells	and	mice	
embryonic	 stem	 cells.	 All	 studies	 confirmed	 impaired	 functionality	 of	 HR	 resulting	 in	 a	
reduction	in	RAD51	foci	formation	in	heterozygous	cells	(Kraakman-Van	der	Zwet	et	al.	2002;	
Yuan	et	al.	1999;	Sioftanos	et	al.	2010;	Keimling	et	al.	2011;	Warren	et	al.	2003).		
	Conversely,	the	results	of	studies	focusing	on	the	effect	of	BRCA1	on	RAD51	formation	and	
HR	were	less	univocal.	Sioftanos	et	al.	detected	a	reduction	in	RAD51	foci	formation	in	BRCA1	
heterozygous	mice	embryonic	stem	cells,	 though	 less	distinct	then	 in	BRCA2	heterozygous	
cells	 (Sioftanos	et	 al.	 2010).	 Yaun	et	 al.	 and	Keimling	et	 al.,	 on	 the	other	hand,	 could	not	
demonstrate	an	effect	of	BRCA1	heterozygosity	on	RAD51	formation	or	HR	capacity	(Yuan	et	
al.	 1999;	 Keimling	 et	 al.	 2011).	 In	 a	 study	using	 lymphoblastoid	 cell	 lines	of	 heterozygous	
BRCA1	mutation	carriers,	Vaclova	et	al.	could	not	directly	demonstrate	a	decrease	in	RAD51	
foci	formation	compared	to	a	control	cell	line	4	h	after	exposure	to	10	Gy.	However,	they	did	
observe	a	significant	increase	in	yH2AX	intensity	in	these	heterozygous	BRCA1	cells	compared	
to	control	cells	4	h	after	irradiation,	implicating	an	increase	in	number	of	DSB		and	argue	that	
this	implies	a	decreased	HR	activation	in	mutation	carriers	(Vaclová	et	al.	2015).	Pathania	et	
al.	did	not	detect	a	reduction	in	radiation-induced	RAD51	foci	in	human	mammary	epithelial	
cells	containing	a	BRCA1	mutation	exposed	to	10	Gy	compared	to	control	cells.	However,	the	
combined	exposure	to	UV	and	IR	did	yield	a	significant	reduction	in	RAD51	foci	(Pathania	et	
al.	2014).	
	
None	of	these	studies	took	the	variation	of	HR-based	DSB	repair	throughout	the	different	cell	
cycle	phases	into	account.	We	demonstrated	that	48%	of	non-synchronized	cycling	MCF10A	
cells	were	 in	 G1	 phase	 of	 the	 cell	 cycle,	 the	 cell	 cycle	 phase	 during	which	 HR	 cannot	 be	
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activated	due	to	the	absence	of	the	homologous	sister	chromatid.	In	our	synchronized	cell	
cultures,	approximately	90%	of	the	cells	were	in	S	or	G2	phase	of	the	cell	cycle,	at	time	of	
irradiation.	Moreover,	more	than	60%	of	cells	were	in	S	phase	at	time	of	irradiation,	the	cell	
cycle	phase	during	which	HR	activation	is	maximal	for	repair	of	DSB	(Mao	et	al.	2008;	Karanam	
et	al.	2012).	As	aphidicolin	induces	DNA	damage	by	DNA	polymerase	inhibition	(Kurose	et	al.	
2006;	 Hanada	 et	 al.	 2007),	 caution	 is	 needed	 when	 analyzing	 results	 of	 aphidicolin	
synchronized	 cell	 cultures.	 Also	 other	 methods	 for	 cell	 cycle	 synchronization,	 such	 as	
thymidine	block	or	hydroxyurea,	induce	DNA	damage,	amongst	which	DSB	(Kurose	et	al.	2006;	
Hanada	et	al.	2007;	Saintigny	et	al.	2001).	In	our	studies,	aphidicolin	synchronization	resulted	
in	the	formation	of	RAD51	foci	in	non-treated	cells,	but	no	significant	difference	was	observed	
between	the	control	and	knockdown	cell	lines	(Figure	4,	no	IR	no	PARPi).	In	non-synchronized	
cell	lines,	much	lower	baseline	RAD51	foci	(means	values	≤	1)	were	obtained	(data	not	shown).	
	
In	an	attempt	to	activate	the	HR	pathway	more	extensively,	we	added	PARPi	to	the	cultures	
prior	 to	 irradiation.	However,	we	did	 not	 observe	 a	 significant	 increase	 in	 the	 number	 of	
RAD51	foci	effect	compared	to	IR	alone.	As	a	consequence,	the	combined	treatment	did	not	
result	in	a	better	discrimination	between	the	knockdown	cell	lines	and	the	control	cell	line.	
This	 might	 be	 due	 to	 an	 exhaustion	 of	 HR	 capacity	 by	 aphidicolin	 synchronization	 and	
exposure	to	IR.	Furthermore,	we	should	consider	the	many	different	functions	PARP	fulfills	in	
the	 DNA	 damage	 response,	 including	 detection	 and	 signaling	 of	 DSB	 and	 stabilization	 of	
stalled	replication	forks	(Pommier	et	al.	2016;	Khodyreva	&	Lavrik	2016).	The	complex	PARP	
network	 is	 not	 fully	 understood	 and	 inhibition	might	 impair	 additional	 HR	 activation	 and	
RAD51	foci	formation	in	our	assay.	We	hypothesize		that	PARP	trapping,	initiated	by	Olaparib	
at	the	SSB	site	(Murai	et	al.	2012;	Pommier	et	al.	2016),	might	impair	HR	activation	once	the	
SSB	is	transformed	in	a	DSB	due	to	replication	fork	collapse.	This	would	also	explain	why	no	
increased	RAD51	 formation	 is	observed	 in	 synchronized	 cells	 after	PARPi	 treatment	alone	
compared	to	non-treated	cells.		
	
In	 conclusion,	we	demonstrated	 that	 in	 cells	 containing	a	knockdown	 for	either	BRCA1	or	
BRCA2,	 the	 HR	 pathway	 is	 impaired,	 which	 results	 in	 the	 absence	 of	 radiation-induced	
formation	of	RAD51	foci	 in	synchronized	cells.	As	 in	both	cell	 lines ≤ 50%	of	the	wild	type	
activity	 is	retained	after	 lentiviral	knockdown,	the	results	obtained	in	the	MCF10A	cell	 line	
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may	mimic	 the	 situation	 in	 healthy	 carriers	 of	 a	 germline	 BRCA1/2	 mutation.	 Therefore,	
applying	 this	 assay	 on	 synchronized	 fibroblasts/breast	 epithelial	 cells/lymphocytes	 of	
heterozygous	 BRCA1	 and	 BRCA2	 mutation	 carriers	 might	 be	 a	 useful	 strategy	 to	 assess	
radiosensitivity	and	HR	capacity	for	these	patients.	This	should	be	thoroughly	evaluated	in	a	
large	 cohort	 of	 patients	with	 known	deleterious	mutations	 located	 in	 different	 functional	
domains	of	both	genes.	In	case	heterozygous	mutation	carriers	can	be	clearly	distinguished	
from	 controls,	 such	 an	 assay	 can	 be	 very	 valuable	 to	 determine	 the	 functional	 effect	 of	
variants	 of	 unknown	 clinical	 significance	 in	 either	 gene,	 which	 aids	 adequate	 genetic	
counseling	of	carriers	of	such	variants.			
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	Supplementary	data	
	
non-irradiated	(0	Gy)	 	 	 	 					irradiated	(2	Gy)	
	
S1:	yH2AX	foci	staining	after	exposure	of	control	MCF10A	cells	to	ionizing	radiation.		
Induction	of	yH2AX	foci	was	assessed	30	min	after	exposure	to	ionizing	radiation	(2	Gy)	or	mock	
irradiation	 (0	 Gy).	 Immunostaining	 was	 performed	 by	 means	 of	 a	 monoclonal	 anti-yH2AX	
antibody	(biolegend	cat	613402)	(Depuydt	et	al.	2013).	 Image	gallery	showing	four	cells	 for	
each	condition	taken	with	Metafer	4	(Metasystems).		
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S2:	Evaluation	of	PARP	inhibition	by	Olaparib.	
Immunodetection	for	poly	(ADP-ribose)	activity	was	performed	according	to	Barazzuol	et	al.	
(Barazzuol	et	al.	2013)	in	synchronized	control	MCF10A	cells.	PARP	activation	was	induced	by	
H2O2	treatment	(20mM,	10	min)	or	exposure	to	ionizing	radation	(3	Gy)	and	visualized	by	anti-
pADPr	 immunostaining	with	FITC	signal	 (green).	Addition	of	Olaparib	(PARPi)	 (5	µM)	1	hour	
before	 H2O2	 treatment	 or	 exposure	 to	 ionizing	 radiation,	 resulted	 in	 an	 absence	 of	 PARP	
activity.	MCF10A	nuclei	were	counterstained	with	DAPI	(blue).	Images	taken	with	Metafer	4	
(Metasystems).	Scale	bar	indicates	20	µm.	
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Abstract	
	
For	21	putative	BRCA1/2	 splice	site	variants	the	concordance	between	mRNA	analysis	and	
predictions	 by	 in	 silico	 programs	 was	 evaluated.	 Aberrant	 splicing	 was	 confirmed	 for	 12	
alterations.	 In	 silico	 prediction	 tools	 were	 helpful	 to	 determine	 for	 which	 variants	 cDNA	
analysis	is	warranted,	however,	predictions	for	variants	in	the	Cartegni	consensus	region	but	
outside	the	canonical	sites,	were	less	reliable.	Learning	algorithms	like	Adaboost	and	Random	
Forest	outperformed	the	classical	tools.	Further	validations	are	warranted	prior	to	implement	
these	novel	tools	in	clinical	settings.			
Additionally,	we	report	here	for	the	first	time	activated	cryptic	donor	sites	in	the	large	exon	
11	of	BRCA2	by	evaluating	 the	effect	at	 the	 cDNA	 level	of	a	novel	 tandem	duplication	 (5’	
breakpoint	in	intron	4;	3’	breakpoint	in	exon	11)	and	of	a	variant	disrupting	the	splice	donor	
site	of	exon	11	(c.6841+1G>C).	Additional	sites	were	predicted,	but	not	activated.	These	sites	
warrant	further	research	to	increase	our	knowledge	on	cis	and	trans	acting	factors	involved	
in	 the	 conservation	 of	 correct	 transcription	 of	 this	 large	 exon.	 This	 may	 contribute	 to	
adequate	design	of	ASOs	(antisense	oligonucleotides),	an	emerging	therapy	to	render	cancer	
cells	sensitive	to	PARP	inhibitor	and	platinum	therapies.	
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Introduction	
The	risk	of	breast	and	ovarian	cancer	increases	drastically	in	individuals	carrying	a	germline	
BRCA1	or	BRCA2	mutation.	Heterozygous	pathogenic	mutations	are	associated	with	a	lifetime	
risk	of	50-80%	for	breast	cancer	and	30-50%	for	ovarian	cancer	(Roy	et	al.	2012).	However,	
due	 to	 an	 evolution	 in	 sequencing	 technologies,	 the	 number	 of	 individuals	 undergoing	
screening	drastically	increased	and	this	led	to	a	significant	rise	in	the	number	of	variants	of	
unknown	clinical	 significance	 (VUS).	 The	detection	of	 a	VUS	 is	 a	 challenge	 for	health	 care	
providers	as	the	impact	on	the	risk	for	breast	or	ovarian	cancer	risk	is	unclear	(Goldgar	et	al.	
2004).	For	missense	variants,	a	number	of	functional	tests	have	been	proposed	(e.g.	(Millot	
et	 al.	 2012;	 Hendriks	 et	 al.	 2014), but	 the	 implementation	 on	 a	 large	 scale	 in	 a	 clinical	
diagnostic	setting	is	not	feasible.	In	contrast,	mRNA	analyses	to	investigate	intronic	and	exonic	
variants	that	might	impair	proper	RNA	splicing,	are	more	widely	used.	The	effect	of	putative	
splice	site	variants	can	be	evaluated	in	silico	as	a	wide	variety	of	tools	have	been	developed	
(Jian	et	al.	2014b).	Indeed,	pre-mRNA	splicing	is	highly	regulated	and	variants	in	the	highly	
conserved	dinucleotides	at	the	splice	site	donor/acceptor	sites	at	the	intron	boundaries,	in	
the	 conserved	 adjacent	 sequences	 or	 variants	 in	 the	 branchpoints	 and	 exonic	 splicing	
enhancers	(ESE)	might	lead	to	aberrant	splicing	(Strachan	&	Read	2010;	Houdayer	et	al.	2012;	
Spurdle	et	al.	2008).	Several	guidelines	have	been	formulated	to	assist	the	decision-making	
process	(Caminsky	et	al.	2014;	Tang	et	al.	2016;	Houdayer	et	al.	2008).	Accurate	prediction	by	
these	 tools	 is	 dependent	 on	 the	 ability	 to	 detect	 the	wild	 type	 (WT)	 splice	 site	 or	 define	
regions	 such	 as	 the	 branchpoints	 or	 ESE.	 Furthermore,	 it	 depends	 on	 the	 degree	 of	
conservation	of	 the	region	 in	which	the	variant	 is	 situated	 (Caminsky	et	al.	2014).	 In	silico	
prediction	 tools	 such	 as	 MaxEntScan	 (MES)	 (Yeo	 &	 Burge	 2004),	 Alternative	 Splice	 Site	
Predictor	(ASSP)	(Wang	&	Marín	2006)	and	human	splicing	finder	(HSF)	(Desmet	et	al.	2009)	
have	previously	been	extensively	validated	for	the	prediction	of	aberrant	splicing	(Caminsky	
et	al.	2014;	Tang	et	al.	2016;	Houdayer	et	al.	2008).	The	major	problem	that	prohibits	the	use	
of	these	tools	in	diagnostic	labs	is	the	difficulty	in	interpreting	the	output	(Jian	et	al.	2014b).	
One	 reason	 for	 this	difficulty	 is	 that	 there	 is	no	unified	 standard	 to	measure	how	splicing	
signals	 change	when	one	 allele	 is	 substituted	by	 another	 because	most	 tools	 only	 output	
prediction	 scores	 for	 potential	 splice	 sites	 given	 an	 input	DNA	 sequence.	Due	 to	 complex	
dependencies	 existing	 among	 the	 bases	 around	 splice	 sites,	 all	 of	 the	 abovementioned	
programs	show	some	limitations	and	none	of	these	was	shown	to	perfectly	predict	the	impact	
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on	 pre-mRNA	 splicing.	 Learning	 algorithms	 such	 as	 AdaBoost	 (Pashaei	 et	 al.	 2016)	 and	
Random	Forest	(Meher	et	al.	2016)	are	now	emerging	and	need	to	be	validated	for	the	use	in	
research	and	clinical	practice.	
Furthermore,	 for	 the	evaluation	of	 the	effect	of	exonic	variants	on	splicing,	ESE-specific	 in	
silico	prediction	tools	such	as	ESEfinder	(Cartegni	et	al.	2003),	RESCUE-ESE	(Fairbrother	et	al.	
2002)	and	the	quantitative	evaluation	of	hexamers	as	exonic	splicing	elements	(Ke	et	al.	2011)	
can	be	applied.		
	
In	this	study	we	evaluated	the	concordance	between	the	“classic	prediction	tools”	and	more	
recently	 developed	 algorithms	 (AdaBoost	 and	 Random	 Forest)	 for	 21	 BRCA1/2	 variants.	
Especially	 for	 variants	 outside	 the	 canonical	 splice	 sites	 (+/-1,	 +/-2),	 currently	 frequently	
applied	prediction	tools	are	less	adequate	(Spurdle	et	al.	2008).	We	compared	the	 in	silico	
output	with	data	of	in	vitro	RNA	splicing	assays.		
	
We	 tested	 the	 effect	 of	 21	 variants	 of	 unknown	 clinical	 significance	 in	BRCA1	 (n=11)	 and	
BRCA2	 (n=10)	on	mRNA	splicing	 in	 short	 term	cultured	peripheral	blood	 lymphocytes.	We	
investigated	the	concordance	between	mRNA	analysis	outcome	and	in	silico	predictions	for	
all	variants.		
	
In	addition	we	evaluated	the	effect	at	 the	cDNA	 level	of	a	novel	 large	tandem	duplication	
spanning	exons	5	to	a	large	part	of	exon	11	in	BRCA2.	We	found	that	besides	a	skip	of	the	
exon,	two	cryptic	splice	sites	were	activated	within	exon	11.	We	confirmed	that	these	were	
also	activated	in	a	patient	with	an	interrupted	donor	site	due	to	a	G>C	substitution	at	position	
+1	of	intron	11.		
	 	
		 186	
Materials	and	Methods	
Variant	selection		
We	 selected	 21	 DNA	 alterations	 in	 BRCA1	 (n=11)	 and	 BRCA2	 (n=10)	 to	 test	 for	 aberrant	
splicing	(Table	1).	These	include	besides	intronic	variants,	also	missense	and	silent	variants	-	
both	within	and	outside	the	Cartegni	consensus	region.	In	addition,	we	investigated	the	effect	
of	a	large	duplication	in	BRCA2	at	the	cDNA	level.	Online	repositories	such	as	ClinVar	(Landrum	
et	 al.	 2015)	 LOVD	 (http://databases.lovd.nl/shared/variants/BRCA1/unique	 and	
http://databases.lovd.nl/shared/variants/BRCA2)	 and	 the	 literature	 were	 checked	 for	
available	 information	of	these	variants.	Some	variants	have	entries	 in	the	ClinVar	or	LOVD	
databases,	 but	 no	 assays	 to	 elucidate	 splicing	 effects	were	 previously	 reported	 and	 their	
pathogenicity	remained	unclear.	
	
In	silico	prediction	
Five	 prediction	 tools	 integrated	 in	 Alamut®	 Visual	 2.8.1	 (Interactive	 Biosoftware,	 France),	
were	used	to	assess	the	impact	of	the	variants	on	splice	sites	 in	silico.	These	programs	are	
also	 freely	 available	 online:	 MaxEntScan	 (MES)	
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html)		(Yeo	&	Burge	2004);	
Human	 Splicing	 Finder	 (HSF)	 (Desmet	 et	 al.	 2009)	 and	 Splice	 Site	 Finder	 (SSF)	 (Shapiro	 &	
Scnapathy	1987),	both	accessible	on	the	HSF	website	(http://www.umd.be/HSF3/);	Splice	Site	
Prediction	 by	 Neural	 Network	 (NNSplice)	 (http://www.fruitfly.org/seq_tools/splice.html)	
(Reese	 et	 al.	 1994)	 and	 GeneSplicer	 (Pertea	 et	 al.	 2001)	
(http://www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml).		
Previous	 evaluation	 of	 these	 in	 silico	 tools	 resulted	 in	 a	 cut-off	 value	 of	 5%	 for	 SSF	 and	
NNsplice	(Houdayer	et	al.	2012;	Tang	et	al.	2016).	The	cut-off	for	MES	varies	between	10%	
(Tang	et	al.	2016)	and	15%	(Houdayer	et	al.	2012;	Jian	et	al.	2014a)	depending	on	the	study.	
The	cut-off	for	HSF	was	set	at	2%	(Tang	et	al.	2016)	and	for	GeneSplicer,	no	cut-off	value	was	
reported	to	our	knowledge.		
Furthermore,	we	 consulted	 the	 dbscSNV	 v1.1	 database	 for	 Adaboost	 and	 Random	 Forest	
scores.	A	score	higher	than	0.6	is	indicative	for	aberrant	splicing	(Jian	et	al.	2014a).	
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All	 variants	 located	 in	 the	 coding	 regions,	 were	 also	 evaluated	 for	 their	 effect	 on	 exonic	
splicing	enhancers	(ESE).	Disruptions	of	these	six	bp	motifs	can	result	in	improper	splicing	and	
can	 be	 predicted	 by	 tools	 such	 as	 ESEFinder	 (Cartegni	 et	 al.	 2003)	 and	 RESCUE-ESE	
(Fairbrother	 et	 al.	 2002).	 Both	 tools	 are	 also	 integrated	 in	 Alamut®	 Visual	 2.8.1.	 The	
quantitative	evaluation	of	all	RNA	hexamers	as	potential	exonic	splicing	elements	(Ke	et	al.	
2011)	was	used	to	calculate	total	exonic	splicing	regulatory	sequence	(ESRseq)	score	change	
(∆ESRseq	scores)	for	every	exonic	variant,	as	stipulated	by	(Di	Giacomo	et	al.	2013).	The	cut-
off	was	experimentally	determined	to	be	-0.663	by	analysis	of	variants	in	exon	7	of	the	BRCA2	
gene	(Di	Giacomo	et	al.	2013).		
Finally,	for	variants	in	the	coding	regions	the	effect	of	amino	acid	substitution	itself	should	
also	 be	 taken	 into	 account.	 Therefore,	 Priors,	 an	 online	 tool	 combining	 amino	 acid	
substitution	severity	and	spliceogenecity-based	probability	for	pathogenicity	of	BRCA1	and	
BRCA2	point	mutations	was	also	consulted	(Vallée	et	al.	2016).	
	
Sample	collection,	cell	cultures,	RNA	isolation	and	cDNA	preparation	
Individuals	with	variants	of	 interest	donated	a	blood	sample	 in	EDTA	tubes	and	signed	an	
informed	 consent.	 From	 these	 blood	 samples,	 peripheral	 blood	 lymphocytes	 (PBL)	 were	
isolated	 using	 LymphoprepTM	 (STEMCELL	 Technologies,	 Canada)	 according	 to	 the	
manufacturer’s	guidelines.	These	PBL	were	cultured	in	RPMI	(completed	with	1	%L-glutamine	
and	0.5	%	penicillin/streptomycin),	 foetal	calf	serum	(10	%),	2-mercaptoethanol	(0.1	%;	all	
Gibco,	USA)	 and	 sodium	pyruvate	 (1	%,	 Life	 Technologies,	USA).	 Phytohaemagglutinin	 (10	
μl/ml,	Gibco)	was	added	 to	 stimulate	 cell	 division.	At	day	7,	puromycin	 (200μg/ml,	 Sigma	
Aldrich,	USA)	was	added	to	the	cultures	to	avoid	nonsense-mediated	decay	(NMD).	Four	to	
six	hours	later,	whole	RNA	was	extracted	using	the	QIAamp®	RNeasy	Mini	Kit	(QIAGEN,	USA)	
according	to	the	manufacturer’s	instructions.	The	total	RNA	and	purity	was	measured	using	
the	DropSense96	reader	(TRINEAN,	Belgium).	The	RNA	was	converted	to	complementary	DNA	
(cDNA)	 using	 either	 the	 iScript™	 cDNA	 Synthesis	 Kit	 (Bio-Rad	 Laboratories,	 USA)	 or	 the	
Superscript®	II	Reverse	Transcriptase	Kit	(Life	Technologies,	USA).		
	
RT-PCR	and	sequencing	
Splicing	aberrations	were	assessed	by	means	of	RT-PCR	using	either	primers	in	separate	exons	
or	primers	situated	at	the	exon	boundaries	 (supplementary	file	S1)	to	avoid	genomic	DNA	
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interference.	Fragment	sizes	were	checked	on	the	Labchip	GX	(Caliper	Life	Sciences,	USA)	or	
on	 agarose	 gel.	 Sanger	 sequencing	 was	 performed	 using	 the	 BigDye®	 Terminator	 Cycle	
Sequencing	Kit	(Life	Technologies).	Transcripts	from	carriers	were	compared	to	at	least	three	
controls	 for	RT-PCR	and	at	 least	one	control	was	 included	for	sequencing	analysis.	For	the	
analysis	 of	BRCA1	 variant	 c.4675+3A>T,	 cloning	was	 performed	using	 the	 TA	Cloning™	 kit	
(ThermoFisher	Scientific)	to	characterize	the	various	aberrant	transcripts	revealed	by	RT-PCR.		
	
Nomenclature	
Nucleotide	and	exon	numbering	for	cDNA	is	based	on	NCBI	entries	NM_007294.3	(BRCA1)	
and	NM_000059.3	 (BRCA2).	 Nucleotide	 +1	 corresponds	 to	 A	 of	 AUG	 translation	 initiation	
codon	 (according	 to	 HGVS	 guidelines).	 NM_007294.3	 omits	 the	 historical	 exon	 4	 and	
renumbers	 the	 remaining	 exon	 sequentially	 (Ensembl	 transcript:	 ENST00000357654.7).	 In	
Table	1,	the	“legacy	numbering"	is	also	provided.	
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Results	
An	overview	of	the	BRCA1	and	BRCA2	variants	evaluated	can	be	found	in	Table	1.	For	this	
study,	 we	 only	 included	 variants	 for	 which	 no	 unequivocal	 conclusions	 on	 pathogenicity	
and/or	 mRNA	 splicing	 data	 were	 available.	 If	 relevant,	 ClinVar	 IDs	 are	 provided.	 Table	 1	
summarizes	 in	 silico	 prediction	 data	 as	well	 as	 the	 results	 of	 cDNA	 analysis	 in	 short-term	
cultured	lymphocytes	in	the	presence	of	puromycin.	Out	of	21	tested	DNA	alterations,	12	DNA	
alterations	(seven	BRCA1	and	five	BRCA2	variants)	resulted	in	one	or	more	aberrant	mRNA	
transcripts.	 Furthermore,	 the	BRCA2	 duplication	 c.425+415_4780dup{ins	 GATCGCAGTGA},	
spanning	exons	5,	6,	7,	8,	9,	10	and	a	large	part	of	exon	11,	was	shown	to	result	in	a	complex	
splicing	pattern.	
	
1. cDNA	analysis	results	for	four	variants	in	canonical	splice	sites	
	
BRCA1	c.5468-1G>A,	is	located	in	the	splice	acceptor	site	of	the	last	coding	exon	23.	Loss	of	
the	WT	splice	site,	unanimously	predicted	by	all	prediction	tools	(Table	1),	results	in	an	out	of	
frame	deletion	of	the	first	11	bp	of	exon	23	as	a	cryptic	splice	site	acceptor	was	activated	11	
bp	 downstream	 of	 the	 wild	 type	 acceptor	 site.	 This	 resulted	 in	 an	 aberrant	 transcript	
(r.5468_5478del),	 leading	 to	 a	 premature	 termination	 codon	 (PTC)	 (p.(Ala1823Valfs*2))	
(Figure	1a).	We	cannot	rule	out	that	this	variant	also	leads	to	skipping	of	exon	23,	the	last	
exon	of	BRCA1,	as	we	have	no	means	to	design	primers	in	the	next	exon.	
Loss	of	the	WT	donor	splice	site	by	BRCA1	c.4986+1G>C,	results	in	the	activation	of	a	cryptic	
splice	 site	at	 c.4986+65.	This	 leads	 to	an	aberrant	 transcript	 in	which	 the	 first	65	 intronic	
nucleotides	 of	 intron	 15	 are	 retained:	 r.4986_4987ins4986+1_486+65,	 p.(1662Phefs*14)	
(Figure	1b).		
BRCA1	 c.5152+2dup	 inactivates	 the	 splice	 donor	 site	 of	 exon	 17,	 resulting	 in	 an	 aberrant	
transcript	lacking	exon	17	(r.5075_5152del;	p.(Asp1692_Trp1718delinsGly))	(Figure	1c).		
BRCA2	 c.6841+1G>C	 results	 in	 the	 abolishment	 of	 the	 WT	 splice	 donor	 site	 of	 exon	 11,	
accurately	predicted	by	all	tools.	This	leads	to	multiple	aberrant	transcripts	of	which	a	skip	of	
exon	11	 (r.1910_6841del,	 p.(Leu638_Gly2281del))	 is	 the	most	 abundant	 (Figure	2a	&	2b).	
However,	additional	isoforms	are	obvious	from	Figure	2a.	These	are	further	described	under	
point	4.	
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Figure	1.	Results	of	in	vitro	mRNA	analysis	of	six	BRCA1	variants	leading	to	aberrant	splicing	
Schematic	 representation	 of	 six	BRCA1	 variants	 leading	 to	 aberrant	 splicing	with	 the	 red	 x	
illustrating	 the	 position	 of	 the	 variant.	 RT-PCR	 results	 on	 agarose	 gel	 or	 Labchip	 GX	 and	
sequencing	results	are	shown	for	the	patient	with	the	mutation	and	a	negative	control.	From	
panel	(e)	it	is	clear	that	r.-25_-20del	represents	a	major	alternative	splicing	event,	observed	in	
both	the	patient	and	controls	(Colombo	et	al.	2014;	Menéndez	et	al.	2012).		
Nucleotide	and	exon	numbering	for	cDNA	is	based	on	NCBI	entry	NM_007294.3.		
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Figure	 2.	 Schematic	 representation	 of	 the	 results	 of	 in	 vitro	mRNA	 analysis	 for	 the	BRCA2	
variant	c.6841+1G>C.		
(a)	RT-PCR	products	of	 the	c.6841+1G>C	variant	and	controls	 in	agarose	gel;	 (b-e)	 splicing	
structural	representation	(up)	and	representative	sequences	(down)	from	one	control	(b)	and	
the	different	splicing	alternative	events.	Nucleotide	and	exon	numbering	for	cDNA	is	based	
on	NCBI	entry	NM_000059.3.	
	
2. cDNA	analysis	results	for	ten	variants	outside	the	canonical	splice	sites	but	in	the	
Cartegni	consensus	region		
The	Cartegni	consensus	region	encompasses	11	bases	of	the	5ʹ	splice	site	(from	the	three	last	
exonic	to	the	eight	first	intronic	bases)	and	14	bases	of	the	3ʹ	site	(from	the	12	last	intronic	to	
the	first	two	exonic	bases)	(Cartegni	et	al.	2002).	
	
Two	exonic	variants	in	this	region	both	result	in	aberrant	splicing.	The	substitution	c.4674A>G,	
affecting	the	second	 last	nucleotide	of	exon	14	 in	BRCA1,	 leads	 to	 the	abolishment	of	 the	
natural	splice	donor	site	as	predicted	by	all	in	silico	tools.	The	lack	of	a	natural	splice	donor	
site	resulted	in	the	activation	of	a	cryptic	splice	site	at	position	c.4664,	only	predicted	by	SSF	
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(score	=	91.56),	leading	to	a	deletion	of	the	last	11	nucleotides	of	exon	14:	r.4665_4675del;	
p.(Gln1556Glyfs*14)	(Table	1	and	Figure	1d).		
	
BRCA2	 c.517G>C,	 located	 in	 the	 first	 nucleotide	of	 exon	7	 leads	 to	 an	 aberrant	 transcript	
containing	 an	 out	 of	 frame	 skip	 of	 exon	 7	 (r.517_631del;	 p.(Gly173Serfs*19))	 due	 to	 the	
inactivation	of	the	WT	splice	donor	(Table	1	and	Figure	4a).	Only	a	small	reduction	in	scores	
was	 provided	 by	 the	 different	 programs	 (for	 MES	 this	 was	 lower	 than	 the	 15%	 cut-off	
proposed	by	(Houdayer	et	al.	2012;	Jian	et	al.	2014a))	but	higher	than	the	10%	cut-off	more	
recently	proposed	by	(Tang	et	al.	2016).	Priors	calculated	a	greater	change	of	pathogenicity	
through	splicing	defects	(probability	=	0.34)	than	as	to	be	expected	from	the	missense	variant	
itself	(probability	=	0.02).	Only	AdaBoost	en	Random	Forest	provided	high	scores	indicative	
for	aberrant	splicing.	
	
Five	 out	 of	 eight	 intronic	 variants	 in	 the	 Cartegni	 consensus	 region	 resulted	 in	 aberrant	
splicing	 and	 in	 silico	 predictions	 for	 these	 variants	 were	 accurate:	 BRCA1	 c.80+5G>A,	
c.134+5G>T	&	c.4675+3A>T	and	BRCA2	c.8488-9T>G	&	c.8954-5A>G.	
RT-PCR	with	primers	located	in	exons	11-16	resulted	in	a	smear	of	PCR	products	on	agarose	
gel	for	patient	with	the	BRCA1	variant	c.4675+3A>T,	where	in	the	two	tested	controls	only	a	
single	 band	 of	 the	 expected	 length	 was	 observed	 (Figure	 3).	 To	 analyze	 the	 products	 of	
different	 lengths,	 cloning	 followed	 by	 sequencing	 was	 performed	 for	 57	 clones.	 Two	
heterozygous	 SNPs	 (c.4308T/C	 and	 c.4837A/G)	 allowed	 to	 determine	 if	 the	 transcript	
originated	from	the	WT	or	the	mutant	allele.	An	overview	of	the	aberrant	mRNA	transcripts	
is	shown	in	Figure	3	and	Table	2.	The	major	effect	of	this	mutation	is	the	activation	of	a	cryptic	
donor	site,	11	nucleotides	upstream	of	the	wild	type	donor	site	of	exon	14,	similar	as	for	the	
patient	with	c.4674A>G.	In	addition,	increased	expression	of	the	naturally	occurring	isoform	
lacking	exon	14	 (out	of	 frame)	was	observed.	 Interestingly,	we	have	no	evidence	that	 this	
represents	a	major	splice	event	in	the	patient	with	c.4674A>G.	However,	for	analysis	of	this	
patient	a	different	primer	set	to	generate	a	shorter	fragment	was	used	(cfr.	Supplementary	
Table)	and	cloning	was	not	performed	in	that	case.	
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Figure	 3.	 Schematic	 representation	 of	 RT-PCR	 and	 sequencing	 results	 obtained	 by	 primers	
located	in	exons	11	and	16	for	BRCA1	c.4675+3A>T	
(a)	RT-PCR	results	on	agarose	gel	revealed	a	smear	of	bands,	(b-g)	cloning	of	the	cDNA	fragment	
revealed	several	different	isoforms	transcribed	both	from	the	mutant	as	well	as	from	the	wild	
type	allele.		
	
Table	2.	Overview	of	aberrant	transcripts	detected	for	BRCA1	c.4675+3A>T	
transcript	 RNA	 Protein	 %	 (number	 of	
clones/total	
sequenced))	
%	 from	 the	
WT	allele	
Fig	
2	
full	length	 /	 /	 43,90%	
(25/57)	
96%	(24/25)	 /	
out	of	frame	skip	of	exon	14			 r.4485_4675del	 p.Ser1496Glyfs*14	 24,60%	
(14/57)	
7%	(1/14)	 b	
out	of	frame	deletion	of	last	
11	nucleotides	of	exon	14	
r.4665_4675del	 p.Gln1556Glyfs*14	 17,50%	
(10/57)	
0%	(0/10)	 c	
in	frame	skip	of	exon	13	and	
14	
r.4358_4675del	 p.Ala1453_Leu1558
del	
3,50%	(2/57)	 0%	(0/2)	 d	
out	of	frame	skip	of	exon	13	
and	the	last	11	nucleotides	of	
exon	14	
c.4385_4484del	 p.Ala1453Gyfs*10	 3,50%	(2/57)	 0%	(0/2)	 e	
full	length	and	insertion	of	66	
nucleotides	from	intron	12	
r.4357_4358ins(6
6)	
p.Lys1452_Ala1453i
ns(22)	
3,50%	(2/57)	 100%	(2/2)	 f	
full	length	and	insertion	of	63	
nucleotides	from	intron	12	
r.4357_4358ins(6
3)	
p.Lys1452_Ala1453i
ns(21)	
1,70%	(1/57)	 100%	(1/1)	 f	
insertion	 of	 66	 nucleotides	
from	 intron	 12	 and	 skip	 of	
exon	14	
r.4357_4358ins(6
6)	 +	
r.4485_4675del	
p.Lys1452_Ala1453i
ns(22)	 +	
p.Ser1496Glyfs*14	
1,70%	(1/57)	 100%	(1/1)	 g	
	
	
		 196	
BRCA1	c.80+5G>A	abolishes	the	WT	donor	site	of	exon	2.	With	primers	located	in	the	non-
coding	exon	1	and	exon	7,	we	found	that	this	variant	leads	to	out	of	frame	skipping	of	exon	2	
(r.-19_80del;	p.?)	leading	to	loss	of	the	translation	initiation	codon	(Table	1	and	Figure	1).	In	
addition,	we	found	both	in	the	controls	and	the	patient	carrying	the	mutation	an	abundant	
alternative	 transcript	 (r.-25_-20del:	 skip	 of	 the	 last	 six	 nucleotides	 of	 exon	 1),	 which	 has	
previously	been	described	as	naturally	occurring	isoform.	
	
BRCA1	c.134+5G>T	inactivates	the	donor	of	exon	3	leading	to	an	out	of	frame	skip	of	exon	3,	
resulting	a	PTC:	r.81_134del;	p.(Cys27*)	(Figure	1f).	Skipping	of	exon	3	has	previously	been	
described	 as	 a	 naturally	 occurring	 isoform	 (Colombo	 et	 al.	 2014)	 ,	 but	 from	 Figure	 1f	 it	
becomes	clear	that	this	isoform	is	hardly	detectable	in	controls	compared	to	the	patient	with	
the	c.134+5G>T	substitution.	
	
BRCA2	c.8954-5A>G	(Figure	4b)	was	found	to	generate	a	cryptic	splice	site,	resulting	in	an	out	
of	 frame	 insertion	 of	 four	 nucleotides	 from	 intron	 22	 (r.8953_8954ins8954-4_8954-1;	
p.(Val2985Aspfs*34)).	As	this	is	an	out	of	frame	transcript,	inducing	a	premature	stop	codon,	
it	is	expected	to	be	prone	to	NMD.		
	
The	outcome	of	two	variants	 in	the	Cartegni	site	of	BRCA2	 intron	19	was	different.	BRCA2	
c.8488-9T>G	creates	a	cryptic	acceptor	site,	leading	to	an	aberrant	transcript	with	an	out	of	
frame	 insertion	 of	 the	 last	 eight	 nucleotides	 of	 intron	 19	 (r.8487_8488ins8488-8_8488-1;	
p.(Trp2830Tyrfs*36))	(Table	1	and	Figure	4c).	In	contrast,	BRCA2	c.8488-12A>G	was	not	found	
to	induce	aberrant	splicing.	This	was	accurately	predicted	by	all	in	silico	prediction	tools	(Table	
1).	
	
Also	three	other	intronic	variants	in	the	Cartegni	consensus	region	(BRCA1	c.4186-10G>A	and	
BRCA2	c.7618-6G>T;	c.8488-12A>G)	did	not	result	 in	aberrant	splicing.	 	 	Based	on	the	MES	
predictions,	aberrant	splicing	for	BRCA1	c.4186-10G>A	(-17.7%)	and	BRCA2	c.8488-12A>G	(-
13.7%)	could	be	expected	based	on	the	cut-off	of	-10%		proposed	by	(Tang	et	al.	2016).	Even	
with	the	more	severe	-15%	cut-off	proposed	by	(Houdayer	et	al.	2012)	aberrant	splicing	was	
expected	for	BRCA1	c.4186-10G>A.		
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For	BRCA2	c.7618-6G>T	the	classic	splice	prediction	tools	showed	increased	scores	for	the	
acceptor	site,	compatible	with	normal	splicing.		
	
	
Figure	4.	Results	of	in	vitro	mRNA	analysis	of	four	BRCA2	variants	
Schematic	representation	of	four	BRCA2	variants	 leading	to	aberrant	splicing	with	the	red	x	
illustrating	 the	 position	 of	 the	 variant.	 RT-PCR	 results	 on	 agarose	 gel	 or	 Labchip	 GX	 and	
sequencing	 results	 are	 shown.	Nucleotide	and	exon	numbering	 for	 cDNA	 is	based	on	NCBI	
entry	NM_000059.3.	
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3. cDNA	analysis	results	for	seven	variants	outside	the	Cartegni	consensus	region	
We	 evaluated	 the	 effect	 at	 the	mRNA	 level	 of	 two	 intronic	 variants	 outside	 the	 Cartegni	
consensus	 region:	 BRCA1	 c.5278-22C>G	 and	 BRCA2	 c.8488-14A>G.	 BRCA2	 c.8488-14A>G	
leads	to	aberrant	splicing.	This	results	from	the	creation	of	a	cryptic	spice	site,	predicted	by	
all	tools	consulted,	and	a	reduction	in	strength	of	the	WT	splice	site,	only	predicted	by	MES.	
The	aberrant	transcript	contains	an	out	of	frame	insertion	of	the	last	13	nucleotides	of	intron	
19:	r.8432_8433ins8433-13_8433-1;	p.(Trp2830Hisfs*19)	(Table	1,	Figure	4d).		
BRCA1	c.5278-22C>G	did	not	result	in	aberrant	splicing,	which	was	correctly	predicted	by	all	
consulted	in	silico	prediction	tools	(Table	1).	
	
None	of	the	five	tested	exonic	variants	outside	the	Cartegni	consensus	region	[two	in	BRCA1:	
c.1878A>G	 (p.=)	 &	 c.4115G>A;	 p.(Cys1372Tyr)	 and	 three	 in	 BRCA2:	 c.3326C>T;	
p.(Ala1109Val),	 c.4899C>G;	 p.(Ile1633Met)	 &	 c.6313A>G;	 p.(Ile2105Val)]	 affected	 mRNA	
splicing.	However,	the	prediction	tool	Priors,	classified	three	variants	[BRCA1	c.1878A>G	(p.=)	
&	c.4115G>A;	p.(Cys1372Tyr);	BRCA2	c.3326C>T;	p.(Ala1109Val)]	as	“moderate	probability	of	
pathogenicity	from	the	creation	of	a	de	novo	splice	donor”	(score	0.3,	see	Table	1).	∆ESRseq	
scoring	 predicted	 a	 splicing	 effect	 for	 BRCA2	 c.3326C>T	 and	 BRCA1	 c.4115G>A	 (∆ESRseq	
scores	below	-0.663,	see	table	1).	ESEfinder	and	RESCUE-ESE	predicted	both	disruption	and/or	
creation	of	a	new	ESE	for	every	variant	except	for	BRCA2	c.4899C>G	(Table	1).	Furthermore,	
BRCA1	 c.4115G>A	 was	 predicted	 to	 activate	 of	 a	 cryptic	 donor	 site	 at	 position	 c.4112.	
However,	this	cryptic	donor	site	was	not	strong	enough	to	compete	with	the	WT	splice	site	
(Table	1).	None	of	the	variants	were	predicted	to	have	an	effect	due	to	an	altered	protein	
structure	(Prior	missense	score	0.02	in	Table	1).	
	
4.	 Identification	of	multiple	cryptic	donor	sites	within	the	large	exon	11	of	BRCA2	 in	
case	of	interruption	of	the	wild	type	exon	11	donor	site	
cDNA	 analysis	 in	 lymphocytes	 of	 a	 patient	 heterozygous	 for	 the	 BRCA2	 variant	 c.426-
415_4780dup{ins	GATCGCAGTGA}	 (Figure	5a)	 revealed	a	 complex	 splicing	pattern.	RT-PCR	
combining	a	forward	primer	in	exon	11	and	a	reverse	primer	in	exon	10,	did	not	result	in	a	
PCR	product	in	controls	but	resulted	in	two	fragments	(Fig	5c	and	5d)	in	the	patient	with	the	
duplication.	A	similar	approach	with	a	forward	primer	in	exon	10	and	a	reverse	primer	in	exon	
7	resulted	in	the	identification	of	an	additional	two	PCR	products	(Fig	5e	and	5f).	We	conclude	
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from	 these	 results	 that	 this	 duplication	 leads	 to	 a	mix	 of	 different	 transcripts.	 The	major	
effects	are	the	 inclusion	of	a	cryptic	exon	in	 intron	4	(r.425+415	to	c.426-209),	skipping	of	
exon	11	and	aberrant	transcripts	due	to		the	activation	of	two	cryptic	donor	sites	within	exon	
11:	c.2398	and	c.3550.	All	combinations	observed	are	out	of	frame.	
	
We	evaluated	if	the	cryptic	donor	sites	at	c.2398	and	c.3550	were	also	activated	in	a	patient	
with	the	BRCA2	c.6841+1G>C	mutation.	Besides	skipping	of	exon	11,	several	other	aberrant	
transcripts	were	observed.	Also	in	this	patient,	the	cryptic	splice	donor	sites	at	c.2398	and	
c.3550	are	activated,	resulting	in	the	skip	of	respectively	4443	and	3291	nucleotides	of	the	3’	
part	 of	 exon	 11:	 r.2399_6841del;	 p.(Asn801_Gly2281del)	 (Figure	 2c)	 and	 r.3551_6841del;	
p.(Thr1185_Gly2281del)	(Figure	2d)	respectively.	The	activation	of	c.2398	leads	to	a	band	of	
1038	bp,	visible	on	the	gel	(Figure	2a),	which	was	confirmed	by	means	of	direct	sequencing.	
No	 band	 in	 concordance	 with	 activation	 of	 c.3550	 was	 observed	 in	 the	 initial	 RT-PCR.	
However,	by	means	of	allele	specific	primers	(supplementary	file	S1),	we	could	confirm	the	
activation	of	this	particular	cryptic	splice	site.		
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Figure	5.	Results	of	RT-PCR	with	a	forward	primer	located	in	exon	10	or	11	and	a	reverse	in	
exon	10	for	the	patient	heterozygous	for	BRCA2	c.426-415_4780dup{ins	GATCGCAGTGA}	
Schematic	representation	of	the	complex	tandem	duplication,	(b)	Result	of	aberrant	transcript	
specific	PCR	analyzed	by	Labchip	GX),	(c-f)	Schematic	representation	of	the	different	aberrant	
transcripts:	
(c) The	 largest	 PCR	 product	 contained	 all	 nucleotides	 from	 the	 start	 of	 the	 primer	 till	
c.4780	 (the	 presumed	 breakpoint	 in	 exon	 11),	 an	 insertion	 of	 11	 nucleotides	
(GATCGCAGTGA),	followed	by	293	nucleotides	from	intron	4	(from	c.425+415	to	c.426-
209)	and	continued	by	all	nucleotides	from	exon	5	to	position	c.4780	in	exon	11		
(d) A	smaller	 fragment	was	produced	by	 the	activation	of	 a	 cryptic	 splice	 site	donor	at	
nucleotide	 position	 c.3550.	 This	 fragment	 does	 not	 contain	 nucleotides	 c.3551	 to	
c.4780,	 the	 11	 bp	 sequence	 GATCGCAGTGA	 nor	 the	 293	 nucleotides	 between	
c.425+415	to	c.426-209	from	intron	4		
(e) a	 smaller	 fragment	was	 observed	 by	 the	 activation	 of	 a	 cryptic	 splice	 site	 donor	 at	
nucleotide	position	c.2398,	followed	by	the	skip	of	the	insertion	of	11	nucleotides	and	
the	293	nucleotides	of	intron	4		
(f) The	shortest	aberrant	fragment	was	the	result	of	a	complete	skip	of	exon	11,	and	the	
skip	of	the	insertion	of	11	nucleotides	and	intron	4		
	
All	aberrant	transcripts	are	out	of	frame,	ultimately	leading	to	a	PTC:	(1)	p.(Met1594Argfs*4),	
(2)	p.(Gly1184°Ile3418delins*9),	(3)	p.(Gly800Valfs*10)	and	(4)	p.(Gly637Valfs*10).		
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Discussion	
We	evaluated	the	effect	at	the	cDNA	level	of	21	variants	of	unknown	clinical	significance	in	
BRCA1	(n=11)	and	BRCA2	(n=10)	and	demonstrated	aberrant	splicing	for	12	variants	(BRCA1	
(n=7)	and	BRCA2	(n=5)).	In	addition,	we	evaluated	the	effect	of	a	large	tandem	duplication	in	
BRCA2,	with	breakpoints	in	intron	4	and	exon	11.	By	incorporating	controls	in	our	assays	and	
consulting	 literature,	 we	 verified	 if	 the	 detected	 transcripts	 represent	 naturally	 occurring	
alternative	transcripts.	None	of	the	detected	aberrant	BRCA2	 transcripts	were	reported	as	
naturally	occurring	alternative	transcripts	(Fackenthal	et	al.	2016).	However,	we	observed	a	
skip	of	exon	11	 in	controls,	 though	be	 it	at	very	 low	 level	 (Figure	2).	Some	of	 the	variants	
studied	 in	 BRCA1,	 lead	 to	 a	 strong	 upregulation	 of	 low	 abundant	 naturally	 occurring	
transcripts	 in	 our	 patients	with	 specific	 variants	 compared	 to	 controls:	 skip	 of	 exon	 2	 (r.-
19_80),	exon	3	(r.81_134del),	exon	13	and	14	(r.	4358_4675del),	exon	14	(r.4485_4675del)	
and	exon	17	(r.5075_5152del).		
In	 addition	 we	 observed	 an	 alternative	 transcript	 containing	 an	 in	 frame	 insertion	 of	 66	
nucleotides	from	intron	13:	r.4357_4358ins(66),	which	has	previously	been	reported	by	our	
group	in	both	a	control	and	a	patient	heterozygous	for	the	BRCA1	variant	4304G>A	(p.=)	(Claes	
et	al.	2003).	The	prevalence	of	the	aberrant	transcript	was	not	quantified	then,	but	we	now	
demonstrate	that	the	transcript	is	present	at	very	low	frequency	(estimated	to	be	<3.5%	of	
the	full	length,	Table	2	&	Figure	2e)	and	may	therefore	have	been	missed	by	(Colombo	et	al.	
2014).		
	
mRNA	splicing	assays	yield	insights	in	the	exact	aberrant	transcript,	which	may	in	turn	shed	
light	on	the	clinical	importance	of	the	variant.	The	majority	of	the	tested	splicing	variants	lead	
to	a	frameshift	and	the	creation	of	a	PTC	and	are	therefore	expected	to	be	degraded	by	NMD	
(Perrin-vidoz	et	al.	2002;	Baert	et	al.	2016;	Ware	et	al.	2006).	Aberrant	BRCA1	transcripts	can	
escape	NMD	when	the	PTC	is	located	near	the	C-terminus	or	near	the	translation	initiation	
codon	(Perrin-vidoz	et	al.	2002).	Based	on	this	rule,	two	of	our	BRCA1	splice	site	variants	are	
predicted	 to	 escape	 NMD.	 BRCA1	 c.134+5G>T,	 is	 situated	 near	 the	 translation	 initiation	
codon,	but	as	translation	would	result	in	only	a	small	protein	(p.(Cys27*)),	we	do	not	expect	
any	functionality	from	this	aberrant	protein	and	classify	this	variant	as	probably	pathogenic.	
The	 second	 splicing	 variant	 which	may	 evade	 NMD	 is	BRCA1	 c.5468-1G>A,	 leading	 to	 an	
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aberrant	transcript	with	a	stop	codon	at	amino	acid	position	p.1825,	situated	in	the	last	exon.	
Unfortunately,	no	data	from	cultured	lymphocytes	without	puromycin	are	available	to	check	
the	expression	of	the	aberrant	transcript	in	the	absence	of	NMD	inhibition.	If	this	transcript	
indeed	avoids	NMD,	we	 still	 assume	a	pathogenic	 effect	 for	 this	 variant	 as	 two	nonsense	
mutations	 resulting	 in	 a	 stop	 codon	 downstream	 of	 amino	 acid	 1825	 (c.5503C>T;	
p.(Arg1835*)	and	c.5559C>A;	p.(Tyr1853*))	are	also	considered	as	pathogenic	mutations	(see	
ClinVar	database	entries	55601	and	55629)	and	evasion	of	NMD	was	demonstrated	for	both	
variants	(Perrin-vidoz	et	al.	2002).		
We	can	expect	a	pathogenic	effect	 for	BRCA1	 c.80+5G>A	as	 the	AUG	translation	 initiation	
codon	is	lost	due	to	the	skip	of	exon	2.	Interruption	of	the	translation	initiation	codon	due	to	
a	 point	mutation	 has	 previously	 been	 classified	 as	 deleterious	 (ClinVar	 ID:	 54432,	 54745,	
54746,	55072	and	267523).		
	
BRCA1	 c.5152+2dup,	 leads	 to	 an	 in	 frame	 skip	 of	 exon	 17	 (r.5075_5152del;	
p.(Arg1692_Trp1717delinsGly)).	 Several	 naturally	 occurring	 transcripts	 lack	 exon	 17	 as	
reported	 by	 (Colombo	 et	 al.	 2014),	 besides	 transcripts	 lacking	 exclusively	 exon	 17,	 also	
transcripts	 lacking	 exons	 13-17	 and	 14-18.	We	 performed	 RT-PCR	with	 a	 forward	 primer	
located	in	exon	15	and	a	reverse	in	exon	21	and	demonstrated	the	skip	of	exon	17	was	only	
present	 in	 the	patient	heterozygous	 for	 c.5152+2dup	 (see	 figure	1b).	 It	 is	expected	 that	a	
transcript	lacking	an	in	frame	exon	will	avoid	NMD.	However,	skipping	this	exon	leads	to	the	
disruption	of	a	large	part	of	the	first	BRCT	domain.	The	BRCT	region	consists	of	two	highly	
conserved	repeats	(1671	–	1745	and	1779	–	1863)	and	is	required	for	several	functions	of	the	
BRCA1	protein,	including	recruitment	to	the	DNA	damage	site,	DNA	end	resection	and	G2/M	
checkpoint	activation,	trough	binding	with	numerous	interaction	partners	(Roy	et	al.	2012).	
Analysis	 of	 several	 missense	 variants	 in	 these	 BRCT	 repeats	 showed	 an	 impaired	 folding	
(Lovelock	et	al.	2006;	Lovelock	et	al.	2007;	Glover	2006).	We	stipulate	that	loss	of	36	amino	
acids	from	the	110	amino	acids	of	the	first	BRCT	repeat	induced	by	BRCA1	c.5152+2dup,	may	
be	detrimental	for	accurate	folding	of	these	motifs.	Similarly,	the	BRCA1	variant	c.5468-1G>A;	
p.(Ala1823Valfs*2)	results	in	loss	of	the	last	30	amino	acids	of	the	second	BRCT	repeat	and	is	
therefore	expected	 to	 cause	 improper	 folding	of	 this	motif.	 Binding	of	 several	 interaction	
partners	might	thus	be	impaired	by	these	two	variants,	leading	to	a	deleterious	effect	of	these	
variants.	 However,	 to	 gain	 more	 insight	 in	 the	 functional	 effect	 western	 blotting	 and	
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functional	assays	may	be	performed	to	further	elucidate	the	effect	of	these	splicing	mutations	
on	the	expression	and	various	functions	of	BRCA1.	
All	 aberrant	 transcripts	 induced	 by	 BRCA2	 c.6841+1G>C	 are	 in	 frame	
(p.(Thr1185_Gly2281del),	p.(Asn801_Gly2281del)	and	p.(Leu638_Gly2281del)).	However,	the	
size	 of	 the	 deletions	 and	 the	 location	 in	 the	 BRC	 repeat	 region,	 necessary	 for	 binding	 of	
RAD51,	an	effector	of	homologous	recombination,	suggest	a	pathogenic	effect.		
	
mRNA	analysis	of	 three	variants	 situated	 in	 intron	19	of	BRCA2	 revealed	different	effects.	
Variants	 c.8488-9T>G	 and	 c.8488-14A>G	 resulted	 in	 aberrant	 splicing,	 whereas	 a	 variant	
situated	in	between	those	two	(c.8488-12A>G)	did	not	impair	proper	mRNA	slicing,	which	was	
adequately	predicted	by	the	prediction	tools	consulted.	Both	c.8488-9T>G	and	c.8488-14A>G	
create	a	novel	acceptor	site	while	the	natural	splice	acceptor	site	 is	relatively	weak,	and	a	
naturally	 occurring	 skip	 of	 exon	 20	 has	 been	 demonstrated	 (Fackenthal	 et	 al.	 2016).	 The	
variant	c.8488-12A>G	for	which	no	aberrant	splicing	was	demonstrated,	does	not	result	in	a	
de	novo	“AG”	splice	acceptor	site.	To	our	knowledge,	only	variants	 in	 the	canonical	 splice	
acceptor	 site	 of	 exon	 20	 of	BRCA2	 (c.8488-1/2)	 have	 previously	 been	 reported	 and	were	
shown	to	result	in	exon	skipping	(ClinVar	and	LOVD)(Fackenthal	et	al.	2016).	We	assume	that	
the	aberrant	transcripts	induced	by	c.8488-9T>G	and	c.8488-14A>G	will	be	degraded	by	NMD	
as	NMD	was	demonstrated	for	all	tested	PTC-introducing	mutations	in	BRCA2,	even	when	the	
stop	codon	is	situated	towards	the	C-terminal	end	(Ware	et	al.	2006).	Therefore,	we	consider	
both	variants	as	likely	deleterious.	
	
Out	 of	 the	 seven	 tested	 exonic	 variants	 studied,	 only	 two	 (BRCA1	 c.4674A>G	 &	 BRCA2	
c.517G>C)	resulted	in	aberrant	splicing.		
BRCA1	 c.4674A>G,	 located	 in	 the	 second	 last	 nucleotide	 of	 exon	 14,	 resulted	 in	 aberrant	
splicing	 due	 to	 an	 abolished	WT	 splice	 donor	 site	 (Table	 1).	 mRNA	 analysis	 revealed	 the	
activation	of	a	cryptic	donor	site	upstream	at	position	c.4664,	only	predicted	by	SSF,	while	
other	possible	cryptic	splice	sites	in	the	area	predicted	by	HSF	were	not	activated.	This	results	
in	an	out	of	frame	skip:	r.4665_4675del;	p.(Gln1556Glyfs*14)	and	the	formation	of	a	PTC.	We	
therefore	classify	this	variant	as	likely	pathogenic.	As	the	splicing	defect	is	due	to	loss	of	the	
natural	 splice	 site,	 we	 were	 not	 surprised	 that	 ∆ESRseq	 scoring	 and	 RESCUE-ESE	
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demonstrated	no	effect	of	the	variant	on	ESE,	while	ESEfinder	predicted	the	creation	of	a	new	
ESE.	
BRCA2	c.517G>C	is	located	in	the	first	nucleotide	of	exon	7	and	induces	aberrant	splicing	due	
to	 loss	of	 the	natural	 splice	 site.	However,	 splice	 site	prediction	 tools	demonstrate	only	a	
marginal	decrease	in	3’	splice	site	strength	(see	Table	1).	The	skip	of	exon	7	(r.517_631del;	
p.(Gly173Serfs*19))	 is	 likely	 to	 undergo	 degradation	 of	 the	 transcript	 by	 NMD.	 ∆ESRseq	
scoring	and	ESEfinder	demonstrated	no	effect	of	the	variant	on	ESE	as	could	be	expected,	
while	RESCUE-ESE	predicted	multiple	effects	on	ESE.	A	variant	at	the	same	position	(c.517G>T)	
was	 previously	 tested	using	 both	minigene	 and	RNA	 splicing	 analysis	 and	 also	 resulted	 in	
skipping	of	exon	7	(Gaildrat	et	al.	2012).	 Interestingly,	a	higher	than	expected	presence	of	
splicing	 mutations	 affecting	 potential	 regulatory	 elements	 leading	 to	 an	 exon	 skip	 are	
detected	in	exon	7	of	BRCA2	(Di	Giacomo	et	al.	2013).	Analysis	of	the	influence	of	ESE	in	this	
exon	 by	means	 of	 an	 ESE	 dependent	 splicing	minigene	 assay	 (pcDNA-Dup	minigene)	 has	
demonstrated	that	a	relatively	large	region	of	this	exon	is	characterized	by	the	presence	of	
ESE’s.	The	combination	with	a	relatively	weak	natural	splice	sites	explains	the	high	number	of	
splicing	variants	in	this	exon	(Di	Giacomo	et	al.	2013).		
	
In	 contrast	 to	 the	 large	 number	 of	 substitutions	 leading	 to	 aberrant	 splicing,	 both	 in	 the	
coding	sequence	and	the	surrounding	intronic	sequence	of	exon	7	of	BRCA2,	no	such	variants	
have	 been	 reported	 in	 the	 large	 exon	 11	 of	 BRCA2	 (Fackenthal	 et	 al.	 2016),	 despite	 the	
presence	of	a	large	number	of	predicted	cryptic	acceptor	and	donor	sites	in	this	exon.	None	
of	the	three	variants	in	exon	11	of	BRCA2	 included	in	this	study	showed	improper	splicing.	
∆ESRseq	scoring	was	shown	to	assist	the	evaluation	of	regulatory	elements	in	selected	exons.	
The	experimentally	determined	cut-off	of	-0,6331	for	variants	in	BRCA2	exon	7	(Di	Giacomo	
et	al.	2013),	did	not	result	in	a	good	correlation	between	∆ESRseq	score	and	mRNA	splicing	in	
other	exons.	For	instance,	the	∆ESRseq	score	of	respectively	-2.9402	and	-1.3814	for	BRCA2	
c.3326C>T	and	BRCA1	 c.4115G>A	would	 imply	an	effect	on	exonic	 splice	 regulation	which	
could	 not	 be	 demonstrated	 by	 mRNA	 analysis.	 Therefore,	 the	 cut-off,	 experimentally	
determined	for	variants	in	BRCA2	exon	7,	containing	a	large	number	of	ESE’s	in	combination	
with	weak	splice	donor	and	acceptor	sites,	may	not	be	applicable	for	variants	in	other	exons.	
Furthermore,	neither	the	results	of	ESEfinder	nor	the	results	of	RESCUE-ESE	were	concordant	
with	the	mRNA	results	for	exonic	variants	included	in	this	study.	This	illustrates	the	limited	
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predictive	value	of	these	tools,	although	some	may	be	useful	for	the	evaluation	of	variants	in	
exons	enriched	for	exonic	splicing	regulators	(ESR)	like	described	in	BRCA2	exon	7,	MLH1	exon	
10,	BRCA1	exon	6,	CFTR	exon	12	and	NF1	exon	37	(Soukarieh	et	al.	2016).	
	
To	date,	no	known	DNA	variations	inducing	aberrant	splicing	of	BRCA2	exon	11	have	been	
reported.	Here,	we	detected	the	activation	of	 two	cryptic	splice	donor	sites	at	c.2398	and	
c.3550	in	the	absence	of	the	WT	splice	site	by	evaluating	the	impact	on	pre-mRNA	splicing	of	
a	 large	 tandem	 duplication	 with	 a	 breakpoint	 2061	 bp	 upstream	 of	 the	 WT	 donor	 site.	
Activation	 of	 both	 cryptic	 splice	 donor	 sites	was	 confirmed	 in	 a	 patient	with	 substitution	
abolishing		the	WT	splice	donor	site	of	exon	11	(c.6841+1G>C).	Scanning	of	exon	11	with	in	
silico	 prediction	 tools	 available	 through	 Alamut	 2.8.1	 revealed	 several	 alternative	 cryptic	
splice	 site	 donors,	 but	 none	 of	 them	 were	 activated	 in	 the	 patient	 with	 the	 variant	
c.6841+1G>C.	The	specific	activation	of	the	cryptic	splice	donor	sites	at	positions	c.2398	and	
c.3550	might	be	due	to	ESE	motifs.	We	can	expect	these	ESE	motifs	to	lie	in	the	close	vicinity	
to	the	activated	splice	sites	(Ke	et	al.	2011;	Caceres	et	al.	2013).	The	 influence	of	possible	
ESE’s	on	the	cryptic	splice	site	c.3550	and	c.2398	should	be	further	experimentally	validated	
(Raponi	et	al.	2014;	Di	Giacomo	et	al.	2013).	In	Alamut	no	ESE	motifs	are	predicted.	Knowledge	
on	 potentially	 activated	 splice	 sites	 in	 case	 of	 inactivation	 of	 the	 wild	 type	 site,	 may	 be	
important	 to	design	adequate	BRCA2	 ASOs	 (antisense	oligonucleotides),	which	have	been	
proposed	as	a	promising	avenue	to	prevent	resistance	to	PARP	inhibitor	therapy	in	several	
tumor	 types	 (Rytelewski	 et	 al.	 2016)	 or	 as	 potential	 therapeutic	 anti-cancer	 agent	 in	
combination	with	cisplatin	(Rytelewski	et	al.	2014).	
	
Another	aim	of	this	study	was	to	test	the	performance	of	in	silico	prediction	tools.	Our	findings	
confirm	 that	 splice	 site	 prediction	 tools	 accurately	 predicted	 the	 effect	 of	 variants	 in	 the	
canonical	splice	sites.	Unfortunately,	accuracy	of	the	splice	site	prediction	tools	decreases	for	
variants	 outside	 these	 sites.	 We	 demonstrated	 that	 Adaboost	 and	 Random	 Forest	
outperformed	 the	classically	used	 tools	 for	variants	outside	 the	canonical	 splice	 sites.	The	
data	from	these	programs	are	extracted	from	dbscSNV	(Liu	et	al.	2016)	which	currently	only	
include	data	on	potential	human	SNVs	within	the	splicing	consensus		regions	−3	to	+8	at	the	
5’	splice	site	and	−12	to	+2	at	the	3’	splice	site.	For	all	variants	studied	and	located	in	these	
regions	the	predictions	were	accurate.	However,	these	programs	provide	only	1	score.	If	this	
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score	is	higher	than	0.6,	aberrant	splicing	is	expected	but	they	do	not	provide	an	indication	
on	the	potential	activation/creation	of	cryptic	splice	sites;		effects	need	to	be	studied	by	cDNA	
analysis.		The	5	prediction	tools	consulted	via	Alamut	(SSF,	MES,	NNsplice,	gene	splicer	and	
HSF),	resulted	in	the	misclassification	of	one	or	two	variants	(BRCA2	c.7618-6G>T	&	c.8488-
12A>G)	in	the	same	cohort,	dependent	on	the	applied	cut-off	for	MES.		
For	 intronic	 variants	outside	 the	Cartegni	 consensus	 region,	 the	 classic	 in	 silico	 prediction	
tools	were	helpful	to	determine	for	which	variants	cDNA	analysis	would	be	useful.	Our	results	
are	in	agreement	with	Théry	et	al.	and	Vreeswijk	et	al.	suggesting	that	cDNA	analysis	is	not	
required	for	intronic	variants	if	no	effect	on	splicing	is	predicted	by	multiple	in	silico	prediction	
tools	(Vreeswijk	et	al.	2009;	Théry	et	al.	2011).		
	
Priors,	a	 recently	published	prediction	 tool,	assesses	whether	pathogenicity	of	a	missense	
variant	is	more	likely	to	originate	from	the	amino	acid	substitution	or	a	splicing	defect	(Vallée	
et	 al.	 2016).	Of	 all	 exonic	 variants	 included	 in	 this	 study	Priors	 gave	 the	highest	 score	 for	
impaired	splicing	(0.34)	for	BRCA1	c.4674A>G	&	BRCA2	c.517G>C	and	we	showed	that	both	
variants	lead	to	aberrant	splicing.	However,	this	score	is	only	marginally	higher	compared	to	
those	 for	other	variants	 [BRCA1	 c.1878A>G	 (p.=)	&	c.4115G>A;	p.(Cys1372Tyr)	and	BRCA2	
c.3326C>T;	 p.(Ala1109Val)]	 not	 leading	 to	 aberrant	 splicing	 (Priors	 score	 of	 0.3).	 The	
marginally	higher	score	for	BRCA2	c.517G>C	is	supported	by	the	relatively	weak	splice	site	
score	reduction	for	the	natural	splice	site	predicted	by	all	tools	for	this	particular	variant	and	
could	be	expected	as	Priors	integrates	MES	scoring.	This	might	also	explain	the	relatively	low	
value	for	BRCA1	c.4674A>G	as	MES	scoring	was	not	as	distinct	compared	to	the	other	tools	
for	this	variant.	We	only	included	two	variants	affecting	splicing;	a	validation	study	testing	a	
large	number	of	exonic	variants	for	aberrant	splicing	would	allow	to	gain	more	insight	in	a	
possible	threshold	above	which	a	strong	correlation	between	in	silico	prediction	and	aberrant	
mRNA	splicing	exists.	
	
To	 conclude,	 we	 confirmed	 aberrant	 splicing	 for	 12	 out	 of	 21	 tested	 DNA	 alterations	
suggesting	that	these	variants	may	be	associated	with	a	pathogenic	effect.	Further	evidence	
may	come	from	multifactorial	likelihood	analysis.	We	demonstrated	that	in	silico	prediction	
tools	may	assist	in	the	evaluation	of	putative	splice	site	mutations.	But	the	specificity	of	 in	
silico	predictions	for	variants	outside	the	canonical	splice	sites	is	lower.	Of	all	consulted	tools,	
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Adaboost	 and	Random	Forest	 scored	 best	 in	 our	 cohort	 to	 indicate	which	 variants	 in	 the	
Cartegni	consensus	region	are	expected	to	lead	to	aberrant	splicing,	but	can	currently	not	be	
used	for	variants	outside	these	regions.	Presently,	mRNA	analysis	remains	necessary	to	verify	
in	silico	predictions	and	to	determine	the	exact	effect	and	allele	specific	transcript	expression.	
Our	study	is	the	first	to	reveal	actively	used	cryptic	splice	donor	sites	within	the	large	exon	11	
of	BRCA2.	This	finding	opens	perspectives	for	new	research	on	the	identification	of	cis	and	
trans	acting	factors	involved	in	correct	splicing	of	this	large	exon.	
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1 RADIOSENSITIVITY	TESTING	
All	high	to	intermediate	risk	“breast	cancer	genes”	known	to	date	are	involved	in	the	DNA	
damage	response	pathway.	Therefore,	heterozygous	mutation	carriers	may	show	enhanced	
radiosensitivity	associated	with	an	increased	carcinogenic	risk	after	exposure	to	ionizing	
radiation.	Currently	used	assays	to	evaluate	enhanced	chromosomal	radiosensitivity	in	
BRCA1	or	BRCA2	mutation	carriers	were	unable	to	univocally	confirm	this	hypothesis	and	
furthermore,	they	do	not	allow	individual	radiosensitivity	assessment.	Several	publications	
are	available	in	the	literature	applying	different	cytogenetic	techniques	to	determine	in	vitro	
chromosomal	radiosensitivity.	These	tests	are	generally	performed	in	peripheral	blood	
lymphocytes.	In	this	thesis,	we	propose	an	alternative	assay,	the	G2	MN	assay,	for	a	better	
evaluation	of	chromosomal	radiosensitivity	in	lymphocytes	of	healthy	BRCA1	and	BRCA2	
mutation	carriers.		
	
1.1 The	G2	micronucleus	assay	
1.1.1 Development	of	the	G2	micronucleus	assay	
To	 date,	 chromosomal	 radiosensitivity	 of	 BRCA1	 and	 BRCA2	 mutation	 carriers	 has	 been	
evaluated	extensively	with	 the	G0	MN	assay	or	 the	G2	chromatid	break	assay.	All	 in	 vitro	
studies	 cited	 in	 the	 introduction	 (chapter	 4	 of	 the	 introduction)	 were	 performed	 in	
lymphocytes	 of	 healthy	 individuals	 (the	 control	 cohort),	 breast	 cancer	 patients	 with	 or	
without	 a	 germline	 mutation	 and	 healthy	 individuals	 with	 a	 BRCA1	 or	 BRCA2	 mutation.	
Generally,	 in	 vitro	 chromosomal	 radiosensitivity	 studies	 could	 demonstrate	 an	 enhanced	
radiosensitivity	 in	 breast	 cancer	 patients.	 Although,	 these	 assays	 are	 suitable	 to	 compare	
radiosensitivity	between	groups	(e.g.	breast	cancer	patients	vs	non-cancer	patients),	their	use	
to	assess	individual	radiosensitivity	is	limited	due	to	overlap	of	MN	distributions	between	the	
control	and	test	cohort	(see	Figure	3.1	a)	(Baeyens	et	al.	2002).	Thus,	 in	order	to	evaluate	
individual	radiosensitivity,	an	arbitrary	cut-off	must	be	determined.		
	
Part	III:	General	discussion	
	 213	
	
Figure	 3.1:	 simulated	 representation	 of	 the	 distribution	 of	 patient	 (or	 test)	 cohort	 results	
compared	 to	 control	 cohort	 results.	 (a)	 two	cohort	with	overlapping	 radiation-induced	MN	
yields	and	(b)	two	cohorts	of	which	the	radiation-induced	MN	yields	do	not	overlap		
	
Studies	investigating	the	effect	of	a	BRCA1	or	BRCA2	mutation	on	radiosensitivity	either	in	
healthy	 individuals	or	breast	cancer	patients	did	not	yield	consistent	results	(Barwell	et	al.	
2007;	Becker	et	al.	2012;	Gutiérrez-Enríquez	et	al.	2011;	Ernestos	et	al.	2010;	Baeyens	et	al.	
2004;	Baeyens	et	al.	2002).	
	
A	major	 limitation	 of	 the	 G0	MN	 assay	 to	 evaluate	 radiosensitivity	 in	 BRCA1	 and	 BRCA2	
mutation	carriers,	 is	the	fact	that	 lymphocytes	are	exposed	to	ionizing	radiation	during	G0	
phase	of	the	cell	cycle,	while,	BRCA1	and	BRCA2	are	mainly	active	in	DNA	damage	response	
pathways	activated	during	S	and	G2	phase	of	the	cell	cycle	(Roy	et	al.	2012).	The	G0	MN	assay	
might	thus	not	be	the	appropriate	assay	to	evaluate	the	effect	of	mutations	in	BRCA1	and	
BRCA2	 on	 chromosomal	 radiosensitivity.	 From	 this	point	of	 view,	 the	G2	chromatid	break	
assay	may	be	better	suited.	In	the	G2	chromatid	break	assay,	lymphocytes	are	cultured	3	days	
prior	 to	exposure	 to	 ionizing	 radiation	and	a	short	post-irradiation	 incubation	 time	of	one	
hour	and	a	half,	 is	 applied.	Colcemid	 is	 added	during	 the	 last	hour	of	 the	post-irradiation	
incubation	 in	order	to	stop	cells	 in	metaphase	 for	analysis	of	chromatid	breaks.	Given	the	
short	post-irradiation	incubation	period,	cells	trapped	in	mitosis	must	have	been	irradiated	in	
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G2	 phase	 of	 the	 cell	 cycle.	 Nonetheless,	 studies	 applying	 this	 assay	 for	 the	 evaluation	 of	
radiosensitivity	in	BRCA1	and	BRCA2	mutation	carriers	did	not	yield	univocal	results	(Buchholz	
et	 al.	 2002;	 Barwell	 et	 al.	 2007;	 Baeyens	 et	 al.	 2004;	 Ernestos	 et	 al.	 2010).	 Bryant	 et	 al.	
proposed	the	‘signal’	model	to	explain	the	formation	of	chromatid	breaks.	In	this	model,	a	
chromatid	 break	 is	 generated	 by	 one	 DSB	 initiating	 a	 recombinational	 exchange.	 This	
exchange	forms	a	chromatid	break	when	incomplete	(Bryant	2004).	It	is	not	known	if	BRCA1	
and	 BRCA2	 are	 involved	 in	 this	 mechanism.	 Furthermore,	 HR	 capacity	 declines	 when	
progressing	through	G2	phase	of	the	cell	cycle	(Karanam	et	al.	2012)	and	as	lymphocytes	are	
irradiated	in	late	G2	phase	for	the	G2	chromatid	break	assay,	HR-mediated	DSB	repair	might	
be	minimal.	
	
To	optimally	evaluate	the	radiosensitivity	phenotype	of	BRCA1	and	BRCA2	mutation	carriers,	
we	designed	a	modified	MN	assay	focusing	on	the	S	and	G2	phases	of	the	cell	cycle.	With	the	
G2	MN	assay,	two	distinct	endpoints:	(1)	the	radiation-induced	MN	yield	and	(2)	the	G2/M	
checkpoint	efficiency	ratio	(or	IRP	in	paper	I),	are	measured.	The	first	endpoint	reflects	the	
DSB	 repair	 capacity	 in	 these	 phases	 of	 the	 cell	 cycle,	 while	 the	 second	 endpoint	 allows	
evaluation	of	the	G2	arrest	capacity.	The	G2	MN	assay	is	described	in	detail	in	chapter	5.1.3	
of	the	introduction	and	the	main	differences	between	the	G2	and	the	G0	MN	protocol	are	
presented	in	Figure	3.2.	
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Figure	3.2:	schematic	overview	of	the	G0	and	G2	micronucleus	assay	protocol	
	
For	the	determination	of	the	optimal	irradiation	dose	and	post-irradiation	incubation	time,	
we	consulted	the	literature	and	performed	preliminary	experiments	in	a	small	control	cohort.	
The	cited	studies	applied	doses	ranging	between	1	and	8	Gy	for	chromosomal	radiosensitivity	
analysis	with	2	Gy	as	most	often	used	dose	point.	We	selected	two	dose	points,	being	2	and	
4	Gy	60Co g-rays.		
We	stimulated	the	lymphocytes	to	proliferate	during	3	days	by	which	we	obtain	a	culture	with	
cells	in	all	phases	of	the	cell	cycle.	After	exposure	to	ionizing	radiation	and	addition	of	cyto	B,	
we	apply	a	short	post-irradiation	incubation	period	of	8	h	to	allow	DSB	repair	and	formation	
of	BN	cells	(see	Figure	3.2).	We	evaluated	the	effect	of	the	chosen	doses	and	the	short	post-
irradiation	incubation	time	on	the	analyzed	BN	cells	by	means	of	a	BrdU	staining	(see	Figure	
3.3).	We	were	able	to	establish	that	80	–	90%	of	BN	cells	were	in	the	G2	phase	at	time	of	
irradiation	(results	after	exposure	to	4	Gy,	paper	II).	
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Figure	3.3:	Results	of	the	BrdU	assay.	Cells	going	through	S	phase,	while	BrdU	is	present	in	the	
culture	medium,	will	 incorporate	 the	 thymidine	analog.	BrdU	 incorporation	 in	 the	DNA	can	
subsequently	be	evaluated	by	means	of	an	immunostaining	with	a	BrdU	specific	antibody.	DAPI	
staining	of	the	nuclei	(blue)	is	shown	in	the	top	panel.	In	the	bottom	panel,	immunostaining	
for	BrdU	with	a	green	fluorescent	label	is	visualized	(images	by	Metafer4,	Metasystems).	
	
To	measure	the	second	endpoint,	the	G2/M	checkpoint	efficiency	ratio,	we	added	an	ATM	
kinase	inhibitor	to	part	of	our	cultures	to	abrogate	the	G2/M	checkpoint	as	ATM	inhibition	
impedes	 cyclin/Cdk	 inhibition,	 required	 for	G2	arrest.	Caffeine	was	 selected	based	on	 the	
studies	by	Terzoudi	and	colleagues,	were	the	G2	chromatid	break	assay	was	combined	with	
caffeine	to	assess	G2	arrest	capacity.	So	far,	this	approach	was	successful	in	AT	patients	and	
ATM	heterozygous	mutation	carriers	(Pantelias	&	Terzoudi	2011;	Terzoudi	2009).		
	
Before	applying	the	assay	on	a	cohort	of	BRCA1	and	BRCA2	mutation	carriers,	we	validated	
the	G2	MN	assay	on	lymphocytes	of	a	variant	AT	patient	as	AT	patients	are	known	to	be	very	
radiosensitive	and	ATM	has	a	role	in	both	HR	and	G2/M	checkpoint	arrest.	Furthermore,	we	
applied	 the	 assay	 on	 the	 patients	 relatives	 harboring	 a	 heterozygous	ATM	 mutation.	We	
compared	the	performance	of	the	G2-MN	assay	with	the	G0	MN	assay	in	parallel	cultures	and	
on	multiple	samplings	to	evaluate	the	robustness	of	the	assays.		
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1.1.2 Validation	 of	 the	 G2	 MN	 assay	 in	 an	 AT	 patient	 and	 its	 application	 in	
heterozygous	ATM	mutation	carriers	
Chromosomal	radiosensitivity	has	been	demonstrated	repeatedly	 in	AT	patients	as	ATM,	a	
key	activator	of	the	DNA	damage	response	pathway,	is	absent	or	impaired	in	these	individuals	
(George	et	al.	2009;	Kiuru	et	al.	2014;	Distel	et	al.	2006;	Kühne	et	al.	2004;	Vral	et	al.	1996).	
Moreover,	AT	patients	are	characterized	by	such	an	increased	radiosensitivity,	that	no	overlap	
in	MN	yields	with	the	control	cohort	 is	observed	(see	Figure	3.1	b).	Therefore,	the	G0	MN	
assay	can	be	used	to	evaluate	individual	radiosensitivity	in	these	patients.		
	
We	had	access	 to	a	 variant	AT	patient,	 compound	heterozygous	 for	 two	deleterious	ATM	
mutations,	to	evaluate	the	performance	of	the	G2	micronucleus	assay	compared	to	the	G0	
MN	 assay	 (paper	 I).	 This	 variant	 AT	 case	 is	 atypical	 as	 residual	 ATM	 kinase	 activity	 was	
demonstrated,	which	is	not	the	case	in	classic	AT	patients.	The	atypical	phenotype	of	this	AT	
patient	was	furthermore	illustrated	by	the	relatively	old	age	(early	twenties)	at	the	time	of	
diagnosis.	While	 radiosensitivity	 is	 well	 documented	 for	 classic	 AT	 patients,	 as	 discussed	
above,	and	can	be	used	as	a	functional	assay	to	phenotypically	complement	the	diagnosis	of	
AT	 in	 these	 patients,	 only	 scant	 data	 are	 available	 on	 the	 suitability/sensitivity	 of	
radiosensitivity	assays	to	support	a	diagnosis	of	AT	in	patients	showing	‘‘milder	or	atypical’’	
forms	of	the	disease	(Jongmans	et	al.	1998;	Gilad	et	al.	1998;	Bartsch	et	al.	2012).	
Performing	 the	 G0	 MN	 assay	 on	 lymphocytes	 of	 this	 variant	 AT	 patient,	 an	 enhanced	
radiosensitivity	could	be	demonstrated	by	a	1.8-fold	 increased	MN	yield	compared	 to	our	
control	 cohort.	 However,	 this	 increase	 is	 lower	 than	 the	 3-	 to	 4-fold	 increase	 typically	
observed	in	classic	AT	patients.	Evaluation	of	the	first	endpoint	with	the	G2	MN	assay	on	three	
independent	 samplings	 demonstrated	 a	 4-fold	 increase	 in	 MN	 yield	 for	 the	 AT	 patient	
compared	to	the	experimental	control.	Assessment	of	the	G2/M	checkpoint	efficiency	ratio	
(2nd	endpoint)	with	the	G2	MN	assay	revealed	a	severely	impaired	G2	arrest	capacity,	which	
is	in	agreement	with	the	studies	by	Terzoudi	et	al.,	evaluating	G2	arrest	capacity	with	the	G2	
chromatid	break	assay	(Pantelias	&	Terzoudi	2011;	Terzoudi	et	al.	2011).	However,	in	case	of	
a	classical	AT	patient	with	no	functional	ATM,	a	checkpoint	ratio	of	one	is	expected	which	
implies	 a	 complete	 disruption	 of	 the	 G2	 arrest	 capacity.	 The	mean	 ratio	 observed	 in	 our	
variant	 AT	 patient	 is	 somewhat	 higher	 (1.85),	 pointing	 to	 remaining	 functionality	 of	 this	
particular	checkpoint.	
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Additionally,	 we	 had	 access	 to	 three	 relatives	 of	 the	 variant	 AT	 patient	 who	 were	
heterozygous	 ATM	mutation	 carriers.	 Chromosomal	 radiosensitivity	 in	 heterozygous	ATM	
mutation	carriers	has	also	been	studied	extensively.	Current	studies,	evaluating	chromosomal	
radiosensitivity	by	means	of	the	G2	chromatid	break	assay,	show	that	these	individuals	are	
more	radiosensitive	compared	to	a	control	cohort,	though	be	it	less	pronounced	compared	
to	AT	patients.	Furthermore,	overlap	between	the	patient	and	control	cohort	is	observed	(see	
Figure	3.1	a)	(Pantelias	&	Terzoudi	2011;	Terzoudi	et	al.	2011;	Tchirkov	et	al.	1997;	Sanford	et	
al.	1990;	Chen	et	al.	1994).	
Evaluation	 of	 G0	 MN	 yields	 in	 these	 heterozygous	 relatives	 demonstrated	 no	 enhanced	
chromosomal	 radiosensitivity.	 When	 applying	 the	 G2	 MN	 assay,	 on	 the	 other	 hand,	 all	
heterozygous	mutation	carriers	showed	increased	MN	yields	and	impaired	G2	arrest	capacity	
intermediate	between	our	controls	and	the	patient.		
	
A	clear	difference	was	noticed	between	the	mother,	carrier	of	the	splice	site	mutation	c.8851-
1G>T	and	the	father	and	niece	with	the	missense	mutation	c.8122G>A	(p.Asp2708Asn)	as	the	
former	was	characterized	by	a	higher	MN	yield	and	a	more	pronounced	impairment	of	the	
G2/M	checkpoint.	This	could	be	attributed	to	the	fact	that	no	full-length	mRNA	transcript	is	
transcribed	 from	 the	 allele	with	 the	 splice	 site	mutation	 identified	 in	 the	mother,	 and	no	
residual	kinase	activity	was	derived	from	the	c.8851-1G>T	allele	in	contrast	to	the	c.8122G>A	
allele.	A	larger	study	including	a	wide	range	of	different	ATM	mutations	would	allow	a	better	
insight	in	this	phenomenon.	
	
1.1.3 Chromosomal	 radiosensitivity	 measured	 by	 the	 G2	MN	 assay	 in	 a	 cohort	 of	
BRCA1	and	BRCA2	mutation	carriers	
Since	the	G2	MN	assay	performed	well	in	heterozygous	ATM	mutation	carriers	(paper	I),	and	
because	ATM	and	BRCA1	and	BRCA2	are	active	in	the	same	DNA	damage	response	pathway,	
we	 applied	 the	 same	 test	 to	 evaluate	 chromosomal	 radiosensitivity	 in	 blood	 samples	 of	
healthy	BRCA1	and	BRCA2	mutation	carriers	and	non-carrier	relatives	(paper	II	&	paper	III).	
Blood	samples	of	healthy,	age	and	gender	matched	volunteers	without	a	personal	or	familial	
history	of	breast	and	ovarian	cancer	were	used	to	determine	the	normal	distribution	of	the	
MN	yield	and	G2/M	checkpoint	ratio	in	the	general	population.	
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BRCA1	
With	 regard	 to	 the	 first	 endpoint	 studied	 with	 the	 G2	 MN	 assay	 a	 significant	 increased	
radiosensitivity	 was	 observed	 in	 the	 cohort	 of	 BRCA1	 mutation	 carriers.	Mean	 radiation-
induced	MN	yields	after	exposure	to	both	2	and	4	Gy	ionizing	radiation	are	shown	in	Figure	
3.4	(paper	II).	
	
	
Figure	3.4:	MN	yields	after	exposure	to	2	or	4	Gy	60Co g-rays.	Significant	differences	compared	
to	the	control	cohort	(p<0.05)	are	indicated	with	*	(figure	from	paper	II).	
	
Evaluation	of	 the	G2/M	checkpoint	efficiency	 ratio,	 the	 second	endpoint,	 in	 the	cohort	of	
BRCA1	 mutation	 carriers	 demonstrated	 an	 impaired	 G2	 arrest	 capacity	 compared	 to	 the	
control	group	(paper	II).		
	
BRCA2	
The	radiation-induced	MN	yield	 in	the	cohort	of	BRCA2	mutation	carriers	was	significantly	
increased	compared	 to	 control	 individuals	after	exposure	 to	2	Gy	 (see	Figure	3.5)	 (results	
paper	 III).	 Evaluation	 of	 the	 G2	 arrest	 capacity	 in	 this	 test	 cohort	 showed	 no	 significant	
difference	 in	 the	activation	of	 the	G2/M	checkpoint	 compared	 to	 the	 controls	 (e.g.	G2/M	
checkpoint	ratio	equals	1.8	versus	2.1	respectively	after	exposure	to	2	Gy).	These	results	were	
anticipated	 as	 BRCA2,	 unlike	 BRCA1,	 is	 not	 involved	 in	 the	 G2/M	 checkpoint	 activation	
(reviewed	by:(Roy	et	al.	2012)).	Our	data	do	not	support	the	results	of	Menzel	et	al.	(2011),	
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to	our	knowledge	the	only	study	suggesting	a	role	for	BRCA2	in	the	G2/M	checkpoint	(Menzel	
et	al.	2011).		
	
Figure	3.5:	MN	yields	after	exposure	to	2	and	4	Gy	60Co g-rays.	Significant	differences	compared	
to	the	control	cohort	(p<0.05)	are	indicated	with	*	(figure	adapted	from	paper	III).	
	
The	increase	in	radiation-induced	MN	yields	after	exposure	to	4	Gy	was	not	significant	in	the	
cohort	of	BRCA2	mutation	carriers	compared	to	the	control	cohort	and	this	dose	point	was	
therefore	not	included	in	paper	III.	We	speculate	that	the	higher	dose	resulted	in	a	prolonged	
or	 irreversible	 G2	 arrest	 of	 heavily	 damaged	 lymphocytes	 of	BRCA2	 mutation	 carriers.	 In	
BRCA1	mutation	 carriers	 on	 the	 other	 hand,	 heavily	 damaged	 cells	 are	more	 likely	 to	 go	
through	mitosis	 and	 become	 BN	 due	 to	 an	 impaired	 G2	 arrest.	 This	 is	 illustrated	 by	 the	
observation	that	out	of	the	eight	BRCA1	mutation	carriers	for	whom	an	increased	radiation-
induced	MN	yield	was	observed,	six	also	demonstrated	an	impaired	G2	arrest.		
The	 impact	 of	 cell	 cycle	 delay,	 and	more	 specifically	 prolonged	G2	 arrest,	was	 previously	
discussed	 by	Nasonova	 and	 Ritter	 as	 they	 observed	 an	 increase	 in	 aberration	 yields	with	
increasing	 culture	 time	 as	more	 damaged	 lymphocytes	were	 able	 to	 overcome	G2	 arrest	
(Nasonova	&	Ritter	2004).	Landsverk	et	al.	demonstrated	the	existence	of	a	secondary,	late	
activation	of	G2	arrest	capacity,	only	observed	after	exposure	to	doses	as	high	as	4	Gy	in	B-
lymphocyte	cancer	cell	lines.	Persistent	phosphorylation	of	Chk1	is	proposed	to	mediate	the	
prolonged	 G2	 arrest	 (Landsverk	 et	 al.	 2011).	 The	 difference	 between	 BRCA1	 and	 BRCA2	
mutation	carriers	observed	in	our	cohort,	might	be	inherent	to	the	fact	that	BRCA1	is	involved	
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in	Chk1	activation	upon	detection	of	DNA	damage	to	initiate	G2	arrest	capacity	(Yarden	et	al.	
2002).	Furthermore,	this	late	activation	of	G2	arrest	could	be	overruled	by	addition	of	an	ATM	
inhibitor	 (Landsverk	et	al.	2011).	 Interestingly,	after	exposure	 to	caffeine,	mean	radiation-
induced	MN	yield	for	BRCA2	mutation	carriers	were	comparable	to	those	of	BRCA1	mutation	
carriers	(data	not	shown).		
	
Taken	together,	we	provide	evidence	of	an	enhanced	radiosensitivity	for	both	healthy	BRCA1	
and	BRCA2	mutation	carriers	as	demonstrated	by	increased	radiation-induced	MN	yields	in	
the	 lymphocytes.	 Furthermore,	 we	 speculate	 that	 the	 observed	 increase	 in	MN	 yields	 in	
healthy	mutation	carriers,	whereas	previously	G0	studies	failed	to	prove	a	similar	correlation	
(Gutiérrez-Enríquez	et	al.	2011;	Baeyens	et	al.	2004),	is	inherent	to	our	study	design.		Indeed,	
several	studies	evaluating	BRCA1	protein	levels	throughout	the	cell	cycle	could	demonstrate	
an	absence	of	BRCA1	in	G0	phase	of	the	cell	cycle,	followed	by	a	modest	incline	during	G1	
phase	(compared	to	G0	phase),	a	major	increase	during	S	phase	and	a	maximum	protein	level	
during	 the	 G2	 phase.	 The	 cell	 cycle	 dependent	 increase	 in	 protein	 level	 is	 based	 on	 an	
induction	 of	mRNA	 transcription	 and	 subsequent	 translation	 during	G1/S	 transition.	 After	
reaching	 a	 peak	 in	 G2	 phase,	 BRCA1	 protein	 levels	 decrease	 again.	 This	 decrease	 upon	
entering	 of	 the	 G1	 phase	 is	 mediated	 by	 a	 decline	 in	 mRNA	 transcription	 and	 protein	
degradation	by	proteases	and	ubiquitination	(Choudhury	et	al.	2004;	Liu	et	al.	2010;	Okada	&	
Ouchi	 2003).	 Several	 papers	 also	 evaluated	 BRCA1	 stability	 after	 exposure	 to	 ionizing	
radiation	independent	of	the	cell	cycle.	These	papers	describe	that	exposure	to	high	doses	
resulted	 in	 degradation	 of	 BRCA1,	 presumably	 to	 facilitate	 radiation-induced	 apoptosis.	
Exposure	to	doses	below	5	Gy	did	not	influence	protein	levels,	which	is	important	information	
in	respect	to	our	experimental	set-up	(Liu	et	al.	2010;	Okada	&	Ouchi	2003).		
	
In	 addition	 to	 variation	 in	 expression	 of	 BRCA1	 protein	 levels	 inherent	 to	 the	 cell	 cycle,	
posttranslational	modifications,	 in	function	of	the	cell	cycle,	 further	enhance	the	cell	cycle	
dependent	activation	of	this	protein.	The	principal	posttranslational	modification	of	BRCA1	is	
phosphorylation,	which	occurs	at	several	amino	acid	sites	(see	Figure	3.6).	Current	working	
hypothesis	is	that	in	its	hypo-phosphorylated	form,	found	in	G1	phase	of	the	cell	cycle,	BRCA1	
is	 involved	in	the	activation	of	c-NHEJ,	while	its	hyper-phosphorylated	isoform,	induced	by	
cell	cycle	transition	and/or	in	response	to	DNA	damage,	mediates	HR	during	S	and	G2	phase	
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of	 the	 cell	 cycle	 (see	 Figure	 3.7)	 (Zhang	 et	 al.	 2004;	 Saha	 &	 Davis	 2016).	 Key	 proteins	
responsible	for	phosphorylation	of	BRCA1	are	ATM	and	checkpoint	kinase	2	(chk2)	(Zannini	
et	al.	2014;	Zhang	et	al.	2004;	Summers	et	al.	2011).			
	
Figure	3.6:	Overview	of	the	functional	domains,	the	interacting	proteins	and	phosphorylation	
sites	of	BRCA1	(Saha	&	Davis	2016).	
	
	
Figure	3.7:	BRCA1	interactions	during	G1	and	S/G2	phase	for	repair	of	radiation-induced	DSB.	
In	the	absence	of	HR	(during	G1	phase),	interaction	of	BRCA1	with	Ku80	and	the	MRN	complex	
promotes	 the	 C-NHEJ	 pathway,	 while	 downregulating	 mutagenic	 A-NHEJ.	 In	 S	 phase,	 the	
interaction	of	BRCA1	with	DNA-PKcs	inhibits	C-NHEJ,	thereby	redirecting	the	pathway	choice	
towards	 HR	 pathway.	 Either	 way,	 BRCA1	 induces	 the	 activation	 of	 the	 least	 error	 prone	
pathway	throughout	all	stages	of	the	cell	cycle	(Saha	&	Davis	2016).		
	
Concerning	 BRCA2	 protein	 expression,	 less	 data	 are	 available.	One	 study	 demonstrated	 a	
more	or	 less	steady	expression	 in	cycling	cells	 for	all	phases	of	 the	cell	 cycle	 (Esashi	et	al.	
2005),	but	no	data	for	G0	cells	are	available	 in	 literature.	Although	steady	levels	of	BRCA2	
Part	III:	General	discussion	
	 223	
protein	 are	 detected	 throughout	 all	 phases	 of	 cycling	 cells,	 BRCA2	 activity,	 like	 BRCA1,	 is	
regulated	 by	 posttranslational	 modifications.	 Current	 studies	 suggest	 a	 role	 for	 cyclin-
dependent	kinases	(Cdk),	checkpoint	kinases	(Chk1	and	Chk2)	and	Plk1	(Polo-like	kinase	1)	in	
response	to	DNA	damage	and	cell	cycle	progression	for	phosphorylation	of	BRCA2	at	various	
amino	 acid	 sites	 (see	 Figure	 3.8)	 (Esashi	 et	 al.	 2005;	 Lee	 et	 al.	 2004).	 The	 Cdk	 and	 Plk1-
mediated	 phosphorylation	 seems	 to	 be	 upregulated	 in	 G2	 phase	 of	 the	 cell	 cycle	 and	 is	
maximal	 during	M	 phase	where	 it	 impairs	 RAD51	 interaction,	 directing	 BRCA2	 towards	 a	
different	 role	 in	 this	 phase	 of	 the	 cell	 cycle.	 This	 alternate	 function	 in	 mitosis	 mediates	
chromosome	condensation	and	stabilization	and/or	segregation	(Lee	2014;	Esashi	et	al.	2005;	
Lee	et	al.	2004).	Induction	of	DNA	damage	impairs	Plk1	and	CDK-dependent	phosphorylation	
of	BRCA2,	enhancing	the	DNA	damage	response	function	of	BRCA2.	This	is	mediated	by	Chk1	
and	 Chk2	 phosphorylation	 of	 the	 C-terminus	 of	 BRCA2	 in	 response	 to	 ionizing	 radiation,	
crucial	for	RAD51	recruitment	and	interaction	(Zannini	et	al.	2014).		
	
Figure	3.8:	Overview	of	the	functional	domains,	interaction	partners	and	phosphorylation	sites	
of	BRCA2	(Lee	2014).	
	
Several	studies	discussed	in	this	chapter	demonstrate	BRCA1	and	BRCA2	activation	and	HR	
mediated	 DSB	 repair	 upon	 induction	 of	 complex	 DSB	 by	 ionizing	 radiation.	We	 therefore	
speculate	that	the	enhanced	radiosensitivity,	observed	by	increased	MN	yields	detected	with	
the	G2	MN	assay	in	mutation	carriers,	is	indeed	due	to	an	impaired	HR	capacity	resulting	in	
less	efficient	repair	of	DSB	and	–	as	a	consequence	–	an	increased	MN	yield.	The	enhanced	
radiosensitivity	phenotype	of	BRCA1	mutation	carriers	can	furthermore	be	attributed	to	an	
impaired	G2	arrest	capacity	as	demonstrated	by	a	significantly	decreased	G2/M	checkpoint	
efficiency	ratio.	This	cell	cycle	dependent	activation	of	both	proteins	not	only	strengthens	our	
theory	that	the	G2	MN	is	a	better	suited	assay	to	evaluate	radiosensitivity	in	healthy	BRCA1	
and	 BRCA2	 mutation	 carriers	 compared	 to	 the	 G0	 MN	 assay,	 it	 also	 indicates	 that	 the	
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radiosensitive	phenotype	observed	with	the	G0	MN	assay	 in	breast	cancer	patients	with	a	
BRCA1	or	BRCA2	mutation	is	not	due	to	the	mutation	status,	but	might	be	inherent	to	the	
cancer	status	(Baeyens	et	al.	2004).	
However,	 caution	 is	needed	when	 interpreting	 the	 results	of	 the	studies	cited	above	with	
respect	 to	our	studies	 in	 lymphocytes	as	most	experiments	were	conducted	 in	cancer	cell	
lines	(e.g.	breast	cancer	cell	 line	MCF7	and	cervical	cancer	cell	 line	Hela).	As	far	as	we	are	
aware	 no	 such	 studies	 were	 conducted	 in	 non-cancerous	 breast	 epithelial	 cell	 lines	 or	
lymphocytes.		
	
1.1.4 Chromosomal	radiosensitivity	measured	by	the	G2	MN	assay	in	non-carriers	
In	 paper	 III,	 in	 vitro	 chromosomal	 radiosensitivity	 of	 a	 group	non-carrier	 relatives	of	 both	
BRCA1	 (n=9)	and	BRCA2	 (n=8)	families	was	 investigated	to	evaluate	whether	the	observed	
increase	in	radiation-induced	MN	yields	in	mutation	carriers	is	linked	to	the	mutation	status.	
No	significantly	increased	radiation-induced	MN	yields	were	observed	compared	to	healthy	
individuals	without	a	personal	or	familial	history	of	breast	or	ovarian	cancer	(MN2Gy=68	versus	
MN2Gy=61).	 Radiosensitivity	 in	 non-carrier	 relatives	 was	 previously	 only	 evaluated	 in	 one	
study.	This	study	reported	no	increased	radiosensitivity	measured	with	the	G0	MN	and	G2	
chromatid	break	assay	in	a	small	cohort	(n=10)	of	relatives	of	both	BRCA1	and	BRCA2	families	
without	the	familial	mutation	when	compared	to	a	population	cohort	(Baeyens	et	al.	2004)	
and	is	in	agreement	with	our	results.	
	
The	mean	radiation-induced	MN	yield	was	higher	for	BRCA2	mutation	carriers	than	for	non-
carrier	relatives,	but	this	difference	was	not	significant	because	of	the	relatively	large	inter-
individual	variation.	The	relatively	high	inter-individual	variation	was	observed	in	all	tested	
cohorts	and	could	be	inherent	to	the	assay	(see	chapter	1.1.4	of	the	general	discussion)	or	
may	be	the	result	of	genetic	modifiers	influencing	radiosensitivity	given	that	MN	formation	
can	be	the	result	of	defects	 in	various	DNA	damage	response	pathways.	Previous	research	
has	 demonstrated	 that	 selected	 SNPs	 in	 DNA	 damage	 repair	 genes	 and	 other	 common	
variants	may	be	associated	with	an	increased	radiosensitivity.	For	example,	data	from	Willems	
et	 al.	 demonstrated	 that	 specific	 SNPs	 in	 Ku70	 and	Ku80,	 involved	 in	 c-NHEJ,	 result	 in	 an	
increased	breast	cancer	risk	and	an	enhanced	chromosomal	radiosensitivity,	observed	by	an	
increase	in	G0	MN	yields	(Willems	et	al.	2008).	Furthermore,	Popanda	et	al.	demonstrates,	in	
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his	 review,	 a	 clear	 influence	 of	 certain	 SNPs	 in	 ATM	 and	 other	 numerous	 DNA	 damage	
response	genes	on	radiosensitivity.	In	these	studies,	radiosensitivity	is	demonstrated	by	an	
increase	 in	 adverse	 side	 effects	 of	 radiotherapy	 in	 carriers	 (Popanda	 et	 al.	 2009).	
Furthermore,	a	limited	number	of	studies	demonstrated	an	increased	breast	cancer	incidence	
in	these	non-carriers	compared	to	a	control	cohort	(Smith	et	al.	2007;	Vos	et	al.	2013;	Evans	
et	al.	2013),	which	might	also	be	attributed	to	the	presence	of	modifiers	such	as	SNPS	or	other	
genetic	alterations.	
	
1.1.5 G2	MN	assay	for	individual	assessment	of	radiosensitivity	
In	addition	to	the	evaluation	of	chromosomal	radiosensitivity	on	a	cohort-level,	we	aimed	to	
develop	 an	 assay	 applicable	 in	 a	 clinical	 setting	 for	 the	 individual	 assessment	 of	
radiosensitivity.	Unfortunately,	MN	distribution	of	mutation	carriers	and	controls	overlap	(see	
Figure	3.1	a),	so	to	define	an	individual	radiosensitivity	phenotype,	a	radiosensitivity	scoring	
system	was	developed.		
	
In	BRCA1	mutation	carriers,	individual	radiosensitivity	assessment	(Radiosensitivity	INDicator	
(RIND)	scoring)	is	based	on	both	endpoints	of	the	G2	MN	assay	taking	into	account	DNA	repair	
and	 G2	 arrest	 capacity	 after	 exposure	 to	 4	 Gy.	 This	 RIND	 score	 varies	 between	 0	 and	 4	
whereby	a	RIND	score	of	0	correlates	with	no	increased	radiosensitivity	and	a	RIND	score	of	
4	equals	a	severely	increased	radiosensitivity.	Scores	varying	between	1	and	3	correlate	to	
different	grades	of	mild	or	moderate	increased	radiosensitivity.	Applying	this	scoring	system,	
72%	 of	 BRCA1	 mutation	 carriers	 show	 some	 degree	 of	 radiosensitivity	 (RIND	 score	 1-4).	
Furthermore,	 28%	BRCA1	mutation	 carriers	 demonstrated	RIND	 scores	 of	 3	 and	4,	 scores	
which	were	never	observed	in	healthy	individuals	(see	Figure	3.9,	paper	II).	
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Figure	 3.9:	 Individual	 radiosensitivity	 scoring	 based	on	RIND	 scores	 after	 exposure	 to	 4	Gy	
60Co g-rays	for	healthy	volunteers	and	BRCA1	mutation	carriers	(paper	II).	
	
For	BRCA2	mutation	carriers	and	non-carriers,	individual	radiosensitivity	scoring	(RS	score)	is	
based	on	the	results	of	the	radiation-induced	MN	yields	after	exposure	to	2	Gy	(see	Figure	
3.10).	An	RS	score	of	0	correlates	to	no	increased	radiosensitivity,	an	RS	score	of	1	indicates	a	
milder	radiosensitive	phenotype	and	an	RS	score	of	2	reflects	a	more	severe	radiosensitive	
phenotype.	BRCA2	mutation	carriers	are	characterized	by	an	increased	RS	score	compared	to	
the	controls	demonstrated	by	50%	of	mutation	carriers	showing	an	RS	score	of	1	or	2,	whereas	
83%	 of	 controls	 are	 not	 radiosensitive	 (RS-score=0).	 RS	 scores	 of	 non-carriers	 do	 not	
significantly	differ	 from	scores	observed	 in	 the	control	 cohort.	This	 scoring	 system	can	be	
valuable	 in	 assisting	 physicians	 in	 their	 decision-making	 regarding	 the	 diagnostic	 and	
therapeutic	exposure	to	ionizing	radiation	at	the	individual	level.	
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Figure	 3.10:	 Individual	 radiosensitivity	 (RS)	 scoring	 for	 healthy	 volunteers,	 non-carriers	 and	
BRCA2	mutation	carriers	(paper	III).		
	
Overlapping	MN	distribution	have	also	been	observed	in	the	past	with	the	G0	MN	assay	when	
comparing	RS	in	breast	cancer	patients	with	healthy	controls.	In	these	studies,	an	arbitrary	
cut-off,	typically	the	90th	percentile	of	the	MN	distribution	from	the	healthy	control	cohort,	
was	determined	to	assess	individual	radiosensitivity	(e.g.	(Baeyens	et	al.	2002)).		
Vral	and	colleagues	previously	demonstrated	that	a	major	–	but	intrinsic	–	problem	of	the	G0	
MN	assay	is	its	high	intra-individual	variability,	which	determines	the	reproducibility	of	the	
assay	 (Vral	 et	 al.	 2002;	 Vral	 et	 al.	 2004).	 The	 observed	 intra-individual	 variation	 can	 be	
attributed	to	different	factors	such	as	the	cell/serum	balance	in	blood	samples,	influenced	by	
immune	status	and	diet	(Fenech	1999;	Roberts	et	al.	1997).	These	factors	may	also	contribute	
to	intra-individual	variation	observed	with	the	G2	MN	assay.	Intra-individual	variation	can	be	
reduced	by	evaluating	the	results	in	multiple	blood	samples	from	a	single	individual.	To	assess	
intra-individual	 variation	 for	 the	 G2	 MN	 assay,	 we	 performed	 multiple	 testing	 of	 seven	
healthy	 volunteers	 and	 four	BRCA1	 mutation	 carriers.	 Despite	 variations	 observed	 in	 the	
radiation-induced	MN	yields	 and	G2/M	checkpoint	 ratios	 between	multiple	 samplings,	 no	
significant	differences	in	RIND	scores	were	observed	when	comparing	all	repeats.	To	reduce	
random	 variation,	 our	MN	 values	 were	 always	 based	 on	 results	 obtained	 in	 two	 parallel	
cultures	set	up	for	every	blood	sample,	as	was	previously	suggested	by	Vral	et	al.	(Vral	et	al.	
2002).		
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Furthermore,	 variations	 in	 genetic	 background	 will	 also	 contribute	 to	 differences	 in	
radiosensitivity	(see	chapter	1.1.3	of	the	discussion),	complicating	individual	assessment	of	
radiosensitivity	 related	 to	 a	 specific	 BRCA1	 or	 BRCA2	mutation.	 In	 paper	 II	 and	 III,	 we	
demonstrated	 that	 non-related	 individuals	 with	 the	 same	 mutation	 can	 exhibit	 different	
RIND/RS	 phenotype.	 Furthermore,	 related	 mutation	 carriers	 do	 not	 necessarily	 show	 an	
identical	 RS/RIND	 score.	Given	 the	 numerous	 pathways	 involved	 in	 the	 formation	of	MN,	
ideally	a	very	large	study	is	required	on	mutation	carriers,	non-carrier	relatives	and	unrelated	
controls,	 to	 link	 the	 results	 of	 a	 radiosensitivity	 assay	 with	 whole	 genome/	
transcriptome/epigenome	 data	 to	 identify	 potential	 genetic	 modifiers	 influencing	 the	
radiosensitive	phenotype.	However,	the	statistical	processing	of	the	vast	amount	of	data	will	
be	challenging.	
	
As	shown	in	this	discussion,	the	G2	MN	assay	has	some	limitations.	Therefore,	we	decided	
that	a	test	evaluating	more	directly	the	HR	capacity	in	lymphocytes	of	mutation	carriers	could	
be	useful.		
	
1.2 The	RAD51	foci	assay	to	assess	radiosensitivity	in	cells	with	reduced	BRCA1	and	BRCA2	
protein	levels	
Activation	of	HR	upon	exposure	to	ionizing	radiation	and	the	impact	of	BRCA1	and	BRCA2	has	
been	 discussed	 in	 chapter	 3.3.2.2	 of	 the	 introduction	 and	 in	 chapter	 1.1.3	 of	 the	 general	
discussion.	 Recently,	 a	 RAD51	 foci	 assay	 has	 been	 developed	 to	 allow	 evaluation	 of	 HR	
activity.	 Performed	 on	 tumor	 biopsies	 irradiated	 ex-vivo,	 the	 RAD51	 foci	 assay	 allows	 to	
identify	HR	deficient	 tumors.	This	may	 facilitate	 the	selection	of	patients	eligible	 for	PARP	
inhibition	treatment,	a	cancer	treatment	strategy	based	on	synthetic	lethality	in	HR	deficient	
tumor	cells	(Willers	et	al.	2015).	Furthermore,	 in	a	small	number	of	studies,	the	assay	was	
used	to	evaluate	radiation-induced	RAD51	foci	formation	in	heterozygous	BRCA1/2	cell	lines	
(Vaclová	et	al.	2015;	Warren	et	al.	2003;	Sioftanos	et	al.	2010).		
	
In	paper	IV,	we	investigated	the	suitability	of	the	RAD51	foci	assay	to	evaluate	HR	capacity	in	
MCF10A	cells	with	reduced	protein	levels	of	BRCA1	and	BRCA2,	obtained	by	RNA	interference.	
Cells	were	synchronized	in	S	phase	of	the	cell	cycle	prior	to	exposure	to	ionizing	radiation	by	
means	of	aphidicolin	as	HR	activation	for	repair	of	DSB	is	maximal	in	this	cell	cycle	phase	(Mao	
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et	al.	2008;	Karanam	et	al.	2012).	We	demonstrated	that	BRCA1	and	BRCA2	knockdown	cell	
lines	are	characterized	by	a	diminished	HR	activity	after	exposure	of	 synchronized	cells	 to	
ionizing	 radiation.	Moreover,	whereas	a	doubling	 in	RAD51	 foci	after	exposure	 to	 ionizing	
radiation	can	be	detected	for	the	control	cells,	no	radiation-induced	foci	were	observed	for	
the	 knockdown	 cell	 lines	 (see	 Figure	 3.11).	 We	 also	 showed	 that	 synchronization	 of	 the	
MCF10A	cells	resulted	in	an	increase	of	RAD51	foci	compared	to	non-synchronized	cells.	This	
can	be	attributed	to	a	higher	number	of	S	phase	cells	applying	HR	for	repair	of	endogenous	
and	aphidicolin-induced	DSB.	
	
	
Figure	3.11:	results	of	the	RAD51	foci	assay.	Significant	differences,	compared	to	the	control	
cell	line	(p<0.05),	are	indicated	with	*	(figure	adapted	from	paper	IV).	IR:	Ionizing	radiation	
	
Our	data	obtained	in	MCF10A	cells	support	the	hypothesis	that	application	of	the	RAD51	foci	
assay	 on	 synchronized	 lymphocytes	 of	 heterozygous	BRCA1	 and	BRCA2	mutation	 carriers	
might	 be	 promising	 to	 evaluate	 HR	 functionality	 and	 radiosensitivity.	 Additionally,	 the	
absence	 of	 overlap	 between	 the	 results	 of	 the	 control	 versus	 the	 BRCA	 knockdown	 cells,	
shown	 in	 Figure	 3.12,	 implies	 that	 this	 assay	 might	 be	 better	 suited	 for	 individual	
radiosensitivity	assessment.	Furthermore,	this	assay	could	be	applied	for	the	evaluation	of	HR	
capacity	 in	 individuals	 with	mutations	 in	 other	 genes	 involved	 in	 HR	 such	 as	 PALB2.	 The	
evaluation	 of	 HR	 activation	 in	 lymphocytes	 with	 the	 RAD51	 foci	 assay	 after	 exposure	 to	
ionizing	radiation	might	also	shed	 light	on	their	sensitivity	 for	PARP	 inhibitor	treatment	as	
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these	 individuals	 might	 develop	 breast	 tumors	 characterized	 by	 HR	 deficiency	 and	 PARP	
inhibitor	sensitivity.	
	
	
Figure	3.12:	Boxplot	of	all	results	of	the	RAD51	foci	assay	(synchronized	and	exposed	to	2	Gy)	
based	on	eight	repeats	per	cell	line.	No	overlap	is	observed	in	RAD51	foci	yields	for	the	control	
versus	the	knockdown	cell	lines.	(results	used	for	this	boxplot	come	from	paper	IV)	
	
Attempts	to	discriminate	even	better	between	BRCA	knockdown	cell	 lines	and	control	cell	
lines	by	specifically	inducing	HR	activation	through	PARP	inhibition	were	unsuccessful	as	no	
significant	 increase	 in	 RAD51	 foci	 were	 obtained	 after	 combined	 treatment	 with	 a	 PARP	
inhibitor	and	ionizing	radiation	compared	to	ionizing	radiation	alone	(paper	IV).	This	might	be	
attributed	 to	 exhaustion	 of	 HR	 activation	 due	 to	 protein	 depletion	 after	 aphidicolin	
synchronization	and	exposure	to	ionizing	radiation.	Moreover,	in	BRCA	knockdown	cell	lines	
and	not	for	the	control	cell	line,	synchronization	alone	seems	to	be	sufficient	for	exhaustion	
of	the	HR	pathway.	We	speculate	that	BRCA1	or	BRCA2	protein	levels	might	be	the	limiting	
factors	in	the	activation	of	HR	in	this	particular	setting.	A	number	of	studies	describe	BRCA1	
and	BRCA2	protein	levels	throughout	the	cell	cycle	(Esashi	et	al.	2005;	Choudhury	et	al.	2004;	
Liu	et	al.	2010;	Okada	&	Ouchi	2003).	However,	evaluation	of	BRCA1	and	BRCA2	protein	levels	
in	 MCF10A	 cells	 and	 lymphocytes	 in	 response	 to	 ionizing	 radiation	 would	 need	 to	 be	
conducted	for	further	investigation.	
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The	absence	of	a	significant	induction	of	RAD51	foci	when	comparing	synchronized	cells	with	
synchronized	cells	exposed	to	a	PARP	inhibitor	(paper	IV)	may	point	towards	another	possible	
explanation,	 inherent	 to	 the	 inhibition	 itself.	 As	 discussed	 in	 the	 introduction	 (chapter	
3.3.2.4),	PARP	 is	 involved	 in	numerous	pathways.	The	effect	of	PARP	 inhibition	 treatment	
predominantly	 relies	 on	 the	 inhibition	 of	 BER	 and	 the	 failure	 to	 repair	 SSB.	 These	 SSB	
subsequently	result	in	stalled	replication	forks	during	synthesis	and	the	formation	of	single-
ended	 DSB,	 that	 are	 exclusively	 repaired	 by	 HR	 (see	 Figure	 3.13	 (1))	 (Murai	 et	 al.	 2012;	
Pommier	 et	 al.	 2016).	 However,	 PARP	 is	 also	 important	 in	 the	 stabilization	 of	 replication	
damage	repair	and	DSB	repair.	Unfortunately,	the	complex	network	mediating	these	PARP	
functions	is	not	completely	understood	and	inhibition	of	PARP	might	interfere	with	initiation	
of	 HR	 and	 RAD51	 foci	 formation	 (Pommier	 et	 al.	 2016;	 Khodyreva	 &	 Lavrik	 2016).	
Furthermore,	we	must	consider	PARP	trapping	during	inhibition.	Application	of	several	PARP	
inhibitors,	including	Olaparib,	results	in	PARP	trapping	(see	Figure	3.13	(2))	(Murai	et	al.	2012;	
Pommier	et	al.	2016).	PARP	trapping	does	not	only	result	in	the	inhibition	of	PARP	function,	
but	also	retains	PARP	at	the	site	of	the	DNA	damage	(single	strand	break,	double	strand	break	
or	replication	damage)	(Murai	et	al.	2012;	Murai	et	al.	2013).	This	might	be	caused	by	binding	
of	the	inhibitor	at	the	NAD+	site,	necessary	for	the	parylation	activity	of	PARP	and/or	allosteric	
conformational	 changes	 resulting	 in	 a	 stabilized	 DNA-PARP	 complex	 (Murai	 et	 al.	 2012).	
Although	studies	demonstrated	that	PARP	trapping	might	be	more	deleterious	than	the	mere	
inhibition	of	its	function,	this	is	not	fully	understood	(Murai	et	al.	2012;	Pommier	et	al.	2016).	
One	possibility	is	the	replication	fork	collision	with	the	PARP-DNA	complexes,	resulting	in	a	
collapse	 and	 single	 ended	 DSB.	 However,	 as	 the	 net	 effect	 is	 not	 different	 than	 that	 of	
inhibition	 alone,	 it	 does	 not	 explain	 the	 additional	 cytotoxicity	 granted	 to	 PARP	 trapping.	
Another	possibility	is	the	inclusion	of	other	proteins	in	the	PARP-DNA	complexes	which	might	
render	 these	 complexes	difficult	 to	 remove	 (Pommier	et	 al.	 2016;	Murai	 et	 al.	 2012).	We	
stipulate	that	the	presence	of	such	a	complex	at	the	stalled	replication	fork	would	impede	
repair	of	the	induced	single	ended	DSB.	However,	limited	information	regarding	repair	and	
repair	kinetics	of	PARP-DNA	complexes	has	been	published.	Murai	at	al.	proposes	a	repair	
model	based	on	different	mechanisms	including,	besides	HR,	the	Fanconi	Anemia	pathway	
(FA),	template	switching	(TS)	and	proteins	such	as	ATM,	FAN1	and	Polymerase	b	(POLB)	(see	
Figure	3.13	(2))	(Murai	et	al.	2012).	
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Figure	3.13:	PARP	inhibition:	(1)	inhibition	by	inactivation	of	PARP	function	and	BER	(see	text)	
and	(2)	inhibition	by	PARP-trapping	(see	text).		
	
Finally,	 we	 must	 consider	 the	 effect	 of	 aphidicolin	 synchronization	 on	 PARP	 inhibitor	
treatment.	Although	aphidicolin	 is	washed	away	from	the	culture	medium	at	the	time	the	
cells	are	exposed	to	a	PARP	inhibitor	and/or	ionizing	radiation,	their	respective	effect	on	a	
mutual	 target,	 being	 the	 replication	 fork,	 should	 be	 considered.	 Aphidicolin	 impairs	
replication	 fork	 functionality	 by	 inhibition	 of	 DNA	 polymerase	 while	 PARP	 stabilizes	 the	
replication	fork.	Inhibition	of	PARP	than	results	in	the	inhibition	of	single	strand	break	repair,	
which	leads	to	replication	fork	collapse	during	synthesis.	
	
The	absence	of	a	PARP	inhibitor	specific	effect	on	HR	may	also	be	inherent	to	our	assay	set-
up,	 in	 which	 we	 apply	 the	 RAD51	 foci	 assay	 in	 control	 and	 BRCA1/2	 knockdown	 breast	
epithelial	 cells	with	 residual	 protein	 expression.	 Up	 to	 now,	 all	 literature	 referring	 to	 the	
RAD51	foci	assay	and	PARP	inhibition	is	limited	to	tumor	biopsies	from	patients	with	germline	
BRCA1	mutation.	 The	 loss	of	 functional	BRCA1	or	BRCA2	 in	 the	 tumor	 cells	 results	 in	HR-
deficiency	which	renders	the	tumor	cells	sensitive	to	PARP	inhibitors	due	to	synthetic	lethality	
(Pommier	et	al.	2016).		
	
1.3 The	carcinogenic	risk	of	medical	exposure	to	IR	of	BRCA1	and	BRCA2	mutation	carriers	
Pathogenic	mutations	in	DNA	damage	response	genes	such	as	BRCA1	and	BRCA2,	resulting	in	
impaired	DNA	damage	 response	may	contribute	 to	genomic	 instability	and	carcinogenesis	
(Aparicio	et	al.	2014).	By	means	of	the	G2	MN	assay,	we	provided	evidence	that	pathogenic	
BRCA1	and	BRCA2	mutations	result	in	an	increased	radiosensitivity.		
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In	 these	papers,	doses	of	2	and	4	Gy	60Co g-rays	were	used.	These	doses	are	considerably	
higher	 than	 those	 received	by	diagnostic	 exposure	 to	 ionizing	 radiation	 (see	 introduction,	
doses	varying	between	1	and	30	mSv),	by	which	direct	extrapolation	of	our	results	to	the	risks	
of	diagnostic	exposure	is	not	possible.	Nevertheless,	such	high	doses	are	necessary	to	induce	
sufficient	DNA	damage	to	obtain	a	measurable	impact	with	the	assays	used	in	this	study	in	
our	control	and	test	cohort.	Furthermore,	this	fits	in	our	original	scope	to	develop	a	biomarker	
for	the	evaluation	of	“individual”	radiosensitivity.	Although	we	did	not	evaluate	the	response	
of	doses	lower	then	2	Gy,	it	has	been	shown	that	even	at	the	very	low	doses	used	in	diagnostic	
settings,	DNA	damage	in	the	form	of	DSB	is	induced.	Rothkamm	and	Löbrich	demonstrated	
that	doses	as	low	as	1	mGy	of	90	kV	X-rays	induce	DSB	in	primary	fibroblast	cultures,	observed	
by	 gH2AX	foci	staining	(Rothkamm	&	Löbrich	2003).		
	
A	major	contributor	of	exposure	to	ionizing	radiation	in	a	diagnostic	setting	in	woman	at	high	
risk	 of	 breast	 cancer	 is	 mammography	 screening.	 Mammography	 screening	 is	 offered	 to	
individuals	at	high	risk	and	starts	at	young	ages	(see	chapter	1.5.2	of	the	introduction)	as	they	
are	at	risk	of	early	onset	breast	cancer.	Despite	the	relatively	low	mean	glandular	dose	of	one	
mammography	screening	(±4	mGy	per	breast),	 its	carcinogenic	risk	cannot	be	discarded	as	
the	repetitive	nature	of	this	screening	method	results	in	a	considerable	cumulative	dose	in	
individuals	starting	mammography	screening	at	young	age.	Furthermore,	breasts	of	younger	
women	 are	 also	 denser	 which	 complicates	 proper	 screening,	 indicated	 by	 a	 decreased	
sensitivity	(Carney	et	al.	2003).	Taking	additional	images	for	a	better	screening	evaluation	or	
the	application	of	a	higher	dose	for	a	higher	resolution	image	will	increase	the	total	glandular	
dose	(personal	communication).	
	
Additionally,	we	should	consider	the	fact	that	30	kV	X-rays	used	in	mammography	screening	
have	 a	 higher	 RBE	 then	 60Co g-rays,	 typically	 used	 to	 perform	 risk	 assessments.	 As	
mammography	 X-rays	 are	 characterized	 by	 a	 higher	 RBE,	 they	 induce	more	 complex	DSB	
compared	to	60Co g-rays,	demonstrated	by	Depuydt	et	al.	 (see	Figure	3.14)	(Depuydt	et	al.	
2013).		
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Figure	3.14:	Mean	number	of	MN/1000	BN	cells	in	function	of	the	mean	number	of	foci/cell	in	
lymphocytes	for	both	radiation	qualities.	Mammography-induced	DSB,	quantified	by	means	of	
the gH2AX	foci	assay,	were	reported	to	yield	a	higher	number	of	MN,	compared	to	an	equal	
amount	of	induced	 gH2AX	foci	by	60Co g-rays	(doses	vary	from	5	to	2000	mGy)	(Depuydt	et	al.	
2013).	
	
Finally,	we	have	to	take	into	account	that	current	risk	evaluations	are	based	on	a	linear	no	
threshold	hypothesis	and	do	not	take	into	account	a	possible	bystander	effect	which	could	
lead	 to	 a	 low-dose	 hypersensitivity	 in	 breast	 glandular	 tissue	 (Averbeck	 2009).	 Breast	
epithelial	cells	are	highly	organized	and	are	characterized	by	gap	junction-mediate	cell-cell	
communication	 which	might	 leave	 these	 cells	 prone	 to	 bystander	 effects	 (Defamie	 et	 al.	
2014).	Indeed,	recent	research	by	our	group	demonstrated	that	breast	epithelial	cells	lining	
the	duct	are	characterized	by	a	 low	dose	hypersensitivity	(see	Figure	3.15)	(Depuydt	et	al.	
n.d.).	 This	would	 imply	an	underestimation	of	 the	carcinogenic	 risk	of	 low	doses	of	30	kV	
mammography	X-rays.	
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Figure	3.15:	dose-response	curve	for	 gH2AX	foci-induction	after	exposure	of	breast	tissue	to	
60Co g-rays	and	30	kV	X-rays.	The	dose-response	curve	for	each	quality	is	visualized	in	full	lines	
and	demonstrates	a	biphasic	nature	for	30	kV	X-rays.	The	dashed	line	demonstrates	the	linear	
regression	for	30	kV	X-rays	omitting	the	2	to	40	mGy	dose	points.	The	regression	in	the	low	
dose	area	 (0-40	mGy)	 is	 8.7	 times	 steeper	 than	 in	 the	higher	dose	 range	 (20	 to	100	mGy)	
(Depuydt	et	al.	n.d.).	
	
Limited	data	are	available	concerning	the	radiation-induced	carcinogenic	risk	in	BRCA1	and	
BRCA2	mutation	carriers.	Whereas	some	clinical	 studies	 reported	an	absence	of	 increased	
breast	cancer	 incidence	in	BRCA	mutation	carriers	after	exposure	to	 ionizing	radiation	in	a	
diagnostic	 setting,	 others	 could	 not	 exclude	 an	 increased	 breast	 cancer	 risk	 for	mutation	
carriers	younger	than	30	or	40	years	(Drooger	et	al.	2015;	Pijpe	et	al.	2012;	Andrieu	et	al.	
2006;	Gronwald	et	al.	2008;	Narod	et	al.	2006).	Several	EU	guidelines	foresee	mammography	
screening,	for	women	at	high	risk,	starting	at	the	age	of	30	(The	Netherlands	(www.hebon.nl)	
and	Belgium	(Gillet	et	al.	2011))	or	40	(UK	(gov.uk)).	The	US	screening	guidelines	provide	the	
opportunity	to	start	mammography	screening	from	25	years	onwards	(NCCN	2016).	However,	
risk	estimates	by	Berrington	de	Gonzalez	et	al.	in	young	BRCA	mutation	carriers	provide	no	
evidence	 of	 a	 net	 benefit	 of	 mammography	 screening	 between	 the	 ages	 of	 30-34	 years	
(Berrington	de	Gonzalez	et	al.	2009).	A	net	benefit	was	only	observed	at	the	age	of	35	years	
and	older.	 These	 calculated	 risk	 estimates	 are	based	on	 several	 assumptions	 including	 an	
increased	risk	of	radiation-induced	breast	cancer	in	mutation	carriers,	which	is	supported	by	
our	experimental	data.	
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The	results	obtained	in	our	studies,	although	performed	at	higher	doses	of	ionizing	radiation,	
suggest	caution	when	exposing	healthy	tissues	of	BRCA	mutation	carriers	to	ionizing	radiation	
for	diagnostic	purposes.	Especially	mammography	screening	 in	mutation	carriers	at	young	
ages	(25	to	35	years)	should	be	avoided	as	the	net	gain	is	small	and	the	detrimental	effects	
could	 outweigh	 the	 benefits	 of	 screening.	 Current	 screening	 settings	 at	 UZ	 Gent	 avoid	
exposure	to	ionizing	radiation	of	young	individuals	at	high	risk	(not	solely	mutation	carriers)	
and	 use	 MRI	 screening.	 A	 first	 mammography	 screening	 is	 conducted	 at	 the	 age	 of	 40,	
followed	by	routine	screening	from	50	years	onwards	(personal	communication).	However,	
this	cautious	screening	plan	is	not	implemented	at	the	national	level.	We	plea	for	a	general	
gentle	use	of	mammography	screening	in	individuals	at	high	risk	due	to	a	germline	mutation	
in	 BRCA1	 or	 BRCA2.	 Techniques	 such	 as	 MRI	 seem	 to	 be	 better	 suited	 to	 screen	 these	
individuals.	Indeed,	despite	reports	concerning	a	lower	specificity	and/or	sensitivity	(Enriquez	
&	Listinsky	2009;	Pataky	et	al.	2013;	Ahern	et	al.	2014),	MRI	screening	is	useful	in	high	risk	
cohorts,	 even	 when	 considering	 the	 higher	 cost	 compared	 to	 mammography	 screening	
(Obdeijn	et	al.	2014;	Ahern	et	al.	2014).	
	
The	 implications	of	our	results	on	radiotherapy	treatment	 for	BRCA1	and	BRCA2	mutation	
carriers	who	developed	breast	cancer	are	difficult	to	assess.	The	main	aim	of	radiotherapy	is	
to	eradicate	the	(breast)	tumor	while	preserving	the	healthy,	surrounding	tissues.	Our	results	
suggest	 that	 the	 healthy	 breast	 tissue	 might	 be	 more	 prone	 to	 health	 consequences	
associated	 with	 an	 impaired	 DNA	 damage	 response	 capacity	 such	 as	 radiation-induced	
carcinogenesis	and	adverse	effects.	Unfortunately,	only	a	limited	number	of	studies	evaluated	
the	carcinogenic	risk	of	adjuvant	radiotherapy	in	BRCA	mutation	carriers	and	results	are	not	
univocal.	 In	 their	 review,	 Drooger	 et	 al.	 specifically	 warn	 against	 the	 exposure	 of	 young	
individuals	(<30	years)	to	ionizing	radiation	for	therapeutic	purposes	as	a	carcinogenic	effect	
could	not	be	excluded	(Drooger	et	al.	2015).		
	
Nevertheless,	we	also	must	consider	the	fact	that	tumors	in	these	individuals	might	be	more	
radiosensitive	due	to	failed	DNA	damage	responses,	including	failed	HR-mediated	repair	of	
DSB,	which	may	be	a	benefit	in	treatment	of	these	individuals.	The	application	of	our	assays	
on	 breast	 tumor	 tissue	 in	 mutation	 carriers	 would	 allow	 the	 evaluation	 of	 the	 possible	
treatment	 benefit	 in	 these	 individuals.	 Furthermore,	 targeted	 therapies	 such	 as	 a	 PARP	
Part	III:	General	discussion	
	 237	
inhibitor,	exploiting	failed	HR-mediated	DSB	repair	in	tumor	cells,	could	be	applied.	Currently,	
an	array	of	PARP	inhibitors	are	being	tested	in	various	clinical	trials	for	their	effectiveness	in	
breast	cancer	treatment	(Livraghi	&	Garber	2015)	and	one,	Olaparib	(Lynparza,	AstraZeneca),	
has	 been	 approved	 for	 ovarian	 cancer	 treatment	 in	 patients	 with	 a	 deleterious	 germline	
BRCA1/2	mutation	(Kim	et	al.	2015).	PARP	inhibitor	treatment	allows	a	more	direct	targeting	
of	the	tumor,	whilst	damage	to	the	surrounding	tissue	is	expected	to	be	smaller,	resulting	in	
fewer	side	effects	compared	to	radiotherapy.	Nonetheless,	adverse	effects	occur	and	appear	
to	be	similar	to	those	observed	after	systemic	treatment	with	chemotherapy.	Furthermore,	
the	inhibition	of	DNA	damage	response	mechanisms	may	result	in	the	induction	of	cancer	due	
to	an	accumulation	of	DSB	in	normal	tissue	(Livraghi	&	Garber	2015).	A	small	number	of	cases	
of	acute	myeloid	leukemia	and	myelodysplastic	syndrome	were	reported	(incidence	<1%),	but	
most	individuals	developing	new	primary	malignancies	were	also	treated	with	DNA-damaging	
chemotherapeutics	 (Sonnenblick	 et	 al.	 2014).	 Further	 research	 to	 elucidate	 the	 long-term	
effects	of	PARP	inhibitor	treatment	are	warranted.		
	
1.4 Choosing	the	appropriate	assay	to	evaluate	individual	radiosensitivity	
The	choice	of	the	radiosensitivity	assay	will	be	inherent	to	the	gene	that	is	mutated.	When	a	
mutation	has	been	detected	or	 is	presumed	 in	a	 gene	 involved	 in	 c-NHEJ,	 radiosensitivity	
analysis	by	means	of	the	G0	MN	is	advisable.	In	case	of	a	mutation	in	a	gene	involved	in	HR,	
the	G2	MN	is	the	more	appropriate	assay	to	evaluate	individual	radiosensitivity.	Additionally,	
the	G2	MN	assay	 can	 be	 applied	 if	mutations	 are	 present	 in	 genes	 involved	 in	 the	G2/M	
checkpoint.	If	a	mutation	is	detected	or	presumed	in	a	gene	that	affects	both	pathways	or	if	
little	information	is	known	about	the	genetic	background,	it	would	be	advisable	to	apply	both	
assays.		
	
For	example,	 in	our	study	performed	on	a	patient	with	a	variant	 form	of	AT	with	 residual	
kinase	activity,	we	obtained	an	enhanced	radiosensitivity	with	both	the	G0	and	the	G2	MN	
assay,	this	as	ATM	is	involved	in	both	pathways.	The	most	discriminative	result	was	obtained	
with	the	G2	MN	assay,	which	may	point	to	the	fact	that	ATM	is	more	important	in	the	DNA	
damage	response	when	cells	are	in	S	or	G2	phase	of	the	cell	cycle	(Claes	et	al.	2013).		
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For	BRCA1	 and	BRCA2	 heterozygous	mutation	carriers,	we	demonstrated	 that	 the	G2	MN	
assay	 is	 the	 more	 appropriate	 tool	 to	 evaluate	 radiosensitivity.	 This	 is	 in	 line	 with	 the	
expectations	 as	 both	 BRCA1	 and	 BRCA2	 are	 mainly	 involved	 in	 DNA	 damage	 response	
pathways	active	in	S	and	G2	phase	of	the	cell	cycle.	In	addition,	the	role	of	BRCA1	in	the	G2/M	
checkpoint	results	in	the	applicability	of	the	second	endpoint	(G2	arrest	capacity),	analyzed	
in	the	G2	MN	assay.	
	
Besides	the	G2	MN	assay,	we	optimized	a	second	biomarker,	the	RAD51	foci	assay.	This	assay	
allows	a	more	direct	evaluation	of	the	HR	pathway	and	might	prove	valuable	for	individual	
assessment	of	HR	efficiency	and	radiosensitivity	in	BRCA1	and	BRCA2	mutation	carriers.	This	
assay	might	also	be	useful	for	individuals	carrying	a	mutation	in	other	genes	that	affect	HR,	
such	as	ATM	and	PALB2.		
	
Whereas	the	RAD51	foci	assay	could	prove	a	valuable	addition	to	or	alternative	for	the	G2	
MN	assay,	a	similar	approach	could	be	considered	for	the	G0	MN	assay.	Evaluation	of	key	c-
NHEJ	proteins	such	as	Artemis	could	shed	light	on	the	functionality	of	this	particular	pathway.	
	
In	general,	it	would	be	advisable	to	perform	a	panel	of	assays	for	thorough	evaluation	of	the	
radiosensitivity	phenotype	of	an	individual.	The	results	may	be	used	to	refine	diagnosis	if	a	
mutation	is	presumed	or	to	tailor	diagnostic	and	therapeutic	exposure	to	ionizing	radiation	of	
individuals	characterized	by	a	genomic	instability	and	high	cancer	risk.	
	
1.5 Limitation	of	the	use	of	lymphocytes	for	analysis	of	individual	radiosensitivity	
Radiosensitivity	tests	are	generally	performed	in	peripheral	blood	lymphocytes	as	they	are	
an	easy-accessible	source	of	patient-own	material.	They	are	a	valuable	cell	type	to	evaluate	
how	individuals	with	a	different	genetic	background	(e.g.	mutation	carriers	versus	controls)	
respond	to	ionizing	radiation	and	therefore,	an	appropriate	cell	source	to	develop	a	clinically	
useful	biomarker	to	assess	of	the	overall	individual	radiosensitivity	(Kote-Jarai	et	al.	2006;	
Rieger	et	al.	2004;	Foray	et	al.	1999).		
	
Nevertheless,	lymphocytes	are	not	the	most	appropriate	cell	type	to	study	the	mechanisms	
underlying	the	formation	of	radiation-induced	breast	cancer.	Cancer	risk	in	BRCA1	and	
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BRCA2	mutation	carriers	is	predominantly	associated	with	breast	and	ovarian	cancer	(van	
Asperen	et	al.	2005;	Thompson	et	al.	2002).	Several	theories,	such	as	the	involvement	of	the	
XIST	RNA	(Sirchia	et	al.	2009)	or	hormones	(Santen	et	al.	2009),	have	been	proposed	to	
explain	this	phenomenon.	None	of	these	theories	seem	to	adequately	explain	the	cell	type	
specific	cancer	development	in	BRCA1	or	BRCA2	mutation	carriers.	
	
Another	possible	explanation	is	the	difference	in	DNA	DSB	repair	pathways	utilized	by	breast	
and	ovarian	epithelial	cells	compared	to	other	cell	types.	While	not	thoroughly	investigated,	
it	is	known	that	different	cell	types	use	the	repair	pathways	to	a	different	extent	(D’Errico	et	
al.	2007).	One	could	suggest	that	breast	and	ovarian	epithelial	cells	in	S	and	G2	phase	mainly	
rely	on	the	HR-pathway	to	repair	DNA	DSB,	while	other	cell	types,	including	fibroblasts	and	
other	epithelial	cells,	rely	on	the	c-NHEJ	pathway.	A	reduced	level	of	BRCA1	or	BRCA2	due	to	
a	 mutation	 would	 render	 the	 HR-pathway	 inefficient	 while	 the	 c-NHEJ	 pathway	 remains	
proficient	(Sedic	&	Kuperwasser	2016).	This	theory	is	supported	by	results	obtained	by	Sedic	
et	al.	(2015)	as	they	demonstrated	an	increased	genomic	instability	in	human	breast	epithelial	
cells	but	not	in	skin	fibroblast	with	pathogenic	mutations	of	BRCA1	(Sedic	et	al.	2015).		
	
Further	 research	 evaluating	 the	 difference	 in	 pathway	 use	 between	 different	 cell	 types,	
including	 breast	 epithelial	 cells,	 fibroblasts	 and	 lymphocytes,	 could	 shed	 light	 on	 this	
phenomenon.	This	could	be	achieved	by	evaluating	the	induction	of	DSB	by	means	of	gH2AX	
foci,	combined	with	the	RAD51	foci	assay	to	measure	HR	activation	and	a	Artemis	foci	assay	
to	quantify	c-NHEJ	activation.	As	cell	cycle	phase	is	a	key	factor	in	this	experimental	setup,	
incorporation	of	a	geminin	staining,	indicative	for	cells	in	S	and	G2	phase,	would	be	advisable	
(Wohlschlegel	et	al.	2002).		
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2 cDNA	ANALYSIS	OF	PUTATIVE	SPLICE	SITE	VARIANTS	
Besides	 assays	 evaluating	 the	 effect	 of	 radiation,	 also	 other	 tests	may	 be	 helpful	 for	 the	
determination	of	a	functional	effect	of	variants	in	BRCA1/2.	Therefore,	a	final	aim	of	this	thesis	
focusses	on	the	determination	of	the	functional	effect	of	putative	splice	site	variants	by	cDNA	
analysis	in	lymphocytes.	The	identification	of	VUS	is	a	major	issue	for	labs	offering	diagnostic	
testing	and	is	reflected	in	the	large	number	of	VUS	reported	in	the	ClinVar	database	(NCBI).	
VUS	 are	 a	 true	 challenge	 for	 health	 care	 providers	 as	 the	 impact	 of	 these	 variants	 on	
breast/ovarian	 cancer	 risk	 is	 unclear.	 mRNA	 analysis	 to	 investigate	 intronic	 and	 exonic	
variants	that	might	impair	proper	RNA	splicing,	a	highly	regulated	process,	are	widely	used.	
In	 paper	 V,	 we	 evaluated	 the	 outcome	 of	 19	 VUS	 at	 the	 cDNA	 level	 and	 assessed	 the	
performance	of	multiple	in	silico	prediction	tools	(discussed	in	chapter	2.1).	We	demonstrated	
aberrant	 splicing	 for	 nine	 variants,	 suggesting	 that	 these	 variants	 are	 likely	 pathogenic	
(discussed	 in	chapter	2.2).	 Improper	mRNA	splicing	was	due	to	the	 loss	of	wild	type	splice	
sites	leading	to	a	skip	of	an	entire	exon	or	originated	from	the	activation	of	cryptic	splice	sites	
leading	to	aberrant	transcripts.	By	studying	the	effect	at	the	cDNA	level	of	a	novel	tandem	
duplication	with	a	5’	breakpoint	in	intron	4	and	a	3’	breakpoint	in	exon	11	of	the	BRCA2	gene,	
we	identified	an	actively	used	cryptic	donor	site	within	the	large	exon	11.	To	our	knowledge,	
this	is	the	first	report	on	an	activated	cryptic	donor	site	in	the	large	exon	11	of	BRCA2.	Many	
more	strong	sites	were	predicted	 in	silico,	but	not	activated.	The	 identification	of	 this	site	
warrants	further	research	to	gain	more	insight	in	cis	and	trans	acting	factors	playing	a	role	in	
the	conservation	of	correct	transcription	of	this	large	exon	in	which	to	date	no	mutations	have	
been	reported	associated	with	aberrant	splicing.	
	
2.1 Aberrant	splicing	and	accuracy	of	in	silico	prediction	tools	
We	evaluated	the	performance	of	a	wide	array	of	in	silico	prediction	tools	for	their	sensitivity	
and	specificity	(paper	V).	The	power	of	these	tools	to	accurately	predict	the	effect	of	splice	
site	variants	is	dependent	on	the	degree	of	conservation	of	the	region	in	which	the	variant	is	
located,	 the	ability	 to	accurately	predict	 the	wild	type	splice	site,	and	the	ability	 to	define	
important	 regions	 such	as	 the	branchpoints	or	ESE	 (Caminsky	et	al.	2014;	Houdayer	et	al.	
2012).	Therefore,	the	efficiency	of	these	splicing	tools	largely	depends	on	the	location	of	the	
variant.	 In	 total,	 three	different	 regions	 are	defined.	 The	 first	 highly	defined	 region	 is	 the	
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canonical	splice	site.	This	region	comprises	the	two	intronic	nucleotides	flanking	each	exon	
and	are	always	GT	at	the	splice	donor	site	and	AG	at	the	splice	acceptor	site.	Variants	located	
in	this	region	are	expected	to	disrupt	proper	mRNA	splicing	and	prediction	tools	perform	well.	
The	effect	of	variants	outside	this	splice	site	consensus	region	is	more	difficult	to	assess.	For	
variants	in	the	cartegni	consensus	region	(see	Figure	3.16),	but	outside	the	canonical	splice	
site,	in	silico	prediction	lacks	specificity.	However,	the	in	silico	prediction	tools	performed	well	
for	our	intronic	variants	outside	the	Cartegni	consensus	region.	We	found	that	neither	of	the	
three	 in	silico	 tools	for	evaluation	of	exonic	variants	(ESEfinder,	ESE-RESCUE	and	DESRseq)	
performed	well.	Additional	optimization	and	validation	could	improve	these	prediction	tools,	
but	for	now,	mRNA	analysis	remains	necessary	to	verify	the	in	silico	prediction	result	and	to	
determine	the	exact	aberrant	transcript	for	pathogenicity	evaluation	of	putative	splice	site	
mutations.	
	
	
Figure	3.16:	The	Cartegni	consensus	region	encompasses	11	bases	of	the	5ʹ	splice	site	(from	
the	three	last	exonic	to	the	eight	first	intronic	bases)	and	14	bases	of	the	3ʹ	site	(from	the	12	
last	intronic	to	the	first	two	exonic	bases)	(Cartegni	et	al.	2002).	
	
2.2 Aberrant	splicing,	pathogenicity	assessment	and	functional	analysis	
Classification	 of	 VUS	 is	 based	 on	 a	multifactorial	 approach	 including	 familial	 segregation,	
frequency	in	cases	versus	controls	and	functional	analysis	(Table	IV).	However,	each	piece	of	
this	puzzle	has	its	limitations	(Couch	et	al.	2008;	Goldgar	et	al.	2008).		
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Table	IV.	Data	relevant	for	multifactorial	likelihood	analysis	for	variant	classification	(Goldgar	et	al.	2008)	
	
	
In	paper	V,	we	evaluated	the	effect	at	the	cDNA	level	for	21	putative	splice	site	variants	and	
found	that	12	of	them	lead	to	aberrant	splicing.	One	limitation	of	our	study	is	that	we	were	
not	able	to	evaluate	for	all	variants	allele-specific	assessment	of	aberrant	splicing.	For	several	
variants	 sequencing	 data	 clearly	 showed	 equal	 expression	 of	 the	 aberrant	 and	 full	 length	
transcript	and	complete	absence	of	the	aberrant	transcript	in	controls.	For	these	variants	our	
data	 provide	 a	 reasonable	 suggestion	 regarding	 pathogenicity.	 However,	 allele-specific	
assessment	 of	 aberrant	 splicing	 in	 combination	with	 a	multifactorial	 likelihood	 analysis	 is	
necessary	to	definitively	classify	a	variant	as	deleterious	(Spurdle	et	al.	2008).	
	
For	 most	 of	 the	 tested	 variants,	 aberrant	 splicing	 led	 to	 the	 formation	 of	 a	 premature	
termination	codon.	Based	on	previous	experimental	work	and	literature,	we	can	expect	the	
activation	of	NMD,	resulting	in	a	degradation	of	the	mRNA	and	a	reduction	in	protein	level	
(Baert	et	al.	2016;	Perrin-vidoz	et	al.	2002;	Ware	et	al.	2006).	In	that	case,	pathogenicity	is	to	
be	expected	as	a	similar	net	result	is	obtained	compared	to	deleterious	frameshift	mutations	
for	which	pathogenicity	is	established.		
	
Certain	 aberrant	 transcripts	 may	 evade	 NMD	 because	 of	 the	 location	 of	 the	 premature	
termination	codon	at	the	C	or	N-terminus	of	BRCA1	or	because	an	in	frame	deletion/insertion	
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does	not	result	in	the	formation	of	a	premature	termination	codon.	For	these	variants,	the	
impact	must	be	assessed	at	multiple	levels.	Initially,	the	aberrant	transcript	abundance	must	
be	evaluated	in	function	of	the	full-length	transcript.	Furthermore,	translation	of	the	aberrant	
transcript	 can	 be	 verified	 by	means	 of	 a	Western	 blot	 analysis.	 If	 an	 aberrant	 protein	 is	
detected,	an	evaluation	of	 its	 impact	on	proper	protein	 functionality	must	be	assessed	by	
means	of	a	functional	assay.	
	
For	two	splice	site	variants	in	BRCA1	(c.5152+2dupT	(p.Asp1692_Trp1718delinsGly)	&	c.5468-
1G>A	 (p.Ala1823Valfs*2)),	 evaluated	 in	 paper	 V,	 pathogenicity	 classification	 was	 less	
straightforward	due	to	the	in	frame	deletion	of	exon	18	and	a	premature	termination	codon	
predicted	to	evade	NMD	respectively.	Although	presently	aberrant	transcript	abundance	has	
not	been	evaluated,	pathogenicity	might	be	expected	given	the	disruption	of	the	functional	
BRCT	domain	and	based	on	pathogenicity	classification	of	other	variants	in	the	region.	The	
disrupted	BRCT	domain	 is	 important	 for,	 amongst	 others,	 BRCA1	 recruitment	 to	 the	DNA	
damage	site	and	DNA	end	resection.	As	 two	main	 functions	of	 the	DNA	damage	response	
activity	of	BRCA1	might	be	disrupted,	subsequent	activation	of	HR	might	be	impaired.	This	
could	be	evaluated	by	means	of	the	G2	MN	assay	or	a	HR-specific	functional	assay	such	as	the	
RAD51	foci	assay.	As	proposed	in	chapter	1.2	of	the	general	discussion,	the	application	of	the	
RAD51	 foci	 assay	 on	 synchronized	 lymphocytes	 of	 individuals	 with	 pathogenic	 BRCA1	 or	
BRCA2	mutations	might	be	promising	to	evaluate	HR	functionality	and	radiosensitivity.	Once	
validated,	 this	 assay	 could	 be	 applied	 for	 pathogenicity	 assessment	 of	 splice	 site	 variants	
leading	to	various	types	of	aberrant	transcripts.	
	
In	 paper	 II,	 we	 evaluated	 the	 effect	 of	 different	 types	 of	 aberrant	 transcripts	 on	
radiosensitivity,	measured	by	the	G2	MN	assay	 in	BRCA1	mutation	carriers.	Therefore,	we	
compared	 the	 effect	 of	 aberrant	 transcripts	 sensitive	 to	 NMD	 and	 aberrant	 transcripts	
escaping	NMD	due	to	the	absence	or	the	5’	location	of	a	PTC	on	the	individual	RIND	scores.	
Haploinsufficiency	 is	the	main	mechanism	suggested	for	breast	carcinogenesis	 (Salmena	&	
Narod	2012)	and	seems	to	be	the	underlying	mechanism	for	 radiosensitivity	 in	 individuals	
with	an	NMD-sensitive	mutation.	However,	we	demonstrated	a	higher	median	RIND	score	for	
individuals	 carrying	 a	 mutation	 in	 the	 5’	 part	 of	 the	 gene,	 for	 which	 no	 NMD	 could	 be	
detected,	compared	to	individuals	with	aberrant	transcripts	susceptible	for	NMD,	which	may	
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point	 towards	 another	mechanism,	 such	as	dominant	negative	effect,	 in	 these	 individuals	
(paper	 II).	 As	 indicated	 in	 paper	 II,	 our	 data	 suggest	 the	 need	 for	 larger	 studies	 involving	
different	types	of	mutations	and	the	RAD51	foci	assay	appears	to	be	well	suited	to	evaluate	
the	effect	of	different	types	of	mutations	on	HR	and	radiosensitivity.		
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3 GENERAL	CONCLUSION	
We	 demonstrated	 that	 the	 G2	MN	 assay	 is	 a	 valuable	 assay	 to	 assess	 radiosensitivity	 in	
cohorts	of	ATM,	BRCA1	and	BRCA2	heterozygous	mutation	carriers.		
Unfortunately,	 intra-individual	 variation	 of	 the	 assay,	 and	 inter-individual	 variation	which	
might	be	caused	by	the	influence	of	other	DNA	damage	response	pathways	on	MN	formation,	
complicate	individual	radiosensitivity	assessment	due	to	overlap	in	MN	yields	between	the	
test	and	control	 cohort.	Therefore,	an	arbitrary	 scoring	 system	was	set	up	which	allows	a	
“graded”	assessment	of	the	individual	radiosensitive	phenotype.	In	search	of	an	assay	to	allow	
a	better	individual	assessment	of	HR	capacity	in	heterozygous	BRCA1	and	BRCA2	mutation	
carriers,	 we	 evaluated	 the	 use	 of	 the	 RAD51	 foci	 assay	 in	 S	 phase	 synchronized	 breast	
epithelial	 cells	 with	 reduced	 BRCA1	 or	 BRCA2	 protein	 levels	 and	 demonstrated	 impaired	
RAD51	foci	formation,	and	thus	HR	capacity,	in	response	to	radiation-induced	DSB.	Both	the	
G2	MN	assay	and	the	RAD51	foci	assays	can	be	applied	for	the	assessment	of	radiosensitivity	
evaluation	 and/or	 HR	 functionality	 in	 patients	 carrying	 a	 mutation	 in	 an	 array	 of	 genes	
involved	in	the	DNA	damage	response	active	during	S	and	G2	phase	of	the	cell	cycle,	or	more	
specifically,	engaged	in	HR	activation.	
	
The	results	obtained	in	these	papers	indicate	that	care	should	be	taken	when	applying	ionizing	
radiation	for	diagnostic	or	therapeutic	purposes	in	(young)	individuals	at	high	risk	of	breast	
cancer	due	 to	a	mutation	 in	BRCA1	or	BRCA2	 as	 they	may	be	at	higher	 risk	of	developing	
radiation-induced	breast	cancer.		
	
These	results	refer	to	individuals	heterozygous	for	an	uniquivocal	deleterious	BRCA1	or	BRCA2	
mutation.	 However,	 a	 major	 burden	 in	 diagnostic	 testing	 of	 the	 BRCA1/2	 genes	 are	 the	
identification	of	VUS.	These	VUS	are	a	true	challenge	for	health	care	providers	as	the	impact	
of	 these	 variants	 on	 breast/ovarian	 cancer	 risk	 is	 unclear.	 We	 evaluate	 the	 effect	 of	 21	
variants	in	BRCA1	and	BRCA2	by	mRNA	analysis	and	demonstrated	aberrant	splicing	for	11	
variants	suggesting	that	 these	are	 likely	pathogenic.	Furthermore,	we	demonstrate	that	 in	
silico	 prediction	 tools	 might	 assist	 in	 the	 evaluation	 of	 these	 putative	 splicing	 variants.	
However,	further	optimization	is	warranted.	Finally,	we	propose	the	RAD51	foci	assay	as	a	
functional	assay	for	variants	affecting	functional	domains.
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Oral	 presentation:	 Development	 of	 an	 S-G2	micronucleus	 assay	 for	 the	
detection	 of	 in	 vitro	 chromosomal	 radiosensitivity	 in	BRCA1	 and	BRCA2	
mutation	carriers.	
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